Compounds > posaconazole
Page last updated: 2024-09-27

posaconazole

Description

KY02111: promotes cardiac differentiation of pluripotent stem cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID468595
CHEMBL ID1397
CHEBI ID64355
SCHEMBL ID991747
MeSH IDM0265888
PubMed CID8582409
CHEMBL ID3186128
SCHEMBL ID15063115
MeSH IDM0265888

Synonyms (144)

Synonym
AC-1350
c37h42f2n8o4
AB01274762-01
noxafil
posaconazole sp
noxafil (tn)
D02555
posaconazole (jan/usan/inn)
4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1s,2s)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one
posaconazole ,
1-((1s,2s)-1-ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5s,3r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
POS ,
171228-49-2
sch-56592
sch 56592
sch56592
DB01263
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1s,2s)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1h-1,2,4-triazol-1-yl)-
4-(p-(4-(p-(((3r,5r)-5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1s,2s)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
posaconazole [usan:inn:ban]
3h-1,2,4-triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3r-(3alpha(1s*,2s*),5alpha))-
posaconazole in combination with mgcd290
AKOS005145917
CHEMBL1397 ,
chebi:64355 ,
(-)-posaconazole
4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2s,3s)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2h-1,2,4-triazol-3(4h)-one
4-(4-(4-(4-(((5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2h-1,2,4-triazol-3(4h)-one
bdbm50181473
pasaconazole
4-[4-(4-{4-[(r)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1s,2s)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one
NCGC00185736-01
6tk1g07bhz ,
unii-6tk1g07bhz
hsdb 7421
dtxcid401474254
tox21_113620
dtxsid6049066 ,
cas-171228-49-2
HY-17373
CS-0998
2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2s,3s)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol
schering 56592
2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol
posaconazole [green book]
3h-1,2,4-triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3r-[3alpha(1s*,2s*),5alpha]]-
posaconazole [who-dd]
posaconazole [jan]
posaconazole [mi]
posaconazole [hsdb]
posaconazole [inn]
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-
posaconazole [mart.]
posaconazole [orange book]
posaconazole [usan]
posaconazole [vandf]
posaconazole [ema epar]
S1257
NCGC00274060-01
tox21_113620_1
P-7020
posaconazole, antibiotic for culture media use only
RAGOYPUPXAKGKH-XAKZXMRKSA-N
4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2s,3s)-2-hydroxypentan-3-yl)-1h-1,2,4-triazol-5(4h)-one
SCHEMBL991747
KS-1413
posaconazol
AB01274762_02
posaconazole, vetranal(tm), analytical standard
mfcd00941162
mmv688774
SW219391-1
2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol
177571-33-4
P2477
BCP01102
Q906453
AMY30591
CCG-270387
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-; noxafil; posaconazole; sch 565
NCGC00274060-07
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)- 4-((4-(4-(4-(1-((1s,2s)-1-ety
gtpl11428
NCGC00274060-02
BP164281
BP163593
posaconazole - form i
posaconazole- bio-x
BP163592
posaconazole - form iii
4-{4-[4-(4-{[(3r,5r)-5-(2,4-difluorophenyl)-5-[(1h-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2s,3s)-2-hydroxypentan-3-yl]-4,5-dihydro-1h-1,2,4-triazol-5-one
EN300-19769273
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-( 1h-1,2,4-triazol-1-yl)-?
posaconazolum
noxafil powdermix kit
4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one
posaconazole delayed-release
(3r-cis)-4-
2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-
posaconazole (mart.)
j02ac04
4-(4-(4-(4-(((3r,5r)-5-(2,4-difluorophenyl)-5-((1h-1,2,4-triazol-1-yl)methyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one
AKOS007976129
n-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide
NCGC00347949-01
ky 02111
1118807-13-8
n-(6-chlorobenzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide
ky02111
CS-1975
HY-13815
AM81229
benzenepropanamide, n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxy-
n-(6-chloro-benzothiazol-2-yl)-3-(3,4-dimethoxy-phenyl)-propionamide
n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide
c18h17cln2o3s
SCHEMBL15063115
DTXSID80429194
HB3465
n-(6-chloro-2-benzothiazolyl)-3,4-d imethoxybenzenepropanamide
AC-32857
CHEMBL3186128
J-002654
ky-02111
HMS3653K03
mfcd08483062
ky0211
NCGC00347949-11
SW219524-1
FT-0713062
BCP07010
Z27365775
S7096
EX-A2089
AS-16445
unii-6axh36yf6m
CCG-268372
2-(3-(3,4-dimethoxyphenyl)propanamido)-6-chlorobenzothiazole
6AXH36YF6M ,
NCGC00347949-08
BK162779
EN300-1266069
n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxy-benzenepropanamide

Research Excerpts

Overview

ExcerptReference
"Posaconazole is a triazole antifungal for prophylaxis of invasive fungal infection and treatment of oropharyngeal candidiasis. "( Herron, J; Kantesaria, B; Krishna, G; Sansone-Parsons, A; Simon, J; Soni, P; Stoltz, R, 2007)
"Posaconazole is an orally bioavailable triazole antifungal agent for the treatment and prophylaxis of invasive fungal infection. "( Kantesaria, B; Krishna, G; Martinho, M; Pedicone, L; Sansone-Parsons, A, 2007)
"Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. "( Otero, MJ; Peña-Lorenzo, D; Pérez-Blanco, JS; Rebollo, N; Sánchez-Hernández, JG; Vázquez-López, L; Zarzuelo-Castañeda, A, 2022)
"Posaconazole is a promising triazole antifungal agent."( Panagopoulou, P; Roilides, E, 2022)
"Posaconazole is an antifungal drug used to treat invasive aspergillosis and candidiasis."( Bouma, E; de Keyzer, C; Delang, L; Jacobs, S; Merits, A; Meutiawati, F; Overheul, GJ; Smit, JM; Taşköprü, E; Teppor, M; van Rij, RP; van Woudenbergh, E; Varghese, FS, 2022)
"Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. "( Dhupad, S; Mahalle, NP; Melinkeri, S; Naik, SS; Narawade, S; Panchakshari, SP; Patwardhan, SA; Prayag, AP; Prayag, PS, 2022)
"Posaconazole is a globally approved broad-spectrum triazole antifungal compound. "( de Almeida, C; de Greef, R; Fauchet, F; Hasegawa, C; Iwasa, T; Winchell, GA; Wrishko, RE; Yoshitsugu, H, 2023)
"Posaconazole is an antifungal drug in the class of triazoles which are known to possess numerous pharmacological properties."( Bodapati, ATS; Lavanya, K; Madku, SR; Reddy, RS; Sahoo, BK, 2023)
"Posaconazole (PSZ) is a triazole antifungal for the management of invasive fungal disease (IFD) in adults and children. "( Garner, LM; Gonzalez, D; McCann, S; McKinzie, CJ; Sinha, J; Wilson, WS, 2023)
"Posaconazole is an antifungal drug currently being used for prophylaxis and treatment of invasive fungal infections such as aspergillosis. "( Göpfert, M; Kluge, S; König, C; Wichmann, D, 2023)
"Posaconazole is a recommended option for antifungal prophylaxis in paediatric patients >12 years of age. "( Ahlmann, M; Fröhlich, B; Gastine, S; Groll, AH; Herbrüggen, H; Müller, C; Thorer, H; Tragiannidis, A; Vasileiou, E, 2019)
"Posaconazole (PCZ) is a triazole approved for prophylaxis of invasive fungal infections."( Cha, K; Chae, H; Cho, SY; Kim, HJ; Kim, M; Kim, Y; Kim, YJ; Lee, DG; Lee, JJ; Yi, Y, 2020)
"Posaconazole is a broad-spectrum antifungal that is not licensed for use in children <13 years of age. "( Alffenaar, JW; Bandodkar, S; Kesson, A; Lai, T; Roberts, JA, 2020)
"Posaconazole is a broad-spectrum triazole antifungal drug licensed for prophylaxis and treatment of invasive fungal infections."( Brüggemann, RJM; Burger, DM; Knibbe, CAJ; Smit, C; van Dongen, EPA; van Donselaar, MH; Verweij, PE; Wasmann, RE; Wiezer, RMJ, 2020)
"Posaconazole is a triazole antifungal with activity against Rhizopus, but data on its use and pharmacokinetics in preterm infants are scarce. "( Demmler-Harrison, GJ; Dinu, D; Fatemizadeh, R; Rodman, E, 2020)
"Posaconazole is a triazole antifungal drug that has an important place in the prophylaxis and salvage treatment of these infections."( Maertens, J; Spriet, I; Van Daele, R, 2020)
"Posaconazole is a CYP3A4 inhibitor and substrate for UGT1A4 and P-gp so drug-drug interactions can occur."( Maertens, J; Spriet, I; Van Daele, R, 2020)
"Posaconazole (POS) is an inhibitor of ergosterol biosynthesis in clinical use for treating invasive fungal infections. "( Ferrão, PM; Garzoni, LR; Meuser-Batista, M; Moreira, OC; Nisimura, LM; Nogueira, ADR; Urbina, JA; Waghabi, MC, 2020)
"Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal diseases. "( Bernardo, V; Fernandez, AJ; Liverman, R; Miles, A; Tippett, A; Yildirim, I, 2020)
"Posaconazole (PCZ) is a clinically approved drug used predominantly for prophylaxis and salvage therapy of fungal infections. "( Celegato, M; Gribaudo, G; Lepesheva, GI; Loregian, A; Luganini, A; Mercorelli, B; Palù, G, 2020)
"Posaconazole is a potentially promising therapy for T."( Kong, WF; Lang, Q; Pasheed Chughtai, A; Yan, HY, 2020)
"Posaconazole is a triazole antifungal drug with strong antifungal effect. "( He, K; Ji, W; Wen, Q; Yang, S; Zhao, H, 2020)
"Posaconazole is an antifungal drug available also as an oral suspension."( Fertaki, S; Kontoyannis, C; Lykouras, M; Orkoula, M, 2020)
"Posaconazole is a triazole antifungal drug that was approved by the U.S. "( Bitencourt, AS; Garcia, CV; Gobetti, C; Mendez, ASL; Oliveira, SS, 2021)
"Posaconazole is an antifungal drug used for prophylaxis and treatment of invasive fungal infections. "( Brüggemann, RJ; Cotton, F; Debaveye, Y; Depuydt, P; Dreesen, E; Fage, D; Gijsen, M; Rijnders, B; Spriet, I; Van Daele, R; Van Zwam, K; Wauters, J, 2021)
"Posaconazole (PSC) is a triazole group anti-fungal agent with the widest spectrum. "( Durgun, ME; Güngör, S; Hacıoğlu, M; Kahraman, E; Özsoy, Y, 2022)
"Posaconazole tablets are a cost-effective alternative to fluconazole and may show better results than the oral suspension formulation."( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2018)
"Posaconazole is an extended-spectrum triazole antifungal used in the treatment and prophylaxis of Aspergillus infections. "( Behr, J; Ceelen, F; Ihle, F; Kneidinger, N; Matthes, S; Neurohr, C; Schramm, R; Stelzer, D; Vogeser, M; Weber, A; Winter, H; Zimmermann, G; Zoller, M, 2018)
"Posaconazole is an antifungal drug used in both prophylaxis and treatment of invasive fungal infections. "( Chauvin, C; Chevallier, P; Dalichampt, M; Deslandes, G; Garnier, A; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Moreau, P; Paré, M; Pere, M; Peterlin, P, 2018)
"Posaconazole is a triazole with limited pharmacokinetic information in children. "( Berger, M; Calore, E; Carraro, F; Cesaro, S; Decembrino, N; Molinaro, M; Perruccio, K; Putti, MC; Rossin, S; Tridello, G; Vicenzi, EB, 2018)
"Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal infections. "( Abzug, MJ; Curtis, D; Hurst, AL; Strommen, A, 2018)
"Posaconazole is a triazole antifungal used to prevent invasive fungal infections (IFIs) in patients receiving chemotherapy or haemotopoietic stem cell transplantation. "( Combarel, D; Funck-Brentano, C; Leblond, V; Leclerc, E; Uzunov, M; Zahr, N, 2018)
"Posaconazole is a broad-spectrum antibacterial drug for the treatment of invasive fungal infections. "( Li, S; Yang, L; Yang, M; Zhao, Z, 2018)
"Posaconazole is a potential alternative for these patients."( Denning, DW; Harris, C; Kosmidis, C; Muldoon, EG; Newton, PJ; Rodriguez-Goncer, I, 2018)
"Posaconazole is a broad-spectrum triazole widely used to prevent and treat invasive mycoses in adults. "( Cesaro, S; Vicenzi, EB, 2018)
"Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFIs). "( Arrieta, AC; Bradley, JS; Carmelitano, P; Gates, D; Groll, AH; Joshi, A; Kartsonis, NA; Lehrnbecher, T; Mangin, E; Paschke, A; Sung, L; Walsh, TJ; Waskin, H; Zwaan, CM, 2019)
"Posaconazole is a second-generation triazole with a broad spectrum. "( Cho, BS; Choi, JH; Choi, SM; Kim, HJ; Kim, SH; Kwon, JC; Lee, DG; Lee, HJ; Lee, JW; Lee, S; Min, CK; Min, WS; Park, SH; Yoo, JH, 2013)
"Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM."( Cho, BS; Choi, JH; Choi, SM; Kim, HJ; Kim, SH; Kwon, JC; Lee, DG; Lee, HJ; Lee, JW; Lee, S; Min, CK; Min, WS; Park, SH; Yoo, JH, 2013)
"Posaconazole is a broad-spectrum triazole antifungal drug with efficacy in prevention of IFI; however, it has not been previously studied as prophylaxis in a Chinese population."( Chen, FP; Chen, XQ; Hu, JD; Huang, XJ; Jin, J; Li, Y; Liang, YM; Liu, T; Shen, Y; Shen, ZX; Wang, JX; Wang, SJ; Wu, DP; Yu, K; Yu, L, 2013)
"Posaconazole is a triazole derivative which is effective in Aspergillosis prophylaxis and treatment."( Bakır, M; Ermerak, NO; Kepenekli, E; Kuzdan, C; Soysal, A; Yüksel, M, 2014)
"Posaconazole is a second generation triazole with a broad spectrum, and it may be suitable for salvage antifungal treatment although posaconazole is not usually considered to be as first-line antifungal therapy for IFI."( Kim, JH; Williams, K, 2014)
"Posaconazole is a most promising antifungal agent against all types of invasive infections with high % of cure rate."( Amin, P; Fule, R, 2014)
"Posaconazole (Noxafil(®)) is a triazole antifungal agent with an extended spectrum of antifungal activity. "( McKeage, K, 2015)
"Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of invasive fungal infections. "( Cranswick, N; Curtis, N; Gwee, A, 2015)
"Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data."( Camargo, JF; Cho-Vega, JH; Yakoub, D, 2015)
"Posaconazole is a promising antifungal agent to be used prophylactically in hematologic patients aged 13 years or younger. "( Annaert, P; Augustijns, P; Bica, AM; Colita, A; Mols, R; Peersman, N; Spriet, I; Vanstraelen, K; Vermeersch, P, 2016)
"Posaconazole is a broad-spectrum antifungal triazole that requires further investigation within the setting of lung transplantation."( Capoccia, M; Carby, M; Chibvuri, M; Firouzi, A; Garcia-Saez, D; Habibi-Parker, K; Lamba, H; Leaver, N; Lyster, H; Mohite, P; Packwood, K; Patil, N; Reed, A; Rogers, P; Sabashnikov, A; Simon, A; Soresi, S; Tate, H; Thakuria, L; Zych, B, 2016)
"Posaconazole is a triazole antifungal drug that with extremely poor aqueous solubility. "( Li, H; Liao, X; Ma, X; Tang, P; Wang, L; Xiong, X; Xu, K, 2017)
"Posaconazole is a commonly used antifungal for the prophylaxis and treatment of invasive fungal infections. "( Cornely, OA; Farowski, F; Hartmann, P, 2016)
"Posaconazole is an important antifungal agent for both prophylaxis and treatment of IFIs; however, detailed pharmacokinetic data are limited among LTRs, particularly those with cystic fibrosis (CF)."( Clancy, CJ; Ensor, C; Joshi, R; Nguyen, MH; Shields, RK; Venkataramanan, R; Zhang, H; Zhao, W, 2016)
"Posaconazole appears to be a safe and effective antifungal agent in diabetic patients with ROCM, especially in those who have toxicity with polyene therapy."( John, AO; Manesh, A; Mathew, B; Rupa, V; Varghese, GM; Varghese, L; Zachariah, A, 2016)
"Posaconazole is an extended-spectrum triazole antifungal with activity against a variety of clinically significant yeasts and moulds. "( Freeman, AF; Hallahan, CW; Holland, SM; Jancel, T; Kim, T; Penzak, SR; Shaw, PA, 2017)
"Posaconazole (POS) is an antifungal compound which has a low oral bioavailability. "( Dong, Z; Wang, Y; Yang, M; Zhang, F; Zhang, Y; Zhao, Z, 2017)
"Posaconazole (PCZ) is a broad-spectrum triazole antifungal agent used for the treatment of diverse fungal infections, including aspergillosis and candidiasis."( Guo, H; Jiang, L; Li, DM; Li, SX; Song, YJ; Zhang, H; Zhao, YJ; Zhu, KJ, 2017)
"Posaconazole is an oral broad-spectrum triazole with activity against many yeasts and molds. "( Rachwalski, EJ; Scheetz, MH; Wieczorkiewicz, JT, 2008)
"Posaconazole appears to be a valuable and promising addition to the antifungal armamentarium for prophylaxis and treatment of various fungal processes. "( Rachwalski, EJ; Scheetz, MH; Wieczorkiewicz, JT, 2008)
"Posaconazole is a new antifungal agent, which exhibits a broad spectrum of activity against fungi including Aspergillus terreus, some zygomycetes and dematiaceous fungi. "( Fleck, R; Hof, H, 2008)
"Posaconazole is a novel oral antifungal triazole with potent and broad-spectrum antifungal activity, favourable pharmacokinetic properties and a limited spectrum of adverse events. "( Groll, AH; Lehrnbecher, T, 2008)
"Posaconazole is a new broad-spectrum triazole antifungal drug that is used in prophylaxis and therapy of opportunistic fungal infections in immunocompromised patients. "( Hoppe-Tichy, T; Lichtenstern, C; Müller, C; Störzinger, D; Swoboda, S; Weigand, MA, 2008)
"Posaconazole is a member of the azole class of antifungals recently approved for the prophylaxis and treatment of invasive fungal infections. "( Morris, MI, 2009)
"Posaconazole is an oral anti-fungal agent with a broader spectrum of activity and better clinical efficacy than other available antifungals. "( Morris, MI, 2009)
"Posaconazole is a recently approved extended-spectrum triazole available as an oral suspension."( Drew, RH; Perfect, JR; Smith, WJ, 2009)
"As posaconazole is an inhibitor of the isoenzyme CYP3A4, interactions with drugs that are metabolized via this pathway, such as vincristine, can be anticipated."( Cociglio, M; Eiden, C; Hansel-Esteller, S; Hillaire-Buys, D; Margueritte, G; Palenzuela, G; Peyriere, H, 2009)
"Posaconazole is an orally administered triazole with a demonstrated in vitro and in vivo activity against most Zygomycetes that is comparable to that of amphotericin B."( Caira, M; Fianchi, L; Pagano, L; Valentini, CG, 2009)
"Posaconazole is a novel, extended-spectrum triazole oral antifungal agent with documented success in the treatment of patients with invasive mucormycosis."( Mezhir, JJ; Mullane, KM; Pai, RK; Roggin, KK; Satoskar, R; Zarling, J, 2009)
"Posaconazole is a new broad-spectrum antifungal agent that is currently only available as an oral suspension and shows high intra- and inter-individual differences in oral bioavailibility. "( Bolek, R; Engelhardt, M; Jung, M; König, A; Kümmerer, K; Neubauer, W; Trittler, R, 2009)
"Posaconazole is a triazole with broad spectrum of activity against multiple fungi including members of the fungal order Mucorales. "( Baraboutis, IG; Davis, GJ; Howard, DS; Lawson, A; Lekakis, LJ; Monohan, G; Prante, J; Ribes, J; Skoutelis, AT, 2009)
"Posaconazole is an extended-spectrum triazole antifungal agent for the treatment and prophylaxis of invasive fungal infection."( Krishna, G; Moton, A; Wang, Z, 2009)
"Posaconazole is a potent broad-spectrum triazole antifungal. "( Bougnoux, ME; Buzyn, A; Elie, C; Jullien, V; Lanternier, F; Lebeaux, D; Lecuit, M; Lortholary, O; Suarez, F; Viard, JP, 2009)
"Posaconazole is a recently approved lipophilic triazole antifungal agent that exhibits potent and broad-spectrum antifungal activity in vitro and in vivo against most Candida spp., Cryptococcus neoformans, Aspergillus spp., many Zygomycetes, endemic fungi and dermatophytes. "( Clancy, CJ; Derendorf, H; Li, Y; Nguyen, MH; Theuretzbacher, U, 2010)
"Posaconazole is a novel antifungal drug for oral application intended especially for therapy of invasive mycoses. "( Burghardt, S; Krüger, R; Lackner, KJ; Vogelsberger, R; Vogeser, M, 2010)
"Posaconazole (POS) is a new antifungal agent for prevention and therapy of mycoses in immunocompromised patients. "( Bille, J; Decosterd, LA; Lamoth, F; Marchetti, O; Pascual, A; Pesse, B; Rochat, B; Sanglard, D, 2010)
"Posaconazole is a safe and partially effective treatment for CPA. "( Baxter, C; Denning, DW; Felton, TW; Hope, WW; Moore, CB; Roberts, SA, 2010)
"Posaconazole is an extended-spectrum triazole with broad activity against a variety of fungal pathogens, both yeasts and molds."( Langston, AA; Mehta, AK, 2009)
"Posaconazole (PSC) is an antifungal drug recommended as an alternative for the treatment of invasive aspergillosis in patients who are refractory or intolerant to primary antifungal therapy. "( Calvo, E; Guarro, J; Mayayo, E; Pastor, FJ; Rodríguez, MM; Salas, V, 2011)
"Posaconazole is an extended-spectrum azole antifungal that exhibits activity against a broad range of fungal pathogens, including yeasts and moulds. "( Baker, K; Klepser, ME; Valente, C; Zoller, E, 2010)
"Posaconazole (Noxafil®) is an oral, second-generation, extended-spectrum triazole whose approved indications include prophylaxis of invasive fungal disease (IFD) in immunocompromised patients. "( Lyseng-Williamson, KA, 2011)
"Posaconazole is a triazole with anti-Aspergillus activity. "( Goodwin, J; Gregson, L; Hope, WW; Howard, SJ; Lestner, JM; Majithiya, JB; Sharp, A; Slater, J; Warn, PA, 2011)
"Posaconazole is an antifungal agent with a protein binding of 98 to 99%."( Cars, O; Chryssanthou, E; Lignell, A; Löwdin, E; Sjölin, J, 2011)
"Posaconazole is an azole antifungal agent with a broad spectrum of activity and a manageable side-effect profile. "( Campbell, L; Marriott, D; Nguyen, Q; Ray, J; Rudham, S, 2011)
"Posaconazole (PCZ) is an orally administered, extended-spectrum triazole antifungal agent with activity against the Mucorales. "( Aliyu, SH; Enoch, DA; Karas, JA; Lewis, SJ; Sule, O, 2011)
"Posaconazole is a novel agent with strong antifungal activity and low toxicity."( Kuo, CH; Liao, HW; Lin, SW; Wu, UI, 2012)
"Posaconazole (Noxafil®) is an extended-spectrum triazole antifungal agent for prevention and treatment of invasive fungal infections. "( Annaert, P; Augustijns, P; Brouwers, J; Spriet, I; Tack, J; Walravens, J, 2011)
"Posaconazole is a broad-spectrum triazole antifungal drug available for oral administration."( Chen, F; Chen, Y; Hu, J; Huang, X; Jie, J; Liang, Y; Liu, T; Shen, Z; Wang, F; Wang, J; Wang, S; Yu, K; Yu, L, 2012)
"Posaconazole is a cost-saving prophylactic strategy (lower costs and greater efficacy) compared with fluconazole or itraconazole in high-risk neutropenic patients."( Carreras, E; Casado, MA; de la Cámara, R; Grau, S; Jarque, I; Sabater, FJ; Sanz, MA, 2012)
"Posaconazole (PCZ) is a triazole antifungal agent that has broad activity against pathogenic fungi and is increasingly used for prophylaxis and treatment of invasive mould infections (IMIs). "( Hoenigl, M; Krause, R; Raggam, RB; Salzer, HJ; Seeber, K; Sill, H; Strohmeier, AT; Valentin, A; Valentin, T; Wölfler, A; Zollner-Schwetz, I, 2012)
"Posaconazole is an extended-spectrum triazole with proven efficacy as antifungal treatment and prophylaxis. "( Krishna, G; Ma, L; Martinho, M; O'Mara, E; Preston, RA, 2012)
"Posaconazole is a broad-spectrum triazole antifungal available as an oral suspension. "( Ameye, L; Aoun, M; Bourguignon, AM; Bron, D; Cotton, F; Csergö, M; Hites, M; Jacobs, F; Rasson, C; Vaes, M, 2012)
"Posaconazole is a triazole antifungal agent used as adjuvant or salvage therapy for the treatment of zygomycosis, an invasive fungal infection associated with high mortality. "( Egelund, EF; Egelund, TA; Ng, JS; Peloquin, CA; Wassil, SK, 2013)
"Posaconazole (SCH 56592) is a novel broad spectrum triazole antifungal agent that is currently in phase III clinical trials for the treatment of systemic fungal infections. "( Hilbert, MJ; Indelicato, SR; Kim, H; Kumari, P; Laughlin, M; Lim, J; Lin, CC; Nomeir, AA, 2003)
"Posaconazole is a potent broad-spectrum azole antifungal agent in clinical development for the treatment of invasive fungal infections. "( Courtney, R; Laughlin, M; Lim, J; Radwanski, E, 2004)
"Posaconazole is an antifungal with a wide-spectrum of activity against common and emerging fungal pathogens. "( Banfield, C; Courtney, R; Laughlin, M; Lim, J; Richards, W; Wexler, D, 2004)
"Posaconazole is a potent, extended-spectrum, investigational triazole anti-fungal that is highly active in pre-clinical in vitro and in vivo models against a wide array of yeasts and moulds, including Aspergillus, Fusarium and Zygomycetes, which are often refractory to polyenes and older azoles. "( Herbrecht, R, 2004)
"Posaconazole is a potent, broad-spectrum triazole antifungal agent currently in clinical development for the treatment of refractory invasive fungal infections. "( Courtney, R; Flannery, B; Gohdes, M; Krieter, P; Martinho, M; Musick, T, 2004)
"Posaconazole is a triazole antifungal in development for the treatment of invasive fungal infections. "( Courtney, R; Laughlin, M; Marbury, T; Martinho, M; Sansone, A; Smith, W; Statkevich, P; Swan, S, 2005)
"Posaconazole is a potent, extended-spectrum triazole antifungal agent currently in clinical development for the treatment of invasive fungal infections. "( Courtney, R; Ezzet, F; Krishna, G; Laughlin, M; Lim, J; Wexler, D, 2005)
"Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. "( Keating, GM, 2005)
"Posaconazole is a novel lipophilic antifungal triazole that inhibits cytochrome P450-dependent 14-alpha demethylase in the biosynthetic pathway of ergosterol. "( Groll, AH; Walsh, TJ, 2005)
"Posaconazole is a well-tolerated agent that offers a diminished toxicity profile compared with other currently marketed systemic antifungal agents."( Alexander, BD; Dodds Ashley, ES, 2005)
"Posaconazole is a new extended-spectrum azole antifungal that has demonstrated in vitro and in vivo activity against zygomycetes."( Abzug, MJ; Anstead, G; Corcoran, G; Gonzalez, CE; Greenberg, RN; Hare, R; Herbrecht, R; Kryscio, RJ; Langston, A; Marr, KA; Mullane, K; Raad, I; Revankar, SG; Schiller, G; Schuster, M; van Burik, JA; Wingard, JR, 2006)
"Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains)."( Gogate, J; Greaves, W; Isaacs, R; Nieto, L; Northland, R; Sanne, I; Skiest, DJ; Vazquez, JA, 2006)
"Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species."( Corcoran, G; Graybill, JR; Hachem, RY; Hare, R; Herbrecht, R; Kontoyiannis, DP; Raad, II, 2006)
"Posaconazole is a novel extended-spectrum triazole that has favorable in vitro, in vivo and clinical activity against a number of yeasts and moulds. "( Hayes, RN; Krishna, G; Shen, JX, 2007)
"Posaconazole is a novel lipophilic antifungal triazole with potent and broad-spectrum activity against opportunistic, endemic and dermatophytic fungi. "( Groll, AH; Walsh, TJ, 2006)
"Posaconazole is a new antifungal drug used in prophylaxis and therapy of fungal infections in patients with immunodeficiency. "( Arndt, M; Cornely, OA; Müller, C; Queckenberg, C; Theisohn, M, 2006)
"Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species."( Chandrasekar, P; Corcoran, G; Donowitz, GR; Gogate, J; Graybill, R; Greene, RE; Hachem, R; Hadley, S; Hardalo, C; Herbrecht, R; Krishna, G; Langston, A; Louie, A; Patterson, TF; Pedicone, L; Perfect, JR; Raad, I; Ribaud, P; Segal, BH; Stevens, DA; van Burik, JA; Walsh, TJ; White, CS, 2007)
"Posaconazole is an orally available, extended-spectrum triazole antifungal being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections, including zygomycosis."( Hilts, A; Page, RL; Schwiesow, J, 2007)
"Posaconazole is a lipophilic triazole antifungal agent that is structurally similar to itraconazole but has an expended spectrum of activity including yeast, molds, and dimorphic fungi. "( Paugam, A, 2007)
"Posaconazole is a triazole antifungal agent for the treatment and prophylaxis of invasive fungal infections. "( Kantesaria, B; Krishna, G; Mant, T; Parsons, A, 2007)
"Posaconazole (POS) is a newer triazole with activity against yeasts and moulds. "( Falusi, E; Gergely, L; Kardos, G; Majoros, L; McNicholas, PM; Sóczó, G, 2007)
"Posaconazole is a new member of the triazole class of antifungals."( Kwon, DS; Mylonakis, E, 2007)
"Posaconazole is an extended-spectrum triazole antifungal agent for the treatment and prophylaxis of invasive fungal infections. "( Kantesaria, B; Krishna, G; Sansone-Parsons, A, 2007)
"Posaconazole is a new drug in the triazole class that has recently been investigated in pivotal Phase III clinical trials. "( Cornely, OA; Farowski, F; Vehreschild, JJ, 2007)
"Posaconazole is a new extended-spectrum triazole recently approved for the management of oropharyngeal candidiasis (OPC)."( Vazquez, JA, 2007)
"Posaconazole is a new azole antifungal with potent activity against Coccidioides species, the causative agent of coccidioidomycosis."( Catanzaro, A; Cloud, GA; Galgiani, JN; Holloway, M; Johnson, RH; Levine, BE; Lutz, JE; Mirels, LF; Rendon, A; Stevens, DA; Williams, PL, 2007)
"Posaconazole (SCH 56592) is a novel triazole antifungal drug that is marketed in Europe and the United States under the trade name 'Noxafil' for prophylaxis against invasive fungal infections. "( Bartner, P; Bennett, F; Cacciapuoti, A; Ganguly, AK; Girijavallabhan, V; Hare, R; Heimark, L; Hilbert, M; Korfmacher, W; Kumari, P; Lin, CC; Liu, YT; Loebenberg, D; Lovey, R; McNamara, P; Miller, G; Nomeir, AA; Pickett, C; Pike, R; Pramanik, BN; Saksena, A; Veals, J; Wang, H, 2008)
"Posaconazole is a new orally administered triazole antifungal and the first member of this class to have comparable in vitro activity to amphotericin B against most zygomycetes."( Rogers, TR, 2008)
"Posaconazole is a triazole antifungal agent with a spectrum of activity that includes Candida and Cryptococcus species, many molds, and some endemic fungi. "( Deresinski, S; Nagappan, V, 2007)
"Posaconazole is a second-generation triazole antifungal agent with a broad spectrum of activity that includes Aspergillus spp., Candida spp. "( Frampton, JE; Scott, LJ, 2008)
"Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. "( Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA, 2001)

Effects

ExcerptReference
"Posaconazole has a favorable safety and tolerability profile; however, caution is advised when co-administered with agents that are CYP3A4 inhibitors, because their concentration may significantly increase, and their levels should be closely monitored. "( Panagopoulou, P; Roilides, E, 2022)
"Posaconazole has a broad antifungal spectrum for both yeasts and molds, with a manageable safety profile. "( Maertens, J; Spriet, I; Van Daele, R, 2020)
"Posaconazole has an important role in the prophylaxis of invasive fungal infections (IFIs), however oral suspension formulation is associated with variable bioavailability. "( Cha, K; Chae, H; Cho, SY; Kim, HJ; Kim, M; Kim, Y; Kim, YJ; Lee, DG; Lee, S; Yu, H, 2015)
"Posaconazole has an excellent safety profile; to date, serious side effects are rare, even with prolonged use."( Clark, NM; Grim, SA; Lynch, JP, 2015)
"Posaconazole has a broad spectrum of activity, a favorable safety profile and excellent prophylactic activity in adults."( Annaert, P; Augustijns, P; Bica, AM; Colita, A; Mols, R; Peersman, N; Spriet, I; Vanstraelen, K; Vermeersch, P, 2016)
"Posaconazole has a large volume of distribution and distributes well into tissues."( Morris, MI, 2009)
"Posaconazole has a large mean apparent volume of distribution after oral administration (V(d)/F), which is approximately 5-25 L/kg, suggesting extensive extravascular distribution and penetration into intracellular spaces."( Clancy, CJ; Derendorf, H; Li, Y; Nguyen, MH; Theuretzbacher, U, 2010)
"Posaconazole has an important role in the prophylaxis and salvage treatment of invasive fungal infections (IFIs), although poor and variable bioavailability remains an important clinical concern. "( Chen, SC; Dolton, MJ; McLachlan, AJ; Ng, K; Pont, L; Ray, JE, 2012)
"Posaconazole has an exquisitely high affinity to this target."( Hof, H, 2006)
"Posaconazole has a favorable safety and tolerability profile; however, caution is advised when co-administered with agents that are CYP3A4 inhibitors, because their concentration may significantly increase, and their levels should be closely monitored. "( Panagopoulou, P; Roilides, E, 2022)
"Posaconazole has shown promising action in case studies against fungal keratitis."( Chogale, MM; Kakade, P; Khare, P; Patravale, VB, 2022)
"Posaconazole diffusion has been documented in various organs, which contrasts with the scarce data available for the human central nervous system (CNS). "( Barde, F; Billaud, E; Cohen, JF; Goldwirt, L; Horodyckid, C; Jullien, V; Lanternier, F; Lesprit, P; Limousin, L; Lortholary, O, 2019)
"Posaconazole (POS) has shown a trypanocidal effect in vivo and in vitro."( Díaz, ML; Echeverría, LE; Eduardo Nieto, J; González, CI; Hernandez, JCM; López-Romero, LA; Morillo, CA; Ochoa, SAG; Rivera, JD; Rojas, LZ; Suárez, EU, 2020)
"Posaconazole has a broad antifungal spectrum for both yeasts and molds, with a manageable safety profile. "( Maertens, J; Spriet, I; Van Daele, R, 2020)
"Posaconazole has been shown to have positive therapeutic effect; however, posaconazole, LAMB and HBOT are not commonly used in low-income and health-challenged countries."( Chegini, Z; Didehdar, M; Khoshbayan, A; Rajaeih, S; Salehi, M; Shariati, A, 2020)
"Posaconazole has shown trypanocidal activity in murine models."( Blanco-Grau, A; Cabezos, J; Gómez i Prat, J; Molina, I; Pahissa, A; Pou, D; Roure, S; Salvador, F; Sánchez-Montalvá, A; Serre, N; Sulleiro, E; Treviño, B; Valerio, L; Vidal, X, 2014)
"Posaconazole has shown superior clinical efficacy in the prevention of invasive fungal disease (IFD) among neutropenic patients as well as cost-effectiveness in the US healthcare setting vs fluconazole or itraconazole (FLU/ITRA) based on oral suspension formulations of each therapy. "( Marcella, SW; Sung, AH; Xie, Y, 2015)
"Posaconazole (PCZ) has become an attractive alternative to voriconazole (VCZ) in transplant recipients with suspected or proven invasive filamentous fungal infections, causing fewer drug interactions. "( Marr, K; Ostrander, D; Shoham, S, 2015)
"Posaconazole has an important role in the prophylaxis of invasive fungal infections (IFIs), however oral suspension formulation is associated with variable bioavailability. "( Cha, K; Chae, H; Cho, SY; Kim, HJ; Kim, M; Kim, Y; Kim, YJ; Lee, DG; Lee, S; Yu, H, 2015)
"Posaconazole has potent in vitro activity against a broad range of fungi and molds, including Aspergillus, Candida, Cryptococcus, filamentous fungi, and endemic mycoses including coccidioidomycosis, histoplasmosis, and blastomycosis."( Clark, NM; Grim, SA; Lynch, JP, 2015)
"Posaconazole has been proven to be effective for antifungal prophylaxis in adults after hematopoietic stem cell transplantation (HSCT). "( Blume, O; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; Handgretinger, R; Hartmann, U; Heinz, WJ; Klinker, H; Lang, P, 2016)
"Posaconazole has a broad spectrum of activity, a favorable safety profile and excellent prophylactic activity in adults."( Annaert, P; Augustijns, P; Bica, AM; Colita, A; Mols, R; Peersman, N; Spriet, I; Vanstraelen, K; Vermeersch, P, 2016)
"Posaconazole has significant activity against the Mucormycetes. "( John, AO; Manesh, A; Mathew, B; Rupa, V; Varghese, GM; Varghese, L; Zachariah, A, 2016)
"Posaconazole has a large volume of distribution and distributes well into tissues."( Morris, MI, 2009)
"Posaconazole has demonstrated in vitro and in vivo activity against Zygomycetes."( Cornely, OA; Rüping, MJ; Vehreschild, JJ, 2009)
"Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. "( Carreras, E; Casado, MA; de la Cámara, R; Grau, S; Jarque, I; Sabater, FJ; Sanz, MA, 2010)
"Posaconazole has a large mean apparent volume of distribution after oral administration (V(d)/F), which is approximately 5-25 L/kg, suggesting extensive extravascular distribution and penetration into intracellular spaces."( Clancy, CJ; Derendorf, H; Li, Y; Nguyen, MH; Theuretzbacher, U, 2010)
"Posaconazole has been recently approved for primary antifungal prophylaxis in patients with prolonged neutropenia after AML induction chemotherapy and patients with GVHD. "( Arnan, M; Duarte, RF; Encuentra, M; Fernández de Sevilla, A; Gudiol, C; Parody, R; Patiño, B; Peralta, T; Sánchez-Ortega, I, 2011)
"Posaconazole has been shown to have activity against aspergillosis."( Danna, R; Herbrecht, R; Papadopoulos, G; Rajagopalan, S, 2010)
"Posaconazole has pharmacokinetic advantages and low side effect profile, which are very important, especially in the seriously ill population."( Alivanis, P; Aperis, G, 2011)
"Posaconazole prophylaxis has proven highly effective in preventing invasive fungal infections, despite relatively low serum concentrations. "( Al Abdallah, Q; Campoli, P; Fielhaber, JA; Filler, SG; Kristof, AS; Laverdiere, M; Robitaille, R; Sheppard, DC; Solis, NV, 2011)
"Posaconazole has become an important part of the antifungal armamentarium in the prophylaxis and salvage treatment of invasive fungal infections (IFIs). "( Dolton, MJ; Marriott, D; McLachlan, AJ; Ray, JE, 2012)
"Posaconazole has been approved for prophylaxis in HSCT."( Campo, M; Chaftari, AM; Hachem, RY; Jiang, Y; Kassis, C; Prince, RA; Raad, II; Ramos, E; Wang, W, 2012)
"Posaconazole has an important role in the prophylaxis and salvage treatment of invasive fungal infections (IFIs), although poor and variable bioavailability remains an important clinical concern. "( Chen, SC; Dolton, MJ; McLachlan, AJ; Ng, K; Pont, L; Ray, JE, 2012)
"Posaconazole has demonstrated strong antifungal efficacy in Phase II and III clinical trials in immunocompromised patients with oropharyngeal and esophageal candidiasis."( Groll, AH; Walsh, TJ, 2005)
"Posaconazole has shown promising clinical efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies-eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis."( Chemaly, RF; Hachem, RY; Kontoyiannis, DP; Raad, II; Torres, HA, 2005)
"Posaconazole has an exquisitely high affinity to this target."( Hof, H, 2006)
"Posaconazole has been recently approved by the US FDA and other regulatory bodies for the treatment of oropharyngeal candidiasis, and the prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients."( Cornely, OA; Farowski, F; Vehreschild, JJ, 2007)
"Posaconazole has shown in vitro and in vivo activity against a wide variety of fungi, including those that are rare and relatively resistant."( Fung, HB; Schiller, DS, 2007)
"Posaconazole has received US Food and Drug Administration approval for the treatment of oropharyngeal candidiasis, including infections refractory to itraconazole and/or fluconazole."( Deresinski, S; Nagappan, V, 2007)

Actions

ExcerptReference
"Posaconazole was found to inhibit amoeba growth within the first 12 hours of exposure, which was faster than any currently used drug."( Colon, BL; Guy, RK; Kyle, DE; Rice, CA, 2019)
"Posaconazole may also allow a reduction in the dose of liposomal amphotericin B, resulting in better tolerance."( Butler, C; Clarke, P; Habibi, M; Howard, D; Kulendra, K, 2010)

Treatment

ExcerptReference
"Posaconazole treatment was discontinued within 7-14 days in 7/84 patients (8.3%) due to poor oral compliance related to mucositis after chemotherapy."( Akalın, H; Demirdöğen, E; Ener, B; Ersal, T; Kazak, E; Mıstık, R; Özkalemkaş, F; Özkocaman, V; Seyhan, S; Ursavaş, A, 2018)
"Posaconazole salvage treatment was effective antifungal therapy for IFI."( Kim, JH; Williams, K, 2014)
"All posaconazole-treated animals had negative haemocultures at 54 days post infection, whilst 50% of those treated with benznidazole had positive results."( Araújo-Jorge, TC; Calvet, CM; de Castro, SL; Molina, JT; Olivieri, BP; Pereira, MC; Urbina, JA, 2010)
"All posaconazole treatment arms had a significantly (P≤0·012) greater proportion of patients with complete cure at week 48 compared with placebo. "( Ashton, S; Elewski, B; Pollak, R; Rich, P; Schlessinger, J; Tavakkol, A, 2012)
"Posaconazole treatment duration for individual patients ranged from 6 weeks to 34 weeks."( Bradsher, RW; Clark, B; Corcoran, G; Goldman, M; Graham, DR; Graybill, JR; Moore, T; Negroni, R; Pankey, G; Restrepo, A; Tobón, A, 2007)
"ATRA treatment and posaconazole were interrupted. "( Atas, U; Aydin Ersoy, M; Iltar, U; Salim, O; Turkoglu, EB; Yucel, OK, 2022)
"Treatment with posaconazole was well tolerated and induced a complete clinical remission within 3 months that continued for 8 months of follow-up."( Bagot, M; Bouaziz, JD; Casanova, JL; Ibrahim, L; Jachiet, M; Lanternier, F; Puel, A; Rybojad, M, 2015)
"Treatment with posaconazole resulted in complete recovery."( Aguilar, C; Bougnoux, ME; Charlier, C; Denis, B; Lecuit, M; Lortholary, O; Noël, N; Rammaert, B, 2012)
"Treatment with posaconazole led to complete resolution of the lesions."( Arias, CA; Fu, J; Galfione, S; Gordon, RA; Lapolla, WJ; Mays, R; Morrison, LK; Mulanovich, V; Oleske, D; Samathanam, CA; Shrikanth, V; Stielow, JB; Sutton, DA; Thompson, EH; Tyring, S; Verkley, GJ; Wanger, A; Wickes, BL, 2012)
"Treatment with posaconazole was clinically and biologically well tolerated."( Campos, F; Fohrer, C; Herbrecht, R; Letscher-Bru, V; Natarajan-Ame, S; Waller, J; Zamfir, A, 2002)
"Treatment with posaconazole, a new triazole in clinical development for the prophylaxis and treatment of fungal infection, resulted in rapid clinical improvement and successful eradication of F proliferatum."( Herbrecht, R; Kessler, R; Kravanja, C; Letscher-Bru, V; Meyer, MH; Waller, J, 2004)
"Treatment with posaconazole resulted in progressive clinical and radiologic improvement."( Al-Abdely, HM; Al-Tawfiq, JA; Alkhunaizi, AM; Hassounah, M; Rinaldi, MG; Sutton, DA, 2005)
"Treatment with posaconazole led to a complete response in 7 of 8 patients with CGD with invasive mold infections (7 proven cases and 1 possible case) after failure or intolerance of treatment with standard antifungal agents."( Anderson, VL; Barnhart, LA; Holland, SM; Malech, HL; Segal, BH; Walsh, TJ, 2005)
"Treatment with posaconazole resulted in clinical improvement and the patient had only intermittently positive fungal cultures for 6 weeks."( Anstead, GM; Graybill, JR; Martinez, M, 2006)

Roles (1)

RoleDescription
trypanocidal drugA drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
N-arylpiperazine
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
oxolanesAny oxacycle having an oxolane (tetrahydrofuran) skeleton.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
conazole antifungal drugAny conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans.
triazole antifungal drugAny triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.45050.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
Fumarate hydrataseHomo sapiens (human)Potency22.38720.00308.794948.0869AID1347053
SMAD family member 3Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency0.74990.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency0.24920.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.14020.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency5.95570.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency9.83740.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency29.84930.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.20780.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.52050.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.72550.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.67100.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.73360.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency10.59090.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.22850.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency10.87970.01238.964839.8107AID1645842
polyproteinZika virusPotency22.38720.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.48890.001019.414170.9645AID743191
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency28.38160.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency25.15670.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency10.59010.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency8.41270.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency10.87970.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.87970.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency8.41270.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency12.45620.009610.525035.4813AID1479145; AID1479148
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.87970.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency5.30800.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency5.30800.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.87970.01238.964839.8107AID1645842
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.01120.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency14.12860.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency6.00810.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency6.00810.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)8.10000.11007.190310.0000AID1473738
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)IC50 (µMol)0.92100.00200.98184.7300AID1487223; AID1487224
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.24580.00011.753610.0000AID1180169; AID1487215; AID1557089; AID394828; AID480595
AromataseHomo sapiens (human)IC50 (µMol)8.40000.00001.290410.0000AID1487225
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)58.10000.00002.800510.0000AID1487219; AID1487220
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)IC50 (µMol)0.31000.00050.29022.7800AID1487221
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)IC50 (µMol)0.02100.00010.27383.5000AID1487222
Sterol 14-alpha demethylaseTrypanosoma cruzi strain CL BrenerIC50 (µMol)0.46400.00101.707010.0000AID1383443; AID1882559
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)6.00000.00401.966610.0000AID1873196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sterol 14-alpha-demethylaseAspergillus flavus AF70Kd0.13100.05600.09350.1310AID1498549
14-alpha sterol demethylase Aspergillus nigerKd0.13100.05600.09350.1310AID1498549
Lanosterol 14-alpha demethylaseCandida albicans SC5314Kd0.08100.04500.09700.1650AID1498548
Sterol 14-alpha demethylaseAspergillus fumigatus Af293Kd2.69001.01003.03004.7900AID575747
Sterol 14-alpha demethylaseTrypanosoma cruzi strain CL BrenerKd0.03900.01800.42852.3000AID1546308; AID728147
14-alpha sterol demethylase Aspergillus fumigatusKd0.07300.03100.84824.0300AID575755
14-alpha sterol demethylase Aspergillus fumigatusKd0.13100.05600.09350.1310AID1498549
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (170)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
immune responseCytochrome P450 11B1, mitochondrialHomo sapiens (human)
regulation of blood pressureCytochrome P450 11B1, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucose homeostasisCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
regulation of blood volume by renal aldosteroneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
renal water homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mineralocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
potassium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sodium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (84)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
steroid hydroxylase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
mitochondrionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2347)

Assay IDTitleYearJournalArticle
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID563830Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID582241Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582250Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575361Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522448Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564622Antimicrobial activity against Aspergillus fumigatus isolate 45 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564615Antimicrobial activity against Aspergillus fumigatus isolate 38 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID598304Antimicrobial activity against Candida albicans ATCC 90028 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID522518Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564403Antimicrobial activity against Aspergillus fumigatus isolate 35 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID405110Antimicrobial activity against Absidia sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID531234Antifungal activity against Candida albicans after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID564611Antimicrobial activity against Aspergillus fumigatus isolate 34 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572681Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369156Antifungal activity against Absidia strain 17 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID369386Antimicrobial activity against Rhodotorula mucilaginosa isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID563368Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID405106Antimicrobial activity against Rhizopus microsporus var. microsporus assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID549317Antifungal activity against Cunninghamella bertholletiae after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID563149Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID524013Cmax in high fat fed healthy human skin at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID572474Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575222Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID567429Antifungal activity against Dipodascus capitatus after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID563141Antifungal activity against Scedosporium aurantiacum CBS 116910 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID557608Antifungal activity against amphotericin B-resistant Aspergillus terreus by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID533026Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on 16HBE cell after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID563359Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID524010Cmax in high fat fed healthy human plasma at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID555613Antimicrobial activity against Aspergillus sclerotiorum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID518593Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K and C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID575348Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522452Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID580601Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 7 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID532142Antifungal activity against Rhizomucor species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID565397Antifungal activity against Rhizopus microsporus FMR 3542 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID564395Antimicrobial activity against Aspergillus fumigatus isolate 27 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID519469Antimicrobial activity against Cryptococcus albidus by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID555574Antimicrobial activity against Candida rugosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1309051Antifungal activity against Candida albicans ATCC MYA-1237 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID531215Antimicrobial activity against Cunninghamella bertholletiae hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID532329Antifungal activity against Geotrichum candidum by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID498014Antifungal activity against Candida tropicalis FMR 10240 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID575749Antimicrobial activity against sterol 14-alpha demethylase isoenzyme A-deficient Aspergillus fumigatus CEA102010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID576481Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID555624Antimicrobial activity against Scopulariopsis brevicaulis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563405Antifungal activity against Aspergillus tubingensis isolate CM-4003 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID580660Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post 2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID557617Antifungal activity against amphotericin B-resistant Aspergillus terreus hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575199Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 80 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID584407Antifungal activity against 7 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID572450Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID541605Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID525596Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID762755Cytotoxicity against Balb-c mouse 3T3 cells assessed as cell death at 500 umol/L by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.
AID432799Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID521569Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed survival of the mouse at 40 mg/kg, po QD2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID555594Antimicrobial activity against Trichosporon dermatis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID498000Antifungal activity against Candida tropicalis FMR 8896 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID522444Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425367Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.25 ug/ml caspofungin measured at 0.5 ug/ml after 48 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID563343Antifungal activity against inoculum of 1x10'4 conidia/ml Fusarium solani isolate 95-2478 after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID564649Antimicrobial activity against Aspergillus fumigatus isolate 22 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1383457Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.17 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID508575Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1419500Antifungal activity against Candida glabrata ATCC 2001 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID583000Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene in reverse orientation without doxycycline-regulatable promoter by broth dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID557625Fungicidal activity against Aspergillus fumigatus2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID425781Antifungal activity against Candida albicans GDH2346 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID567432Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID524027T>MIC90 in fungus infected patient skin at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID532148Antifungal activity against Mucor hiemalis2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522564Drug level in sRhizopus oryzae infected mouse serum at 40 mg/kg2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID531469Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring G54V, G54E, G54R and G54W mutation in cyp51A gene after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID525544Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID572440Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522534Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID532162Antifungal activity against Candida glabrata by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID516343Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as abnormalities in nuclear DNA at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID575229Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID432800Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID498164Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID541577Tmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID555579Antimicrobial activity against Candida intermedia by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID524011Cmax in high fat fed healthy human plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID580591Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID563352Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID564178Antimicrobial activity against Aspergillus fumigatus isolate 19 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1557088Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID525414Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 1 mg/kg/day, ip administered 24 hrs pos2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID432797Antifungal activity against Candida kefyr ATCC 46764 at 3 ug/ml after 14 to 18 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID369361Antimicrobial activity against Candida parapsilosis blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID572211Cmax in fasted healthy human plasma at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID580664Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivated parasite at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post inf2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID565551Antifungal activity against Rhizopus microsporus IHEM 15210 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID563834Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID567448Antifungal activity against Trichosporon sp. after 4 days by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID572689Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID567446Antifungal activity against Trichosporon mucoides assessed as percent susceptible/dose-dependent isolates after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID480593Inhibition of rat recombinant PFT expressed in insect Sf9 cells by scintillation proximity assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
AID563806Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID576478Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID673467Plasma concentration in Swiss mouse at 20 mg/kg, po after 8 hrs2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID525406Antifungal activity against Candida glabrata isolate 4370 after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID561922Terminal half life in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID1265842Antifungal activity against azole-resistant Candida albicans MYA-1003 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran-22015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID541588AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID584387Antifungal activity against 36 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID557809Drug level in patient serum with chronic graft-versus-host disease by HPLC analysis2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
AID582244Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID555586Antimicrobial activity against Saccharomyces cerevisiae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID567425Antifungal activity against Rhodotorula mucilaginosa after 7 days by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID567443Antifungal activity against Trichosporon asahii after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID535619Antifungal activity against Candida tropicalis T19 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID498002Antifungal activity against Candida tropicalis FMR 8898 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID581877Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx receiving antifungal drug after 23 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID728147Binding affinity to Trypanosoma cruzi recombinant full length CYP51 by spectrophotometric analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID564168Antimicrobial activity against Aspergillus fumigatus isolate 9 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1487221Inhibition of CYP11B1 in human hepatocyte microsomes using deoxycortisol substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID498173Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID541595Ratio of AUC (0 to 24 hrs) in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID432801Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID1265818Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID563394Antifungal activity against Aspergillus niger isolate CM-3641 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID673471Plasma concentration in Swiss mouse at 50 mg/kg, po after 24 hrs2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID547618Antitrypanosomal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID563402Antifungal activity against Aspergillus niger isolate CM-5095 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID522451Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563139Antifungal activity against Scedosporium apiospermum CBS 117407 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID1419546Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-908192017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID576468Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID567444Antifungal activity against Trichosporon asahii after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID572429Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576260T>MIC90 for Aspergillus spp. infected lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID532144Antifungal activity against Absidia species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564405Antimicrobial activity against Aspergillus fumigatus isolate 37 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564390Antimicrobial activity against Aspergillus fumigatus isolate 22 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID555611Antimicrobial activity against Aspergillus ustus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID567440Antifungal activity against Trichosporon jirovecii after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID322856Antifungal activity against azole-resistant Aspergillus fumigatus V28/78-CM3275 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID572657Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572446Apparent total body clearance in fasted healthy human at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369388Antimicrobial activity against Candida africana isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID555581Antimicrobial activity against Candida metapsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID576440Cmax in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID546077Antifungal activity against Candida pelliculosa isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID555617Antimicrobial activity against Fusarium solani by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID547564Antifungal activity against Candida tropicalis after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID564599Antimicrobial activity against Aspergillus fumigatus isolate 22 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID565558Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 20 mg/kg, po BID for 5 days measured after 3 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID563381Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID1419495Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2876 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID535684Antibacterial activity against Cryptococcus gattii after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID369357Antimicrobial activity against Candida guilliermondii isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID555597Antimicrobial activity against Ustilago spp by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID522435Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID285222Antimicrobial activity against Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID525593Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID555585Antimicrobial activity against Dipodascus capitatus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID518607Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID572662Toxicity in healthy human assessed as adverse events at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575754Antimicrobial activity against Aspergillus fumigatus AF2932010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID525543Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID575358Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522493Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID438901Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in mouse 3T3 cells2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.
AID581892Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525541Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID559691Antimicrobial activity against Rhizopus oryzae after 24 hrs by broth microdilution checkerboard procedure2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID560251Antifungal activity against Candida krusei FMR9728 by M27-A2 broth dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID1487219Inhibition of CYP2C9 in human hepatocyte microsomes using diclofenac substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID522467Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522422Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID581903Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525142Antifungal activity against Fusarium thapsinum by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1898161Antifungal activity against Candida albicans 162
AID555807Antimicrobial activity against Rhizopus oryzae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1898177Antifungal activity against Candida auris BS12372
AID522473Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID557622Antifungal activity against Rhizopus hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID581895Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563392Antifungal activity against Aspergillus niger isolate CM-3586 obtained from catheter of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID521571Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed as pulmonary fungal burden at 40 mg/kg, po QD2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID557615Antifungal activity against Cunninghamella by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID279070AUC (0-12 hrs) in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID1487212Inhibition of CYP51 in Trichophyton rubrum assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID525139Antifungal activity against Fusarium moniliforme clade 1 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID584601Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID565561Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 40 mg/kg, po QD measured after 24 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID532041Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID555572Antimicrobial activity against Candida lusitaniae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564837Antimicrobial activity against Aspergillus fumigatus isolate 46 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID598230Antimicrobial activity against Candida tropicalis isolate 11 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID730407Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as decrease in blood parasitemia level at 100 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post inf2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID425780Antifungal activity against Candida albicans M61 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID565568Antifungal activity against Rhizopus microsporus UTHSC 01-983 infected in OF1 mouse assessed as reduction in fungal load in brain at 20 mg/kg, QD for 5 days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID555799Antimicrobial activity against Exophiala dermatitidis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID522454Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID545329Antimicrobial activity against Candida albicans isolate R after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID564632Antimicrobial activity against Aspergillus fumigatus isolate 5 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522497Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID555591Antimicrobial activity against Rhodotorula mucilaginosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID498175Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID576479Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1419501Antifungal activity against Candida krusei ATCC 6258 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID535689Antibacterial activity against Cryptococcus gattii serotype B after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID279201Antifungal activity against Aspergillus niger hyphae2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID576459Ratio of AUC (0 to 24 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID567333Antifungal activity against Saccharomyces cerevisiae after 5 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID425377Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured at 15 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID575225Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID498158Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID522704Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID542726Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 30 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID522528Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572427Tmax in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID673493Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 50 mg/kg, po administered 8 days after post infection qd for 5 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID508314Antifungal activity against Aspergillus fumigatus isolate V59-73 harboring G54W mutation in Cyp51A protein by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1689824Antifungal activity against Aspergillus fumigatus ASFU77 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID564379Antimicrobial activity against Aspergillus fumigatus isolate 11 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID278439Increase in survival of Absidia corymbifera 4535 infected neutropenic CD1 mouse at 20 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID572439Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572475Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID394826Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes expressing beta-galactosidase in mouse 3T3 fibroblast after 7 days by alamar blue assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Rational modification of a candidate cancer drug for use against Chagas disease.
AID519465Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID564638Antimicrobial activity against Aspergillus fumigatus isolate 11 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID498177Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID531232Antimicrobial activity against Cunninghamella bertholletiae hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID1383453Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.00165 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID522486Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564431Antimicrobial activity against Aspergillus fumigatus isolate 13 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID521969Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID1180169Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Design and optimization of highly-selective fungal CYP51 inhibitors.
AID259825Antiprotozoal activity against Trypanosoma cruzi amastigotes2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
AID520620Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID521801Antifungal activity against fluconazole-resistant Candida glabrata isolate 4198 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs post infection measu2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID576453AUC (0 to 12 hrs) in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522477Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID565555Antifungal activity against Rhizopus microsporus UTHSC 07-371 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1898174Antifungal activity against Candida krusei 467
AID730405Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as increase in host survival at 50 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infection meas2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID531231Antimicrobial activity against Syncephalastrum racemosum hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID598297Antimicrobial activity against Candida parapsilosis isolate 39 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID532145Antifungal activity against Rhizopus microsporus var. oligosporus2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID547566Antifungal activity against Candida parapsilosis after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID555618Antimicrobial activity against Fusarium proliferatum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1498551Potency index, ratio of VNI Kd(app) to compound Kd(app) for Aspergillus fumigatus CYP512018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID1419552Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-10032017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID563374Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID564161Antimicrobial activity against Aspergillus fumigatus isolate 2 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID581861Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID673463Inhibition of CYP3A4/6 in human liver microsomes at 20 uM2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID283329Antifungal activity against Absidia spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID542724Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 60 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID563145Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID557620Antifungal activity against Rhizomucor hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575228Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID560480Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID555813Antimicrobial activity against Exophiala jeanselmei by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID598225Antimicrobial activity against Candida albicans isolate 48 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID582220Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID546068Antifungal activity against Candida albicans isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID567436Antifungal activity against Trichosporon mucoides after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID1534782Intrinsic clearance in human liver microsomes at 1 uM by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID279061Half life in >=65 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID564523Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID508325Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1062796Plasma concentration in Swiss mouse at 20 mg/kg, po after 0.5 hrs by LC/MS analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID563365Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID535685Antibacterial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID564406Antimicrobial activity against Aspergillus fumigatus isolate 38 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575190Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID509115Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID547565Antifungal activity against Candida glabrata after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID518403Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220I mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID557607Antifungal activity against Aspergillus fumigatus by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1557078Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1484687Leishmanicidal activity against Leishmania panamensis L334 promastigotes forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID1419550Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC 12372017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564423Antimicrobial activity against Aspergillus fumigatus isolate 5 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572459Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID518605Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, E427K, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID542727Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 60 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID522407Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1557080Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID582235Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582231Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532348Antifungal activity against Fusarium oxysporum by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID279075AUC (0-12 hrs) in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID564197Antimicrobial activity against Aspergillus fumigatus isolate 38 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID278446Reduction of number of infection foci in Rhizopus oryzae 4570 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID576443Ratio of AUC (0 to 12 hrs) in lung transplant recipient alveolar cell to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID582223Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID541597Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID535690Antibacterial activity against Cryptococcus gattii serotype C after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID572470Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563353Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID519431Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4387 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID369379Antimicrobial activity against Candida fermentati isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID322865Antifungal activity against azole-resistant Aspergillus fumigatus V49/77-CM4050 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID322858Antifungal activity against azole-resistant Aspergillus fumigatus V34/76-CM3277 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID572458Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1706420Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi Tulahuen strain C2C4 infected in Swiss mouse assessed as reduction in parasitemia at 20 mg/kg, po qd administered for 20 days starting from day 8 post infection follow2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1557075Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1817557Antifungal activity against Aspergillus fumigatus ATCC 204305 assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID1557084Antifungal activity against Candida dubliniensis T-99 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID498170Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532349Antifungal activity against Sporothrix schenckii by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID576487Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1419493Antifungal activity against Candida albicans ATCC 10231 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID369389Antimicrobial activity against Trichosporon isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID584587Antifungal activity against 111 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564839Antimicrobial activity against Aspergillus fumigatus isolate 48 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584396Antifungal activity against 13 days cultured Candida krusei isolated from invasive fungal infected subject blood after 12 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID560475Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment 2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID561920Apparent oral clearance in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564408Antimicrobial activity against Aspergillus fumigatus isolate 40 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572460Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID425800Antifungal activity against Candida parapsilosis PA/71 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm after 24 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID557614Antifungal activity against Mucor by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID598228Antimicrobial activity against Candida krusei isolate 48 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID555812Antimicrobial activity against Saksenaea vasiformis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID581873Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool receiving antifungal drug after 22 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID518609Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, E427K, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID519428Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3599 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID432795Antifungal activity against Candida kefyr ATCC 46764 at 0.5 ug/ml after 14 to 18 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID563416Antifungal activity against Aspergillus niger isolate CM-4262 after 48 hrs by EUCAST broth dilution method Ophthalmic2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID522550Antifungal activity against drug-susceptible Rhizopus oryzae infected in OF1 mouse assessed as mouse survival at 30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522525Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1265817Antifungal activity against azole-resistant Candida albicans ATCC 90819 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID522494Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID524738Antimicrobial activity against Fusarium proliferatum after 48 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID1419574Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus terreus ATCC MYA-36332017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID279072Apparent total clearance in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID541611Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID557621Antifungal activity against Absidia hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564202Antimicrobial activity against Aspergillus fumigatus isolate 43 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1898226Cytotoxicity against human Caco-2 cells assessed as cell viability at 64 ug/ml incubated for 24 hrs by CCK-8 assay
AID567434Antifungal activity against Saccharomyces cerevisiae after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID405109Antimicrobial activity against Rhizomucor sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID285223Antimicrobial activity against Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID581883Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1587054Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 12.5 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and m2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID522544Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID509392Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse body weight at 20 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID1419573Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus terreus ATCC MYA-36332017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID584400Antifungal activity against 35 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 165 days after 138 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581866Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405097Antimicrobial activity against Absidia sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID405103Antimicrobial activity against Rhizopus sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID598298Antimicrobial activity against Candida parapsilosis isolate 44 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID1898175Antifungal activity against Candida glabrata ATCC2001
AID525597Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID557609Antifungal activity against Aspergillus flavus by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575353Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID572688Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID518612Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A E130D mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID564167Antimicrobial activity against Aspergillus fumigatus isolate 8 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564669Antimicrobial activity against Aspergillus fumigatus isolate 42 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283336Antifungal activity against Rhizopus spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID555584Antimicrobial activity against Candida zeylanoides by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID522442Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572690Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD and diarrhea2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563349Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID673486Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase of host survival at 2 mg/kg, po administered 8 days after post infection qd for 5 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID565400Antifungal activity against Rhizopus microsporus IHEM 13267 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID547568Antifungal activity against Candida dubliniensis after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID531228Antimicrobial activity against Rhizopus spp. hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID1595044Antifungal activity against Cryptococcus neoformans LA314 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID576495AUC (0 to 12 hrs) in healthy human epithelial lining fluid at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID519466Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID564617Antimicrobial activity against Aspergillus fumigatus isolate 40 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572477Apparent volume of distribution in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522553Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522543Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425163Antifungal activity against Candida glabrata isolate 4205 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID564173Antimicrobial activity against Aspergillus fumigatus isolate 14 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522479Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID519429Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4330 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID531235Antifungal activity against Candida glabrata after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID531222Antimicrobial activity against Rhizopus spp. conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID567437Antifungal activity against Trichosporon inkin after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID532129Antifungal activity against Candida lusitaniae2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID572691Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532319Antifungal activity against Candida parapsilosis by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1184056Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigotes expressing green florescent protein infected in cardiomyocytes assessed as inhibition of parasite growth at 10 nM after 72 hrs by fluorescence microscopy2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
AID563361Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID425372Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured at 5 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID598293Antimicrobial activity against Candida glabrata isolate 32 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID1062774Toxicity in Swiss mouse at 20 mg/kg, po2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID555616Antimicrobial activity against Penicillium spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563344Antifungal activity against inoculum of 1x10'4 conidia/ml Fusarium solani isolate 95-2478 after 48 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID545663Cellular uptake in PMNC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID546080Antifungal activity against Candida pulcherrima isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID567426Antifungal activity against Rhodotorula mucilaginosa after 7 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID1309058Antifungal activity against Aspergillus terreus ATCC MYA3633 after 48 hrs by CLSI M38-A2 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1309053Antifungal activity against Candida glabrata ATCC 2001 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID584399Antifungal activity against 59 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID565567Antifungal activity against Rhizopus microsporus IHEM 4770 infected in OF1 mouse assessed as reduction in fungal load in brain at 20 mg/kg, QD for 5 days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID555589Antimicrobial activity against Cryptococcus neoformans var. neoformans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID572483Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1706433Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID555593Antimicrobial activity against Trichosporon ovoides by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID581865Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth receiving antifungal drug after 115 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563366Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID582254Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID283339Antifungal activity against Syncephalastrum spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID572428Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369163Antifungal activity against Mucor strain 43 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID572672Toxicity in healthy human assessed as dizziness at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID555567Antimicrobial activity against Candida parapsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID572454Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564207Antimicrobial activity against Aspergillus fumigatus isolate 48 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575355Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID425368Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.015 ug/ml caspofungin measured at 4 ug/ml measured after 48 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID522515Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID535620Antifungal activity against Candida tropicalis T26 blood stream isolate harboring Fks1p LLTLSLRDP mutant protein2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID555615Antimicrobial activity against Aspergillus spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555811Antimicrobial activity against Rhizomucor spp.by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID545151Antimicrobial activity against Candida albicans isolate R after 48 hrs by EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID564373Antimicrobial activity against Aspergillus fumigatus isolate 5 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1265821Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID278469Percentage of infected spleen in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID1595050Antifungal activity against Aspergillus niger assessed as reduction in fungal cell growth incubated for 72 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID546073Antifungal activity against Candida tropicalis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID563415Antifungal activity against Aspergillus foetidus isolate CM-4002 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID555605Antimicrobial activity against Aspergillus flavus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID561911AUClast in healthy human at 400 mg/kg, po by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID520618Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID572679Toxicity in healthy human assessed as asthenia at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564432Antimicrobial activity against Aspergillus fumigatus isolate 14 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID555612Antimicrobial activity against Aspergillus niveus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID565566Antifungal activity against Rhizopus microsporus IHEM 4770 infected in OF1 mouse assessed as reduction in fungal load in brain at 40 mg/kg, QD for 5 days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1062803Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as cure rate at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of immunosup2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID522556Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564380Antimicrobial activity against Aspergillus fumigatus isolate 12 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522502Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID547546Antifungal activity against Cryptococcus gattii after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID557632Fungicidal activity against Mucor2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID498149Antifungal activity against Candida tropicalis FMR 10236 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID545668Ratio of intracellular to extracellular cellular uptake in RBC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID575197Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 40 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID521792Fungistatic activity against Candida glabrata isolate 4293 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID278463Percentage of infected brain in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID283330Antifungal activity against Cunninghamella spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID522458Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID730420Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI extracellular trypomastigotes forms transfected with beta-galactosidase gene infected in rat L6 cells assessed as inhibition of parasite growth after 4 days2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID405108Antimicrobial activity against Mucor circinelloides assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID565564Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 20 mg/kg, po BID for 5 days measured after 24 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID278438Increase in survival of Rhizopus oryzae 4570 infected neutropenic CD1 mouse at 80 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID564614Antimicrobial activity against Aspergillus fumigatus isolate 37 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID581880Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth after 124 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID369362Antimicrobial activity against Candida tropicalis blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID369384Antimicrobial activity against Candida palmioleophila isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID555569Antimicrobial activity against Candida glabrata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID572215Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID555808Antimicrobial activity against Mucor spp.by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564206Antimicrobial activity against Aspergillus fumigatus isolate 47 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283331Antifungal activity against Cunninghamella spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID1534783Kinetic solubility of compound in pH 7.4 PBS by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID572452Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1498549Binding affinity to Aspergillus fumigatus CYP51 by spectral titration method2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID522468Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541601Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522478Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564201Antimicrobial activity against Aspergillus fumigatus isolate 42 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID425371Antifungal activity against Candida glabrata isolate 4293 at 15 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID584404Antifungal activity against 3 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID518597Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q88H mutant gene and by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID564662Antimicrobial activity against Aspergillus fumigatus isolate 35 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID425788Antifungal activity against Candida parapsilosis PA/71 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID563403Antifungal activity against Aspergillus tubingensis isolate CM-3123 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID508587Antifungal activity against Aspergillus fumigatus isolate V59-73 harboring G54W mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID555622Antimicrobial activity against Paecilomyces lilacinus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563414Antifungal activity against Aspergillus tubingensis isolate CM-4001 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID582218Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545666Ratio of intracellular to extracellular cellular uptake in PBMC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID518613Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A L252L mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID575071Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 80 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1171001Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as increase in lanosterol level at 100 nM incubated for 24 hrs by GC-MS method2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID555568Antimicrobial activity against Candida tropicalis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID509395Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 40 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID529667Antimicrobial activity against Paecilomyces variotii by microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Susceptibility testing and molecular classification of Paecilomyces spp.
AID576463Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID557616Antifungal activity against Aspergillus fumigatus hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564160Antimicrobial activity against Aspergillus fumigatus isolate 1 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID279197Antifungal activity against Aspergillus niger conidia2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1265841Antifungal activity against azole-resistant Candida albicans MYA-1237 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran-22015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID531233Antifungal activity against Candida tropicalis after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID581889Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth receiving antifungal drug after 109 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522511Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563387Antifungal activity against Aspergillus niger isolate CM-3236 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID598299Antimicrobial activity against Candida parapsilosis isolate 19 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID549321Antifungal activity against Rhizomucor pusillus after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID519445Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-2270 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID572677Toxicity in healthy human assessed as asthenia at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID541617Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID572435Tmax in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563398Antifungal activity against Aspergillus tubingensis isolate CM-4264 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID555590Antimicrobial activity against Trichosporon asahii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532046Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID498006Antifungal activity against Candida tropicalis FMR 10232 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID581901Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID509107Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID369371Antimicrobial activity against Candida parapsilosis isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID522474Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522434Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID555601Antimicrobial activity against Trichosporon mycotoxinivorans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID369153Antifungal activity against Rhizopus strain 3 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID582242Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID509394Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 20 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID563794Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID518401Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G138C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1557085Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID322857Antifungal activity against azole-resistant Aspergillus fumigatus V34/75-CM3276 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1265816Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID582216Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID519549Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-2280 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID581907Ratio of CDR2 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to CDR2 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564619Antimicrobial activity against Aspergillus fumigatus isolate 42 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584600Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID369360Antimicrobial activity against Candida glabrata blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID498193Drug level in patient undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID547353Antifungal activity against Candida lusitaniae after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID567431Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID369152Antifungal activity against Rhizopus strain 0 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID1265839Antifungal activity against azole-resistant Candida albicans ATCC 90819 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID532341Antifungal activity against Mucor species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID567439Antifungal activity against Trichosporon jirovecii after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID545667Ratio of intracellular to extracellular cellular uptake in PMNC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID541596Ratio of AUC (0 to 24 hrs) in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID576448Tmax in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522519Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541586Tmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID563364Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID582233Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581911Ratio of CDR2 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to CDR2 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID584408Antifungal activity against 10 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563380Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID563805Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID541616Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID369376Antimicrobial activity against Candida guilliermondii isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID547620Antitrypanosomal activity against Trypanosoma cruzi PSD-I infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID564656Antimicrobial activity against Aspergillus fumigatus isolate 29 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1898169Antifungal activity against Candida tropicalis 112936
AID498182Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID557628Fungicidal activity against Aspergillus niger2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID535686Antibacterial activity against Cryptococcus neoformans serotype A after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID555602Antimicrobial activity against Trichosporon spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1689823Antifungal activity against Aspergillus fumigatus ASFU7 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID564640Antimicrobial activity against Aspergillus fumigatus isolate 13 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564515Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID518615Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID498005Antifungal activity against Candida tropicalis FMR 10231 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564506Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID278457Reduction of infection foci size in Absidia corymbifera 4535 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID572653Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID555599Antimicrobial activity against Cryptococcus laurentii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID516322Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as abnormalities in nuclear DNA at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID575204Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID259830Disruption of calcium homeostasis in Trypanosoma cruzi2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
AID582253Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532140Antifungal activity against Aspergillus flavus2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID547619Antitrypanosomal activity against Trypanosoma cruzi Sylvio-X10/7 infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1487217Inhibition of CYP51 in Cryptococcus neoformans assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID498145Antifungal activity against Candida tropicalis FMR 10232 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID516337Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as reduction in episterol content at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID564628Antimicrobial activity against Aspergillus fumigatus isolate 1 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1898178Antifungal activity against Candida auris 887
AID564600Antimicrobial activity against Aspergillus fumigatus isolate 23 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563377Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID279054Tmax in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID555570Antimicrobial activity against Candida krusei by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID541604Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID555603Antimicrobial activity against Aspergillus fumigatus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID369392Antimicrobial activity against Trichosporon inkin isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1419566Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida albicans ATCC 102312017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID369367Antimicrobial activity against Candida guilliermondii blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID521568Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed survival of the mouse at 40 mg/kg, po QD2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID1557095Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID572442Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID581867Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1706436Inhibition of Trypanosoma cruzi Tulahuen C4 strain CYP51 expressed in Escherichia coli by fluorescence based assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID532340Antifungal activity against Mucor hiemalis by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID572466Half life in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID541875Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID576456Ratio of Cmax in lung transplant recipient plasma after 12 hrs to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID580662Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of low level of circulating parasites at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 25 days p2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID542418Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID498165Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564027Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID531219Antimicrobial activity against Absidia corymbifera hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID581888Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth after 109 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531226Antimicrobial activity against Cunninghamella bertholletiae conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID584596Antifungal activity against 177 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID498167Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID1817568Antifungal activity against pan-azole resistant Aspergillus fumigatus SR47013 harbouring Cyp51A Y121F mutant assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID555600Antimicrobial activity against Trichosporon domesticum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555810Antimicrobial activity against Rhizopus microsporus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1419505Antifungal activity against Aspergillus terreus ATCC MYA-3633 incubated for 48 hrs by CLSI M38-A2 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID531237Antifungal activity against Candida guilliermondii after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID375464Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected BALB/c mouse model of acute Chagas disease assessed as parasitemia burden in blood at 20 mg/kg, po administered twice daily 7 days after parasite infection for 21 days measured 100 days2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.
AID572670Toxicity in healthy human assessed as dizziness at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID480595Inhibition of human recombinant CYP3A42010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
AID531210Antimicrobial activity against Rhizopus oryzae conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID561916AUC (0 to infinity) in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564419Antimicrobial activity against Aspergillus fumigatus isolate 1 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID519447Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3914 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID369390Antimicrobial activity against Candida famata isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1595046Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID518614Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A S400I mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID564838Antimicrobial activity against Aspergillus fumigatus isolate 47 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1684560Antifungal activity against Mucor circinelloides ATCC 265792021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID508331Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID572424AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID541896Cardiotoxicity in healthy human assessed as corrected QT intervals at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID535618Antifungal activity against Candida tropicalis T3 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID563393Antifungal activity against Aspergillus niger isolate CM-3636 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID557612Antifungal activity against Absidia by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1383458Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.5 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1898167Antifungal activity against Candida parapsilosis 90018
AID555627Antimicrobial activity against Hormographiella aspergillata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563363Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID524026T>MIC90 in fungus infected patient skin at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID564601Antimicrobial activity against Aspergillus fumigatus isolate 24 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564438Antimicrobial activity against Aspergillus fumigatus isolate 20 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564424Antimicrobial activity against Aspergillus fumigatus isolate 6 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID369349Antimicrobial activity against Candida albicans isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID524030Ratio of AUC in skin to plasma in healthy human at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID567433Antifungal activity against Saccharomyces cerevisiae after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID581898Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth after 116 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID567441Antifungal activity against Trichosporon domesticum after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID567442Antifungal activity against Trichosporon domesticum after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID563370Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID524029Toxicity in healthy human assessed as treatment related treatment-emergent adverse events at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID564381Antimicrobial activity against Aspergillus fumigatus isolate 13 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563144Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID522520Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID581868Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool after 26 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID555583Antimicrobial activity against Candida pintolopesii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1882559Inhibition of recombinant Trypanosoma cruzi Tulahuen strain CYP51 expressed in Escherichia coli JM1092022Bioorganic & medicinal chemistry, 03-15, Volume: 58Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.
AID555805Antimicrobial activity against Lecythophora hoffmannii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID509100Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in OF1 mouse assessed as increase in mouse survival at 20 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID576465Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID279069Tmax in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID279043Cmax in >=65 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID560468Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID498357Apparent oral clearance in patient with diarrhea undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID532131Antifungal activity against Candida guilliermondii2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564166Antimicrobial activity against Aspergillus fumigatus isolate 7 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID518602Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID580584Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID564392Antimicrobial activity against Aspergillus fumigatus isolate 24 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1265846Antifungal activity against azole-resistant Candida albicans ATCC 90819 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID576466Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID572209Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522416Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID549327Antifungal activity against Actinomucor spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID516335Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as reduction in fecosterol content at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID555576Antimicrobial activity against Candida pelliculosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532342Antifungal activity against Cunninghamella species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575196Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 20 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555058Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 10281 infected in immunosuppressed-OF1 mouse assessed as prolonged survival of mouse at 100 mg/kg, po administered 1 day post infection measured 20 days post bacterial infection2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID279055AUC (0-12 hrs) in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID555866Antimicrobial activity against Beauveria bassiana by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1898152Antifungal activity against Aspergillus fumigatus 7544 incubated for 48 hrs by microbroth dilution method
AID532325Antifungal activity against Cryptococcus neoformans var. neoformans by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522471Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1484684Leishmanicidal activity against Leishmania mexicana 68 promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID1419570Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus flavus ATCC MYA-36312017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID557630Fungicidal activity against Absidia2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555796Antimicrobial activity against Scedosporium prolificans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID582229Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522523Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498155Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID555614Antimicrobial activity against Aspergillus glaucus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID575346Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID560457Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID564660Antimicrobial activity against Aspergillus fumigatus isolate 33 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID532130Antifungal activity against Candida tropicalis2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555610Antimicrobial activity against Aspergillus ochraceus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1383452Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.0005 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID498007Antifungal activity against Candida tropicalis FMR 10333 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID580580Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID522431Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID555578Antimicrobial activity against Candida norvegensis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID508583Ratio of AUC to MIC for wild type Aspergillus fumigatus infected in CD1 mouse2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID425375Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of caspofungin MIC measured at 15 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID555607Antimicrobial activity against Aspergillus nidulans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID560252Antifungal activity against Candida krusei FMR9729 by M27-A2 broth dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID576458Cmax in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522529Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID524025T>MIC90 in fungus infected patient plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID525140Antifungal activity against Fusarium moniliforme clade 2 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID555596Antimicrobial activity against Cryptococcus albidus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1487213Inhibition of CYP51 in Candida albicans assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID369391Antimicrobial activity against Trichosporon asahii isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID522397Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID582228Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID576455Cmin in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522456Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532135Antifungal activity against Trichosporon inkin2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID576452AUC (0 to 24 hrs) in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID584391Antifungal activity against 16 days cultured Candida glabrata isolated from invasive fungal infected subject blood after 17 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265820Antifungal activity against azole-resistant Candida albicans MYA-1003 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID508311Antifungal activity against Aspergillus fumigatus isolate AZN 8196 harboring wild type Cyp51A protein by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID522463Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID279050AUC (0-12 hrs) in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID567430Antifungal activity against Dipodascus capitatus after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID563829Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID576451Ratio of AUC (0 to 12 hrs) in lung transplant recipient epithelial lining fluid to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID555275Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 10281 infected in immunosuppressed-OF1 mouse assessed as reduction in spleen fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID564371Antimicrobial activity against Aspergillus fumigatus isolate 3 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID565556Antifungal activity against Rhizopus microsporus UTHSC 01-983 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID572663Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1557096Ratio of MIC for Candida glabrata ATCC 66032 after 48 hrs to MIC for Candida glabrata ATCC 66032 after 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID369350Antimicrobial activity against Candida glabrata isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID564631Antimicrobial activity against Aspergillus fumigatus isolate 4 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID542728Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as reduction of fungal burden in kidneys at 60 mg/kg/day, po administered 8 hrs post infection for 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID1419498Antifungal activity against ITC and FLC-resistant Candida albicans ATCC 1237 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564503Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID564401Antimicrobial activity against Aspergillus fumigatus isolate 33 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563581Metabolic stability in healthy human plasma assessed as compound recovery at 6 mg/kg BID2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.
AID598231Antimicrobial activity against Candida tropicalis isolate 15 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID575203Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522413Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522403Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID582219Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564428Antimicrobial activity against Aspergillus fumigatus isolate 10 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID279064Tmax in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID1419551Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-10032017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID525542Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID575371Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555571Antimicrobial activity against Candida guilliermondii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563401Antifungal activity against Aspergillus tubingensis isolate CM-5094 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID555625Antimicrobial activity against Trichoderma spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID369355Antimicrobial activity against Candida kefyr isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID279199Antifungal activity against Aspergillus terreus hyphae2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID369353Antimicrobial activity against Cryptococcus neoformans isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID563383Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID555628Antimicrobial activity against Fusarium equiseti by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564603Antimicrobial activity against Aspergillus fumigatus isolate 26 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522450Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID576496AUC (0 to 12 hrs) in healthy human alveolar cell at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522421Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498184Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID498139Antifungal activity against Candida tropicalis FMR 8896 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID563801Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID546071Antifungal activity against Clavispora lusitaniae isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID567427Antifungal activity against Dipodascus capitatus after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID555623Antimicrobial activity against Acremonium sp.by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1062778Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of immunosuppression measured on d2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID525411Fungistatic activity against Candida parapsilosis ATCC 22019 assessed as 99.9% reduction of int initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID563412Antifungal activity against Aspergillus tubingensis isolate CM-3654 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID582247Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564417Antimicrobial activity against Aspergillus fumigatus isolate 49 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564665Antimicrobial activity against Aspergillus fumigatus isolate 38 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID322862Antifungal activity against azole-resistant Aspergillus fumigatus V45/07-CM3819 isolate from patient with chronic granulomatous disease by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID575755Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B expressed in Escherichia coli assessed as tight binding affinity constant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1484683Leishmanicidal activity against Leishmania major KK promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID522503Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1833887Inhibition of Naegleria fowleri CYP51 catalytic activity using [3-3H]sterol substrate measured after 1 hr by RP-HPLC analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID572465Half life in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576447Ratio of Cmax in lung transplant recipient epithelial lining fluid after 12 hrs to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID283335Antifungal activity against Rhizomucor spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID498159Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID369359Antimicrobial activity against Candida albicans blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID584397Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID480594Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 7 days by alamar blue assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
AID278467Percentage of infected lung in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID530559Antimicrobial activity against Aspergillus fumigatus isolate DK infected in NMRI mouse assessed as survival rate at 20 mg/kg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
AID519468Antimicrobial activity against Cryptococcus gattii by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID563142Antifungal activity against Scedosporium aurantiacum IHEM 15458 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID541574Cmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID498168Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID575495Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 by EUCAST microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID519440Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3305 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID524012Cmax in high fat fed healthy human skin at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID564393Antimicrobial activity against Aspergillus fumigatus isolate 25 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1383455Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.0165 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID279049Tmax in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID1898150Antifungal activity against Cryptococcus neoformans H99 incubated for 72 hrs by microbroth dilution method
AID555802Antimicrobial activity against Cladosporium spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID508324Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID524739Antimicrobial activity against Fusarium oxysporum after 48 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID519467Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID576444AUC (0 to 12 hrs) in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID541878T>MIC90 in healthy human plasma at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522517Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541589AUC (0 to 12 hrs) in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID563391Antifungal activity against Aspergillus tubingensis isolate CM-3585 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID557627Fungicidal activity against Aspergillus flavus2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID279076Half life in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID279058Cmax in >=65 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID555629Antimicrobial activity against Fusarium reticulatum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555801Antimicrobial activity against Hortaea werneckii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID533028Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on CFBE41o cell after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID564164Antimicrobial activity against Aspergillus fumigatus isolate 5 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID549310Antifungal activity against Rhizopus oryzae after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID522411Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID584403Antifungal activity against 1 day cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581893Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531224Antimicrobial activity against Mucor spp. conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID582222Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1487220Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID564374Antimicrobial activity against Aspergillus fumigatus isolate 6 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1419542Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida albicans ATCC 641242017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564625Antimicrobial activity against Aspergillus fumigatus isolate 48 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564616Antimicrobial activity against Aspergillus fumigatus isolate 39 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584412Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID547567Antifungal activity against Candida krusei after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID557610Antifungal activity against Aspergillus niger by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID509099Antifungal activity against Fonsecaea monophora CBS 1172362010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID425787Antifungal activity against Candida albicans GDH2346 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID555274Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 5205 infected in immunosuppressed-OF1 mouse assessed as reduction in kidney fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID555575Antimicrobial activity against Candida famata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID582246Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532154Antifungal activity against Penicillium species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519470Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID522536Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564192Antimicrobial activity against Aspergillus fumigatus isolate 33 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID673469Plasma concentration in Swiss mouse at 50 mg/kg, po after 1 hr2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID576483Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1265845Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiom2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID525595Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID279044Tmax in >=65 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID541876T>MIC90 in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID572443Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572665Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID285220Effect on survival in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID531225Antimicrobial activity against Syncephalastrum racemosum conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID582230Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID498358Apparent volume of distribution in patient without diarrhea undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID532125Antifungal activity against Candida albicans2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555800Antimicrobial activity against Aureobasidium pullulans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID582251Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID671571Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 20 mg/kg, po administered 8 day after post infection qd for 20 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID565402Antifungal activity against Rhizopus microsporus IHEM 10123 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID564186Antimicrobial activity against Aspergillus fumigatus isolate 27 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1595047Antifungal activity against Candida krusei assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID508317AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID584418Antifungal activity against 62 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID509114Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID547545Antifungal activity against Cryptococcus neoformans after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID572479Apparent volume of distribution in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1689822Antifungal activity against Aspergillus fumigatus ASFU76 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID549315Antifungal activity against Mycocladus corymbifer after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID521793Fungistatic activity against Candida parapsilosis ATCC 22019 assessed as 99.9% reduction of int initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID1419497Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2310 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID584594Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581891Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532155Antifungal activity against Fusarium solani2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1474110AUC in human at 200 mg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID279200Antifungal activity against Aspergillus flavus hyphae2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID555577Antimicrobial activity against Candida coliculosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID369363Antimicrobial activity against Cryptococcus neoformans blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID369373Antimicrobial activity against Cryptococcus neoformans isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID584393Antifungal activity against 1 day cultured Candida albicans isolated from HSCT recipient with acute or chronic GVHD mouth after 2 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID369161Antifungal activity against Mucor strain 28 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID1557077Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID518606Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, L358L, E427K, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID564189Antimicrobial activity against Aspergillus fumigatus isolate 30 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID542417Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID582238Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1706421Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi Tulahuen strain C2C4 infected in Swiss mouse assessed as reduction in parasitemia at 20 mg/kg, po qd administered for 20 days starting from day 8 post infection and me2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID546072Antifungal activity against Candida glabrata isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID531207Antimicrobial activity against Rhizomucor spp. conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID498179Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID369369Antimicrobial activity against Candida albicans isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID519439Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3303 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1898159Antifungal activity against Candida albicans 12#
AID1419544Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-28762017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564181Antimicrobial activity against Aspergillus fumigatus isolate 22 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564397Antimicrobial activity against Aspergillus fumigatus isolate 29 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575351Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1062788Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 20 mg/kg, po qd administered on day 8 post-infection measured on same day by microscopic analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID555608Antimicrobial activity against Aspergillus sydowii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564620Antimicrobial activity against Aspergillus fumigatus isolate 43 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1477763Antifungal activity against drug resistant Candida albicans DF2672R after 24 hrs by two fold serial dilution method2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Semisynthesis and Biological Evaluation of Xanthone Amphiphilics as Selective, Highly Potent Antifungal Agents to Combat Fungal Resistance.
AID369378Antimicrobial activity against Candida haemulonii isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID519464Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID555598Antimicrobial activity against Rhodotorula glutinis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID565559Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 40 mg/kg, po QD for 5 days measured after 3 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1684561Antifungal activity against Fusarium solani ATCC 588772021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID498162Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID563350Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID522408Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572445Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID518599Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q141H mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID559895Plasma concentration in patient with Aspergillus infection at 600 to 800 mg/kg/day2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.
AID525601Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID522548Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID533025Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on 16HBE cell after 24 to 48 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID522647Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522540Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID584388Antifungal activity against 42 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522443Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425364Antifungal activity against Candida glabrata isolate 4370 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID278465Percentage of infected lung in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID557633Fungicidal activity against Cunninghamella2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522439Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564383Antimicrobial activity against Aspergillus fumigatus isolate 15 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID369372Antimicrobial activity against Candida tropicalis isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1171002Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as increase in eburicol level at 100 nM incubated for 24 hrs by GC-MS method2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID1898151Antifungal activity against Candida albicans SC5314 incubated for 24 hrs by microbroth dilution method
AID564025Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID572423AUC in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522438Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1487216Inhibition of CYP51 in Candida glabrata assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID522537Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1898162Antifungal activity against Candida albicans 14#
AID405101Antimicrobial activity against Cunninghamella sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID509391Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse body weight at 10 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID1898166Antifungal activity against Candida parapsilosis 660
AID1484685Leishmanicidal activity against Leishmania mexicana 390 promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID582221Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID546078Antifungal activity against Candida kefyr isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID535688Antibacterial activity against Cryptococcus neoformans serotype AD after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID508320Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID549326Antifungal activity against Actinomucor spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID582217Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265837Antifungal activity against azole-resistant Candida albicans ATCC 64124 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID581874Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx after 61 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID508329Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID575356Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID581864Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID549325Antifungal activity against Cunninghamella spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID565569Antifungal activity against Rhizopus microsporus UTHSC R-3466 infected in OF1 mouse assessed as reduction in fungal load in kidney at 20 mg/kg, QD for 5 days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID563395Antifungal activity against Aspergillus niger isolate CM-3672 obtained from cutaneous layer of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID279065AUC (0-12 hrs) in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID519446Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-4060 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1062794Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as reduction in blood parasitemia at 20 mg/kg, po qd administered on day 8 post-infection for 10 days by microscopic analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID532159Antifungal activity against Bipolaris australiensis2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID508319Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID283337Antifungal activity against Rhizopus spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID564369Antimicrobial activity against Aspergillus fumigatus isolate 1 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572481Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576474Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID564633Antimicrobial activity against Aspergillus fumigatus isolate 6 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522485Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564651Antimicrobial activity against Aspergillus fumigatus isolate 24 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID278473Percentage of infected kidney in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID564177Antimicrobial activity against Aspergillus fumigatus isolate 18 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564643Antimicrobial activity against Aspergillus fumigatus isolate 16 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522430Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID581869Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool receiving antifungal drug after 26 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1557082Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID564378Antimicrobial activity against Aspergillus fumigatus isolate 10 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563351Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID576467Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID561918AUClast in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564664Antimicrobial activity against Aspergillus fumigatus isolate 37 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564426Antimicrobial activity against Aspergillus fumigatus isolate 8 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563814Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID564179Antimicrobial activity against Aspergillus fumigatus isolate 20 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564367Antimicrobial activity against Aspergillus fumigatus isolate 49 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID425378Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of amphotericin B MIC measured at 5 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID530564Antimicrobial activity against Aspergillus fumigatus isolate AT infected in NMRI mouse assessed as survival rate at 20 mg/kg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
AID575492Antifungal activity against azole-resistant Aspergillus fumigatus isolate T22 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 0.5 mg/l relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID535687Antibacterial activity against Cryptococcus neoformans serotype D after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID1419502Antifungal activity against Candida parapsilosis ATCC 22019 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID522426Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522522Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID279059Tmax in >=65 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID557619Antifungal activity against Aspergillus niger hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575207Antifungal activity against Cunninghamella echinulata FMR 10973 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID425159Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID563382Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID279038Cmax in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID531239Antifungal activity against Candida lusitaniae after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID546074Antifungal activity against Candida dubliniensis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID582245Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563410Antifungal activity against Aspergillus tubingensis isolate CM-3177 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID285224Antimicrobial activity against Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID369351Antimicrobial activity against Candida parapsilosis isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1301913Inhibition of hedgehog pathway in mouse ASZ cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by qPCR method2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID572471Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369381Antimicrobial activity against Candida utilis isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID572462Half life in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564404Antimicrobial activity against Aspergillus fumigatus isolate 36 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID279053Cmax in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID555620Antimicrobial activity against Fusarium verticillioides by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID498146Antifungal activity against Candida tropicalis FMR 10333 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID567447Antifungal activity against Trichosporon sp. after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID522547Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522552Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563354Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID432803Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID1851973Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as inhibition of parasite growth incubated for 48 hrs by Hoechst 3348 staining based analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID575201Antifungal activity against Cunninghamella bertholletiae FMR-9598 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID524740Antimicrobial activity against Fusarium subglutinans after 48 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID581871Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool receiving antifungal drug after 36 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564411Antimicrobial activity against Aspergillus fumigatus isolate 43 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID582232Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID369358Antimicrobial activity against Candida lusitaniae isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID283604Average plasma concentration in Candida albicans infected juvenile acute myelogenous leukemia patient with bone marrow transplantation at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID508574Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564190Antimicrobial activity against Aspergillus fumigatus isolate 31 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID516344Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as cell death at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID575362Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID508588Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein infected in CD1 mouse assessed as 50% effective pharmacodynamic index administered orally qd for 14 days measured post last dose2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID522466Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID575498Antifungal activity against Aspergillus lentulus isolate2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID522446Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID541894Toxicity in healthy human assessed as urine analysis at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID572685Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID530563Antimicrobial activity against Aspergillus fumigatus isolate AT infected in NMRI mouse assessed as survival rate at 5 mg/kg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
AID564176Antimicrobial activity against Aspergillus fumigatus isolate 17 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID730404Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as increase in host survival at 100 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infection mea2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID531236Antifungal activity against Candida parapsilosis after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID541873Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID575215Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555797Antimicrobial activity against Alternaria alternata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID572666Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID519433Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4420 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID575219Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1419553Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida glabrata ATCC 20012017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID521791Fungistatic activity against Candida glabrata isolate 4205 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID560469Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment 2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID1309046Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID522533Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID549329Antifungal activity against Apophysomyces spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID525398Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID522538Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID598224Antimicrobial activity against Candida albicans isolate 47 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID555606Antimicrobial activity against Aspergillus niger by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID581882Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID572468Half life in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID582249Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1419499Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-1003 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID1898170Antifungal activity against Candida tropicalis ATCC750
AID498166Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564511Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID322861Antifungal activity against azole-resistant Aspergillus fumigatus V41/26-CM3820 isolate from patient with pulmonary fibrosis by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID522483Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID519425Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3537 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID584417Antifungal activity against 12 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322853Antifungal activity against azole-resistant Aspergillus fumigatus V13/02-CM3271 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID576446Cmin in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID575354Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID557631Fungicidal activity against Rhizopus2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522535Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID582243Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532351Antifungal activity against Bipolaris australiensis by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582225Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID557626Fungicidal activity against amphotericin B-resistant Aspergillus terreus2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532160Antifungal activity against Rhinocladiella aquaspersa2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID405092Antimicrobial activity against Rhizopus sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID498010Antifungal activity against Candida tropicalis FMR 10236 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID1557091Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID498174Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID425171Antifungal activity against Candida glabrata isolate 4205 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID508328Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID575485Antifungal activity against azole-resistant Aspergillus fumigatus isolate R13 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 0.5 mg/l relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID575497Antifungal activity against Aspergillus nidulans isolate2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID521796Fungistatic activity against Candida glabrata isolate 4205 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID555806Antimicrobial activity against Mycocladus corymbiferus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564606Antimicrobial activity against Aspergillus fumigatus isolate 29 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID598223Antimicrobial activity against Candida albicans isolate 41 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID572210Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID582999Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51B gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID673496Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 2 mg/kg, ip administered 8 days after post infection qd for 5 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID498178Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID508327Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564416Antimicrobial activity against Aspergillus fumigatus isolate 48 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID369352Antimicrobial activity against Candida tropicalis isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID532161Antifungal activity against Candida albicans by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555051Antimicrobial activity against Fusarium oxysporum FMR 10281 by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID521789Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 25 mg/kg/day, ip administered 24 hrs po2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID508332Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564605Antimicrobial activity against Aspergillus fumigatus isolate 28 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1309050Antifungal activity against Candida albicans ATCC MYA-2310 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID369356Antimicrobial activity against Candida dubliniensis isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID521567Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed as decrease in (1-3)-beta-D-glucan concentration in serum at 40 mg/kg, po QD (RVb= 758 pg/ml)2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID278442Increase in survival of neutropenic CD1 mouse infected with 0.1 mega Rhizopus oryzae 4745 at 50 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID1534780Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID425373Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured at 15 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID555798Antimicrobial activity against Alternaria infectoria by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID283334Antifungal activity against Rhizomucor spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID531220Antimicrobial activity against Syncephalastrum racemosum hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID563357Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID567445Antifungal activity against Trichosporon mucoides assessed as percent susceptible isolates after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID584411Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522406Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID518611Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID541895Toxicity in healthy human assessed as vital adverse effects at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID541879Toxicity in healthy human plasma assessed as blood chemistry analysis at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID582998Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID564389Antimicrobial activity against Aspergillus fumigatus isolate 21 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID525412Fungistatic activity against Candida glabrata 4370 assessed as 99.9% reduction of int initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID1309055Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID564514Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID584416Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID557611Antifungal activity against Rhizomucor by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID369365Antimicrobial activity against Candida kefyr blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID532320Antifungal activity against Candida krusei by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564507Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID582227Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563406Antifungal activity against Aspergillus tubingensis isolate CM-4005 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID522441Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563389Antifungal activity against Aspergillus niger isolate CM-3506 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID279041Half life in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID532149Antifungal activity against Mucor species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575342Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID405105Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID369377Antimicrobial activity against Candida lusitaniae isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID564183Antimicrobial activity against Aspergillus fumigatus isolate 24 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID518402Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220R mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID546069Antifungal activity against Candida krusei isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID522560Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564026Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID283602Average plasma concentration in Fusarium spp infected juvenile osteosarcoma patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID531208Antimicrobial activity against Cunninghamella bertholletiae conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID405107Antimicrobial activity against Mucor sp. after assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID369370Antimicrobial activity against Candida glabrata isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID498142Antifungal activity against Candida tropicalis FMR 9726 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID559692Antimicrobial activity against Mycocladus corymbiferus after 24 hrs by broth microdilution checkerboard procedure2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID498015Antifungal activity against Candida tropicalis FMR 10241 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID575747Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme A expressed in Escherichia coli2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID541600Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID564667Antimicrobial activity against Aspergillus fumigatus isolate 40 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564400Antimicrobial activity against Aspergillus fumigatus isolate 32 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283598Average plasma concentration in Fusarium spp infected juvenile chronic myelogenous leukemia patient with bone marrow transplantation at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID557613Antifungal activity against Rhizopus by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522453Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID278453Reduction of infection foci size in Rhizopus oryzae 4570 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID425370Antifungal activity against Candida glabrata isolate 4293 at 5 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID525141Antifungal activity against Fusarium moniliforme clade 3 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID584390Antifungal activity against 14 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID283328Antifungal activity against Absidia spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID283601Average plasma concentration in Aspergillus spp infected juvenile cystic fibrosis patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID541618Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1534784Inhibition of human ERG expressed in CHO cells at 25 uM by electrophysiology assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID572463Half life in fasted healthy human at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564384Antimicrobial activity against Aspergillus fumigatus isolate 16 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522461Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID673487Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase of host survival at 10 mg/kg, po administered 8 days after post infection qd for 5 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID555573Antimicrobial activity against Candida kefyr by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID531212Antimicrobial activity against Absidia corymbifera conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID498161Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532128Antifungal activity against Candida krusei2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555604Antimicrobial activity against Aspergillus terreus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID525598Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method relative to wildtype sCandida alb2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID555595Antimicrobial activity against Trichosporon jirovecii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555619Antimicrobial activity against Fusarium oxysporum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555050Antimicrobial activity against Fusarium oxysporum FMR 5205 by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID576259Ratio of fCmax in lung transplant recipient plasma after 12 hrs to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID279068Cmax in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID563418Antifungal activity against Aspergillus tubingensis isolate CM-4897 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID555631Antimicrobial activity against Chrysonilia sitophila by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1898163Antifungal activity against Candida albicans 305
AID283608Average plasma concentration in Coccidioides immitis infected juvenile at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID520619Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID572208Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID531238Antifungal activity against Candida krusei after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID576460AUC (0 to 24 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID279195Antifungal activity against Aspergillus terreus conidia2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID547563Antifungal activity against Candida albicans after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID563345Antifungal activity against inoculum of 1x10'5 conidia/ml Fusarium solani isolate 95-2478 after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID369387Antimicrobial activity against Candida inconspicua isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1557081Antifungal activity against Candida parapsilosis ATCC 90018 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID498353Cmax in patient undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID1898173Antifungal activity against Candida krusei 397
AID1419547Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-23102017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID575491Antifungal activity against azole-resistant Aspergillus fumigatus isolate T18 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 0.5 mg/l relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID563378Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID555587Antimicrobial activity against Yarrowia lipolytica by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID522516Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID549322Antifungal activity against Rhizomucor variabilis after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID542725Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 10 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID561907AUC (0 to infinity) in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID532133Antifungal activity against Cryptococcus neoformans var. neoformans2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID498183Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID563396Antifungal activity against Aspergillus niger isolate CM-4004 obtained from after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID564841Antimicrobial activity against Aspergillus fumigatus isolate 50 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID425165Antifungal activity against Candida glabrata isolate 4293 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID279198Antifungal activity against Aspergillus fumigatus hyphae2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID564375Antimicrobial activity against Aspergillus fumigatus isolate 7 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576482Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID258672Antifungal activity against Aspergillus species2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].
AID1487214Inhibition of CYP51 in Aspergillus fumigatus assessed as inhibition of microbe growth incubated for 48 to 168 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID525400Antifungal activity against Candida glabrata isolate 4198 after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID541572Cmin in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID285216Mortality rate in Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1309056Antifungal activity against Aspergillus flavus ATCC MYA-3631 after 48 hrs by CLSI M38-A2 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID575223Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID283597Average plasma concentration in Aspergillus spp infected juvenile burkitt's lymphoma patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID522449Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522469Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572416AUC in fasted healthy human at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID524016AUC (0 to 12 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID508582Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564621Antimicrobial activity against Aspergillus fumigatus isolate 44 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575069Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 40 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID559695Antimicrobial activity against Rhizomucor pusillus after 24 hrs by broth microdilution checkerboard procedure2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID521794Fungistatic activity against Candida glabrata 4370 assessed as 99.9% reduction of int initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID581863Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth after 115 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID580585Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID279056Half life in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID563388Antifungal activity against Aspergillus niger isolate CM-3257 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519444Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3769 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563346Antifungal activity against inoculum of 1x10'5 conidia/ml Fusarium solani isolate 95-2478 after 48 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID369159Antifungal activity against Snycephalastrum sp. strain 23 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID555809Antimicrobial activity against Cunninghamella bertholletiae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID369158Antifungal activity against Cunninghamella sp. strain 12 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID498148Antifungal activity against Candida tropicalis FMR 10235 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID522549Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID565401Antifungal activity against Rhizopus microsporus IHEM 9503 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID522414Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564439Antimicrobial activity against Aspergillus fumigatus isolate 21 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID394828Inhibition of human recombinant CYP3A42009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Rational modification of a candidate cancer drug for use against Chagas disease.
AID322852Antifungal activity against azole-resistant Aspergillus fumigatus M03/669-CM2627 isolate from patient by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID532335Antifungal activity against Absidia corymbifera by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1265814Antifungal activity against azole-resistant Candida albicans ATCC 10231 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1595045Antifungal activity against Candida glabrata assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID561924AUC (0 to infinity) in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID498144Antifungal activity against Candida tropicalis FMR 10231 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564658Antimicrobial activity against Aspergillus fumigatus isolate 31 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283332Antifungal activity against Mucor spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID369160Antifungal activity against Rhizomucor sp. strain 25 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID564368Antimicrobial activity against Aspergillus fumigatus isolate 50 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564187Antimicrobial activity against Aspergillus fumigatus isolate 28 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563152Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID563399Antifungal activity against Aspergillus tubingensis isolate CM-4296 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID567435Antifungal activity against Trichosporon mucoides after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID598226Antimicrobial activity against Candida krusei isolate 31 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID369368Antimicrobial activity against Candida lusitaniae blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID581897Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx receiving antifungal drug after 21 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563369Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID572675Toxicity in healthy human assessed as headache at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575364Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID567428Antifungal activity against Dipodascus capitatus after 4 days by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID572447Apparent total body clearance in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID498152Antifungal activity against Candida tropicalis FMR 10239 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID572678Toxicity in healthy human assessed as asthenia at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572456Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564163Antimicrobial activity against Aspergillus fumigatus isolate 4 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID565563Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 40 mg/kg, po QD for 5 days measured after 24 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID555795Antimicrobial activity against Scedosporium apiospermum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID531468Antimicrobial activity against azole-susceptible Aspergillus fumigatus after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID572220Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575360Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1419514Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID1587052Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 50 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and mea2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID530558Antimicrobial activity against Aspergillus fumigatus isolate DK infected in NMRI mouse assessed as survival rate at 5 mg/kg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
AID516346Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as effect on cell division at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID1557090Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID498153Antifungal activity against Candida tropicalis FMR 10240 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID547569Antifungal activity against Candida guilliermondii after 24 to 72 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID562118Tmax in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID581912Ratio of ERG11 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to ERG11 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID498138Antifungal activity against Candida tropicalis FMR 8895 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID524020AUC (0 to 24 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID564420Antimicrobial activity against Aspergillus fumigatus isolate 2 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575191Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID584401Antifungal activity against 60 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1860607Antitrypanosomal activity against Trypanosoma cruzi infected in Vero cells assessed as relapse day after washout at 25 times EC50 for 8 days followed by washout by microscopic analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.
AID518595Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, F495I mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID555582Antimicrobial activity against Candida orthopsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID560486Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID508585Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID541576Cmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1851972Solubility of compound in water at 0.1 M HCl at pH 1 by LC-UV analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID581879Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID546070Antifungal activity against Candida parapsilosis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID279048Cmax in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID560481Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment 2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID564174Antimicrobial activity against Aspergillus fumigatus isolate 15 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564413Antimicrobial activity against Aspergillus fumigatus isolate 45 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283338Antifungal activity against Syncephalastrum spp after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID532137Antifungal activity against Geotrichum candidum2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564370Antimicrobial activity against Aspergillus fumigatus isolate 2 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID508576Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID522480Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID581894Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405096Antimicrobial activity against Mucor sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID581875Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx receiving antifungal drug after 61 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563148Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID575205Antifungal activity against Cunninghamella echinulata UTHSC 03-3725 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1546310Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 20A trypomastigote expressing GFP infected in BALB/c mouse cardiomyocytes assessed as reduction in parasitemia measured after 72 hrs by fluorescence assay2020Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1
A new chemotype with promise against Trypanosoma cruzi.
AID572457Half life in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369354Antimicrobial activity against Candida krusei isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID555592Antimicrobial activity against Trichosporon inkin by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564396Antimicrobial activity against Aspergillus fumigatus isolate 28 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576488Ratio of fAUC (0 to 12 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID516338Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as reduction in fecosterol content at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID555803Antimicrobial activity against Cladophialophora bantiana by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID533027Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on CFBE41o cell after 24 to 48 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID564518Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID1419568Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida krusei ATCC 62582017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID405094Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID581878Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522492Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID576441Ratio of AUC (0 to 24 hrs) in lung transplant recipient alveolar cell to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID557811Drug level in patient serum with infection by HPLC analysis2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
AID584386Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582248Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564654Antimicrobial activity against Aspergillus fumigatus isolate 27 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572422AUC in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564634Antimicrobial activity against Aspergillus fumigatus isolate 7 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576442AUC (0 to 24 hrs) in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID369151Toxicity in invasive zygomycosis diseased patient assessed as mortality2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID557618Antifungal activity against Aspergillus flavus hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582237Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID521570Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed as pulmonary fungal burden at 40 mg/kg, po QD2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID563372Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID572441Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522400Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID279062Apparent total clearance in >=65 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID567438Antifungal activity against Trichosporon inkin after 48 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID581872Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool after 22 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID555580Antimicrobial activity against Candida inconspicua by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID557624Antifungal activity against Cunninghamella hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID285219Effect on survival in Trypanosoma cruzi Y infected C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID575359Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522399Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522558Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522545Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID584405Antifungal activity against 23 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575213Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID563137Antifungal activity against Scedosporium boydii FMR 8627 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID580598Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1474112Ratio of drug concentration at steady state in human at 200 mg, po TID after 8 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425365Antifungal activity against Candida glabrata isolate 4370 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID565399Antifungal activity against Rhizopus microsporus IHEM 18821 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID576485Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID279074Tmax in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID584591Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID283333Antifungal activity against Mucor spp after 48 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID598227Antimicrobial activity against Candida krusei isolate 43 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID522531Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541575Cmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522436Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID525404Antifungal activity against Candida glabrata isolate 4293 after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID572676Toxicity in healthy human assessed as headache at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522506Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572671Toxicity in healthy human assessed as dizziness at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563347Drug concentration in uninfected nonimmunosppressed ICR mouse serum at 50 mg/kg, po BID after 4 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID671574Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as level of parasite in blood at 20 mg/kg, po qd for 20 days measured after 30 day2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID563371Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID522524Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522501Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522559Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1898171Antifungal activity against Candida krusei 463
AID598229Antimicrobial activity against Candida tropicalis isolate 33 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID279045AUC (0-12 hrs) in >=65 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID572415AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1487225Inhibition of CYP19 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID581906Ratio of CDR1 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to CDR1 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522432Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID575488Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 assessed as fungal growth at 0.5 mg/l relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID532338Antifungal activity against Rhizopus oryzae by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1898164Antifungal activity against Candida albicans 20#
AID369374Antimicrobial activity against Candida krusei isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID598303Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 25 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID369155Antifungal activity against Absidia strain 11 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID521798Antifungal activity against 2.44 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 15 mg/kg/day, po administered 24 hrs po2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID522527Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID555626Antimicrobial activity against Phialemonium curvatum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID498147Antifungal activity against Candida tropicalis FMR 10234 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID518616Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54E mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID541606Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID498181Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 dayss2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532146Antifungal activity against Rhizopus oryzae2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575350Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID522460Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1684563Antifungal activity against Aspergillus flavus ATCC 36312021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID509113Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID541587Tmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID405111Antimicrobial activity against Absidia corymbifera assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID322864Antifungal activity against azole-resistant Aspergillus fumigatus V49/09-CM4023 isolate from patient with chronic obstructive pulmonary disease by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID575073Antifungal activity against Cunninghamella bertholletiae FMR 9598 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1301912Inhibition of hedgehog pathway in mouse C3H10T1/2 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by qPCR method2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID564604Antimicrobial activity against Aspergillus fumigatus isolate 27 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563821Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID522526Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425366Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.015 ug/ml caspofungin measured at 0.5 ug/ml after 48 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID584589Antifungal activity against 15 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID498355Apparent volume of distribution in patient undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID584599Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265840Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1557089Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID283607Average plasma concentration in Scedosporium apiospermum infected juvenile chronic myelogenous leukemia patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID581876Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx after 23 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322859Antifungal activity against azole-resistant Aspergillus fumigatus V34/77-CM3278 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID532126Antifungal activity against Candida glabrata2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522424Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425382Antifungal activity against 2.44 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as reduction in colony forming units treated with a therapeutic regimen of sterile saline solution from day 1 to day 2 followed by 15 mg/kg/day drug a2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID509108Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID564835Antimicrobial activity against Aspergillus fumigatus isolate 44 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1171004Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as reduction in fecosterol level at 100 nM incubated for 24 hrs by GC-MS method2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID1265819Antifungal activity against azole-resistant Candida albicans MYA-1237 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID522499Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID519448Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-3147 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID497999Antifungal activity against Candida tropicalis FMR 8895 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID572216Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID580597Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID278437Increase in survival of Rhizopus oryzae 4570 infected neutropenic CD1 mouse at 20 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID522557Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564193Antimicrobial activity against Aspergillus fumigatus isolate 34 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572217Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576490Protein binding in human plasma at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID532337Antifungal activity against Rhizopus microsporus var. oligosporus by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID524019AUC (0 to 12 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID572658Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID508577Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID575482Antifungal activity against azole-resistant Aspergillus fumigatus isolate T11 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 0.5 mg/l relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID572430Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1595051Antifungal activity against Candida albicans V-01-191A-261 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID1689827Antifungal activity against Mucor circinelloides MURI1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID580578Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID541592Ratio of Cmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1383456Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.05 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID522507Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID524736Antimicrobial activity against Fusarium verticillioides after 48 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID557623Antifungal activity against Mucor hyphae by EUCAST method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID572667Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1898176Antifungal activity against Candida auris 791
AID564394Antimicrobial activity against Aspergillus fumigatus isolate 26 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID531214Antimicrobial activity against Rhizomucor spp. hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID584593Antifungal activity against 56 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID572473Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576471Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID518594Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S297T, F495 mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1487215Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID560462Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID572680Toxicity in healthy human assessed as asthenia at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID508333Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564388Antimicrobial activity against Aspergillus fumigatus isolate 20 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID508323Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID532150Antifungal activity against Cunninghamella species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532350Antifungal activity against Curvularia lunata by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID375462Terminal half life in rat2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.
AID541614Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522563Drug level in human serum at 400 mg, po bid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498001Antifungal activity against Candida tropicalis FMR 8897 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID522554Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564391Antimicrobial activity against Aspergillus fumigatus isolate 23 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID532336Antifungal activity against Absidia species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID525591Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID564608Antimicrobial activity against Aspergillus fumigatus isolate 31 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1557079Antifungal activity against Candida glabrata ATCC 2001 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID279040AUC (0-12 hrs) in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID509106Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID575357Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID549312Antifungal activity against Mucor circinelloides after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID522555Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564626Antimicrobial activity against Aspergillus fumigatus isolate 49 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575214Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID509399Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 20 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID532324Antifungal activity against Saccharomyces cerevisiae by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID498004Antifungal activity against Candida tropicalis FMR 9727 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID565562Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 20 mg/kg, po BID for 5 days measured after 24 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1301915Antiproliferative activity against mouse MERP MB cells assessed as cell growth inhibition using methyl-[3H]thymidine after 48 hrs by liquid scintillation spectrophotometry2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID572668Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID584394Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322854Antifungal activity against azole-resistant Aspergillus fumigatus V13/03-CM3272 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1294729Antileishmanial activity against beta-lactamase expressing Leishmania amazonensis amastigotes overnight infected in CD1 mouse macrophages incubated for 72 hrs by nitrocefin dye based assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
AID508318AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID522482Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564624Antimicrobial activity against Aspergillus fumigatus isolate 47 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID279066Half life in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID516323Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as abnormalities in nuclear membrane at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID519443Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-4328 obtained from cornea of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID532127Antifungal activity against Candida parapsilosis2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564188Antimicrobial activity against Aspergillus fumigatus isolate 29 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID498354Apparent oral clearance in patient undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID531227Antimicrobial activity against Absidia corymbifera hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID572413AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532158Antifungal activity against Curvularia lunata2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID279057Apparent total clearance in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID781109Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in 3T3 cells after 7 days by beta-galactosidase assay2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.
AID1534787Inhibition of hedgehog signaling pathway in hedgehog-dependent mouse Ptch-CKO cells assessed as inhibition of cell growth2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID563358Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID580667Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1265844Antifungal activity against azole-resistant Candida albicans ATCC 64124 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1689828Antifungal activity against Fusarium sp. assessed as reduction in microbial growth after 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID581902Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545662Cellular uptake in PBMC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID557812Drug level in patient serum with invasive aspergillosis by HPLC analysis2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
AID563809Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID432796Antifungal activity against Candida kefyr ATCC 46764 at 1.5 ug/ml after 14 to 18 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID576470Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID575345Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID541594Ratio of AUC (0 to 24 hrs) in healthy human plasma at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID581904Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564415Antimicrobial activity against Aspergillus fumigatus isolate 47 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID519423Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3134 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID541612Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522429Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522405Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID561910Cmax in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564510Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID283596Average plasma concentration in ITT population of adult patients with Aspergillus infection at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID572660Toxicity in healthy human assessed as adverse events at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563404Antifungal activity against Aspergillus tubingensis isolate CM-3810 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID572659Toxicity in healthy human assessed as adverse events at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575070Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID564028Antifungal activity against Fusarium oxysporum isolate infected in ICR mouse2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID509112Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID283605Average plasma concentration in Candida albicans infected juvenile with inherited immunodeficiency at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID425167Antifungal activity against Candida glabrata isolate 4370 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID576484Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1474111Drug concentration at steady state in human at 200 mg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID508313Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID561908AUC (0 to infinity) in healthy human at 400 mg/kg, po by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID561915Terminal half life in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID582255Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525602Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID575218Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1309049Antifungal activity against Candida albicans ATCC MYA-90819 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID283606Average plasma concentration in Aspergillus spp infected juvenile acute lymphoblastic leukemia patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID522433Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID369395Antimicrobial activity against Trichosporon loubieri isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID564641Antimicrobial activity against Aspergillus fumigatus isolate 14 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID279051Half life in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID1062780Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 10 mg/kg, po qd administered on day 8 post-infection for 20 days measured on day 28 post-infection by microscopic analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID575372Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID581908Ratio of ERG11 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to ERG11 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1184055Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigotes expressing green florescent protein infected in cardiomyocytes assessed as inhibition of parasite growth after 72 hrs by fluorescence microscopy2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
AID1684564Antifungal activity against Fusarium falciforme ATCC 36362021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID508580Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID519442Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3740 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID581900Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID560487Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment 2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID560456Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID572419AUC in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564645Antimicrobial activity against Aspergillus fumigatus isolate 18 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID405093Antimicrobial activity against Rhizopus arrhizus after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID575352Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID559694Antimicrobial activity against Rhizopus microsporus after 24 hrs by broth microdilution checkerboard procedure2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID564623Antimicrobial activity against Aspergillus fumigatus isolate 46 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564203Antimicrobial activity against Aspergillus fumigatus isolate 44 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID518604Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID278450Reduction of number of infection foci in Absidia corymbifera 4535 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID564655Antimicrobial activity against Aspergillus fumigatus isolate 28 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID598222Antimicrobial activity against Candida albicans isolate 31 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID521566Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed as decrease in (1-3)-beta-D-glucan concentration in serum at 40 mg/kg, po QD (RVb= 707 pg/ml)2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
AID1419543Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-28762017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID524007Tmax in high fat fed healthy human plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID564430Antimicrobial activity against Aspergillus fumigatus isolate 12 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576439Tmax in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID509102Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 20 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID564612Antimicrobial activity against Aspergillus fumigatus isolate 35 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522551Antifungal activity against drug-intermediate Rhizopus oryzae infected in OF1 mouse assessed as mouse survival at 30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522487Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541602Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID563825Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID283594Average plasma concentration in ITT population of adult patients with invasive fungal infection at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID283595Average plasma concentration in ITT population of juvenile patients with Aspergillus infection at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID545165Antimicrobial activity against Candida albicans isolate C after 48 hrs by EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID564613Antimicrobial activity against Aspergillus fumigatus isolate 36 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572482Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID509400Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 40 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID532327Antifungal activity against Trichosporon inkin by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555630Antimicrobial activity against Hormographiella verticillata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1484686Leishmanicidal activity against Leishmania panamensis LS94 promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID541877T>MIC90 in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID730419Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID1595049Antifungal activity against Candida tropicalis assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID564407Antimicrobial activity against Aspergillus fumigatus isolate 39 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID532345Antifungal activity against Penicillium marneffei by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID565075Antimicrobial activity against Blastoschizomyces capitatus by microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
AID1689826Antifungal activity against Rhizopus oryzae RHPOR2 assessed as reduction in microbial growth after 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID531217Antimicrobial activity against Rhizopus oryzae hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID519435Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4428 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID572431Tmax in fasted healthy human at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID580666Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivation of infection at 20 mg/kg/day, po administered once daily for 20 consecutive days measured 22 days post infe2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID519430Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4370 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID584395Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID561917Tmax in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564194Antimicrobial activity against Aspergillus fumigatus isolate 35 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID559693Antimicrobial activity against Mucor circinelloides after 24 hrs by broth microdilution checkerboard procedure2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID584592Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545330Antimicrobial activity against Candida albicans isolate C after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID1534781Half life in human liver microsomes at 1 uM by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID576494AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID369382Antimicrobial activity against Candida lipolytica isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID1851971Solubility of compound in water at pH 7 by LC-UV analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID572426AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID279060AUC (0-12 hrs) in >=65 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID369383Antimicrobial activity against Candida pelliculosa isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID564024Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID522410Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID541599Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID541603Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID531229Antimicrobial activity against Rhizomucor spp. hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID541593Ratio of Cmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID576477Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID541591Ratio of Cmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp.2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID278471Percentage of infected spleen in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID563390Antifungal activity against Aspergillus tubingensis isolate CM-3507 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID508316AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID575220Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID279063Cmax in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID369366Antimicrobial activity against Candida dubliniensis blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID498011Antifungal activity against Candida tropicalis FMR 10237 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID575363Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID564172Antimicrobial activity against Aspergillus fumigatus isolate 13 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1898168Antifungal activity against Candida parapsilosis 700
AID572214Cmax in healthy human plasma at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369393Antimicrobial activity against Candida rugosa isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID565560Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 20 mg/kg, po BID for 5 days measured after 3 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID532332Antifungal activity against Aspergillus flavus by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555609Antimicrobial activity against Aspergillus versicolor by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID564196Antimicrobial activity against Aspergillus fumigatus isolate 37 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID518598Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, N125I mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID516329Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as blebbing of the cell membrane at 0.25 uM after 48 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID563360Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID546076Antifungal activity against Candida rugosa isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID508578Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1419571Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus nidulans ATCC 381632017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID498140Antifungal activity against Candida tropicalis FMR 8897 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID584402Antifungal activity against 88 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID576473Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID532151Antifungal activity against Scedosporium prolificans2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564185Antimicrobial activity against Aspergillus fumigatus isolate 26 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID518405Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220K mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID582234Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID278433Antimicrobial activity against Rhizopus oryzae 45702007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID1706435Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis relative to2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID563138Antifungal activity against Scedosporium boydii FMR 6694 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID563375Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID498356Apparent oral clearance in patient without diarrhea undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID1534785Substrate activity at P-gp in human Caco2 cells by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID541613Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID375461Terminal half life in mouse2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.
AID572418AUC in fasted healthy human at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572476Apparent volume of distribution in fasted healthy human at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID555566Antimicrobial activity against Candida albicans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID572682Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID509104Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 10 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID524023AUC (0 to 24 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID555588Antimicrobial activity against Galactomyces geotrichum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID549324Antifungal activity against Cunninghamella spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID564635Antimicrobial activity against Aspergillus fumigatus isolate 8 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572455Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532153Antifungal activity against Penicillium marneffei2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1309057Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by CLSI M38-A2 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID278440Increase in survival of Absidia corymbifera 4535 infected neutropenic CD1 mouse at 80 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID1689825Antifungal activity against Rhizopus oryzae RHPOR1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID584414Antifungal activity against 16 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1419565Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida albicans ATCC 102312017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID522484Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID279071Half life in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID532157Antifungal activity against Sporothrix schenckii2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1487224Inhibition of CYP17 hydroxylase in human hepatocyte microsomes using pregnenolone substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID283603Average plasma concentration in Candida krusei infected juvenile acute lymphoblastic leukemia patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID564377Antimicrobial activity against Aspergillus fumigatus isolate 9 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1309054Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID531230Antimicrobial activity against Mucor spp. hyphae after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID1587053Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 25 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and mea2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID564659Antimicrobial activity against Aspergillus fumigatus isolate 32 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575343Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID541573Cmin in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID560463Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID1171003Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as reduction in episterol level at 100 nM incubated for 24 hrs by GC-MS method2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID521790Fungistatic activity against Candida glabrata isolate 4198 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID564648Antimicrobial activity against Aspergillus fumigatus isolate 21 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID565552Antifungal activity against Rhizopus microsporus UTHSC R-3466 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID541897Half life in human2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID532331Antifungal activity against Aspergillus terreus by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID598300Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 14 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID1557094Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID575198Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1309048Antifungal activity against Candida albicans ATCC MYA-2876 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID564609Antimicrobial activity against Aspergillus fumigatus isolate 32 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575344Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID563417Antifungal activity against Aspergillus tubingensis isolate CM-4352 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID278455Reduction of infection foci size in Rhizopus oryzae 4570 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID572684Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID498180Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532352Antifungal activity against Rhinocladiella aquaspersa by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1265815Antifungal activity against azole-resistant Candida albicans ATCC 64124 after 48 hrs by microbroth dilution method2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID564382Antimicrobial activity against Aspergillus fumigatus isolate 14 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564435Antimicrobial activity against Aspergillus fumigatus isolate 17 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564436Antimicrobial activity against Aspergillus fumigatus isolate 18 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID541609Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID564425Antimicrobial activity against Aspergillus fumigatus isolate 7 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID498008Antifungal activity against Candida tropicalis FMR 10234 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532346Antifungal activity against Penicillium species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID560474Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
AID572218Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564646Antimicrobial activity against Aspergillus fumigatus isolate 19 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID545665Drug uptake in plasma of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID598302Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 30 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID572221Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID1419548Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-23102017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564840Antimicrobial activity against Aspergillus fumigatus isolate 49 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584595Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522510Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563355Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID532134Antifungal activity against Cryptococcus neoformans var. gattii2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519427Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3583 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID673468Plasma concentration in Swiss mouse at 20 mg/kg, po after 24 hrs2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID1498545Inhibition of Candida albicans CYP51 assessed as reduction in [3-3H]lanosterol 14alpha-demethylation at 0.75 uM preincubated for 60 secs followed by NADPH addition measured after 60 mins by RP-HPLC analysis relative to control2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID1419567Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida krusei ATCC 62582017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID518596Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S52T mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID582226Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID561909AUClast in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564636Antimicrobial activity against Aspergillus fumigatus isolate 9 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1547544Trypanosomacidal activity against Trypanosoma cruzi strain Y trypomastigotes assessed as reduction in number of infected cells at slower rate at 0.04 uM measured for 24 to 96 hrs by Hoechst 33342 staining based fluorescence imaging assay2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Discovery of Potent
AID285221Effect on survival in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID582239Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563407Antifungal activity against Aspergillus tubingensis isolate CM-4688 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID425379Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of amphotericin B MIC measured at 15 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID581886Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265843Antifungal activity against azole-resistant Candida albicans ATCC 10231 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1498550Potency index, ratio of VNI Kd(app) to compound Kd(app) for Candida albicans CYP512018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID279047Apparent total clearance in >=65 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID576258fAUC (0 to 12 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID498013Antifungal activity against Candida tropicalis FMR 10239 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID369162Antifungal activity against Mucor strain 39 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID405102Antimicrobial activity against Apophysomyces elegans after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID519434Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4426 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID518608Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, M172V, L358L, E427K, C454C mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID565398Antifungal activity against Rhizopus microsporus CBS 102277 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID581909Ratio of URA3 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to URA3 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID498154Antifungal activity against Candida tropicalis FMR 10241 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID522423Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID531211Antimicrobial activity against Rhizopus microsporus conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID564422Antimicrobial activity against Aspergillus fumigatus isolate 4 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID259824Antiprotozoal activity against Trypanosoma cruzi epimastigotes2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
AID1062804Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment measured on day 37 post-infection by mi2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID521788Antifungal activity against 2.44 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 25 mg/kg/day, ip administered 24 hrs po2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID532044Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID563802Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID546081Antifungal activity against Candida intermedia isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID498176Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID575200Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID561913Apparent oral clearance in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID522420Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563419Antifungal activity against Aspergillus tubingensis isolate CM-4899 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID555621Antimicrobial activity against Paecilomyces variotii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID584413Antifungal activity against 9 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID561921Elimination rate in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID524015Cmin in high fat fed healthy human skin at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID557629Fungicidal activity against Rhizomucor2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532156Antifungal activity against Fusarium oxysporum2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575341Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID532138Antifungal activity against Aspergillus fumigatus2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555804Antimicrobial activity against Scytalidium hyalinum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID258671Antifungal activity against Candida albicans2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].
AID563798Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID516342Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as abnormalities in nuclear membrane at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID524014Cmin in high fat fed healthy human plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID532042Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID563411Antifungal activity against Aspergillus niger isolate CM-3551 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID564652Antimicrobial activity against Aspergillus fumigatus isolate 25 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID541615Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID572469Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572438Tmax in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576486Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID584398Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID730408Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as decrease in blood parasitemia level at 50 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infe2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID575068Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 20 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID518400Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54W mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID425363Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID563420Antifungal activity against Aspergillus foetidus isolate CM-4995 obtained from prosthesis after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID522418Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID549319Antifungal activity against Rhizopus microsporus after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID564376Antimicrobial activity against Aspergillus fumigatus isolate 8 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522417Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572683Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522521Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1062795Plasma concentration in Swiss mouse at 20 mg/kg, po after 24 hrs by LC/MS analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID524022AUC (0 to 24 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID1383454Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.005 uM by fluorescence based analysis (Rvb = 100%)2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID522401Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID405099Antimicrobial activity against Rhizomucor sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID518404Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220V mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID549311Antifungal activity against Rhizopus oryzae after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID575202Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID519422Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-1290 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID522561Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564204Antimicrobial activity against Aspergillus fumigatus isolate 45 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID522470Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564195Antimicrobial activity against Aspergillus fumigatus isolate 36 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572219Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID425369Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.25 ug/ml caspofungin measured at 4 ug/ml measured after 48 hrs2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID572448Apparent total body clearance in fasted healthy human at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522459Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID524024T>MIC90 in fungus infected patient plasma at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID565403Antifungal activity against Rhizopus microsporus IHEM 4770 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1898165Antifungal activity against Candida albicans 28#
AID565565Antifungal activity against Rhizopus microsporus FMR 3542 infected in OF1 mouse assessed as reduction in fungal load in brain at 40 mg/kg, QD for 5 days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1301914Antiproliferative activity against HUVEC assessed as inhibition of VEGF induced cell proliferation after 72 hrs by MTS assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID581899Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth receiving antifungal drug after 116 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID549314Antifungal activity against Mycocladus corymbifer after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID549313Antifungal activity against Mucor circinelloides after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1294748Antileishmanial activity against Leishmania amazonensis infected in mouse J774 cells after 72 hrs using 2 hrs parasite exposed mouse J774 cells2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
AID564668Antimicrobial activity against Aspergillus fumigatus isolate 41 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563413Antifungal activity against Aspergillus tubingensis isolate CM-4000 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID576475Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522488Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498156Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532043Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID564644Antimicrobial activity against Aspergillus fumigatus isolate 17 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572414AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572669Toxicity in healthy human assessed as dizziness at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369364Antimicrobial activity against Candida krusei blood isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID575226Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID572207Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID405100Antimicrobial activity against Absidia corymbifera after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID572417AUC in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576449Ratio of AUC (0 to 24 hrs) in lung transplant recipient epithelial lining fluid to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID546079Antifungal activity against Candida lipolytica isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID581896Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx after 21 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575349Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID564414Antimicrobial activity against Aspergillus fumigatus isolate 46 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID508581Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID563822Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID581884Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth after 108 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1419503Antifungal activity against Aspergillus flavus ATCC MYA-3631 incubated for 48 hrs by CLSI M38-A2 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID498151Antifungal activity against Candida tropicalis FMR 10238 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564666Antimicrobial activity against Aspergillus fumigatus isolate 39 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1487222Inhibition of CYP11B2 in human hepatocyte microsomes using deoxycorticosteroid substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID279073Cmax in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID369375Antimicrobial activity against Candida dubliniensis isolate from superficial infection2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID564385Antimicrobial activity against Aspergillus fumigatus isolate 17 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID565554Antifungal activity against Rhizopus microsporus UTHSC 04-3294 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1419572Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus nidulans ATCC 381632017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID673470Plasma concentration in Swiss mouse at 50 mg/kg, po after 8 hrs2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID532333Antifungal activity against Aspergillus niger by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID542722Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 10 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID576492Cmax in healthy human epithelial lining fluid at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID425161Antifungal activity against Candida glabrata isolate 4198 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID522512Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID508321Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564205Antimicrobial activity against Aspergillus fumigatus isolate 46 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID369154Antifungal activity against Rhizopus strain 8 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID522498Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563348Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID564670Antimicrobial activity against Aspergillus fumigatus isolate 43 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584409Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405112Antimicrobial activity against Cunninghamella sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID509101Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in OF1 mouse assessed as increase in mouse survival at 40 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID580668Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID278449Reduction of number of infection foci in Absidia corymbifera 4535 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID425362Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID532132Antifungal activity against Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID576438Ratio of Cmax in lung transplant recipient alveolar cell after 12 hrs to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID522508Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID582224Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575206Antifungal activity against Cunninghamella echinulata FMR 10974 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID519426Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3538 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID522465Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID575217Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1265848Antifungal activity against azole-resistant Candida albicans MYA-1237 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID522530Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522542Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498141Antifungal activity against Candida tropicalis FMR 8898 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID508586Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID279052Apparent total clearance in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID498172Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID519432Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4415 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1498548Binding affinity to Candida albicans CYP51 by spectral titration method2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID541898Protein binding in human2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID278434Antimicrobial activity against Rhizopus oryzae 47452007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID564522Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID1265836Antifungal activity against azole-resistant Candida albicans ATCC 10231 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID532152Antifungal activity against Scedosporium apiospermum2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532347Antifungal activity against Fusarium solani by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID522425Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID532323Antifungal activity against Candida guilliermondii by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID598301Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 27 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID542723Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 30 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID572686Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532330Antifungal activity against Aspergillus fumigatus by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID565557Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 40 mg/kg, po QD measured after 3 hrs post last dose2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID564199Antimicrobial activity against Aspergillus fumigatus isolate 40 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575224Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1419540Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida albicans ATCC 641242017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID1419504Antifungal activity against Aspergillus nidulans ATCC 38163 incubated for 48 hrs by CLSI M38-A2 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID1557086Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID564657Antimicrobial activity against Aspergillus fumigatus isolate 30 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID498143Antifungal activity against Candida tropicalis FMR 9727 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID576476Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID516336Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as accumulation of lanosterol and eburicol precursors at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID524021AUC (0 to 24 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID508584Antifungal activity against wild type Aspergillus fumigatus infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID522462Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID522404Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID576454T>MIC90 for Aspergillus spp. infected lung transplant recipient plasma at 400 mg, po every 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID283593Average plasma concentration in ITT population of juvenile patients with invasive fungal infection at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID524017AUC (0 to 12 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID1487218Inhibition of CYP51 in Aspergillus flavus assessed as inhibition of microbe growth incubated for 48 to 168 hrs by CLSI M27-A3 guideline based method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID564387Antimicrobial activity against Aspergillus fumigatus isolate 19 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID549316Antifungal activity against Cunninghamella bertholletiae after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID572467Half life in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID508312Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID405098Antimicrobial activity against Mucor circinelloides after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID584410Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564437Antimicrobial activity against Aspergillus fumigatus isolate 19 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID584588Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID580579Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID425782Antifungal activity against Candida parapsilosis PA/71 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID531223Antimicrobial activity against Rhizomucor spp. conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID563810Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID522491Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564663Antimicrobial activity against Aspergillus fumigatus isolate 36 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID581890Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581870Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool after 36 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID519436Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-4063 obtained from bronchoalveolar aspirate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID576462AUC (0 to 12 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID545152Antimicrobial activity against Candida albicans isolate R after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID1684562Antifungal activity against Aspergillus fumigatus ATCC 36262021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID516327Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as appearance of large autophagic vesicles at 0.25 uM after 48 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID673461Kinetic solubility of the compound at pH 6.5 by nephelometric analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID369380Antimicrobial activity against Saccharomyces cerevisiae isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID563373Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID508589Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein infected in CD1 mouse assessed as 50% effective pharmacodynamic index administered orally qd for 14 days measured post last dose2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID572674Toxicity in healthy human assessed as headache at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572212Cmax in healthy human plasma at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522539Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID584389Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID572687Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID561919Cmax in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID522472Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1265847Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiom2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1419554Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida glabrata ATCC 20012017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID549320Antifungal activity against Rhizomucor pusillus after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID575347Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID564519Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID522481Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522562Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID498163Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID557810Drug level in patient serum with acute graft-versus-host disease by HPLC analysis2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
AID581905Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID546075Antifungal activity against Candida guilliermondii isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID565404Antifungal activity against Rhizopus microsporus IHEM 5234 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID582252Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1684559Antifungal activity against Mucor ramosissimus ATCC 902862021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections.
AID576461Ratio of AUC (0 to 12 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID532321Antifungal activity against Candida lusitaniae by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID525600Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID509103Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 40 mg/kg, po qd administered 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID279042Apparent total clearance in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID564618Antimicrobial activity against Aspergillus fumigatus isolate 41 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID285217Mortality rate in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID278458Reduction of infection foci size in Absidia corymbifera 4535 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID531209Antimicrobial activity against Mucor spp. conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID425374Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of caspofungin MIC measured at 5 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID522398Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID561923AUClast in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID581860Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1557083Antifungal activity against Candida guilliermondii T-47 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID285218Mortality rate in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID525590Antibacterial activity against azole-susceptible Candida albicans DSY294 by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID532322Antifungal activity against Candida tropicalis by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID561912Cmax in healthy human at 400 mg/kg, po by ITT analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID564630Antimicrobial activity against Aspergillus fumigatus isolate 3 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID581910Ratio of CDR1 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to CDR1 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531216Antimicrobial activity against Mucor spp. hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID563817Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID576491Cmax in healthy human plasma at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID532045Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID572434Tmax in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID498003Antifungal activity against Candida tropicalis FMR 9726 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID541607Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID532139Antifungal activity against Aspergillus terreus2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID518600Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, A284A mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID519438Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-3227 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519424Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3364 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID673466Plasma concentration in Swiss mouse at 20 mg/kg, po after 1 hr2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID563797Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID521970Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID576464Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID278445Reduction of number of infection foci in Rhizopus oryzae 4570 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID525599Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method sCandida albicans DSY2942010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID563140Antifungal activity against Scedosporium apiospermum IHEM 14464 by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID564650Antimicrobial activity against Aspergillus fumigatus isolate 23 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572432Tmax in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564429Antimicrobial activity against Aspergillus fumigatus isolate 11 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID516328Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as swelling of nuclear membrane at 0.25 uM after 48 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID279067Apparent total clearance in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID405104Antimicrobial activity against Rhizopus arrhizus assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID564399Antimicrobial activity against Aspergillus fumigatus isolate 31 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564191Antimicrobial activity against Aspergillus fumigatus isolate 32 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575208Antifungal activity against Cunninghamella echinulata UTHSC 01-2298 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID565550Antifungal activity against Rhizopus microsporus IHEM 13311 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1419494Antifungal activity against Candida albicans ATCC 64124 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID598232Antimicrobial activity against Candida tropicalis isolate 22 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID541571Cmin in healthy human plasma at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID572213Cmax in fasted healthy human plasma at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532339Antifungal activity against Rhizopus species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564421Antimicrobial activity against Aspergillus fumigatus isolate 3 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572655Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576450Cmax in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID541874Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID522475Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID563379Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID405095Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID522402Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522419Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID524009Tmax in high fat fed healthy human skin at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID572480Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522541Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID425169Antifungal activity against Candida glabrata isolate 4198 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID1309052Antifungal activity against Candida albicans ATCC MYA-1003 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID532141Antifungal activity against Aspergillus niger2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1419549Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC 12372017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID564627Antimicrobial activity against Aspergillus fumigatus isolate 50 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1546308Binding affinity to full length Trypanosoma cruzi Tulahuen C4 C-terminal His-tagged CYP51 expressed in Escherichia coli HMS174 (DE3) assessed as induction of shift in Soret band by spectrophotometry2020Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1
A new chemotype with promise against Trypanosoma cruzi.
AID572656Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID563813Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID564610Antimicrobial activity against Aspergillus fumigatus isolate 33 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564653Antimicrobial activity against Aspergillus fumigatus isolate 26 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID581881Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth receiving antifungal drug after 124 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID425786Antifungal activity against Candida albicans M61 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
AID425376Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured at 5 ug/disk after 24 hrs by halo assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID498150Antifungal activity against Candida tropicalis FMR 10237 assessed as compound concentration causing =>99% reduction in microbial growth2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID563818Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID576261Cmin in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID498359Apparent volume of distribution in patient with diarrhea undergoing allogenic hematopoietic stem cell transplantation2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
AID1851975Cytotoxicity against mouse 3T3 cells2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID519449Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-4518 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID572478Apparent volume of distribution in fasted healthy human at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572461Half life in fasted healthy human at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID549318Antifungal activity against Rhizopus microsporus after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID524737Antimicrobial activity against Fusarium solani after 48 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID532136Antifungal activity against Trichosporon asahii2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID584597Antifungal activity against 1 day cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID572437Tmax in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID541880Toxicity in healthy human plasma assessed as hematological analysis at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID564372Antimicrobial activity against Aspergillus fumigatus isolate 4 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1309047Antifungal activity against Candida albicans ATCC 64124 after 48 hrs by CLSI M27-A3 method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID576469Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID541598Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1498546Inhibition of Aspergillus fumigatus CYP51 assessed as reduction in [3-3H]eburicol 14alpha-demethylation at 0.75 uM preincubated for 60 secs followed by NADPH addition measured after 60 mins by RP-HPLC analysis relative to control2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic
AID541590AUC (0 to 12 hrs) in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID576257fAUC (0 to 24 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID581862Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564433Antimicrobial activity against Aspergillus fumigatus isolate 15 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575751Antimicrobial activity against sterol 14-alpha demethylase isoenzyme B-deficient Aspergillus fumigatus CEA102010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID598296Antimicrobial activity against Candida parapsilosis isolate 26 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID572421AUC in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564182Antimicrobial activity against Aspergillus fumigatus isolate 23 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563376Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated 2 days prior of infection2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID555276Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 5205 infected in immunosuppressed-OF1 mouse assessed as reduction in spleen fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.
AID369394Antimicrobial activity against Pichia ohmeri isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID498160Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564412Antimicrobial activity against Aspergillus fumigatus isolate 44 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575499Antifungal activity against Aspergillus fumigatus isolates harboring Cyp51A TR/L98H mutation by EUCAST method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1706434Cytotoxicity against rat 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1689829Antifungal activity against Scedosporium apiospermum SCAP1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189New azole antifungals with a fused triazinone scaffold.
AID1419515Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID576489Ratio of fAUC (0 to 24 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp.2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID1265849Antifungal activity against azole-resistant Candida albicans MYA-1003 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID522415Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522496Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564647Antimicrobial activity against Aspergillus fumigatus isolate 20 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID542729Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as reduction of fungal burden in brain at 60 mg/kg/day, po administered 8 hrs post infection for 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID279196Antifungal activity against Aspergillus flavus conidia2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID521797Fungistatic activity against Candida glabrata isolate 4293 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID522476Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID572436Tmax in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564184Antimicrobial activity against Aspergillus fumigatus isolate 25 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID582236Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID564639Antimicrobial activity against Aspergillus fumigatus isolate 12 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID525592Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID516334Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as reduction in episterol content at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID522428Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522513Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564169Antimicrobial activity against Aspergillus fumigatus isolate 10 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID535617Antifungal activity against Candida tropicalis T7 blood stream isolate2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID598295Antimicrobial activity against Candida glabrata isolate 49 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID498012Antifungal activity against Candida tropicalis FMR 10238 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID565553Antifungal activity against Rhizopus microsporus UTHSC 03-1802 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID278435Antimicrobial activity against Absidia corymbifera 45352007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID581887Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID549328Antifungal activity against Apophysomyces spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID564427Antimicrobial activity against Aspergillus fumigatus isolate 9 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564661Antimicrobial activity against Aspergillus fumigatus isolate 34 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1171000Volume of distribution in human2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID584590Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID521795Fungistatic activity against Candida glabrata isolate 4198 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID509098Antifungal activity against Fonsecaea monophora CBS 269.372010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID522489Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID542732Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic mouse assessed as reduction of fungal burden in brain at 60 mg/kg/day, po administered 8 hrs post infection for 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID522546Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-51 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID322863Antifungal activity against azole-resistant Aspergillus fumigatus V48/27-CM3936 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1419569Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus flavus ATCC MYA-36312017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID532344Antifungal activity against Scedosporium apiospermum by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID584598Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID531470Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring M220V, M220K, M220T and M220I mutation in cyp51A gene after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID1873196Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by liquid scintillation counter analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID522504Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID405113Antimicrobial activity against Apophysomyces elegans assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID572661Toxicity in healthy human assessed as adverse events at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564607Antimicrobial activity against Aspergillus fumigatus isolate 30 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563826Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Experimental murine scedosporiosis: histopathology and azole treatment.
AID564398Antimicrobial activity against Aspergillus fumigatus isolate 30 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564637Antimicrobial activity against Aspergillus fumigatus isolate 10 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID425158Antifungal activity against Candida glabrata isolate 4198 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID564198Antimicrobial activity against Aspergillus fumigatus isolate 39 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID575227Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID508326Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID572425AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID369385Antimicrobial activity against Geotrichum capitatum isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID580596Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID519450Antimicrobial activity against Aspergillus fumigatus ATCC 2004305 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID522457Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID584369Ratio of URA3 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to URA3 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID598292Antimicrobial activity against Candida glabrata isolate 30 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID572673Toxicity in healthy human assessed as headache at 400 mg BID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564386Antimicrobial activity against Aspergillus fumigatus isolate 18 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572451Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID564162Antimicrobial activity against Aspergillus fumigatus isolate 3 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID531221Antimicrobial activity against Absidia corymbifera conidia after 24 hrs by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID1706437Selectivity index, ratio of IC50 for cytotoxicity against rat 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID524018AUC (0 to 12 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID575216Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID508579Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID283599Average plasma concentration in Aspergillus fumigatus infected juvenile chronic granulomatous disease patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID564200Antimicrobial activity against Aspergillus fumigatus isolate 41 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID572433Tmax in fasted healthy human at 200 mg QID, po administered as suspension for 7 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID525402Antifungal activity against Candida glabrata isolate 4205 after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID598294Antimicrobial activity against Candida glabrata isolate 46 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID518603Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID563400Antifungal activity against Aspergillus niger isolate CM-4316 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID564170Antimicrobial activity against Aspergillus fumigatus isolate 11 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID562117Cmax in healthy human at 400 mg/kg, po2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID1419496Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-90819 incubated for 48 hrs by modified CLSI M27-A3 protocol based method2017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID1062802Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 amastigotes infected in rat L6 cells after 96 hrs by colorimetric method2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID522490Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522500Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564171Antimicrobial activity against Aspergillus fumigatus isolate 12 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID549323Antifungal activity against Rhizomucor variabilis after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID498171Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID524006Tmax in high fat fed healthy human plasma at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID522509Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID575752Antimicrobial activity against Aspergillus fumigatus CEA102010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID522495Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID525594Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID522412Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID531213Antimicrobial activity against Syncephalastrum racemosum conidia after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID564602Antimicrobial activity against Aspergillus fumigatus isolate 25 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID564165Antimicrobial activity against Aspergillus fumigatus isolate 6 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576472Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID369157Antifungal activity against Absidia strain 18 zygomycota by conventional morphological method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
AID509398Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 10 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID541608Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID498169Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 dayss2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532147Antifungal activity against Rhizopus species2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID563409Antifungal activity against Aspergillus tubingensis isolate CM-3125 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID673495Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 10 mg/kg, ip administered 8 days after post infection qd for 5 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID545664Cellular uptake in RBC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID564836Antimicrobial activity against Aspergillus fumigatus isolate 45 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID322855Antifungal activity against azole-resistant Aspergillus fumigatus V27/28-CM3273 isolate from patient by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID576493Cmax in healthy human alveolar cell at 400 mg, po BID by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID572449Apparent total body clearance in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID576480Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID584419Antifungal activity against 85 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID584406Antifungal activity against 25 days cultured Candida glabrata isolated from invasive fungal infected subject blood receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522409Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID522440Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID432802Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID581885Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth receiving antifungal drug after 108 days prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID516333Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as accumulation of lanosterol and eburicol precursors at 5 uM after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID576457Tmax in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID524008Tmax in high fat fed healthy human skin at 400 mg, po bid after 1 day2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID498157Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID564402Antimicrobial activity against Aspergillus fumigatus isolate 34 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID542731Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic mouse assessed as reduction of fungal burden in kidneys at 60 mg/kg/day, po administered 8 hrs post infection for 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID575221Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID279046AUC (0-12 hrs) in >=65 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID425170Antifungal activity against Candida glabrata isolate 4205 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID522437Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID1898160Antifungal activity against Candida albicans 25#
AID529668Antimicrobial activity against Paecilomyces lilacinus by microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Susceptibility testing and molecular classification of Paecilomyces spp.
AID1383443Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as inhibition of microbe growth by fluorescence based analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID572464Half life in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID531218Antimicrobial activity against Rhizopus microsporus hyphae after 24 hrs by XTT method in presence of amphotericin B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
AID564180Antimicrobial activity against Aspergillus fumigatus isolate 21 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID598306Antimicrobial activity against Candida parapsilosis ATCC 22019 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID542730Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic BALB/c mouse assessed as improved time to death at 60 mg/kg/day, po administered 24 hrs post infection for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
AID580586Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1851974Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as reduction in parasite growth at Emax concentration incubated for 48 hrs by Hoechst 3348 staining based analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID564629Antimicrobial activity against Aspergillus fumigatus isolate 2 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID563397Antifungal activity against Aspergillus niger isolate CM-4213 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID509105Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen compound administered qd 1 day after infection for 7 days2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID541610Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1898225Cytotoxicity against HUVEC assessed as cell viability at 64 ug/ml incubated for 24 hrs by CCK-8 assay
AID1898172Antifungal activity against Candida krusei 629
AID1557087Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1898179Antifungal activity against Candida auris D12
AID563578Cmin in healthy human plasma before initiation of 6 mg/kg BID2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.
AID1487223Inhibition of CYP17 lyase in human hepatocyte microsomes using 17a-hydroxypregnenolone substrate by HPLC/MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
AID564642Antimicrobial activity against Aspergillus fumigatus isolate 15 by oxygen consumption method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1265838Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID522505Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID279077Apparent total clearance in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID524028Toxicity in healthy human assessed as treatment-emergent adverse events at 400 mg, po bid after 8 days2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
AID278475Percentage of infected kidney in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID519441Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3764 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID522532Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 after 24 to 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID564175Antimicrobial activity against Aspergillus fumigatus isolate 16 by CLSI M38-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID563362Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID580590Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID508330Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID564410Antimicrobial activity against Aspergillus fumigatus isolate 42 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID283600Average plasma concentration in Candida spp infected juvenile acute myelogenous leukemia patient at 800 mg/day, po2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
AID572654Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572453Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID518610Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, E427K mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID584602Antifungal activity against 19 days cultured Candida krusei isolated from invasive fungal infected subject blood receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID508315AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID532334Antifungal activity against Rhizomucor species by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID516321Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as cell death at 0.25 uM after 72 hrs by electron microscopy2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
AID582240Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545166Antimicrobial activity against Candida albicans isolate C after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID522464Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID531471Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring Tandem repeat-L98H (TR) mutation in cyp51A gene after 48 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID521799Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs po2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID572444Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID673500Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 20 mg/kg, po administered after 2 cycles of immunosuppression qd for 10 days2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID572664Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID279194Antifungal activity against Aspergillus fumigatus conidia2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
AID584392Antifungal activity against 19 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID580592Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID584415Antifungal activity against 31 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID497819Antifungal activity against Fusarium sp. clinical isolates after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro activity of thimerosal against ocular pathogenic fungi.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID572420AUC in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID575496Antifungal activity against Aspergillus niger isolate2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1599287Antiviral activity against DENV2 16881 infected in African green monkey Vero cells by qRT-PCR analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID522427Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID369396Antimicrobial activity against Trichosporon mucoides isolate2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
AID572472Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID532328Antifungal activity against Trichosporon asahii by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564434Antimicrobial activity against Aspergillus fumigatus isolate 16 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1484682Leishmanicidal activity against Leishmania amazonensis JOSEPHA promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID563367Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID561914Elimination rate in healthy human at 400 mg/kg administered via nasogastric tube2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
AID521800Antifungal activity against fluconazole-susceptible Candida glabrata isolate 4205 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs post infection mea2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
AID522455Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID518601Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, L339L mutant gene by CLSI method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID498009Antifungal activity against Candida tropicalis FMR 10235 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.
AID532326Antifungal activity against Cryptococcus neoformans var. gattii by EUCAST method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID564409Antimicrobial activity against Aspergillus fumigatus isolate 41 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID576445T>MIC90 for Aspergillus spp. infected lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LS/MS analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
AID598305Antimicrobial activity against Candida krusei ATCC 6258 after 48 hrs by microdilution broth method2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.
AID1484681Leishmanicidal activity against Leishmania donovani 1S MHOM/SD/00/1S-2D promastigote forms after 18 hrs by indirect microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID532143Antifungal activity against Absidia corymbifera2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID279039Tmax in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
AID572222AUC in fasted healthy human at 400 mg administered as single dose suspension2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID572484Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
AID522447Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 at 5 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
AID322860Antifungal activity against azole-resistant Aspergillus fumigatus V34/78-CM3279 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID509393Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 10 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID563356Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
AID508322Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1851976Selectivity index, ratio of CC50 for cytotoxicity against mouse 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID564418Antimicrobial activity against Aspergillus fumigatus isolate 50 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
AID1419545Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-908192017European journal of medicinal chemistry, Jun-16, Volume: 133Novel alkylated azoles as potent antifungals.
AID278461Percentage of infected brain in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Posaconazole prophylaxis in experimental systemic zygomycosis.
AID1557076Antifungal activity against Candida albicans P-87 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1534779Inhibition of hedgehog signaling pathway in mouse ASZ cells assessed as decrease in Gli1 mRNA expression after 48 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID425383Antifungal activity against 1.04 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as reduction in colony forming units treated with a therapeutic regimen of sterile saline solution from day 1 to day 2 followed by 30 mg/kg/day drug a2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
AID563408Antifungal activity against Aspergillus foetidus isolate CM-5264 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID575212Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,539)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's25 (1.62)18.2507
2000's395 (25.67)29.6817
2010's902 (58.61)24.3611
2020's217 (14.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials103 (6.54%)5.53%
Trials0 (0.00%)5.53%
Reviews178 (11.30%)6.00%
Reviews0 (0.00%)6.00%
Case Studies350 (22.22%)4.05%
Case Studies0 (0.00%)4.05%
Observational37 (2.35%)0.25%
Observational0 (0.00%)0.25%
Other907 (57.59%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (75)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections[NCT03336502]Phase 170 participants (Actual)Interventional2017-12-20Completed
Pharmacokinetic of Intravenous Posaconazole in Critically Ill Patients[NCT05275179]10 participants (Actual)Observational2021-02-11Completed
A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis[NCT00423267]Phase 316 participants (Actual)Interventional2007-05-31Completed
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potentia[NCT03796533]120 participants (Anticipated)Interventional2018-12-10Recruiting
A Phase 0 Clinical Trial of Two Candidate Azoles (Ketoconazole and Posaconazole) for Patients With Recurrent High Grade Glioma[NCT03763396]Early Phase 130 participants (Anticipated)Interventional2019-08-01Active, not recruiting
Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)[NCT01377480]Phase 2120 participants (Actual)Interventional2011-07-06Completed
Pharmacokinetics of Posaconazole Given as a Single Intravenous Dose to Obese Subjects: Dosing Obese With Noxafil® Under a Trial (DONUT)[NCT03246386]Phase 424 participants (Actual)Interventional2017-11-05Completed
An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects[NCT03614455]Early Phase 136 participants (Actual)Interventional2018-07-13Completed
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies[NCT04771130]Phase 1/Phase 2260 participants (Anticipated)Interventional2021-05-24Recruiting
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (T[NCT04368559]Phase 3462 participants (Anticipated)Interventional2020-05-11Recruiting
Prospective Validation and Clinical Evaluation of a New Posaconazole Dosing Regimen for Children and Adolescents With Cystic Fibrosis and Aspergillus Infection[NCT04966234]Phase 2/Phase 3135 participants (Anticipated)Interventional2021-04-22Recruiting
An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral F901318 (Combined With Fluconazole and Posaconazole) in AML[NCT03036046]Phase 1/Phase 20 participants (Actual)Interventional2017-03-31Withdrawn(stopped due to Study no longer required)
A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis[NCT04218851]Phase 230 participants (Anticipated)Interventional2020-07-02Active, not recruiting
Modified Release Posaconazole in Patients With Cystic Fibrosis[NCT03421366]20 participants (Anticipated)Observational2018-03-01Recruiting
PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE[NCT01162967]Phase 278 participants (Actual)Interventional2010-09-30Completed
A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)[NCT03760445]Phase 1/Phase 20 participants (Actual)Interventional2019-11-15Withdrawn(stopped due to It was determined that the study design may not be optimal given the changing AML treatment landscape.)
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05520)[NCT01075984]Phase 1279 participants (Actual)Interventional2010-02-23Completed
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir[NCT00817765]Phase 124 participants (Anticipated)Interventional2009-01-31Completed
Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment[NCT03318159]Phase 240 participants (Anticipated)Interventional2018-04-20Recruiting
Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment[NCT02020213]Phase 40 participants (Actual)Interventional2013-12-31Withdrawn
Universal Posaconazole Prophylaxis Versus Pre-emptive Posaconazole Therapy for Fungal Infection Management Post-lung Transplantation[NCT03561415]Phase 2140 participants (Anticipated)Interventional2018-07-02Not yet recruiting
A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2[NCT04665037]Phase 240 participants (Anticipated)Interventional2022-02-22Recruiting
Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study[NCT05065658]351 participants (Anticipated)Observational2020-03-01Recruiting
Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection[NCT03717623]Phase 4100 participants (Anticipated)Interventional2019-08-01Recruiting
A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection[NCT00686543]Phase 475 participants (Actual)Interventional2007-12-31Completed
P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.[NCT00704951]0 participants (Actual)Observational2008-07-31Withdrawn
Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole[NCT00726609]214 participants (Actual)Observational2006-01-31Completed
Single Patient Emergency Treatment Use of Posaconazole in Invasive Fungal Infections[NCT00686621]0 participants Expanded AccessApproved for marketing
A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection[NCT00811928]Phase 3252 participants (Actual)Interventional2008-11-30Completed
Investigation of POsaconazole Prophylaxis in Children With Chronic Granulomatous Disease (CGD): Pharmacokinetics and Tolerability (iPOD)[NCT00799071]Phase 212 participants (Actual)Interventional2009-02-28Completed
A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis[NCT05468372]Phase 230 participants (Anticipated)Interventional2022-07-01Recruiting
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections[NCT02805946]Phase 421 participants (Actual)Interventional2017-04-28Completed
Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia[NCT00936117]Phase 225 participants (Actual)Interventional2009-09-30Completed
A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection[NCT00811642]Phase 363 participants (Actual)Interventional2008-11-30Completed
Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant[NCT00750737]Phase 346 participants (Actual)Interventional2008-06-30Completed
[NCT01901172]Phase 161 participants (Actual)Interventional2013-08-31Completed
Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections[NCT00034658]Phase 3336 participants (Actual)Interventional1998-12-31Completed
Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors.[NCT01951430]229 participants (Actual)Observational2014-03-31Completed
A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrom[NCT01200355]Phase 4113 participants (Actual)Interventional2010-09-09Completed
PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia[NCT03828773]320 participants (Anticipated)Interventional2019-02-11Recruiting
Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis[NCT02875743]Phase 4120 participants (Actual)Interventional2016-12-07Completed
Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice[NCT01436578]273 participants (Actual)Observational2012-02-29Completed
An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail[NCT00491764]Phase 2218 participants (Actual)Interventional2007-06-30Completed
Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients[NCT02968134]Phase 48 participants (Actual)Interventional2017-01-16Completed
A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease[NCT04966585]Phase 424 participants (Anticipated)Interventional2022-08-17Recruiting
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy[NCT02203773]Phase 1212 participants (Actual)Interventional2014-10-06Terminated(stopped due to Strategic considerations)
Efficacy, Safety and Serum Concentration of Posaconazole Tablets for Prevention of Pulmonary Fungal Infections in Patients With Hematopoietic Stem Cell Transplantation: An Open, Prospective, Observational, Multicenter Cohort Study[NCT04725942]360 participants (Anticipated)Observational2021-01-31Not yet recruiting
Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095[NCT00177749]Phase 410 participants Interventional2004-08-31Terminated(stopped due to Study is complete Analysis is complete)
Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections[NCT00033982]Phase 350 participants Interventional2002-04-11Completed
[NCT00034645]Phase 3600 participants (Actual)Interventional1999-01-31Completed
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia[NCT04194086]Phase 1/Phase 242 participants (Actual)Interventional2018-11-01Completed
Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections[NCT00034632]Phase 30 participants Interventional2001-04-30Completed
Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts[NCT00034671]Phase 298 participants (Actual)Interventional2001-01-31Completed
A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients[NCT00044486]Phase 3602 participants (Actual)Interventional2002-07-31Completed
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial[NCT04825275]Early Phase 110 participants (Anticipated)Interventional2022-02-08Recruiting
Effect of Inflammation on Pharmacokinetics of Posaconazole[NCT02492802]64 participants (Actual)Observational2015-08-13Completed
An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects[NCT03095547]Phase 10 participants (Actual)Interventional2017-05-31Withdrawn(stopped due to study no longer required in current format)
A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)[NCT01782131]Phase 3585 participants (Actual)Interventional2013-09-25Completed
A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area[NCT02372357]Phase 414 participants (Actual)Interventional2012-02-29Completed
Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients[NCT00002446]Phase 3300 participants Interventional1998-08-31Completed
Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial[NCT04876716]Phase 3650 participants (Anticipated)Interventional2021-05-11Recruiting
A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients[NCT01667107]Phase 426 participants (Actual)Interventional2013-01-23Terminated(stopped due to Study terminated due to an unfavorable risk-benefit analysis)
Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections[NCT02387983]Phase 165 participants (Actual)Interventional2015-05-06Completed
A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients[NCT00002399]Phase 2500 participants InterventionalCompleted
Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp[NCT02714504]239 participants (Actual)Interventional2008-08-31Completed
Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children[NCT02358499]Phase 131 participants (Actual)Interventional2015-01-31Completed
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles[NCT03066011]2,015 participants (Actual)Observational2017-03-16Completed
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)[NCT04752163]Phase 1/Phase 217 participants (Actual)Interventional2021-03-25Completed
An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects[NCT01984229]Phase 123 participants (Actual)Interventional2013-12-31Completed
"A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The TIP Study."[NCT00550732]Phase 240 participants (Actual)Interventional2007-12-31Completed
Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615)[NCT01777763]Phase 1230 participants (Actual)Interventional2009-06-30Completed
A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients[NCT03378479]Phase 488 participants (Actual)Interventional2017-12-27Completed
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)[NCT01716234]Phase 1142 participants (Actual)Interventional2008-04-17Terminated(stopped due to Study was terminated early (10 July 2015) based on preliminary analysis of pharmacokinetic data.)
A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia[NCT02452034]Phase 1118 participants (Actual)Interventional2015-09-07Completed
A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection[NCT02180165]Phase 3116 participants (Actual)Interventional2014-07-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adverse Events (AEs)
Discontinuations Due to an AE
Medically Significant Changes in Clinical Laboratory Results - Lab Values
Medically Significant Changes in Clinical Laboratory Results - Vital Signs
Participants With Invasive Fungal Infection (IFI)
Steady State (ss) Average Concentration (Cavg) of Posaconazole of Serial PK (Subgroup 1) on Day 10
Steady State Maximum Concentration (ssCmax) of POS of Serial PK (Subgroup 1) on Day 10
Steady State Minimum Concentration (ssCmin) of POS of Serial PK (Subgroup 1) on Day 10
Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of POS of Serial PK (Subgroup 1) on Day 10
Time to Steady-state Maximum Concentration (ssTmax) of POS of Serial PK (Subgroup 1) on Day 10
Total Body Clearance (CL) of POS of Serial PK (Subgroup 1) on Day 10
Percentage of Participants With ssCavg ≥500 ng/mL of Serial PK (Subgroup 1) on Day 10
POS Plasma Trough Concentrations in the Serial PK and Sparse PK Subgroups
POS Plasma Trough Concentrations in the Serial PK and Sparse PK Subgroups
Survival Status
Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period A
Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period B
Number of Participants With Treatment-emergent Adverse Events (TEAEs) That Occurred With POS in Period B
Number of Participants With Treatment-emergent Adverse Events (TEAEs)That Occurred With POS or FLU in Period A
Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) in Period B
Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A
Number of Participants With Laboratory Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS in Period B
Number of Participants With Laboratory Test Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS or FLU in Period A
Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction
Single Dose Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC)
Single Dose Maximum Concentration of IV Posaconazole (Cmax)
Single Dose Time of Observed Maximum Concentration of IV Posaconazole (Tmax)
Single Dose Trough Concentration of IV Posaconazole (Cmin)
Steady State Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC)
Steady State Area Under the Concentration Versus Time Curve of Oral Posaconazole (AUC)
Steady State Average Concentration of IV Posaconazole (Cavg)
Steady State Average Concentration of Oral Posaconazole (Cavg)
Steady State Maximum Concentration of IV Posaconazole (Cmax)
Steady State Maximum Concentration of Oral Posaconazole (Cmax)
Steady State Time of Observed Maximum Concentration of IV Posaconazole (Tmax)
Steady State Time of Observed Maximum Concentration of Oral Posaconazole (Tmax)
Steady State Trough Concentration of IV Posaconazole (Cmin)
Steady State Trough Concentration of Oral Posaconazole (Cmin)
Mean POS Plasma Concentrations on Days 2, 3, and 8.
Mean POS Plasma Concentrations on Days 8 and 15 Stratified by Randomized Dosing Regimen
Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 3 and ≥/<500 ng/mL on Day 8
Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 8 and ≥/<500 ng/mL on Day 15
Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 3 and ≥/<700 ng/mL on Day 8
Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15
Number of Participants Reporting Adverse Drug Reactions.
Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization
Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization
Number of Participants With Clinical Failure During Treatment
Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization
Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period
Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy
Time From Randomization to the First Onset of Proven or Probable IFI
Maximum Observed Concentration in Plasma (Cmax)
Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up
Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment
Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment
Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment
Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment
Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment
Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment
Incidence of Invasive Fungal Infection (IFI)
Efficacy Outcome Measured as Success or Failure
Time to Failure
To Compare Overall Survival Rates at 6 Weeks
To Compare the Incidence of Possible, Probable or Proven Invasive Fungal Infections Between Patients Who Receive Posaconazole and Those Who Receive Micafungin During Treatment Phase
To Compare the Number of Days on Study Drug Between Patients Who Receive Posaconazole and Patients Who Receive Micafungin.
Complete Cure of Onychomycosis at Week 48.
Effective Treatment of Onychomycosis at Week 48.
Treatment Success of Onychomycosis at Week 48
Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose
Posaconazole Exposure Expressed as Area Under the Unbound Concentrations-time Curve From Time Zero to Infinity
C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L
Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population
Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population
Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population
Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population
Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population
Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population
Percentage of Participants Who Died Through Day 84 in the FAS Population
Percentage of Participants Who Died Through Day 84 in the ITT Population
Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event
Percentage of Participants With at Least One Adverse Event
Percentage of Participants With at Least One Drug Related Adverse Event
Percentage of Participants With at Least One Serious Adverse Event
Percentage of Participants With at Least One Serious Drug Related Adverse Event
Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)
Percentage of Participants With Tier 1 Treatment Emergent Adverse Events
Steady State Average Concentration (Cavg) of Posaconazole With Food Intake
Maximum Serum Concentration of Posaconazole (Cmax)
Percentage of Participants Who Develop Invasive Fungal Infection
Time to Maximum Serum Concentration of Posaconazole (Tmax)
Time to Reach a Serum Concentration of Posaconazole of >=0.5 mg/L
Concentration of Posaconazole in Bronchoalveolar Lavage (BAL) and Serum
AUC0-24hr of Posaconazole on Day 1
Cmax of Posaconazole on Day 1
Cmin of Posaconazole on Day 1
Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of Posaconazole on Day 8
Steady-state Maximum Concentration (ssCmax) of Posaconazole on Day 8
Steady-state Minimum Concentration (ssCmin) of Posaconazole on Day 8
Time to Steady-state Maximum Concentration (ssTmax) of Posaconazole on Day 8
Tmax of Posaconazole on Day 1
Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8
Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of RO5424802: Cohort B
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Alectinib: Cohort A
AUC0-inf of RO5468924: Cohort A
AUC0-inf of RO5468924: Cohort B
AUClast of Alectinib: Cohort B
AUClast of RO5468924: Cohort A
AUClast of RO5468924: Cohort B
Cmax of Alectinib: Cohort B
Cmax of RO5468924: Cohort A
Cmax of RO5468924: Cohort B
Maximum Observed Plasma Concentration (Cmax) of Alectinib: Cohort A
Metabolite/Parent Ratio for AUC0-inf: Cohort B
Metabolite/Parent Ratio for Cmax: Cohort B
t1/2 of Alectinib: Cohort B
t1/2 of RO5468924: Cohort A
t1/2 of RO5468924: Cohort B
Terminal Half-life (t1/2) of Alectinib: Cohort A
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alectinib: Cohort A
Tmax of Alectinib: Cohort B
Tmax of RO5468924: Cohort A
Tmax of RO5468924: Cohort B
Number of Participants Experiencing Adverse Events (AEs)
Overall Survival at 3 Months
Percentage of Participants With a CR or PR by 12 Weeks
Percentage of Participants With Infection-free Survival After the Last Dose of Study Drug
Percentage of Participants With Complete Response (CR) or Partial Response (PR) by 12 Weeks or End of Treatment
Percentage of Participants With CR or PR by 4 Weeks and by 26 Weeks
Apparent Total Body Clearance (CL/F) for Posaconazole Tablet
Average Concentration (Cavg) of Posaconazole Tablet
Minimum Concentration (Cmin) of Posaconazole Tablet
Number of Participants Discontinuing Study Treatment Due to an AE
Number of Participants Surviving at Day 65
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Number of Participants With Treatment-Related AEs
Maximum Concentration (Cmax) of Posaconazole Tablet
Time to Maximum Concentration (Tmax) of Posaconazole Tablet
Average Concentration of Posaconazole (Cavg) on Day 1 (Single Dose)
Average Concentration of Posaconazole (Cavg) on Day 7 (Steady State)
Number of Participants With an Adverse Event
Number of Participants With an Adverse Event Leading to Study Drug Discontinuation
Apparent Total Body Clearance (CL/F) for POS Administered by PFS
Number of Participants Who Discontinued Treatment of Study Drug Due to an Adverse Event (AE)
Number of Participants With an Adverse Event (AE)
Total Body Clearance (CL) for POS Administered by IV
Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose for POS
Average Steady-state Plasma Concentration (Cavg) for POS
Maximum Plasma Concentration (Cmax) for POS
Minimum Plasma Concentration (Cmin) for POS
Time of Maximum Plasma Concentration (Tmax) for POS
Number of Participants With an Adverse Event
Percentage of Participants With Chronic Pulmonary Aspergillosis With Clinical Response of Resolution in Cohort 2 at Day 42
Percentage of Participants With Chronic Pulmonary Aspergillosis With Clinical Response of Resolution in Cohort 2 at Day 84
Percentage of Participants With Chronic Pulmonary Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 42
Percentage of Participants With Chronic Pulmonary Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 84
Percentage of Participants With Chronic Pulmonary Aspergillosis With Radiological Response of Resolution in Cohort 2 at Day 42
Percentage of Participants With Invasive Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 42
Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 42
Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 84
Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 84 as Assessed by the Clinical Investigator
Percentage of Participants With Successful Overall Response for Invasive Aspergillosis and Chronic Pulmonary Aspergillosis in Cohort 2 at End of Trial (Day 84)
Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 42
Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 42 as Assessed by the Clinical Investigator
Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 84
Percentage of Participants With Successful Overall Response for Zygomycosis in Cohort 2 at Day 42
Percentage of Participants With Successful Overall Response for Zygomycosis in Cohort 2 at Day 84
Percentage of Participants With Invasive Aspergillosis With Clinical Response of Resolution or Improvement in Cohort 2 at Day 42
Percentage of Participants With Invasive Aspergillosis With Clinical Response of Resolution or Improvement in Cohort 2 at Day 84
Percentage of Participants With Invasive Aspergillosis With Radiological Response of Resolution or Improvement in Cohort 2 at Day 42
Percentage of Participants With Invasive Aspergillosis With Radiological Response of Resolution or Improvement in Cohort 2 at Day 84

Adverse Events (AEs)

Number of participants with one or more AEs where AEs are defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. (NCT03336502)
Timeframe: Up to 58 days

InterventionNumber of Participants (Number)
POS IV (MK-5592)70

[back to top]

Discontinuations Due to an AE

Number of participants discontinued from study medication due to an AE where AEs are defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. (NCT03336502)
Timeframe: Up to 28 days

InterventionParticipants (Number)
POS IV (MK-5592)9

[back to top]

Medically Significant Changes in Clinical Laboratory Results - Lab Values

The number of participants with clinical laboratory values outside of normal range (NCT03336502)
Timeframe: Up to 28 days

InterventionParticipants (Number)
Serial PK (Subgroup 1)30
Sparse PK (Subgroup 2)35

[back to top]

Medically Significant Changes in Clinical Laboratory Results - Vital Signs

The number of participants with values of vital signs outside of normal range (NCT03336502)
Timeframe: Up to 28 days

InterventionParticipants (Number)
Serial PK (Subgroup 1)27
Sparse PK (Subgroup 2)31

[back to top]

Participants With Invasive Fungal Infection (IFI)

Number of participants with possible, probable, or proven IFI observed during the whole study period (NCT03336502)
Timeframe: Up to 28 days

InterventionParticipants (Number)
POS IV (MK-5592)2

[back to top]

Steady State (ss) Average Concentration (Cavg) of Posaconazole of Serial PK (Subgroup 1) on Day 10

"Characterization of the pharmacokinetics (PK) parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Steady-state Cavg, where Cavg is defined as AUC0-24hr divided by the dosing interval.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Interventionng/mL (Mean)
Serial PK (Subgroup 1)2986.28

[back to top]

Steady State Maximum Concentration (ssCmax) of POS of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Cmax is defined as the maximum concentration of POS in plasma.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Interventionng/mL (Mean)
Serial PK (Subgroup 1)4612.22

[back to top]

Steady State Minimum Concentration (ssCmin) of POS of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Cmin is defined as the minimum concentration of POS in plasma.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Interventionng/mL (Mean)
Serial PK (Subgroup 1)2311.33

[back to top]

Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of POS of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. AUC0-24 is defined as area under the plasma concentration-time curve from time 0 extrapolated to 24 hours.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Interventionhr*ng/mL (Mean)
Serial PK (Subgroup 1)71670.8

[back to top]

Time to Steady-state Maximum Concentration (ssTmax) of POS of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Tmax is defined as the time it takes to achieve maximum concentration of POS in plasma.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Interventionhr (Mean)
Serial PK (Subgroup 1)1.63

[back to top]

Total Body Clearance (CL) of POS of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. CL is defined as the time it takes for POS to be completely removed from the body's blood stream.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

InterventionmL/hr (Mean)
Serial PK (Subgroup 1)4767.90

[back to top]

Percentage of Participants With ssCavg ≥500 ng/mL of Serial PK (Subgroup 1) on Day 10

"Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Steady-state Cavg, where Cavg is defined as AUC0-24hr divided by the dosing interval. The percentage of participants with ssCavg ≥500 ng/mL are presented.~Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.~Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only." (NCT03336502)
Timeframe: Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

InterventionPercentage of Participants (Number)
Cavg 500 ng/mL to < 2500 ng/mLCavg 2500 ng/ML to < 3650 ng/mLCavg 3650 ng/mL or higher
Serial PK (Subgroup 1)40.733.325.9

[back to top]

POS Plasma Trough Concentrations in the Serial PK and Sparse PK Subgroups

Pre-dose plasma trough concentrations by study day between serial PK and Sparse PK - where serial PK is defined as multiple serial blood sampling of more than 6 timepoints; and sparse PK is defined as few blood samples taken and single or limited timepoints (NCT03336502)
Timeframe: Day 3, Day 6, Day 10, Day 15, Day 22, Day 28

Interventionng/mL (Mean)
Day 3Day 6Day 10Day 15
Serial PK (Subgroup 1)1800.932106.072473.782471.63

[back to top]

POS Plasma Trough Concentrations in the Serial PK and Sparse PK Subgroups

Pre-dose plasma trough concentrations by study day between serial PK and Sparse PK - where serial PK is defined as multiple serial blood sampling of more than 6 timepoints; and sparse PK is defined as few blood samples taken and single or limited timepoints (NCT03336502)
Timeframe: Day 3, Day 6, Day 10, Day 15, Day 22, Day 28

Interventionng/mL (Mean)
Day 3Day 6Day 10Day 15Day 22Day 28
Sparse PK (Subgroup 2)203325142466268026033180

[back to top]

Survival Status

Survival assessment as to whether a participant is alive or dead, included all participants who died - 2 during study treatment, 1 during safety follow-up, 2 during survival follow-up (Day 60 to 70 post dose), and 1 participant who died during serious AE (SAE) follow-up at 97 days after first dose but was beyond the safety and the survival follow-up period (NCT03336502)
Timeframe: Up to 98 days

InterventionParticipants (Number)
AliveDead
POS IV (MK-5592)646

[back to top]

Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period A

(NCT00423267)
Timeframe: 12 months

InterventionParticipants (Number)
Posaconazole0
Fluconazole0

[back to top]

Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period B

(NCT00423267)
Timeframe: 12 months

InterventionParticipants (Number)
Posaconazole0

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) That Occurred With POS in Period B

Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state. (NCT00423267)
Timeframe: 12 months

InterventionParticipants (Number)
Posaconazole8

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs)That Occurred With POS or FLU in Period A

Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state. (NCT00423267)
Timeframe: 12 months

InterventionParticipants (Number)
Posaconazole8
Fluconazole5

[back to top] [back to top] [back to top]

Number of Participants With Laboratory Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS in Period B

Severity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. This is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE; Grade 2 Moderate AE; Grade 3 Severe AE; Grade 4 Life-threatening or disabling AE; Grade 5 Death related to AE. (NCT00423267)
Timeframe: 12 months

InterventionParticipants (Number)
HematologyLiver function testsRenal function testsElectrolytes
Posaconazole21110

[back to top]

Number of Participants With Laboratory Test Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS or FLU in Period A

Severity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. This is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE; Grade 2 Moderate AE; Grade 3 Severe AE; Grade 4 Life-threatening or disabling AE; Grade 5 Death related to AE. (NCT00423267)
Timeframe: 12 months

,
InterventionParticipants (Number)
HematologyLiver function testsRenal function testsElectrolytes
Fluconazole1312
Posaconazole4400

[back to top]

Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction

Blood samples were collected for qualitative polymerase chain reaction (PCR) assay for Trypanosoma cruzi deoxyribonucleic acid (DNA). Successful response was defined as a negative qualitative PCR value at the Day 180 follow up visit. (NCT01377480)
Timeframe: Day 180

InterventionPercentage of participants (Number)
Posaconazole15.6
Placebo10.0
Posaconazole + Benznidazole82.1
Benznidazole + Placebo86.7

[back to top]

Single Dose Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, and 12 hours after start of infusion on Day 1 (Cohorts 0, 1 and 2)

Interventionhour*ng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)5940
POS 200 mg IV BID (Cohort 1)5390
POS 300 mg IV BID (Cohort 2)8240

[back to top]

Single Dose Maximum Concentration of IV Posaconazole (Cmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, and 12 hours after start of infusion on Day 1 (Cohorts 0, 1 and 2)

Interventionng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)881
POS 200 mg IV BID (Cohort 1)990
POS 300 mg IV BID (Cohort 2)1590

[back to top]

Single Dose Time of Observed Maximum Concentration of IV Posaconazole (Tmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, and 12 hours after start of infusion on Day 1 (Cohorts 0 and 1)

InterventionHours (Median)
POS 200 mg IV Single Dose (Cohort 0)1.42
POS 200 mg IV BID (Cohort 1)1.48
POS 300 mg IV BID (Cohort 2)1.54

[back to top]

Single Dose Trough Concentration of IV Posaconazole (Cmin)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: 12 hours after start of infusion on Day 1 (Cohorts 0, 1 and 2)

Interventionng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)318
POS 200 mg IV BID (Cohort 1)295
POS 300 mg IV BID (Cohort 2)467

[back to top]

Steady State Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, 12, and 24 hours after start of infusion on Day 14 (Cohorts 1 and 2), or Day 10 (Cohort 3)

Interventionhour*ng/mL (Mean)
POS 200 mg IV BID (Cohort 1)28241
POS 300 mg IV BID (Cohort 2)33754
POS 300 mg IV BID (Cohort 3)37586

[back to top]

Steady State Area Under the Concentration Versus Time Curve of Oral Posaconazole (AUC)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 3, 5, 8 and 12 hours after dosing on Day 7 (Cohort 0), or Day 28 (Cohorts 1 and 2)

Interventionhour*ng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)5080
POS 200 mg IV BID (Cohort 1)6920
POS 300 mg IV BID (Cohort 2)3970

[back to top]

Steady State Average Concentration of IV Posaconazole (Cavg)

Blood samples were collected from participants for the determination of plasma POS concentration. Cavg was calculated as steady state AUC / dosing interval (24 hours). (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, 12, and 24 hours after start of infusion on Day 14 (Cohorts 1 and 2), or Day 10 (Cohort 3)

Interventionng/mL (Mean)
POS 200 mg IV BID (Cohort 1)1180
POS 300 mg IV BID (Cohort 2)1410
POS 300 mg IV BID (Cohort 3)1566

[back to top]

Steady State Average Concentration of Oral Posaconazole (Cavg)

Blood samples were collected from participants for the determination of plasma POS concentration. Cavg was calculated as steady state AUC / dosing interval (12 hours). (NCT01075984)
Timeframe: Predose and 3, 5, 8 and 12 hours after dosing on Day 7 (Cohort 0), or Day 28 (Cohorts 1 and 2)

Interventionng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)423
POS 200 mg IV BID (Cohort 1)570
POS 300 mg IV BID (Cohort 2)331

[back to top]

Steady State Maximum Concentration of IV Posaconazole (Cmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, and 12 hours after start of infusion on Day 14 (Cohorts 1 and 2), or Day 10 (Cohort 3)

Interventionng/mL (Mean)
POS 200 mg IV BID (Cohort 1)1947
POS 300 mg IV BID (Cohort 2)2610
POS 300 mg IV BID (Cohort 3)3696

[back to top]

Steady State Maximum Concentration of Oral Posaconazole (Cmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 3, 5, 8 and 12 hours after dosing on Day 7 (Cohort 0), or Day 28 (Cohorts 1 and 2)

Interventionng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)494
POS 200 mg IV BID (Cohort 1)811
POS 300 mg IV BID (Cohort 2)430

[back to top]

Steady State Time of Observed Maximum Concentration of IV Posaconazole (Tmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 1, 1.5, 1.75, 4, 8, and 12 hours after start of infusion on Day 14 (Cohorts 1 and 2), or Day 10 (Cohort 3)

InterventionHours (Median)
POS 200 mg IV BID (Cohort 1)1.00
POS 300 mg IV BID (Cohort 2)1.50
POS 300 mg IV BID (Cohort 3)1.52

[back to top]

Steady State Time of Observed Maximum Concentration of Oral Posaconazole (Tmax)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: Predose and 3, 5, 8 and 12 hours after dosing on Day 7 (Cohort 0), or Day 28 (Cohorts 1 and 2)

InterventionHours (Median)
POS 200 mg IV Single Dose (Cohort 0)3.03
POS 200 mg IV BID (Cohort 1)3.05
POS 300 mg IV BID (Cohort 2)5.54

[back to top]

Steady State Trough Concentration of IV Posaconazole (Cmin)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: 24 hours after start of infusion on Day 14 (Cohorts 1 and 2), or Day 10 (Cohort 3)

Interventionng/mL (Mean)
POS 200 mg IV BID (Cohort 1)958
POS 300 mg IV BID (Cohort 2)1046
POS 300 mg IV BID (Cohort 3)1164

[back to top]

Steady State Trough Concentration of Oral Posaconazole (Cmin)

Blood samples were collected from participants for the determination of plasma POS concentration. (NCT01075984)
Timeframe: 12 hours after dosing on Day 7 (Cohort 0), or Day 28 (Cohorts 1 and 2)

Interventionng/mL (Mean)
POS 200 mg IV Single Dose (Cohort 0)370
POS 200 mg IV BID (Cohort 1)532
POS 300 mg IV BID (Cohort 2)316

[back to top]

Mean POS Plasma Concentrations on Days 2, 3, and 8.

Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 2, 3, and 8

Interventionng/mL (Mean)
Day 2Day 3Day 8
POS 200 mg TID Days 1-8230346637

[back to top]

Mean POS Plasma Concentrations on Days 8 and 15 Stratified by Randomized Dosing Regimen

Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 8 and 15

,,
Interventionng/mL (Mean)
Day 8Day 15
POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15620660
POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15849930
POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15473671

[back to top]

Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 3 and ≥/<500 ng/mL on Day 8

Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 3 and 8

InterventionParticipants (Number)
Day 3 <250 ng/mL and Day 8 <500 ng/mLDay 3 <250 ng/mL and Day 8 ≥500 ng/mLTotal Day 3 <250 ng/mLDay 3 ≥250 ng/mL and Day 8 <500 ng/mLDay 3 ≥250 ng/mL and Day 8 ≥500 ng/mLTotal Day 3 ≥250 ng/mL
POS 200 mg TID Days 1-81721982230

[back to top]

Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 8 and ≥/<500 ng/mL on Day 15

Individual mean concentrations calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 8 and 15

,,
InterventionParticipants (Number)
Day 8 <250 ng/mL and Day 15 <500 ng/mLDay 8 <250 ng/mL and Day 15 ≥500 ng/mLTotal Day 8 <250 ng/mLDay 8 ≥250 ng/mL and Day 15 <500 ng/mLDay 8 ≥250 ng/mL and Day 15 ≥500 ng/mLTotal Day 8 ≥250 ng/mL
POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-153256814
POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-1530301111
POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-153143912

[back to top]

Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 3 and ≥/<700 ng/mL on Day 8

Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 3 and 8

InterventionParticipants (Number)
Day 3 <350 ng/mL and Day 8 <700 ng/mLDay 3 <350 ng/mL and Day 8 ≥700 ng/mLTotal Day 3 <350 ng/mLDay 3 ≥350 ng/mL and Day 8 <700 ng/mLDay 3 ≥350 ng/mL and Day 8 ≥700 ng/mLTotal Day 3 ≥350 ng/mL
POS 200 mg TID Days 1-82532871421

[back to top]

Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15

Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose. (NCT00686543)
Timeframe: Predose (0 hour) and 5 hours postdose on Days 8 and 15

,,
InterventionParticipants (Number)
Day 8 <350 ng/mL and Day 15 <700 ng/mLDay 8 <350 ng/mL and Day 15 ≥700 ng/mLTotal Day 8 <350 ng/mLDay 8 ≥350 ng/mL and Day 15 <700 ng/mLDay 8 ≥350 ng/mL and Day 15 ≥700 ng/mLTotal Day 8 ≥350 ng/mL
POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-155166713
POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-153032911
POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15527369

[back to top]

Number of Participants Reporting Adverse Drug Reactions.

"The severity of an Adverse Drug Reaction is determined on the basis of the following definitions:~Mild: The abnormality, symptom or event is noticed but well tolerated.~Moderate: Symptoms impair normal activities and may require intervention.~Severe: Clinical status is significantly impaired, normal activity is no longer possible, intervention is required." (NCT00726609)
Timeframe: Before starting treatment with posaconazole, during treatment, and until 100 days after treatment.

InterventionParticipants (Number)
AllMildModerateSevere
Posaconazole (Assigned by Physician in Normal Practice)5230211

[back to top]

Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization

Death from any cause. (NCT00811928)
Timeframe: Randomization date to Day 100

Interventionparticipants (Number)
Posaconazole3
Fluconazole8

[back to top] [back to top]

Number of Participants With Clinical Failure During Treatment

"Clinical failure was defined as follows:~Presence of a proven or probable IFI~Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total~Discontinuation due to adverse event (AE) possibly or probably related to study drug~Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase" (NCT00811928)
Timeframe: Up to 12 weeks (84 days)

Interventionparticipants (Number)
Posaconazole37
Fluconazole51

[back to top]

Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization

Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: From randomization date to Day 100

Interventionparticipants (Number)
Posaconazole5
Fluconazole16

[back to top]

Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period

Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks [84 days]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: Up to 12 Weeks (84 days) plus 7 days

Interventionparticipants (Number)
Posaconazole4
Fluconazole11

[back to top]

Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy

The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: Up to 12 weeks (84 days)

InterventionDays (Number)
Posaconazole4
Fluconazole1

[back to top]

Time From Randomization to the First Onset of Proven or Probable IFI

The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: From randomization date to Day 100

InterventionDays (Number)
Posaconazole8
Fluconazole2

[back to top]

Maximum Observed Concentration in Plasma (Cmax)

"Pharmacokinetic samples were obtained on day 1, day 3 and day 10 of prophylaxis. A total of 15 samples (3 ml each sample) per participant were obtained, with thrice daily dosing planned around standard meal times. On day 1 and day 3 of prophylaxis sampling was done pre dose (0), and at 3, 5, 10 and 24 hours (±10 minutes) post dose from the time of the first dose of the day. On day 10 of prophylaxis sampling was done pre dose (0), and at 3, 5, and 10 hours (±10 minutes) post dose from the time of the first dose of the day.~Posaconazole levels were assayed by high performance liquid chromatography (HPLC). The testing range for posaconazole is from 125 - 5000 ng/ml. There are no established therapeutic ranges for posaconazole." (NCT00936117)
Timeframe: Pharmacokinetics: Day 1, Day 3 and Day 10 of prophylaxis.

,
Interventionng/ml (Median)
Day 2, Hour 24Day 4, Hour 24Day 9, Hour 24
Posaconazole (Females)200300770
Posaconazole (Males)290580800

[back to top]

Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up

Total number of participant deaths was assessed at the end of 2 week post-treatment follow-up (14 weeks). The total number of deaths was compared to the number of survivors at baseline. (NCT00811642)
Timeframe: Follow-up week 14

InterventionParticipants (Number)
SurvivalDeath
Posaconazole572

[back to top]

Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment

"EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:~Complete Response: resolution of Invasive Fungal Infection (IFI) attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.~Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.~Stable disease: no progress in IFI attributable symptoms, if present at enrollment.~Failure: deterioration in IFI attributable clinical symptoms." (NCT00811642)
Timeframe: Treatment week 12

InterventionParticipants (Number)
Complete responsePartial responseStableFailure
Posaconazole6321110

[back to top]

Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment

"EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:~Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.~Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.~Stable disease: no progress in IFI attributable symptoms, if present at enrollment.~Failure: deterioration in IFI attributable clinical symptoms." (NCT00811642)
Timeframe: Treatment week 4

InterventionParticpants (Number)
Complete responsePartial responseStable diseaseFailure
Posaconazole239117

[back to top]

Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment

"EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:~Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.~Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.~Stable disease: no progress in IFI attributable symptoms, if present at enrollment.~Failure: deterioration in IFI attributable clinical symptoms." (NCT00811642)
Timeframe: Treatment week 8

InterventionParticipants (Number)
Complete responsePartial responseStable diseaseFailure
Posaconazole3341111

[back to top]

Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment

"EVALUATION OF FUNGAL ERADICATION:~Participants' mycological response to therapy was assessed by the following:~Eradication: Negative culture or histologically documented absence of infecting~fungal pathogen from a primary site previously positive.~Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.~Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen." (NCT00811642)
Timeframe: Treatment week 12

InterventionParticipants (Number)
EradicationPresumable eradicationDisease persistent
Posaconazole278

[back to top]

Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment

"EVALUATION OF FUNGAL ERADICATION:~Participants' mycological response to therapy was assessed by the following:~Eradication: Negative culture or histologically documented absence of infecting~fungal pathogen from a primary site previously positive.~Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.~Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen." (NCT00811642)
Timeframe: Treatment week 4

InterventionParticipants (Number)
EradicationPresumed eradicationDisease persistence
Posaconazole269

[back to top]

Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment

"EVALUATION OF FUNGAL ERADICATION:~Participants' mycological response to therapy was assessed by the following:~Eradication: Negative culture or histologically documented absence of infecting~fungal pathogen from a primary site previously positive.~Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.~Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen." (NCT00811642)
Timeframe: Treatment week 8

InterventionParticipants (Number)
EradicationPresumable eradicationDisease persistence
Posaconazole269

[back to top]

Incidence of Invasive Fungal Infection (IFI)

Percentage of participants that developed IFI within 7 days of antifungal prophylaxis therapy (Posaconazole or ABLC). (NCT00750737)
Timeframe: Within 7 days of antifungal prophylaxis therapy

Interventionpercentage of participants (Number)
Posaconazole 200 mg Oral0
Amphotericin B Lipid Complex (ABLC) 7.5 mg/kg IV5

[back to top]

Efficacy Outcome Measured as Success or Failure

Success: Defined as the absence of proven or probable invasive fungal infection through the end of prophylaxis and absence of Grade 1-4 toxicity related to prophylaxis requiring the discontinuation of the drug. Failure: Presence of proven or probable fungal infection or development of Grade 1-4 toxicity related to prophylaxis while on study drug and requiring discontinuation of study drug or inability to tolerate intravenous ABLC (due to infusion related toxicities) or oral Posaconazole (due to mucositis or vomiting). (NCT00750737)
Timeframe: Day 1 through Day 42

,
Interventionpercentage of participants (Number)
SuccessFailure
Amphotericin B Lipid Complex (ABLC) 7.5 mg/kg IV2179
Posaconazole 200 mg Oral6238

[back to top]

Time to Failure

Clinical failure is defined as: 1) need for systemic antifungal therapy (AmBisome) for > 3 consecutive days for presumptive fungal infection, toxicity or intolerance of study medication or 2) death. (NCT01200355)
Timeframe: 2 years

InterventionDays (Median)
Micafungin16
Posaconazole13

[back to top]

To Compare Overall Survival Rates at 6 Weeks

(NCT01200355)
Timeframe: 6 weeks from randomization between the two treatment arms.

InterventionParticipants (Count of Participants)
Micafungin7
Posaconazole2

[back to top]

To Compare the Incidence of Possible, Probable or Proven Invasive Fungal Infections Between Patients Who Receive Posaconazole and Those Who Receive Micafungin During Treatment Phase

(NCT01200355)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Micafungin5
Posaconazole3

[back to top]

To Compare the Number of Days on Study Drug Between Patients Who Receive Posaconazole and Patients Who Receive Micafungin.

(NCT01200355)
Timeframe: 2 years

Interventiondays (Median)
Micafungin11
Posaconazole12

[back to top]

Complete Cure of Onychomycosis at Week 48.

Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis). (NCT00491764)
Timeframe: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48

InterventionParticipants (Number)
Posaconazole 100 mg QD for 24 Weeks8
Posaconazole 200 mg QD for 24 Weeks.20
Posaconazole 400 mg QD for 24 Weeks.15
Posaconazole 400 mg QD for 12 Weeks.7
Terbinafine 250 mg QD for 12 Weeks.13
Placebo for 24 Weeks0

[back to top]

Effective Treatment of Onychomycosis at Week 48.

Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or >5 mm growth of unaffected nail (NCT00491764)
Timeframe: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48

InterventionParticipants (Number)
Posaconazole 100 mg QD for 24 Weeks9
Posaconazole 200 mg QD for 24 Weeks.24
Posaconazole 400 mg QD for 24 Weeks.16
Posaconazole 400 mg QD for 12 Weeks.11
Terbinafine 250 mg QD for 12 Weeks.19
Placebo for 24 Weeks0

[back to top]

Treatment Success of Onychomycosis at Week 48

Treatment success was defined as negative mycology (negative culture and negative KOH) and =<10% nail involvement. (NCT00491764)
Timeframe: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48

InterventionParticipants (Number)
Posaconazole 100 mg QD for 24 Weeks11
Posaconazole 200 mg QD for 24 Weeks.24
Posaconazole 400 mg QD for 24 Weeks.22
Posaconazole 400 mg QD for 12 Weeks.11
Terbinafine 250 mg QD for 12 Weeks.20
Placebo for 24 Weeks0

[back to top]

Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose

The primary outcome is plasma posaconazole exposure expressed as the area under the total plasma concentration-time curve from time zero to infinity resulting from a single dose of 300 mg of posaconazole administered intravenously. (NCT02968134)
Timeframe: 48 hours

Interventionng*h/mL (Median)
Posaconazole17932

[back to top]

Posaconazole Exposure Expressed as Area Under the Unbound Concentrations-time Curve From Time Zero to Infinity

This is a measure of free posaconazole ( not bound to plasma proteins) exposure in the plasma. This is an important measure of exposure because its the free concentration that distributes into targets sites of infection to produce clinical effect. (NCT02968134)
Timeframe: 48 hours

Interventionng*h/mL (Median)
Posaconazole97.2

[back to top]

C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L

Posaconazole drug exposure during treatment in different stages of inflammation. To determine the differences in concentrations between patients a random additive effect was used. Additionally, to correct for differences in intervals between observations a first-order autoregressive correlation was used. The Wald type III test was used to assess the influence of inflammation on posaconazole concentration. (NCT02492802)
Timeframe: 6 months after start of treatment

Interventionmg/L (Median)
Posaconazole concentrationC reactive protein
Posaconazole1.823.5

[back to top]

Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population

The number of participants who died due to IA receiving POS versus VOR through Day 42 was assessed. (NCT01782131)
Timeframe: Up to 42 days

InterventionParticipants (Count of Participants)
Posaconazole16
Voriconazole10

[back to top]

Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population

The number of participants who died due to IA receiving POS versus VOR in the FAS population through Day 84 was assessed. (NCT01782131)
Timeframe: Up to 84 days

InterventionParticipants (Count of Participants)
Posaconazole22
Voriconazole14

[back to top]

Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population

The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 12 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease. (NCT01782131)
Timeframe: Up to 12 weeks (± 4 weeks)

InterventionPercentage of Participants (Number)
Posaconazole42.3
Voriconazole46.2

[back to top]

Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population

The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 6 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease. (NCT01782131)
Timeframe: Up to 6 weeks (± 2 weeks)

InterventionPercentage of Participants (Number)
Posaconazole44.8
Voriconazole45.6

[back to top]

Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population

The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the Full Analysis Set (FAS) population through Day 42 was assessed. (NCT01782131)
Timeframe: Up to ~42 days

InterventionPercentage of Participants (Number)
Posaconazole19.0
Voriconazole18.7

[back to top]

Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population

The percentage of participants who died with posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) in the Intention to Treat (ITT) population through Day 42 was assessed. (NCT01782131)
Timeframe: Up to ~42 days

InterventionPercentage of Participants (Number)
Posaconazole15.3
Voriconazole20.6

[back to top]

Percentage of Participants Who Died Through Day 84 in the FAS Population

The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the FAS population through Day 84 was assessed. (NCT01782131)
Timeframe: Up to ~ 84 days

InterventionPercentage of Participants (Number)
Posaconazole34.4
Voriconazole31.0

[back to top]

Percentage of Participants Who Died Through Day 84 in the ITT Population

The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the ITT population through Day 84 was assessed. (NCT01782131)
Timeframe: Up to ~84 days

InterventionPercentage of Participants (Number)
Posaconazole28.1
Voriconazole30.7

[back to top]

Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event

An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product. (NCT01782131)
Timeframe: Up to ~12 weeks

InterventionPercentage of Participants (Number)
Posaconazole32.3
Voriconazole35.5

[back to top]

Percentage of Participants With at Least One Adverse Event

An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product. (NCT01782131)
Timeframe: Up to ~16 weeks (± 2 weeks)

InterventionPercentage of Participants (Number)
Posaconazole97.6
Voriconazole97.6

[back to top] [back to top]

Percentage of Participants With at Least One Serious Adverse Event

A serious adverse event (SAE) was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment. (NCT01782131)
Timeframe: Up to ~16 weeks (± 2 weeks)

InterventionPercentage of Participants (Number)
Posaconazole61.8
Voriconazole59.9

[back to top] [back to top]

Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)

The number of participants experiencing mortality at Day 42, Day 84 and Day 114 in participants with proven or probable IA receiving POS versus VOR were assessed. The Kaplan-Meier estimate reports the number of participants who experienced death (all causes) through Day 114 or ~16 weeks. Participants who did not have any endpoint event until last visit or who were lost to follow-up and had no event were censored at the time of last available information (last study visit). For Day 42 and Day 84, missing or 'unable to determine' responses were considered as failures (dead). (NCT01782131)
Timeframe: Up to ~16 weeks (± 2 weeks)

,
InterventionParticipants (Count of Participants)
Day 42 (missing responses were included as dead)Day 84 (missing responses were included as dead)Day 114
Posaconazole315664
Voriconazole325356

[back to top]

Percentage of Participants With Tier 1 Treatment Emergent Adverse Events

The percentage of participants with Tier 1 treatment-emergent adverse events (TEAEs) was determined. The Tier 1 TEAEs included hepatic safety (elevated aspartate serum transaminase [AST] or alanine serum transaminase [ALT] value ≥3x upper limit of normal (ULN) and an elevated total bilirubin value ≥2x ULN and, at the same time, an alkaline phosphatase value <2 ULN); central nervous system (CNS) and visual disturbances (eye disorders, nervous system disorders, psychiatric disorders), dermatologic reactions, and adrenal insufficiency or temporally associated TEAEs of hypotension. (NCT01782131)
Timeframe: Up to ~16 weeks (± 2 weeks)

,
InterventionPercentage of Participants (Number)
Abnormal Hepatic Laboratory ValueCNS and Visual DisturbancesDermatologic ReactionsAdrenal Insufficiency or Temporal Hypotension
Posaconazole3.832.316.38.0
Voriconazole3.535.919.27.0

[back to top]

Steady State Average Concentration (Cavg) of Posaconazole With Food Intake

The characterization of the pharmacokinetics (PK) parameters of POS was determined from plasma samples taken at steady-state after receiving oral tablet of POS. Steady-state Cavg, where Cavg is defined as area under the concentration time-curve from 0 to 24 hours (AUC0-24hr) divided by the dosing interval. Data is presented in POS group column only. No evaluation of food intake on the VOR capsule was presented. (NCT01782131)
Timeframe: Baseline, and at pre-dose on Day 7, Week 2, Week 4, Week 6, and Week 12

Interventionng/mL (Mean)
Week 1Week 2Week 4Week 6Week 12
Posaconazole16251992199420052169

[back to top]

Maximum Serum Concentration of Posaconazole (Cmax)

Blood samples for measurement of serum posaconazole were collected approximately 4 hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43. The maximum serum concentration of posaconazole was recorded. (NCT01667107)
Timeframe: Four hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43

Interventionmg/L (Mean)
Cystic Fibrosis Participants1.481
Non-Cystic Fibrosis Participants1.539

[back to top]

Percentage of Participants Who Develop Invasive Fungal Infection

Invasive fungal infection was assessed using the Mycoses Study Group/European Organisation for Research and Treatment of Cancer (MSG/EORTC) criteria. Infections counted in the analysis were those classified as 'proven', 'probable', or 'possible' according to the criteria. (NCT01667107)
Timeframe: Up to Day 84

InterventionPercentage of participants (Number)
Cystic Fibrosis Participants12.5
Non-Cystic Fibrosis Participants16.7

[back to top]

Time to Maximum Serum Concentration of Posaconazole (Tmax)

Blood samples for measurement of serum posaconazole were collected approximately 4 hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43. The time required to achieve the maximum serum concentration of posaconazole was recorded. (NCT01667107)
Timeframe: Four hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43

InterventionDays (Mean)
Cystic Fibrosis Participants19.5
Non-Cystic Fibrosis Participants23.1

[back to top]

Time to Reach a Serum Concentration of Posaconazole of >=0.5 mg/L

Blood samples for measurement of serum posaconazole were collected approximately 4 hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43. A posaconazole concentration >=0.5 mg/L is the therapeutic level, the concentration thought to lead to antifungal efficacy. The time at which the serum posaconazole concentration reached >=0.5 mg/mL and remained at that level for all subsequent assessments was recorded. (NCT01667107)
Timeframe: Four hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43

InterventionDays (Mean)
Cystic Fibrosis Participants12.2
Non-Cystic Fibrosis Participants11.9

[back to top]

Concentration of Posaconazole in Bronchoalveolar Lavage (BAL) and Serum

Concurrent BAL and serum samples for measurement of posaconazole concentration were to be collected during any clinically-indicated bronchoscopy. A participant could have more than 1 bronchoscopy. (NCT01667107)
Timeframe: Up to Day 42

,
Interventionmg/L (Mean)
BALSerum
Cystic Fibrosis Participants1.1160.829
Non-Cystic Fibrosis Participants0.7640.7488

[back to top]

AUC0-24hr of Posaconazole on Day 1

The AUC0-24hr was calculated to determine the mean plasma drug concentration from immediately after dosing to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

Interventionhr*ng/mL (Mean)
Posaconazole14500

[back to top]

Cmax of Posaconazole on Day 1

The Cmax was calculated to determine the maximum plasma drug concentration up to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

Interventionng/mL (Mean)
Posaconazole730

[back to top]

Cmin of Posaconazole on Day 1

The Cmin was calculated in order to determine the lowest measurable drug concentration from immediately after dosing to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

Interventionng/mL (Mean)
Posaconazole997

[back to top]

Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of Posaconazole on Day 8

The ssAUC0-24hr was calculated to determine the mean plasma drug concentration in the Intensive and Sparse PK subgroup from immediately after dosing to 24 hours post-dose on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

Interventionhr*ng/mL (Mean)
Posaconazole38600

[back to top]

Steady-state Maximum Concentration (ssCmax) of Posaconazole on Day 8

The ssCmax was calculated in order to determine the maximum post-dose plasma drug concentration in the Intensive and Sparse PK subgroup on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

Interventionng/mL (Mean)
Posaconazole2150

[back to top]

Steady-state Minimum Concentration (ssCmin) of Posaconazole on Day 8

The ssCmin was calculated in order to determine the lowest measurable drug concentration in the Intensive and Sparse PK subgroup up to 24 hours post-dose on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation [CV]), where CV is calculated as (100 x standard deviation/arithmetic mean). (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

Interventionng/mL (Mean)
Posaconazole1310

[back to top]

Time to Steady-state Maximum Concentration (ssTmax) of Posaconazole on Day 8

The ssTmax was calculated in order to determine the amount of time required to reach ssCmax in the Intensive and Sparse PK subgroup on Day 8. (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

Interventionhr (Median)
Posaconazole4.04

[back to top]

Tmax of Posaconazole on Day 1

The Tmax was calculated in order to determine the time required to reach Cmax in the Immediate and Sparse PK subgroup on Day 1. (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

InterventionHours (Median)
Posaconazole3.99

[back to top]

Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8

The ssCavg was calculated in order to determine the percentage of participants achieving the pharmacokinetic (PK) target of ssCavg >500 ng/mL on Day 8 when plasma drug levels had reached steady state. (NCT02387983)
Timeframe: Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

InterventionPercentage of Participants (Number)
ssCavg < 500 ng/mL500 ng/mL ≤ ssCavg < 2500 ng/mL2500 ng/mL ≤ ssCavg < 3750 ng/mLssCavg ≥ 3750 ng/mL
Posaconazole0.088.911.10

[back to top]

Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery

Proportion of patients who develop invasive fusariosis until neutrophil recovery, for an average of 4 weeks (NCT02714504)
Timeframe: Until neutrophil recovery, for an average of 4 weeks

InterventionParticipants (Count of Participants)
Observational6
Anti-mold Prophylaxis8

[back to top]

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of RO5424802: Cohort B

AUC (0-inf) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0 - t) plus AUC (t - inf). (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionh*ng/mL (Mean)
Cohort B: Alectinib (Period 1)2850
Cohort B: Alectinib + Posaconazole (Period 3)4990

[back to top]

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Alectinib: Cohort A

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours*nanograms per milliliter (h*ng/mL) (Mean)
Cohort A: Alectinib (Period 1)634
Cohort A: Alectinib + Posaconazole (Period 3)1030

[back to top]

AUC0-inf of RO5468924: Cohort A

AUC (0-inf) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0 - t) plus AUC (t - inf). RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionh*ng/mL (Mean)
Cohort A: Alectinib (Period 1)201
Cohort A: Alectinib + Posaconazole (Period 3)256

[back to top]

AUC0-inf of RO5468924: Cohort B

AUC (0-inf) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0 - t) plus AUC (t - inf). RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionh*ng/mL (Mean)
Cohort B: Alectinib (Period 1)1550
Cohort B: Alectinib + Posaconazole (Period 3)1110

[back to top]

AUClast of Alectinib: Cohort B

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionh*ng/mL (Mean)
Cohort B: Alectinib (Period 1)2770
Cohort B: Alectinib + Posaconazole (Period 3)4910

[back to top]

AUClast of RO5468924: Cohort A

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionh*ng/mL (Mean)
Cohort A: Alectinib (Period 1)138
Cohort A: Alectinib + Posaconazole (Period 3)65.1

[back to top]

AUClast of RO5468924: Cohort B

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionh*ng/mL (Mean)
Cohort B: Alectinib (Period 1)1460
Cohort B: Alectinib + Posaconazole (Period 3)910

[back to top]

Cmax of Alectinib: Cohort B

(NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionng/mL (Mean)
Cohort B: Alectinib (Period 1)147
Cohort B: Alectinib + Posaconazole (Period 3)171

[back to top]

Cmax of RO5468924: Cohort A

RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionng/mL (Mean)
Cohort A: Alectinib (Period 1)6.52
Cohort A: Alectinib + Posaconazole (Period 3)2.54

[back to top]

Cmax of RO5468924: Cohort B

RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionng/mL (Mean)
Cohort B: Alectinib (Period 1)59.6
Cohort B: Alectinib + Posaconazole (Period 3)15.5

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Alectinib: Cohort A

(NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionnanograms per milliliter (ng/mL) (Mean)
Cohort A: Alectinib (Period 1)27.6
Cohort A: Alectinib + Posaconazole (Period 3)35.0

[back to top]

Metabolite/Parent Ratio for AUC0-inf: Cohort B

AUC (0-inf) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0 - t) plus AUC (t - inf). RO5468924 is M4 metabolite of Alectinib. The ratio is molecular weight adjusted. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionratio (Geometric Mean)
Cohort B: Alectinib (Period 1)0.541
Cohort B: Alectinib + Posaconazole (Period 3)0.232

[back to top]

Metabolite/Parent Ratio for Cmax: Cohort B

RO5468924 is M4 metabolite of Alectinib. The ratio is molecular weight adjusted. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionratio (Geometric Mean)
Cohort B: Alectinib (Period 1)0.393
Cohort B: Alectinib + Posaconazole (Period 3)0.0953

[back to top]

t1/2 of Alectinib: Cohort B

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionhours (Mean)
Cohort B: Alectinib (Period 1)18.4
Cohort B: Alectinib + Posaconazole (Period 3)24.8

[back to top]

t1/2 of RO5468924: Cohort A

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours (Mean)
Cohort A: Alectinib (Period 1)23.9
Cohort A: Alectinib + Posaconazole (Period 3)79.6

[back to top]

t1/2 of RO5468924: Cohort B

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionhours (Mean)
Cohort B: Alectinib (Period 1)25.3
Cohort B: Alectinib + Posaconazole (Period 3)69.6

[back to top]

Terminal Half-life (t1/2) of Alectinib: Cohort A

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours (Mean)
Cohort A: Alectinib (Period 1)19.6
Cohort A: Alectinib + Posaconazole (Period 3)26.9

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alectinib: Cohort A

(NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours (Median)
Cohort A: Alectinib (Period 1)8.15
Cohort A: Alectinib + Posaconazole (Period 3)8.00

[back to top]

Tmax of Alectinib: Cohort B

(NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours (Median)
Cohort B: Alectinib (Period 1)8.00
Cohort B: Alectinib + Posaconazole (Period 3)8.00

[back to top]

Tmax of RO5468924: Cohort A

RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period

Interventionhours (Median)
Cohort A: Alectinib (Period 1)12.0
Cohort A: Alectinib + Posaconazole (Period 3)11.9

[back to top]

Tmax of RO5468924: Cohort B

RO5468924 is M4 metabolite of Alectinib. (NCT01984229)
Timeframe: Predose (0 hours) and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing in each treatment period, and additional samples were collected in Period 3 at 120, 144, 168, 192, and 216 hours after dosing

Interventionhours (Median)
Cohort B: Alectinib (Period 1)12.0
Cohort B: Alectinib + Posaconazole (Period 3)11.9

[back to top]

Number of Participants Experiencing Adverse Events (AEs)

An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the study drug. (NCT00550732)
Timeframe: Up to 12 months

InterventionNumber of participants (Number)
Posaconazole39

[back to top]

Overall Survival at 3 Months

Total number of participant survivors was assessed at 3 months. (NCT00550732)
Timeframe: 3 months

InterventionPercentage of Participants (Number)
Posaconazole85

[back to top]

Percentage of Participants With a CR or PR by 12 Weeks

Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. (NCT00550732)
Timeframe: Up to 12 Weeks

InterventionPercentage of participants (Number)
Posaconazole75

[back to top]

Percentage of Participants With Infection-free Survival After the Last Dose of Study Drug

Infection-free survival was the proportion of evaluable participants included in the efficacy analysis who are infection-free and alive at 6 months post last dose visit. Infection-free is defined as the resolution of signs and symptoms of infection. (NCT00550732)
Timeframe: Up to 6 months

InterventionPercentage of participants (Number)
Posaconazole56

[back to top]

Percentage of Participants With Complete Response (CR) or Partial Response (PR) by 12 Weeks or End of Treatment

Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. (NCT00550732)
Timeframe: Up to 6 months

InterventionPercentage of participants (Number)
Complete ResponsePartial Response
Posaconazole2646

[back to top]

Percentage of Participants With CR or PR by 4 Weeks and by 26 Weeks

Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. (NCT00550732)
Timeframe: Up to 26 weeks

InterventionPercentage of Participants (Number)
Week 4, CRWeek 26, CRWeek 4, PRWeek 26, PR
Prosaconazole6262848

[back to top]

Apparent Total Body Clearance (CL/F) for Posaconazole Tablet

Blood samples for the assessment of CL/F, the rate at which posaconazole was removed from the body, were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose. (NCT01777763)
Timeframe: Predose on Day 1 up to 24 hours postdose on Day 8

InterventionL/hr (Mean)
Posaconazole 200 mg10.9
Posaconazole 300 mg9.39

[back to top]

Average Concentration (Cavg) of Posaconazole Tablet

"Posaconazole steady-state concentrations of posaconazole in the plasma reached after regular and repeated dosing were used to estimate pharmacokinetic (PK) parameters for each participant where Cavg was defined as area under the plasma concentration versus time curve divided by the dosing interval.~Blood samples for the assessment of Cavg were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose." (NCT01777763)
Timeframe: Predose on Day 1 up to 24 hours postdose on Day 8

Interventionng/mL (Mean)
Posaconazole 200 mg981
Posaconazole 300 mg1580

[back to top]

Minimum Concentration (Cmin) of Posaconazole Tablet

Cmin was defined as posaconazole trough level immediately before a participant received the dose of posaconazole tablets on the specified day. Trough (Cmin) level blood samples for determination of posaconazole in plasma were collected for all participants on Day 1, Day 2, Day 3, and Day 8. On Day 1, the trough level sample was collected the before the first dose of study drug. On Day 2, trough samples were collected approximately 12 hours after the second dose of study drug was administered on Day 1. On all subsequent days, trough samples were collected approximately 24 hours following the previous day's dose of study drug. (NCT01777763)
Timeframe: Predose on Day 1 up to 24 hours postdose on Day 8

Interventionng/mL (Mean)
Posaconazole 200 mg812
Posaconazole 300 mg1310

[back to top]

Number of Participants Discontinuing Study Treatment Due to an AE

AEs are any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to this study drug. These AEs resulted in participants stopping study drug treatment. This measure includes participants who discontinued due to AEs and also includes treatment failures that were attributed to AEs. (NCT01777763)
Timeframe: Up to Day 28

InterventionParticipants (Number)
Posaconazole 200 mg3
Posaconazole 300 mg38

[back to top]

Number of Participants Surviving at Day 65

Number of Participants Alive at Day 65 (NCT01777763)
Timeframe: Day 65

InterventionParticipants (Number)
Posaconazole 200 mg18
Posaconazole 300 mg192

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs)

AEs are any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to this study drug. Treatment-emergent AEs are any events not present before starting study drug treatment or any events that were present before treatment that worsened in either intensity or frequency after exposure to study drug. (NCT01777763)
Timeframe: Up to Day 65

InterventionParticipants (Number)
Posaconazole 200 mg20
Posaconazole 300 mg207

[back to top] [back to top]

Maximum Concentration (Cmax) of Posaconazole Tablet

Blood samples for the assessment of Cmax were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose. (NCT01777763)
Timeframe: Predose on Day 1 up to 24 hours postdose on Day 8

,
Interventionng/mL (Mean)
Day 1Day 8
Posaconazole 200 mg6521310
Posaconazole 300 mg9082090

[back to top]

Time to Maximum Concentration (Tmax) of Posaconazole Tablet

Blood samples for the assessment of Tmax were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose. (NCT01777763)
Timeframe: Predose on Day 1 up to 24 hours postdose on Day 8

,
InterventionHours (Median)
Day 1Day 8
Posaconazole 200 mg44
Posaconazole 300 mg44

[back to top]

Average Concentration of Posaconazole (Cavg) on Day 1 (Single Dose)

Blood samples for determination of plasma posaconazole concentration were collected predose and approximately 3, 5, 8, and 12 hours after the first dose on Day 1. The 12-hour sample was not obtained for the TID dose groups. Day 1 pharmacokinetic samples were not collected for participants 3 months to <2 years of age weighing <6.5 kg. (NCT01716234)
Timeframe: Up to 12 hours after the first dose (BID dose groups) or up to 8 hours after the first dose (TID dose (TID dose groups)

Interventionng/mL (Mean)
POS 12 BID 2 to <7 Years122
POS 12 BID 7 to <18 Years107
POS 18 BID 2 to <7 Years112
POS 18 BID 7 to <18 Years113
POS 18 TID 2 to <7 Years68.4
POS 18 TID 7 to <18 Years57.9
POS 12 TID 3 Months to <2 Years68.5

[back to top]

Average Concentration of Posaconazole (Cavg) on Day 7 (Steady State)

Blood samples for determination of plasma posaconazole concentration were collected predose and approximately 3, 5, 8, and 12 hours after the first dose on Day 7 (steady state). The 12-hour sample was not obtained for the TID dose groups. The target Cavg range was 500 to <2500 ng/mL. (NCT01716234)
Timeframe: Up to 12 hours after the first dose on Day 7 (BID dose groups) or up to 8 hours after the first dose on Day 7 (TID dose

Interventionng/mL (Mean)
POS 12 BID 2 to <7 Years604
POS 12 BID 7 to <18 Years1050
POS 18 BID 2 to <7 Years485
POS 18 BID 7 to <18 Years1240
POS 18 TID 2 to <7 Years620
POS 18 TID 7 to <18 Years1150
POS 12 TID 3 Months to <2 Years453

[back to top]

Number of Participants With an Adverse Event

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions. (NCT01716234)
Timeframe: Up to Day 58

InterventionParticipants (Number)
POS 12 BID 2 to <7 Years21
POS 12 BID 7 to <18 Years21
POS 18 BID 2 to <7 Years16
POS 18 BID 7 to <18 Years26
POS 18 TID 2 to <7 Years13
POS 18 TID 7 to <18 Years30
POS 12 TID 3 Months to <2 Years1

[back to top]

Number of Participants With an Adverse Event Leading to Study Drug Discontinuation

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions. (NCT01716234)
Timeframe: Up to Day 28

InterventionParticipants (Number)
POS 12 BID 2 to <7 Years7
POS 12 BID 7 to <18 Years9
POS 18 BID 2 to <7 Years2
POS 18 BID 7 to <18 Years9
POS 18 TID 2 to <7 Years3
POS 18 TID 7 to <18 Years6
POS 12 TID 3 Months to <2 Years0

[back to top]

Apparent Total Body Clearance (CL/F) for POS Administered by PFS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma CL/F of posaconazole administered by PFS. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for participants that received PFS treatment. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

InterventionL/hr (Geometric Mean)
3.5 mg/kg POS (2<7 Years Old)4.97
3.5 mg/kg POS (7-17 Years Old)7.67
4.5 mg/kg POS (2<7 Years Old)3.49
4.5 mg/kg POS (7-17 Years Old)7.84
6 mg/kg POS (2<7 Years Old)4.60
6 mg/kg POS (7-17 Years Old)8.39

[back to top]

Number of Participants Who Discontinued Treatment of Study Drug Due to an Adverse Event (AE)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT02452034)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
3.5 mg/kg POS (2<7 Years Old)3
3.5 mg/kg POS (7-17 Years Old)3
4.5 mg/kg POS (2<7 Years Old)0
4.5 mg/kg POS (7-17 Years Old)2
6 mg/kg POS (2<7 Years Old)4
6 mg/kg POS (7-17 Years Old)6

[back to top]

Number of Participants With an Adverse Event (AE)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT02452034)
Timeframe: 14 days after end of treatment (Up to 42 days)

InterventionParticipants (Count of Participants)
3.5 mg/kg POS (2<7 Years Old)13
3.5 mg/kg POS (7-17 Years Old)21
4.5 mg/kg POS (2<7 Years Old)15
4.5 mg/kg POS (7-17 Years Old)16
6 mg/kg POS (2<7 Years Old)19
6 mg/kg POS (7-17 Years Old)29

[back to top]

Total Body Clearance (CL) for POS Administered by IV

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma CL of posaconazole administered by IV. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for participants that received IV treatment. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

InterventionL/hr (Geometric Mean)
3.5 mg/kg POS (2<7 Years Old)3.39
3.5 mg/kg POS (7-17 Years Old)6.64
4.5 mg/kg POS (2<7 Years Old)2.97
4.5 mg/kg POS (7-17 Years Old)6.69
6 mg/kg POS (2<7 Years Old)3.27
6 mg/kg POS (7-17 Years Old)4.76

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose for POS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma AUC from time 0-24 hours post-dose (AUC0-24hr) of posaconazole. A non compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for each treatment arm according to the formulation that participants received (IV or PFS). Participants receiving both formulations were counted once for each formulation. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy for each formulation (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

,,,,,
Interventionhr*ng/mL (Geometric Mean)
IVPFS
3.5 mg/kg POS (2<7 Years Old)1780012200
3.5 mg/kg POS (7-17 Years Old)2730020700
4.5 mg/kg POS (2<7 Years Old)2560021600
4.5 mg/kg POS (7-17 Years Old)2980028700
6 mg/kg POS (2<7 Years Old)3110023000
6 mg/kg POS (7-17 Years Old)4420025000

[back to top]

Average Steady-state Plasma Concentration (Cavg) for POS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma Cavg of posaconazole. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for each treatment arm according to the formulation that participants received (IV or PFS). Participants receiving both formulations were counted once for each formulation. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy for each formulation (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

,,,,,
Interventionng/mL (Geometric Mean)
IVPFS
3.5 mg/kg POS (2<7 Years Old)743510
3.5 mg/kg POS (7-17 Years Old)1140861
4.5 mg/kg POS (2<7 Years Old)1070901
4.5 mg/kg POS (7-17 Years Old)12401200
6 mg/kg POS (2<7 Years Old)1300960
6 mg/kg POS (7-17 Years Old)18401040

[back to top]

Maximum Plasma Concentration (Cmax) for POS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma Cmax of posaconazole. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for each treatment arm according to the formulation that participants received (IV or PFS). Participants receiving both formulations were counted once for each formulation. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy for each formulation (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

,,,,,
Interventionng/mL (Geometric Mean)
IVPFS
3.5 mg/kg POS (2<7 Years Old)1590884
3.5 mg/kg POS (7-17 Years Old)24501340
4.5 mg/kg POS (2<7 Years Old)23201550
4.5 mg/kg POS (7-17 Years Old)23101670
6 mg/kg POS (2<7 Years Old)30601510
6 mg/kg POS (7-17 Years Old)33401370

[back to top]

Minimum Plasma Concentration (Cmin) for POS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma Cmin of posaconazole. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for each treatment arm according to the formulation that participants received (IV or PFS). Participants receiving both formulations were counted once for each formulation. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy for each formulation (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

,,,,,
Interventionng/mL (Geometric Mean)
IVPFS
3.5 mg/kg POS (2<7 Years Old)400254
3.5 mg/kg POS (7-17 Years Old)670579
4.5 mg/kg POS (2<7 Years Old)501476
4.5 mg/kg POS (7-17 Years Old)737790
6 mg/kg POS (2<7 Years Old)626542
6 mg/kg POS (7-17 Years Old)1160713

[back to top]

Time of Maximum Plasma Concentration (Tmax) for POS

Blood was collected from pre-dose up to 24 hours post-dose in order to determine the plasma Tmax of posaconazole. A non-compartmental analysis of posaconazole plasma concentrations was performed. Results are reported for each treatment arm according to the formulation that participants received (IV or PFS). Participants receiving both formulations were counted once for each formulation. (NCT02452034)
Timeframe: Any day from Day 7 to Day 10 of therapy for each formulation (up to 28 days) at pre-dose, within 15 minutes after end of infusion (up to 2 hours), and 4, 6, 8, 12, 24 hours post-infusion

,,,,,
InterventionHours (Median)
IVPFS
3.5 mg/kg POS (2<7 Years Old)1.783.83
3.5 mg/kg POS (7-17 Years Old)1.772.20
4.5 mg/kg POS (2<7 Years Old)1.783.82
4.5 mg/kg POS (7-17 Years Old)1.756.14
6 mg/kg POS (2<7 Years Old)1.754.00
6 mg/kg POS (7-17 Years Old)1.772.78

[back to top]

Number of Participants With an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product is also an AE. (NCT02180165)
Timeframe: Up to approximately Day 98

InterventionParticipants (Count of Participants)
Cohort 1: Posaconazole15
Cohort 1: Voriconazole6
Cohort 2: Posaconazole57
Cohort 2: Voriconazole27

[back to top]

Percentage of Participants With Chronic Pulmonary Aspergillosis With Clinical Response of Resolution in Cohort 2 at Day 42

A clinical response of resolution is defined as resolution of attributable signs and symptoms of disease, as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole43.8
Cohort 2: Voriconazole73.9

[back to top]

Percentage of Participants With Chronic Pulmonary Aspergillosis With Clinical Response of Resolution in Cohort 2 at Day 84

A clinical response of resolution is defined as resolution of attributable signs and symptoms of disease, as assessed by the CAC. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole45.8
Cohort 2: Voriconazole82.6

[back to top]

Percentage of Participants With Chronic Pulmonary Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 42

A mycological response of eradication is defined as fungus detected from culture or microscopy at the screening is eradicated at the time of evaluation (including presumed eradication), as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole33.3
Cohort 2: Voriconazole21.7

[back to top]

Percentage of Participants With Chronic Pulmonary Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 84

A mycological response of eradication is defined as fungus detected from culture or microscopy at the screening is eradicated at the time of evaluation (including presumed eradication), as assessed by the CAC. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole35.4
Cohort 2: Voriconazole21.7

[back to top]

Percentage of Participants With Chronic Pulmonary Aspergillosis With Radiological Response of Resolution in Cohort 2 at Day 42

A radiological response of resolution is defined as resolution of radiological lesions, as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole58.3
Cohort 2: Voriconazole87.0

[back to top]

Percentage of Participants With Invasive Aspergillosis With Mycological Response of Eradication in Cohort 2 at Day 42

A mycological response of eradication is defined as fungus detected from culture or microscopy at the screening is eradicated at the time of evaluation (including presumed eradication), as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole20.0
Cohort 2: Voriconazole0

[back to top]

Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 42

Successful treatment (or successful overall response) is defined as favorable response to treatment assessed by CAC. The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole56.3
Cohort 2: Voriconazole87.0

[back to top]

Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 84

Successful treatment (or successful overall response) is defined as favorable response to treatment assessed by CAC. The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole58.3
Cohort 2: Voriconazole87.0

[back to top]

Percentage of Participants With Successful Overall Response for Chronic Pulmonary Aspergillosis in Cohort 2 at Day 84 as Assessed by the Clinical Investigator

Successful treatment (or successful overall response) for chronic pulmonary aspergillosis is defined as favorable response to treatment assessed by the clinical investigator.The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole60.4
Cohort 2: Voriconazole78.3

[back to top]

Percentage of Participants With Successful Overall Response for Invasive Aspergillosis and Chronic Pulmonary Aspergillosis in Cohort 2 at End of Trial (Day 84)

Successful treatment (or successful overall response) for invasive aspergillosis is defined as complete response and partial response to treatment assessed by CAC. Successful treatment (or successful overall response) for chronic pulmonary aspergillosis is defined as favorable response to treatment.The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole58.5
Cohort 2: Voriconazole88.5

[back to top]

Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 42

Successful treatment (or successful overall response) is defined as complete response and partial response to treatment assessed by the clinical adjudication committee (CAC). The 95% confidence interval (CI) is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole40.0
Cohort 2: Voriconazole100

[back to top]

Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 42 as Assessed by the Clinical Investigator

Successful treatment (or successful overall response) for invasive aspergillosis is defined as complete response and partial response to treatment assessed by the clinical investigator.The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole80.0
Cohort 2: Voriconazole66.7

[back to top]

Percentage of Participants With Successful Overall Response for Invasive Aspergillosis in Cohort 2 at Day 84

Successful treatment (or successful overall response) is defined as complete response and partial response to treatment assessed by CAC. The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole60.0
Cohort 2: Voriconazole100

[back to top]

Percentage of Participants With Successful Overall Response for Zygomycosis in Cohort 2 at Day 42

Zygomycosis is an infection caused by zygomycete fungi. Successful treatment (or successful overall response) is defined as complete response and partial response to treatment assessed by CAC. The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 42

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole66.7

[back to top]

Percentage of Participants With Successful Overall Response for Zygomycosis in Cohort 2 at Day 84

Zygomycosis is an infection caused by zygomycete fungi. Successful treatment (or successful overall response) is defined as complete response and partial response to treatment assessed by CAC. The 95% CI is based on the Clopper-Pearson exact method. (NCT02180165)
Timeframe: Day 84

InterventionPercentage of participants (Number)
Cohort 2: Posaconazole100

[back to top]

Percentage of Participants With Invasive Aspergillosis With Clinical Response of Resolution or Improvement in Cohort 2 at Day 42

A clinical response of resolution is defined as resolution of attributable signs and symptoms of disease, and a clinical response of improvement is defined as improvement of attributable signs and symptoms of disease as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

,
InterventionPercentage of participants (Number)
ResolutionImprovement
Cohort 2: Posaconazole60.020.0
Cohort 2: Voriconazole066.7

[back to top]

Percentage of Participants With Invasive Aspergillosis With Clinical Response of Resolution or Improvement in Cohort 2 at Day 84

A clinical response of resolution is defined as resolution of attributable signs and symptoms of disease, and a clinical response of improvement is defined as improvement of attributable signs and symptoms of disease as assessed by the CAC. (NCT02180165)
Timeframe: Day 84

,
InterventionPercentage of participants (Number)
ResolutionImprovement
Cohort 2: Posaconazole60.020.0
Cohort 2: Voriconazole33.333.3

[back to top]

Percentage of Participants With Invasive Aspergillosis With Radiological Response of Resolution or Improvement in Cohort 2 at Day 42

A radiological response of resolution is defined as resolution of radiological lesions, and a radiological response of improvement is defined as major reduction in size of radiological lesions as assessed by the CAC. (NCT02180165)
Timeframe: Day 42

,
InterventionPercentage of participants (Number)
ResolutionImprovement
Cohort 2: Posaconazole040.0
Cohort 2: Voriconazole0100

[back to top]

Percentage of Participants With Invasive Aspergillosis With Radiological Response of Resolution or Improvement in Cohort 2 at Day 84

A radiological response of resolution is defined as resolution of radiological lesions, and a radiological response of improvement is defined as major reduction in size of radiological lesions as assessed by the CAC. (NCT02180165)
Timeframe: Day 84

,
InterventionPercentage of participants (Number)
ResolutionImprovement
Cohort 2: Posaconazole060.0
Cohort 2: Voriconazole0100

[back to top]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
amiodarone[no description available]medium601-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amphotericin b[no description available]medium3750antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
amphotericin b[no description available]medium3755antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
voriconazole[no description available]medium4200conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
voriconazole[no description available]medium4201conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
voriconazole[no description available]medium4205conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
itraconazole[no description available]medium583piperazines
cancidas[no description available]medium300
benzonidazole[no description available]medium420C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
benzonidazole[no description available]medium422C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
ravuconazole[no description available]medium3901,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles		antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor
fluconazole[no description available]medium2030conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
fluconazole[no description available]medium2032conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
fluconazole[no description available]medium20310conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine[no description available]medium340aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
ketoconazole[no description available]medium330dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoconazole[no description available]medium331dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
anidulafungin[no description available]medium430antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
tacrolimus[no description available]medium240macrolide lactambacterial metabolite;
immunosuppressive agent
tacrolimus[no description available]medium243macrolide lactambacterial metabolite;
immunosuppressive agent
cyclosporine[no description available]medium40homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
sirolimus[no description available]medium130antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
sirolimus[no description available]medium131antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
eberconazole[no description available]medium10dibenzannulene;
imidazoles;
organochlorine compound
albaconazole[no description available]medium40
micafungin[no description available]medium550antibiotic antifungal drug;
echinocandin		antiinfective agent
micafungin[no description available]medium553antibiotic antifungal drug;
echinocandin		antiinfective agent
terbinafine[no description available]medium440acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
terbinafine[no description available]medium441acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
isavuconazole[no description available]medium6401,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
tipifarnib[no description available]medium40imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
natamycin[no description available]medium30antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
tacrine[no description available]medium20acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
amitriptyline[no description available]medium40carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
azelastine[no description available]medium10monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
carvedilol[no description available]medium30carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
clomipramine[no description available]medium40dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
doxazosin[no description available]medium30aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
fluphenazine[no description available]medium30N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
fluoxetine[no description available]medium40(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
haloperidol[no description available]medium40aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
homochlorocyclizine[no description available]medium10diarylmethane
lomerizine[no description available]medium10diarylmethane
loperamide[no description available]medium30monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine[no description available]medium40benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
naftopidil[no description available]medium10piperazines
nefazodone[no description available]medium30aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
perphenazine[no description available]medium30N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
prazosin[no description available]medium30aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
promazine[no description available]medium20phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
raloxifene[no description available]medium201-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
sibutramine[no description available]medium20organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
imatinib[no description available]medium50aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
norethindrone acetate[no description available]medium103-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
cycloheximide[no description available]medium20antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
phenothiazine[no description available]medium10phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
cyproterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
kainic acid[no description available]medium10dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
3,3',4',5-tetrachlorosalicylanilide[no description available]medium10dichlorobenzene;
salicylanilides		drug allergen
metergoline[no description available]medium10carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
clobetasol propionate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
amitraz[no description available]medium10formamidines;
tertiary amino compound		acaricide;
environmental contaminant;
insecticide;
xenobiotic
bopindolol[no description available]medium10aromatic ether;
benzoate ester;
methylindole;
secondary amino compound
nelfinavir[no description available]medium60aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
dyclonine hydrochloride[no description available]medium10hydrochloridetopical anaesthetic
ergocornine[no description available]medium10ergot alkaloid
1-benzylimidazole[no description available]medium10
u 74006f[no description available]medium10corticosteroid hormone
desloratadine[no description available]medium30benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
docetaxel[no description available]medium10hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
terconazole[no description available]medium301-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
dihydroergocristine monomesylate[no description available]medium10methanesulfonate saltalpha-adrenergic antagonist;
geroprotector;
vasodilator agent
sm 8668[no description available]medium10
benztropine[no description available]medium20diarylmethane
mycophenolate mofetil[no description available]medium40carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
vinorelbine[no description available]medium20acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
furazolidone[no description available]medium10
nitrofurazone[no description available]medium10
2,3-n-octanoylsphingosine[no description available]medium10N-acylsphingosine
nifurtimox[no description available]medium90nitrofuran antibiotic
nifursol[no description available]medium10
naloxonazine[no description available]medium10
rwj 68354[no description available]medium10
mk 936[no description available]medium10
clotrimazole[no description available]medium110conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
lanosterol[no description available]medium5014alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid		bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
fenarimol[no description available]medium10monochlorobenzenes;
pyrimidines;
tertiary alcohol
ly 56110[no description available]medium10
6-chloro-1,4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic acid[no description available]medium10
melatonin[no description available]medium10acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
pyrazinamide[no description available]medium20monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
1-(3-chlorophenyl)piperazine[no description available]medium10monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
acetaminophen[no description available]medium50acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetazolamide[no description available]medium30monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
albendazole[no description available]medium20aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol[no description available]medium20phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alprenolol[no description available]medium20secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
diatrizoic acid[no description available]medium20acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
aminoglutethimide[no description available]medium10dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
theophylline[no description available]medium20dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
dan 2163[no description available]medium10aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amlexanox[no description available]medium10monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine[no description available]medium20dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amoxapine[no description available]medium20dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amsacrine[no description available]medium10acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole[no description available]medium30nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
anthralin[no description available]medium10anthracenesantipsoriatic
antipyrine[no description available]medium10pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aspirin[no description available]medium40benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole[no description available]medium10benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol[no description available]medium20ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine[no description available]medium20aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
baclofen[no description available]medium30amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
benzbromarone[no description available]medium301-benzofurans;
aromatic ketone		uricosuric drug
benzocaine[no description available]medium10benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
bicalutamide[no description available]medium30(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502[no description available]medium20biphenyls;
imidazoles
bisacodyl[no description available]medium20diarylmethane
bromopride[no description available]medium10benzamides
bronopol[no description available]medium10nitro compound
bumetanide[no description available]medium20amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
busulfan[no description available]medium20methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
caffeine[no description available]medium30purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil[no description available]medium40aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamazepine[no description available]medium20dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carmustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen[no description available]medium10carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
celecoxib[no description available]medium20organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chlorambucil[no description available]medium20aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlordiazepoxide[no description available]medium20benzodiazepine
chloroquine[no description available]medium30aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorpheniramine[no description available]medium20monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine[no description available]medium30organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide[no description available]medium20monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone[no description available]medium20isoindoles;
monochlorobenzenes;
sulfonamide
chlorzoxazone[no description available]medium201,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cifenline[no description available]medium10diarylmethane
ciclopirox[no description available]medium20cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
ciglitazone[no description available]medium10aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol[no description available]medium20lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine[no description available]medium40aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
ciprofibrate[no description available]medium20cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin[no description available]medium40aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
citalopram[no description available]medium202-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clioquinol[no description available]medium20monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine[no description available]medium20monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clofibrate[no description available]medium20aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clomiphene[no description available]medium20tertiary amineestrogen antagonist;
estrogen receptor modulator
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide[no description available]medium10sulfonamide
dapsone[no description available]medium20substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
desipramine[no description available]medium20dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
diazepam[no description available]medium201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide[no description available]medium20benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dipyridamole[no description available]medium50piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disopyramide[no description available]medium20monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram[no description available]medium30organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
domperidone[no description available]medium10benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
donepezil[no description available]medium20aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxepin[no description available]medium20dibenzooxepine;
tertiary amino compound		antidepressant
ebastine[no description available]medium10organic molecular entity
enoxacin[no description available]medium101,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
ethacrynic acid[no description available]medium20aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ethosuximide[no description available]medium20dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
brl 42810[no description available]medium302-aminopurines;
acetate ester		antiviral drug;
prodrug
4-biphenylylacetic acid[no description available]medium10biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
felodipine[no description available]medium20dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fenofibrate[no description available]medium30aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fleroxacin[no description available]medium10difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
flumazenil[no description available]medium20ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
fluorescite[no description available]medium20benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil[no description available]medium30nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
flutamide[no description available]medium20(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
furosemide[no description available]medium30chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gemfibrozil[no description available]medium20aromatic etherantilipemic drug
gliclazide[no description available]medium10N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glimepiride[no description available]medium20sulfonamide
glipizide[no description available]medium20aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glyburide[no description available]medium30monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
guanfacine[no description available]medium20acetamides
hydrochlorothiazide[no description available]medium30benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroflumethiazide[no description available]medium20benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxyurea[no description available]medium30one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
lidocaine[no description available]medium20benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ifosfamide[no description available]medium20ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine[no description available]medium20dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone[no description available]medium20bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide[no description available]medium20indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indomethacin[no description available]medium30aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iohexol[no description available]medium10benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iproniazid[no description available]medium20carbohydrazide;
pyridines
avapro[no description available]medium30azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
isoniazid[no description available]medium30carbohydrazideantitubercular agent;
drug allergen
isradipine[no description available]medium20benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
ketamine[no description available]medium20cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin[no description available]medium10aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
lamotrigine[no description available]medium201,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole[no description available]medium40benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide[no description available]medium20(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole[no description available]medium20nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lofepramine[no description available]medium10aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lomustine[no description available]medium20N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
maprotiline[no description available]medium20anthracenes
mebendazole[no description available]medium20aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mefenamic acid[no description available]medium20aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
metformin[no description available]medium20guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
metoclopramide[no description available]medium40benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metoprolol[no description available]medium20aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole[no description available]medium20C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
mexiletine[no description available]medium20aromatic ether;
primary amino compound		anti-arrhythmia drug
midazolam[no description available]medium60imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midazolam[no description available]medium63imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
minoxidil[no description available]medium20dialkylarylamine;
tertiary amino compound
mirtazapine[no description available]medium20benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
moclobemide[no description available]medium10benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
acecainide[no description available]medium10acetamides;
benzamides		anti-arrhythmia drug
nadolol[no description available]medium20tetralins
nalidixic acid[no description available]medium201,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
nefopam[no description available]medium10benzoxazocine;
tertiary amino compound
neostigmine[no description available]medium10quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine[no description available]medium30cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nicardipine[no description available]medium30benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium40C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimesulide[no description available]medium20aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine[no description available]medium302-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine[no description available]medium20C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam[no description available]medium101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine[no description available]medium20C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
norfloxacin[no description available]medium20fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline[no description available]medium20organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
ofloxacin[no description available]medium303-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
omeprazole[no description available]medium60aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
omeprazole[no description available]medium61aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron[no description available]medium20carbazoles
oxaprozin[no description available]medium201,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxybutynin[no description available]medium20acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
papaverine[no description available]medium30benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pemoline[no description available]medium201,3-oxazolescentral nervous system stimulant
pentamidine[no description available]high40aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentoxifylline[no description available]medium30oxopurine
phenacetin[no description available]medium10acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
pindolol[no description available]medium20indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone[no description available]medium20aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piracetam[no description available]medium10organonitrogen compound;
organooxygen compound
piribedil[no description available]medium10N-arylpiperazine
ono 1078[no description available]medium10chromones
pyranoprofen[no description available]medium10pyridochromene
praziquantel[no description available]medium30isoquinolines
primaquine[no description available]medium20aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone[no description available]medium20pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probenecid[no description available]medium30benzoic acids;
sulfonamide		uricosuric drug
procainamide[no description available]medium20benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
prochlorperazine[no description available]medium30N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine[no description available]medium20pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promethazine[no description available]medium30phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone[no description available]medium20aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propranolol[no description available]medium40naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
ranitidine[no description available]medium10aralkylamine
riluzole[no description available]medium20benzothiazoles
risperidone[no description available]medium201,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rofecoxib[no description available]medium10butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
sulfadiazine[no description available]medium20pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sotalol[no description available]medium20ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
vorinostat[no description available]medium30dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole[no description available]medium20isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanitran[no description available]medium10sulfonamide
sulfasalazine[no description available]medium30
sulfisoxazole[no description available]medium10isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sumatriptan[no description available]medium20sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
gatifloxacin[no description available]medium10N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene[no description available]medium10acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
temozolomide[no description available]medium20imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin[no description available]medium20furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline[no description available]medium20phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terfenadine[no description available]medium10diarylmethane
thiotepa[no description available]medium20aziridines
tiapride[no description available]medium10benzamides
tilorone[no description available]medium10aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole[no description available]medium20imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tizanidine[no description available]medium20benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
nikethamide[no description available]medium10pyridinecarboxamide
tolbutamide[no description available]medium20N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolnaftate[no description available]medium10monothiocarbamic esterantifungal drug
trazodone[no description available]medium20monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene[no description available]medium30pteridinesdiuretic;
sodium channel blocker
trimethoprim[no description available]medium30aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
troglitazone[no description available]medium20chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
thenoyltrifluoroacetone[no description available]medium10
undecylenic acid[no description available]medium10undecenoic acidantifungal drug;
plant metabolite
urapidil[no description available]medium10piperazines
venlafaxine[no description available]medium20cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vigabatrin[no description available]medium20gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
pirinixic acid[no description available]medium10aryl sulfide;
organochlorine compound;
pyrimidines
ici 204,219[no description available]medium20carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zaleplon[no description available]medium20nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zonisamide[no description available]medium201,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone[no description available]medium10monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
prednisolone[no description available]medium3011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
reserpine[no description available]medium30alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
penicillamine[no description available]medium20non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
carbon tetrachloride[no description available]medium10chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
chloramphenicol[no description available]medium30C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ethinyl estradiol[no description available]medium1017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
tubocurarine[no description available]medium10bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
apomorphine[no description available]medium20aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
kanamycin a[no description available]medium30kanamycinsbacterial metabolite
levodopa[no description available]medium10amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
colchicine[no description available]medium20alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
triamcinolone diacetate[no description available]medium10corticosteroid hormone
cytarabine[no description available]medium100beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
medroxyprogesterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
triamcinolone acetonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
methylprednisolone[no description available]medium506-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
rotenone[no description available]medium10organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
phenformin[no description available]medium10biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
aminophylline[no description available]medium20mixturebronchodilator agent;
cardiotonic drug
galantamine[no description available]medium20benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
procarbazine hydrochloride[no description available]medium10hydrochlorideantineoplastic agent
betamethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
emetine[no description available]medium20isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dimenhydrinate[no description available]medium20diarylmethane
1-naphthylisothiocyanate[no description available]medium10isothiocyanateinsecticide
megestrol acetate[no description available]medium2020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
erythromycin[no description available]medium20cyclic ketone;
erythromycin
hydroxychloroquine sulfate[no description available]medium20
levonorgestrel[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
ethambutol hydrochloride[no description available]medium10hydrochlorideantitubercular agent
antimycin a[no description available]medium20benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
pregnenolone carbonitrile[no description available]medium10aliphatic nitrile
metylperon[no description available]medium10aromatic ketone
stavudine[no description available]medium30dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dicloxacillin[no description available]medium20dichlorobenzene;
penicillin		antibacterial drug
cladribine[no description available]medium20organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
metocurine[no description available]medium10isoquinolines
etidronate disodium[no description available]medium10organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
zalcitabine[no description available]medium20pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
camptothecin[no description available]medium10delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
mafenide acetate[no description available]medium10carboxylic acid
diacerein[no description available]medium10anthraquinone
selegiline hydrochloride, (r)-isomer[no description available]medium10hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
thiamphenicol[no description available]medium10monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pancuronium bromide[no description available]medium10bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
ornidazole[no description available]medium10C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
danazol[no description available]medium2017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
fludarabine phosphate[no description available]medium20nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
amoxicillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
timolol[no description available]medium20timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin[no description available]medium10tryptamines
oxcarbazepine[no description available]medium20cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
carbidopa[no description available]medium20catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
zidovudine[no description available]medium30azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
feprazone[no description available]medium10organic molecular entity
tobramycin[no description available]medium30amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel[no description available]medium20taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide[no description available]medium20beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ribavirin[no description available]medium301-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin[no description available]medium20alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
diltiazem[no description available]medium305-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
vecuronium bromide[no description available]medium10organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
nitazoxanide[no description available]medium30benzamides;
carboxylic ester
acarbose[no description available]medium20tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
lorcainide[no description available]medium10acetamides
captopril[no description available]medium30alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
staurosporine[no description available]medium10indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
foscarnet sodium[no description available]medium10one-carbon compound;
organic sodium salt		antiviral drug
atracurium besylate[no description available]medium10organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
nicorandil[no description available]medium10nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
pergolide mesylate[no description available]medium10methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
cefadroxil anhydrous[no description available]medium20cephalosporinantibacterial drug
talniflumate[no description available]medium10benzofurans
fenoldopam mesylate[no description available]medium10benzazepine
cefaclor anhydrous[no description available]medium20cephalosporinantibacterial drug;
drug allergen
pefloxacin[no description available]medium10fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
cefotetan[no description available]medium20
lovastatin[no description available]medium20delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine[no description available]medium10aminopyridine
enoximone[no description available]medium10aromatic ketone
stepronin[no description available]medium10N-acyl-amino acid
simvastatin[no description available]medium30delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
simvastatin[no description available]medium31delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan[no description available]medium10benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride[no description available]medium10dimethoxybenzene
cabergoline[no description available]medium20N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
atomoxetine hydrochloride[no description available]medium10hydrochlorideadrenergic uptake inhibitor;
antidepressant
quinapril[no description available]medium20dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
mifepristone[no description available]medium203-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
salmeterol xinafoate[no description available]medium10naphthoic acid
finasteride[no description available]medium203-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod[no description available]medium20imidazoquinolineantineoplastic agent;
interferon inducer
sertindole[no description available]medium10heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
adapalene[no description available]medium10adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
aromasil[no description available]medium2017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
sparfloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton[no description available]medium201-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
cidofovir anhydrous[no description available]medium30phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
bromfenac[no description available]medium20aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gemcitabine hydrochloride[no description available]medium10hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
aripiprazole[no description available]medium20aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
atorvastatin calcium anhydrous[no description available]medium10organic calcium salt
lamivudine[no description available]medium30monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
duloxetine hydrochloride[no description available]medium10duloxetine hydrochlorideantidepressant
valsartan[no description available]medium30biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
zolmitriptan[no description available]medium20oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adefovir dipivoxil[no description available]medium206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine[no description available]medium30monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
paroxetine hydrochloride[no description available]medium10hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
bupropion hydrochloride[no description available]medium10aromatic ketone
trazodone hydrochloride[no description available]medium10hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
doxazosin mesylate[no description available]medium10methanesulfonate saltgeroprotector
efavirenz[no description available]medium60acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz[no description available]medium61acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
mevastatin[no description available]medium102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride[no description available]medium10hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
plerixafor[no description available]medium30azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir[no description available]medium40carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
ticlopidine hydrochloride[no description available]medium10hydrochloride
epirubicin hydrochloride[no description available]medium10
pazufloxacin[no description available]medium10quinolines
repaglinide[no description available]medium20piperidines
telmisartan[no description available]medium40benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
miconazole nitrate[no description available]medium10
zoledronic acid[no description available]medium301,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
artemisinin[no description available]medium20organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide[no description available]medium20sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone[no description available]medium103-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether[no description available]medium10artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
uk 68798[no description available]medium20aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
hp 873[no description available]medium201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
loxapine succinate[no description available]medium10succinate saltgeroprotector
betamipron[no description available]medium10organonitrogen compound;
organooxygen compound
uroxatral[no description available]medium10hydrochloride
aceclofenac[no description available]medium20amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
thiocolchicoside[no description available]medium10glycoside
doripenem[no description available]medium20carbapenems
rosiglitazone[no description available]medium20aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
tamiflu[no description available]medium10phosphate salt
bexarotene[no description available]medium20benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098[no description available]medium10acetamides
flunisolide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
ketorolac tromethamine[no description available]medium10organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
clarithromycin[no description available]medium40macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
nicotine[no description available]medium103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
gliquidone[no description available]medium10isoquinolines
lopinavir[no description available]medium20amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
moxifloxacin hydrochloride[no description available]medium10hydrochlorideantibacterial drug
fulvestrant[no description available]medium2017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine[no description available]medium10imidazolesanticoronaviral agent
sr141716[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous[no description available]medium20primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
racecadotril[no description available]medium10N-acyl-amino acid
tadalafil[no description available]medium20benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
plavix[no description available]medium10azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
clofarabine[no description available]medium30adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
pramipexole[no description available]medium20benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib[no description available]medium20isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mk 0663[no description available]medium10bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
gefitinib[no description available]medium30aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
methotrexate[no description available]medium50dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
sulbactam[no description available]medium10penicillanic acids
olmesartan medoxomil[no description available]medium20biphenyls
abiraterone[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
febuxostat[no description available]medium301,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
lexapro[no description available]medium10
docetaxel anhydrous[no description available]medium20secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
levofloxacin[no description available]medium409-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ezetimibe[no description available]medium30azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
cox 189[no description available]medium20amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
xamoterol[no description available]medium10morpholines
naproxen[no description available]medium40methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
telbivudine[no description available]medium30pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
atropine[no description available]medium20
ramelteon[no description available]medium20indanes
deferasirox[no description available]medium50benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
bms204352[no description available]medium10
tbc-11251[no description available]medium20benzodioxoles
tolvaptan[no description available]medium20benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
lenalidomide[no description available]medium20aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lacosamide[no description available]medium20N-acyl-amino acid
vincaleukoblastine[no description available]medium20acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
vincristine sulfate[no description available]medium10organic sulfate saltantineoplastic agent;
geroprotector
wortmannin[no description available]medium10acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
bortezomib[no description available]medium30amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir[no description available]medium601,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
ritonavir[no description available]medium611,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
pentostatin[no description available]medium20coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
quinidine[no description available]medium40cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem[no description available]medium20alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
digitoxin[no description available]medium10cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir[no description available]medium40L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
perindopril erbumine[no description available]medium10addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol[no description available]medium20piperidines
rocuronium bromide[no description available]medium10organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
linezolid[no description available]medium30acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
pemirolast potassium salt[no description available]medium10
eplerenone[no description available]medium203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
ao 128[no description available]medium10organic molecular entity
loteprednol etabonate[no description available]medium1011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
fluticasone propionate[no description available]medium1011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
tretinoin[no description available]medium40retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
mupirocin[no description available]medium10alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
zithromax[no description available]medium40macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
decitabine[no description available]medium202'-deoxyribonucleoside
teniposide[no description available]medium20aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
valrubicin[no description available]medium10anthracycline;
trifluoroacetamide
melphalan[no description available]medium20L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
rubitecan[no description available]medium10C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
arginine vasopressin[no description available]medium20vasopressincardiovascular drug;
hematologic agent;
mitogen
trilostane[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
leuprolide acetate[no description available]medium10acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
propylthiouracil[no description available]medium20pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
mercaptopurine[no description available]medium50aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
levosulpiride[no description available]medium10sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
eszopiclone[no description available]medium20zopiclonecentral nervous system depressant;
sedative
methimazole[no description available]medium201,3-dihydroimidazole-2-thionesantithyroid drug
cinnarizine[no description available]medium10diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
sulindac[no description available]medium20monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
epalrestat[no description available]medium10monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin[no description available]medium10isoquinolines
tamoxifen[no description available]medium20stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
fusidic acid[no description available]medium2011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
valinomycin[no description available]medium10cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
hmr 3647[no description available]medium20
latoconazole[no description available]medium10conazole antifungal drug;
imidazole antifungal drug
maraviroc[no description available]medium20tropane alkaloid
toremifene citrate[no description available]medium10stilbenoidanticoronaviral agent
nelarabine[no description available]medium20beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
gestodene[no description available]medium10steroidestrogen
orlistat[no description available]medium30beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine[no description available]medium30cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
azilect[no description available]medium10
dasatinib[no description available]medium601,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
sitagliptin[no description available]medium30triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
tolcapone[no description available]medium302-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
calcitriol[no description available]medium20D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
alprostadil[no description available]medium20prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
vitamin d 2[no description available]medium20hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
pulmicort[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone[no description available]medium20
eprosartan[no description available]medium30dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
brompheniramine maleate[no description available]medium10maleate saltanti-allergic agent
dexchlorpheniramine maleate[no description available]medium10organic molecular entity
entacapone[no description available]medium302-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
l 660,711[no description available]medium20quinolines
travoprost[no description available]medium10(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
tranilast[no description available]medium10amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
imipenem[no description available]medium10carbapenems
etretinate[no description available]medium10enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin[no description available]medium20retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
ketotifen fumarate[no description available]medium10organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
dinoprost tromethamine[no description available]medium10organic molecular entity
rosuvastatin calcium[no description available]medium10N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride[no description available]medium10allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
acitretin[no description available]medium20acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
levetiracetam[no description available]medium20pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
nalmefene[no description available]medium10morphinane alkaloid
naloxone[no description available]medium20morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
topiramate[no description available]medium40cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
demycarosylturimycin h[no description available]medium10
acipimox[no description available]medium10pyrazinecarboxylic acid
atosiban[no description available]medium10oligopeptide
bimatoprost[no description available]medium10monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
latanoprost[no description available]medium10isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
nateglinide[no description available]medium20phenylalanine derivative
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium20dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine[no description available]medium10ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
butorphanol[no description available]medium20morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefixime[no description available]medium20cephalosporinantibacterial drug;
drug allergen
lisinopril[no description available]medium30dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ramipril[no description available]medium20azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
indinavir sulfate[no description available]medium30dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalapril maleate[no description available]medium10maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
enalaprilat anhydrous[no description available]medium20dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trandolapril[no description available]medium20dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin[no description available]medium20gamma-amino acidanticonvulsant;
calcium channel blocker
alvimopan anhydrous[no description available]medium20peptide
famotidine[no description available]medium201,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cci 15641[no description available]medium10cephalosporin
tenofovir disoproxil fumarate[no description available]medium10fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
dexbrompheniramine maleate[no description available]medium10brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
rifaximin[no description available]medium20acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
everolimus[no description available]medium30cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
cefpodoxime proxetil[no description available]medium10carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
fluphenazine[no description available]medium10
nitrofurantoin[no description available]medium20imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
roxithromycin[no description available]medium10roxithromycinenvironmental contaminant;
xenobiotic
cefdinir[no description available]medium20cephalosporin;
ketoxime		antibacterial drug
bisoprolol, fumarate (1:1) salt[no description available]medium10
artesunate[no description available]medium20artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
etoposide phosphate[no description available]medium10furonaphthodioxole
ciclesonide[no description available]medium10organic molecular entity
temsirolimus[no description available]medium20macrolide lactam
dutasteride[no description available]medium20(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna[no description available]medium10fumarate saltantihypertensive agent
vildagliptin[no description available]medium20amino acid amide
sgd 301-76[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate[no description available]medium10(trifluoromethyl)benzenes
thioacetazone[no description available]medium10
dexlansoprazole[no description available]medium20benzimidazoles;
sulfoxide
gemifloxacin mesylate[no description available]medium10methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
rivaroxaban[no description available]medium20aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
hki 272[no description available]medium10nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib[no description available]medium10N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pazopanib[no description available]medium20aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
amg 009[no description available]medium10
cefotaxime sodium[no description available]medium10organic sodium salt
losartan potassium[no description available]medium10
dactolisib[no description available]medium10imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
rabeprazole sodium[no description available]medium10organic sodium salt
bivalirudin[no description available]medium20polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin[no description available]medium10heterodetic cyclic peptide;
peptide hormone
ly-146032[no description available]medium20heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
warfarin sodium[no description available]medium10
pravastatin sodium[no description available]medium10organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium[no description available]medium10
sl 80.0750[no description available]medium10
mesna[no description available]medium20organosulfonic acid
clavulanate potassium[no description available]medium10potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
piperacillin sodium[no description available]medium10organic sodium salt
oxacillin sodium[no description available]medium10organic sodium salt
cefazolin sodium[no description available]medium10organic sodium salt
azlocillin sodium[no description available]medium10organic sodium salt
tetracycline[no description available]medium20
piroxicam[no description available]medium20benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
roquinimex[no description available]medium10aromatic amide
mobic[no description available]medium401,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex[no description available]medium10heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam[no description available]medium10benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
minocycline hydrochloride[no description available]medium10
tigecycline[no description available]medium20
lornoxicam[no description available]medium10heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
entecavir[no description available]medium302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir[no description available]medium402-aminopurines;
oxopurine		antimetabolite;
antiviral drug
rifampin[no description available]medium100cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
rifampin[no description available]medium101cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine[no description available]medium20benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine[no description available]medium20dacarbazine
didanosine[no description available]medium30purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir[no description available]medium402-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valtrex[no description available]medium10organic molecular entity
olanzapine[no description available]medium20benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
raltitrexed[no description available]medium10N-acyl-amino acid
allopurinol[no description available]medium20nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
citrovorum factor[no description available]medium20tetrahydrofolic acid
rifapentine[no description available]medium20N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
aprepitant[no description available]medium30(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
tegaserod maleate[no description available]medium10maleate saltserotonergic agonist
rifabutin[no description available]medium20
vt-1161[no description available]medium40organic molecular entity
bekanamycin[no description available]medium20kanamycins
betaine[no description available]medium10amino-acid betaine;
glycine derivative		fundamental metabolite
bupropion[no description available]medium10aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
aminocaproic acid[no description available]medium10amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
niacin[no description available]medium10pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
pyridoxine[no description available]medium10hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiamine[no description available]medium20primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phenytoin[no description available]medium60imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
phenytoin[no description available]medium61imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
acebutolol[no description available]medium10aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetohydroxamic acid[no description available]medium10acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
alaproclate[no description available]medium10alpha-amino acid ester
alendronate[no description available]medium101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin[no description available]medium10monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron[no description available]medium10imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam[no description available]medium10organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
altretamine[no description available]medium10triamino-1,3,5-triazine
amantadine[no description available]medium20adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ambenonium[no description available]medium10quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
amifostine anhydrous[no description available]medium10diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
p-aminohippuric acid[no description available]medium10N-acylglycineDaphnia magna metabolite
bendazac[no description available]medium10indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
bendroflumethiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
betaxolol[no description available]medium10propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol[no description available]medium10carbamate ester;
quaternary ammonium ion		muscarinic agonist
biperiden[no description available]medium10piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bisoprolol[no description available]medium10secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
buspirone[no description available]medium10azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
secbutabarbital[no description available]medium10barbiturates
candesartan[no description available]medium20benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbinoxamine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carisoprodol[no description available]medium10carbamate estermuscle relaxant
cetirizine[no description available]medium10ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlorcyclizine[no description available]medium10diarylmethane
chlormezanone[no description available]medium101,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chlorothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
clonazepam[no description available]medium101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine[no description available]medium10clonidine;
imidazoline
chlorazepate[no description available]medium101,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
cyclobenzaprine[no description available]medium10carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
cyclofenil[no description available]medium10organic molecular entity
cyproheptadine[no description available]medium10piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
deferoxamine[no description available]medium10acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
amphetamine[no description available]medium10primary amine
diclofenac[no description available]medium20amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
dichlorphenamide[no description available]medium10dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine[no description available]medium10carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
pentetic acid[no description available]medium10pentacarboxylic acidcopper chelator
diflunisal[no description available]medium10monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dimercaprol[no description available]medium10dithiol;
primary alcohol		chelator
diphenhydramine[no description available]medium10ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
valproic acid[no description available]medium20branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
doxapram[no description available]medium10morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxylamine[no description available]medium10pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol[no description available]medium10aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyphylline[no description available]medium10oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
edrophonium[no description available]medium10phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
estazolam[no description available]medium10triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethotoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
etidronate[no description available]medium201,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etodolac[no description available]medium10monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
felbamate[no description available]medium10carbamate esteranticonvulsant;
neuroprotective agent
fenoldopam[no description available]medium10benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen[no description available]medium10monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fexofenadine[no description available]medium10piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fipexide[no description available]medium10benzodioxoles
flavoxate[no description available]medium10carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
flecainide[no description available]medium10aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
flurazepam[no description available]medium101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurbiprofen[no description available]medium10fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fomepizole[no description available]medium10pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet[no description available]medium10carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
gabapentin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glafenine[no description available]medium10aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester[no description available]medium10benzenes
granisetron[no description available]medium10aromatic amide;
indazoles
guaifenesin[no description available]medium10methoxybenzenes
guanethidine[no description available]medium10azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanidine[no description available]medium10carboxamidine;
guanidines;
one-carbon compound
hydralazine[no description available]medium10azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydroxychloroquine[no description available]medium20aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyzine[no description available]medium10hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ibuprofen[no description available]medium30monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine[no description available]medium10primary amine
ioversol[no description available]medium10amidobenzoic acid
isocarboxazid[no description available]medium10benzenes
isoproterenol[no description available]medium10catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine[no description available]medium10alkylbenzene
ketoprofen[no description available]medium10benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac[no description available]medium10amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
labetalol[no description available]medium10benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lomefloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
lorazepam[no description available]medium20benzodiazepine
lorazepam[no description available]medium21benzodiazepine
losartan[no description available]medium30biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine[no description available]medium10dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
mecamylamine[no description available]medium10primary aliphatic amine
mechlorethamine[no description available]medium10nitrogen mustard;
organochlorine compound		alkylating agent
meclizine[no description available]medium10diarylmethane
meclofenamic acid[no description available]medium10aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
memantine[no description available]medium10adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
mepenzolate[no description available]medium10diarylmethane
meperidine[no description available]medium10ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
mepivacaine[no description available]medium10piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate[no description available]medium10organic molecular entity
mesalamine[no description available]medium10amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mesoridazine[no description available]medium10phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
metaproterenol[no description available]medium10aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
methadone[no description available]medium10benzenes;
diarylmethane;
ketone;
tertiary amino compound
methazolamide[no description available]medium20sulfonamide;
thiadiazoles
methocarbamol[no description available]medium20aromatic ether;
carbamate ester;
secondary alcohol
methoxsalen[no description available]medium10aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methyclothiazide[no description available]medium10benzothiadiazine
methylphenidate[no description available]medium10beta-amino acid ester;
methyl ester;
piperidines
metolazone[no description available]medium10organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metyrapone[no description available]medium10aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
midodrine[no description available]medium10amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone[no description available]medium10bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
mitotane[no description available]medium10diarylmethane
mitoxantrone[no description available]medium20dihydroxyanthraquinoneanalgesic;
antineoplastic agent
modafinil[no description available]medium10monocarboxylic acid amide;
sulfoxide
moxisylyte[no description available]medium10monoterpenoid
nabumetone[no description available]medium20methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
naratriptan[no description available]medium10heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nialamide[no description available]medium10organonitrogen compound;
organooxygen compound
nilutamide[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nitroglycerin[no description available]medium10nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nizatidine[no description available]medium101,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine[no description available]medium10isoquinolinesdopamine uptake inhibitor
orphenadrine[no description available]medium10ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
aminosalicylic acid[no description available]medium10aminobenzoic acid;
phenols		antitubercular agent
pamidronate[no description available]medium10phosphonoacetic acid
pantoprazole[no description available]medium20aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
pentobarbital[no description available]medium10barbituratesGABAA receptor agonist
perhexiline[no description available]medium20piperidinescardiovascular drug
phenobarbital[no description available]medium20barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenoxybenzamine[no description available]medium10aromatic amine
phentermine[no description available]medium10primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid[no description available]medium20monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
polythiazide[no description available]medium10benzothiadiazine
duodote[no description available]medium10pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
procarbazine[no description available]medium10benzamides;
hydrazines		antineoplastic agent
propantheline[no description available]medium10xanthenes
propofol[no description available]medium10phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
protriptyline[no description available]medium10carbotricyclic compoundantidepressant
pyridostigmine[no description available]medium10pyridinium ion
pyrimethamine[no description available]medium20aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134[no description available]medium10benzodiazepine
quetiapine[no description available]medium10dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole[no description available]medium20benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
rimantadine[no description available]medium20alkylamine
rizatriptan[no description available]medium10tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
ropinirole[no description available]medium10indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
salicylsalicylic acid[no description available]medium10benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
secobarbital[no description available]medium10barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
risedronic acid[no description available]medium10pyridines
succinylcholine[no description available]medium10quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
sulfamethizole[no description available]medium10sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfathiazole[no description available]medium101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]medium10alkylbenzene
temazepam[no description available]medium20benzodiazepine
temazepam[no description available]medium21benzodiazepine
thalidomide[no description available]medium20phthalimides;
piperidones
thiabendazole[no description available]medium101,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
thioridazine[no description available]medium20phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
ticlopidine[no description available]medium20monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tiopronin[no description available]medium10N-acyl-amino acid
tolazamide[no description available]medium10N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolmetin[no description available]medium10aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
ultram[no description available]medium10aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid[no description available]medium10amino acid
triazolam[no description available]medium10triazolobenzodiazepinesedative
trifluoperazine[no description available]medium30N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trihexyphenidyl[no description available]medium10amine
trimethadione[no description available]medium10oxazolidinoneanticonvulsant;
geroprotector
trimethobenzamide[no description available]medium20benzamides;
tertiary amino compound		antiemetic
trimetrexate[no description available]medium10
trimipramine[no description available]medium10dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
tyramine[no description available]medium10monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
delavirdine[no description available]medium30aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zolpidem[no description available]medium10imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
cortisone acetate[no description available]medium10corticosteroid hormone
mitomycin[no description available]medium10mitomycinalkylating agent;
antineoplastic agent
phentolamine[no description available]medium10imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol[no description available]medium10glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
thyroxine[no description available]medium102-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine[no description available]medium101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
spironolactone[no description available]medium103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
cysteine[no description available]medium10cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
prednisone[no description available]medium8011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
estrone[no description available]medium1017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone[no description available]medium1017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
penicillin g[no description available]medium10penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
pilocarpine[no description available]medium10pilocarpineantiglaucoma drug
triiodothyronine[no description available]medium102-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
glutamine[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
vincristine[no description available]medium10acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine[no description available]medium10carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
methyltestosterone[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
tetrabenazine[no description available]medium10benzoquinolizine;
cyclic ketone;
tertiary amino compound
edetic acid[no description available]medium10ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride[no description available]medium10quaternary ammonium salt
mepazine[no description available]medium10phenothiazines
cloxacillin[no description available]medium10penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
calcium acetate[no description available]medium10calcium saltchelator
methionine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
mebanazine[no description available]medium10benzenes
oxacillin[no description available]medium10penicillinantibacterial agent;
antibacterial drug
cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
benziodarone[no description available]medium10aromatic ketone
ampicillin[no description available]medium10beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol[no description available]medium10mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
arginine[no description available]medium10arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
perflutren[no description available]medium10fluoroalkane;
fluorocarbon
fluoxymesterone[no description available]medium1011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
methsuximide[no description available]medium10organic molecular entity
tromethamine[no description available]medium10primary amino compound;
triol		buffer
brompheniramine[no description available]medium10organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
penicillin v[no description available]medium10penicillin allergen;
penicillin
isosorbide dinitrate[no description available]medium10glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
pseudoephedrine[no description available]medium10phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion[no description available]medium10aromatic ketone;
tertiary amine		appetite depressant
benzonatate[no description available]medium10benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
methylergonovine[no description available]medium10ergoline alkaloid
cinchophen[no description available]medium10quinolines
nafcillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
methohexital[no description available]medium10acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
ephedrine[no description available]medium10phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
azacitidine[no description available]medium30N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
nandrolone decanoate[no description available]medium10steroid ester
dextropropoxyphene[no description available]medium101-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
chenodeoxycholic acid[no description available]medium10bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
4-hydroxybutyric acid[no description available]medium104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
dihydroergotamine[no description available]medium10ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
medroxyprogesterone[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
methamphetamine[no description available]medium10amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
levocarnitine[no description available]medium10carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
sulfanilylurea[no description available]medium10benzenes;
sulfonamide
lactulose[no description available]medium10glycosylfructosegastrointestinal drug;
laxative
pamabrom[no description available]medium10
acetylcysteine[no description available]medium30acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
diphenoxylate[no description available]medium10ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
ethambutol[no description available]medium20ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
vancomycin[no description available]medium40glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
d-alpha tocopherol[no description available]medium20alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
ibufenac[no description available]medium10monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metaxalone[no description available]medium10aromatic ether
spectinomycin[no description available]medium10cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
dronabinol[no description available]medium10benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride[no description available]medium10aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide[no description available]medium10benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
dexbrompheniramine[no description available]medium10brompheniramineanti-allergic agent;
H1-receptor antagonist
megestrol[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
streptomycin[no description available]medium10antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
carbenicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
clomacran[no description available]medium10acridines
methenamine hippurate[no description available]medium10N-acylglycine
olsalazine[no description available]medium10azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
sodium thiosulfate[no description available]medium10inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
selegiline[no description available]medium10selegiline;
terminal acetylenic compound		geroprotector
clemastine[no description available]medium20monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
cephalexin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
fenclozic acid[no description available]medium10
laxagetten 4,4'-diacetoxydiphenylpyridylemethane[no description available]medium10
daunorubicin[no description available]medium60aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
alclofenac[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
bromocriptine[no description available]medium20indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
oxyphenisatin[no description available]medium10indoles
fludrocortisone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
ursodeoxycholic acid[no description available]medium10bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
dexchlorpheniramine[no description available]medium10chlorphenamine
clometacin[no description available]medium10N-acylindole
cefazolin[no description available]medium20beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
moricizine[no description available]medium10carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
amineptin[no description available]medium10amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
pirprofen[no description available]medium10pyrroline
dobutamine[no description available]medium10catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
penbutolol[no description available]medium10ethanolamines
cephradine[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
ticrynafen[no description available]medium10aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
methyldopa[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
vecuronium[no description available]medium10acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
benoxaprofen[no description available]medium101,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
exifone[no description available]medium10benzophenones
mefloquine[no description available]medium30[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
sufentanil[no description available]medium10anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
torsemide[no description available]medium10aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
epirubicin[no description available]medium10aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
idarubicin[no description available]medium40anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
piperacillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
paroxetine[no description available]medium10aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
cefoperazone[no description available]medium10cephalosporinantibacterial drug
atracurium[no description available]medium10diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
pergolide[no description available]medium10diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
fialuridine[no description available]medium10
alfentanil[no description available]medium10monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
miglustat[no description available]medium10piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate[no description available]medium10organic molecular entity
tolrestat[no description available]medium10naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
balsalazide[no description available]medium10
pravastatin[no description available]medium103-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
atomoxetine[no description available]medium10aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
alpidem[no description available]medium10imidazoles
fosphenytoin[no description available]medium10imidazolidine-2,4-dione
ranolazine[no description available]medium30aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
esmolol[no description available]medium10aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
adefovir[no description available]medium206-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
clopidogrel[no description available]medium10methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tiagabine[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
topotecan[no description available]medium10pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine[no description available]medium20organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide[no description available]medium10benzenes;
organic amino compound
remifentanil[no description available]medium10alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin[no description available]medium30aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
duloxetine[no description available]medium10duloxetine
irinotecan[no description available]medium10carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
ibandronic acid[no description available]medium20
ziprasidone[no description available]medium101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
tasosartan[no description available]medium10biphenyls
tiludronic acid[no description available]medium10organochlorine compound
tirofiban[no description available]medium10L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine[no description available]medium10carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
trovafloxacin[no description available]medium10
cefprozil[no description available]medium10cephalosporin;
semisynthetic derivative		antibacterial drug
fenofibric acid[no description available]medium10aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
oseltamivir[no description available]medium20acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
histamine phosphate[no description available]medium10phosphate salthistamine agonist
tilbroquinol[no description available]medium10organohalogen compound;
quinolines
bendamustine[no description available]medium10benzimidazoles
droxicam[no description available]medium10organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
ebrotidine[no description available]medium10sulfonamide
sertraline[no description available]medium10dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
acamprosate[no description available]medium10acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine[no description available]medium10aminopyrimidine
nebivolol[no description available]medium10chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
dexrazoxane[no description available]medium10razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
fenoxypropazine[no description available]medium10aromatic ether
nitrefazole[no description available]medium10imidazoles
atovaquone[no description available]medium30hydroxy-1,2-naphthoquinone
rivastigmine[no description available]medium10carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan[no description available]medium10carbazoles
eletriptan[no description available]medium10indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
moexipril[no description available]medium20peptide
mci 9038[no description available]medium10peptide
perindopril[no description available]medium10alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
paliperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
nitisinone[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
almotriptan[no description available]medium10indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
desvenlafaxine[no description available]medium10cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
tamsulosin[no description available]medium105-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide[no description available]medium10aromatic amide;
heteroarene
dexpanthenol[no description available]medium10amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir[no description available]medium40sulfonamideprodrug
fosamprenavir[no description available]medium41sulfonamideprodrug
escitalopram[no description available]medium101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
10-propargyl-10-deazaaminopterin[no description available]medium10N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
atazanavir[no description available]medium30carbohydrazideantiviral drug;
HIV protease inhibitor
ertapenem[no description available]medium10carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
conivaptan[no description available]medium10benzazepineaquaretic;
vasopressin receptor antagonist
moxifloxacin[no description available]medium10aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
pralnacasan[no description available]medium10
clevidipine[no description available]medium10dihydropyridine
solifenacin[no description available]medium10isoquinolines
dexmethylphenidate[no description available]medium10methyl phenyl(piperidin-2-yl)acetateadrenergic agent
cinacalcet[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lubiprostone[no description available]medium20
paromomycin[no description available]medium10amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
17 alpha-hydroxyprogesterone caproate[no description available]medium10corticosteroid hormone
varenicline[no description available]medium20
fiduxosin[no description available]medium10
erlotinib[no description available]medium40aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
etravirine[no description available]medium30aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
dronedarone[no description available]medium101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
lapatinib[no description available]medium20furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir[no description available]medium30carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
sorafenib[no description available]medium20(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
regadenoson[no description available]medium10purine nucleoside
benzarone[no description available]medium101-benzofurans
estramustine[no description available]medium1017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
oxytocin[no description available]medium10heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
griseofulvin[no description available]medium201-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
pancuronium[no description available]medium10acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
abacavir[no description available]medium302,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
metyrosine[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
clindamycin phosphate[no description available]medium10
tolterodine[no description available]medium10tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
darifenacin[no description available]medium101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
retinol[no description available]medium10retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
rosuvastatin[no description available]medium10dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
mycophenolic acid[no description available]medium102-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
clindamycin[no description available]medium10
fosfomycin[no description available]medium10epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
octreotide[no description available]medium10
eptifibatide[no description available]medium10homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
dactinomycin[no description available]medium10actinomycinmutagen
tenofovir[no description available]medium20nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
riboflavin[no description available]medium10flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
sodium bicarbonate[no description available]medium10one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
arsenic trioxide[no description available]medium10arsenic oxideantineoplastic agent;
insecticide
sr 90107[no description available]medium10
meglumine iodipamide[no description available]medium10organoammonium saltradioopaque medium
thyrotropin-releasing hormone[no description available]medium10peptide hormone;
tripeptide		human metabolite
s 1033[no description available]medium20(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
etomidate[no description available]medium10ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
pyrantel[no description available]medium101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
thiothixene[no description available]medium10N-methylpiperazineanticoronaviral agent
thioguanine anhydrous[no description available]medium202-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
succimer[no description available]medium10dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
digoxin[no description available]medium30cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
streptozocin[no description available]medium10
ethionamide[no description available]medium10pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
lincomycin[no description available]medium10carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
ranitidine[no description available]medium30C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc[no description available]medium10
toremifene[no description available]medium20aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
dermatan sulfate[no description available]medium10amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
dolasetron[no description available]medium10indolyl carboxylic acid
fospropofol[no description available]medium10alkylbenzene
rasagiline[no description available]medium10indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
montelukast[no description available]medium10aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium[no description available]medium10isoquinolines
hemabate[no description available]medium10
paricalcitol[no description available]medium10hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
7432 s[no description available]medium10cephalosporin;
dicarboxylic acid		antibacterial drug
epoprostenol[no description available]medium10prostaglandins Imouse metabolite
indocyanine green[no description available]medium101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
triprolidine[no description available]medium10N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
pitavastatin[no description available]medium10cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
ethamolin[no description available]medium10long-chain fatty acid
alatrofloxacin mesylate[no description available]medium10
codeine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
estropipate[no description available]medium10piperazinium salt;
steroid sulfate
hydromorphone[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
ly 163892[no description available]medium10carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone[no description available]medium10
oxycodone[no description available]medium10organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone[no description available]medium10morphinane alkaloid
vitamin k 1[no description available]medium10phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
trospium chloride[no description available]medium10
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
benzphetamine[no description available]medium10amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
deamino arginine vasopressin[no description available]medium10heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine[no description available]medium20medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
goserelin[no description available]medium10organic molecular entity
nalbuphine[no description available]medium10organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
silodosin[no description available]medium10indolecarboxamide
fluvoxamine[no description available]medium10(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
su 11248[no description available]medium30monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
levorphanol[no description available]medium10morphinane alkaloid
naltrexone[no description available]medium20cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
dextromethorphan[no description available]medium106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
benazepril[no description available]medium10benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
verteporfin[no description available]medium20
zimeldine[no description available]medium10styrenes
enalapril[no description available]medium10dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
trientine hydrochloride[no description available]medium10
n-methylscopolamine bromide[no description available]medium10
bleomycin[no description available]medium10bleomycinantineoplastic agent;
metabolite
ximelagatran[no description available]medium10amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
cefuroxime[no description available]medium103-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone[no description available]medium101,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime[no description available]medium20cephalosporin;
oxime O-ether		antibacterial drug
pafuramidine[no description available]medium10
ceftazidime[no description available]medium10cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
aliskiren[no description available]medium10monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
cefotaxime[no description available]medium101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam[no description available]medium10beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefpodoxime[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
palonosetron[no description available]medium10azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
ixabepilone[no description available]medium101,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
ceftizoxime[no description available]medium10cephalosporinantibacterial drug
1-methyl-d-lysergic acid butanolamide[no description available]medium10ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
dantrolene[no description available]medium10
etonogestrel[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
lu 208075[no description available]medium10diarylmethane
bibx 1382bs[no description available]medium10substituted aniline
fesoterodine[no description available]medium10diarylmethane
gemifloxacin[no description available]medium101,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
fosinopril[no description available]medium10
armodafinil[no description available]medium102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
sincalide[no description available]medium10oligopeptide
tapentadol[no description available]medium10alkylbenzene
pentagastrin[no description available]medium10organic molecular entity
cefditoren[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
prasugrel hydrochloride[no description available]medium10
baci-im[no description available]medium10homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
bms 477118[no description available]medium20adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
nystatin a1[no description available]medium40nystatins
milnacipran[no description available]medium10acetamides
scopolamine hydrobromide[no description available]medium10
enfuvirtide[no description available]medium10
ganirelix[no description available]medium10polypeptide
teriparatide[no description available]medium10polypeptide
salmon calcitonin[no description available]medium10heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide[no description available]medium10polypeptide
exenatide[no description available]medium10
sodium lactate[no description available]medium10lactate salt;
organic sodium salt		food acidity regulator;
food preservative
sodium iothalamate[no description available]medium10
cetrorelix[no description available]medium10oligopeptideantineoplastic agent;
GnRH antagonist
ascorbic acid[no description available]medium10ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
raltegravir[no description available]medium101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
oxytetracycline, anhydrous[no description available]medium10
minocycline[no description available]medium10
warfarin[no description available]medium20benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline[no description available]medium10
tipranavir[no description available]medium20sulfonamideantiviral drug;
HIV protease inhibitor
fertinex[no description available]medium10
folic acid[no description available]medium10folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
valacyclovir[no description available]medium30L-valyl esterantiviral drug
sildenafil[no description available]medium10piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
vardenafil[no description available]medium10imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
leucovorin[no description available]medium10formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
bl 4162a[no description available]medium10imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod[no description available]medium20carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
pemetrexed[no description available]medium20N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
valganciclovir[no description available]medium10L-valyl ester;
purines		antiviral drug;
prodrug
fosaprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
levomefolate calcium[no description available]medium10organic calcium saltantidepressant
miltefosine[no description available]medium90phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hoe 33342[no description available]medium10bibenzimidazole;
N-methylpiperazine		fluorochrome
bisbenzimidazole[no description available]medium10bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
hexaconazole[no description available]medium10dichlorobenzene;
tertiary alcohol;
triazoles		chelator
econazole[no description available]medium20dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
ketoconazole[no description available]medium60cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
miconazole[no description available]medium70dichlorobenzene;
ether;
imidazoles
mangostin[no description available]medium30aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
quinacrine[no description available]medium20acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
methicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
amodiaquine[no description available]medium20aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
niclosamide[no description available]medium10benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
salmeterol xinafoate[no description available]medium10ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
betulinic acid[no description available]medium20hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
baicalin[no description available]medium20dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
honokiol[no description available]medium20biphenyls
lycorine[no description available]medium20indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor
pacein[no description available]medium10
schizandrin a[no description available]medium10
lupeol[no description available]medium10pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
naringenin[no description available]medium10(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
1-O-Acetyllycorine[no description available]medium10alkaloid
carbenoxolone[no description available]medium10
citral[no description available]medium10enal;
monoterpenoid;
polyprenal		plant metabolite;
volatile oil component
lanatoside c[no description available]medium10
curcumin[no description available]medium30aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
hirsutine[no description available]medium10
quercitrin[no description available]medium10alpha-L-rhamnoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		antileishmanial agent;
antioxidant;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite
caryophyllene[no description available]medium10beta-caryophyllenefragrance;
insect attractant;
metabolite;
non-steroidal anti-inflammatory drug
brefeldin a[no description available]medium10macrolide antibioticPenicillium metabolite
peridinin[no description available]medium10
andrographolide[no description available]medium10carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
cyclo(leucyl-prolyl)[no description available]medium10dipeptide;
homodetic cyclic peptide;
pyrrolopyrazine		bacterial metabolite;
marine metabolite
osu 03012[no description available]medium10antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
lactimidomycin[no description available]medium10macrolide
sofosbuvir[no description available]medium20isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
tatanan a[no description available]medium10
melarsoprol[no description available]medium20triazines
fexinidazole[no description available]medium10
obtusifoliol[no description available]medium1014alpha-methyl steroid;
3beta-sterol		mouse metabolite;
plant metabolite
anethole trithione[no description available]medium10methoxybenzenes
b 844-39[no description available]medium10diarylmethane
candesartan cilexetil[no description available]medium10biphenyls
1,3-benzodioxole[no description available]medium10benzodioxole
tryptoquivaline[no description available]medium10aromatic ether;
indole alkaloid;
organic heteropentacyclic compound		breast cancer resistance protein inhibitor;
mycotoxin
6-prenylchrysin[no description available]medium107-hydroxyflavonol;
dihydroxyflavone
chlorprothixene[no description available]medium10chlorprothixene
zd 6474[no description available]medium10aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
sq 109[no description available]medium20
apigenin[no description available]medium10trihydroxyflavoneantineoplastic agent;
metabolite
tectochrysin[no description available]medium10monohydroxyflavone;
monomethoxyflavone		antidiarrhoeal drug;
antineoplastic agent;
plant metabolite
topiroxostat[no description available]medium10
bosutinib[no description available]medium10aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
3,3',4,5'-tetramethoxy-trans-stilbene[no description available]medium10
proguanil[no description available]medium10biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rilpivirine[no description available]medium20aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
timcodar[no description available]medium10
tivozanib[no description available]medium10aromatic ether
ko 143[no description available]medium10beta-carbolines;
tert-butyl ester
regorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
fostamatinib[no description available]medium10
gdc 0449[no description available]medium10benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
ponatinib[no description available]medium10(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
cobicistat[no description available]medium201,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
alectinib[no description available]medium20aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib[no description available]medium21aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
novobiocin[no description available]medium10carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
chir 258[no description available]medium10
amg531[no description available]medium10
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester[no description available]medium10piperidines
pa 824[no description available]medium10
sulfaphenazole[no description available]medium10primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
alpha-naphthoflavone[no description available]medium10extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
aminolevulinic acid[no description available]medium104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
coumarin[no description available]medium10coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid[no description available]medium10monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
thioctic acid[no description available]medium10dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
picolinic acid[no description available]medium10pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
3-aminobenzamide[no description available]medium10benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pleconaril[no description available]medium10
4-(2-aminoethyl)benzenesulfonylfluoride[no description available]medium10
2-aminothiazole[no description available]medium101,3-thiazoles;
primary amino compound
benzamide[no description available]medium10benzamides
camostat[no description available]medium10benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
camphor, (+-)-isomer[no description available]medium10bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite
cetylpyridinium[no description available]medium10pyridinium ion
chloroxylenol[no description available]medium10monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
danthron[no description available]medium10dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
deferiprone[no description available]medium104-pyridonesiron chelator;
protective agent
ebselen[no description available]medium10benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
2-hexyloxybenzamide[no description available]medium10aromatic ether;
benzamides		antifungal agent
gabexate[no description available]medium10benzoate ester
glutaral[no description available]medium10dialdehydecross-linking reagent;
disinfectant;
fixative
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
hexylresorcinol[no description available]medium10resorcinols
beta-thujaplicin[no description available]medium10cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
hycanthone[no description available]medium10thioxanthenesmutagen;
schistosomicide drug
kojic acid[no description available]medium104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
lapachol[no description available]medium10
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide[no description available]medium10benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide[no description available]medium10aromatic amine
entinostat[no description available]medium10benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
ethylmaleimide[no description available]medium10maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
nafamostat[no description available]medium10benzoic acids;
guanidines
osalmide[no description available]medium10organic molecular entity
oxethazaine[no description available]medium10amino acid amide
palmidrol[no description available]medium10endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
phenazopyridine[no description available]medium10diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic
phenylmethylsulfonyl fluoride[no description available]medium10acyl fluorideserine proteinase inhibitor
pimobendan[no description available]medium10benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pj-34[no description available]medium10phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
probucol[no description available]medium10dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
rolipram[no description available]medium10pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
scriptaid[no description available]medium10isoquinolines
sebacic acid[no description available]medium10alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite
fenofibrate[no description available]medium10benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
suprofen[no description available]medium10aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
triflupromazine[no description available]medium10organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trigonelline[no description available]medium10alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
tyrphostin a9[no description available]medium10alkylbenzenegeroprotector
vesnarinone[no description available]medium10organic molecular entity
idoxuridine[no description available]medium10organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
phenylethyl alcohol[no description available]medium10benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
zoxazolamine[no description available]medium10benzoxazole
ficusin[no description available]medium10psoralensplant metabolite
tubercidin[no description available]medium10antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
trifluridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
9,10-anthraquinone[no description available]medium10anthraquinone
salicylanilide[no description available]medium10benzanilide fungicide;
salicylamides;
salicylanilides
gramine[no description available]medium10aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
aminacrine[no description available]medium10aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
methyl gallate[no description available]medium10gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
monobenzone[no description available]medium10benzyl etherallergen;
dermatologic drug;
melanin synthesis inhibitor
ditiocarb[no description available]medium10dithiocarbamic acidschelator;
copper chelator
catechin[no description available]medium10catechinantioxidant;
plant metabolite
lucanthone[no description available]medium10thioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug
cepharanthine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
aloe emodin[no description available]medium10aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
chrysophanic acid[no description available]medium10dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
osthol[no description available]medium10botanical anti-fungal agent;
coumarins		metabolite
flavanone[no description available]medium10flavanones
phloretic acid[no description available]medium10hydroxy monocarboxylic acidplant metabolite
oleanolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
angelicin[no description available]medium10furanocoumarin
diperodon[no description available]medium10carbamate ester
metformin hydrochloride[no description available]medium10hydrochlorideenvironmental contaminant;
hypoglycemic agent;
xenobiotic
5,5'-dimethyl-2,2'-bipyridyl[no description available]medium10bipyridines
dichlorobenzyl alcohol[no description available]medium10benzyl alcohols;
dichlorobenzene		antiseptic drug
dideoxyadenosine[no description available]medium10adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
vidarabine[no description available]medium40beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
3-deazaadenosine[no description available]medium10
ancitabine[no description available]medium10diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
chloropyramine[no description available]medium10aminopyridine
levamisole[no description available]medium106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
n'-nitrosonornicotine[no description available]medium10pyridines;
pyrrolidines
pyridoxal phosphate[no description available]medium10pyridinecarbaldehyde
oltipraz[no description available]medium101,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
fiacitabine[no description available]medium10
brequinar[no description available]medium10biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
celgosivir[no description available]medium10
zanamivir[no description available]medium10guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
octyl gallate[no description available]medium10gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
arctigenin[no description available]medium10lignan
epigallocatechin gallate[no description available]medium10flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose[no description available]medium10gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
cephalotaxine[no description available]medium10benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound
desipramine hydrochloride[no description available]medium10hydrochloridedrug allergen
mefloquine hydrochloride[no description available]medium10hydrochloride
aloxistatin[no description available]medium10epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
propazole[no description available]medium10benzimidazoles
prulifloxacin[no description available]medium10fluoroquinolone antibiotic;
quinolone antibiotic
bergenin[no description available]medium10trihydroxybenzoic acidmetabolite
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
oxprenolol hydrochloride[no description available]medium10
opipramol hydrochloride[no description available]medium10
moroxydine[no description available]medium10biguanides
thioxolone[no description available]medium10benzoxathioleantiseborrheic
nobiletin[no description available]medium10methoxyflavoneantineoplastic agent;
plant metabolite
leupeptin[no description available]medium10aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
tetrandrine[no description available]medium20bisbenzylisoquinoline alkaloid;
isoquinolines
calpeptin[no description available]medium10amino acid amide
fangchinoline[no description available]medium10aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
maslinic acid[no description available]medium10dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
loganin[no description available]medium10beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite
aucubin[no description available]medium10organic molecular entitymetabolite
catalpol[no description available]medium10organic molecular entitymetabolite
lekoptin[no description available]medium102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
n-methyladenosine[no description available]medium10methyladenosine
sivelestat[no description available]medium10N-acylglycine;
pivalate ester
pyronaridine[no description available]medium10aminoquinoline
geniposide[no description available]medium10terpene glycoside
daidzin[no description available]medium107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
sophocarpine[no description available]medium10
marimastat[no description available]medium10hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
elacridar[no description available]medium10
celastrol[no description available]medium10monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine[no description available]medium10leucine derivative
vadimezan[no description available]medium10monocarboxylic acid;
xanthones		antineoplastic agent
e 64[no description available]medium10dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
umifenovir[no description available]medium10indolyl carboxylic acid
safinamide[no description available]medium10amino acid amide
ilomastat[no description available]medium10hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
vx 497[no description available]medium10
bcx 1812[no description available]medium103-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
olmesartan[no description available]medium10biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
celastrol methyl ester[no description available]medium10carboxylic ester
resiquimod[no description available]medium10imidazoquinoline
tanshinone ii a[no description available]medium10abietane diterpenoid
anacardic acid[no description available]medium10hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
migalastat[no description available]medium10piperidines
limonin[no description available]medium10epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
scutellarin[no description available]medium10glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor
chelidonine[no description available]medium10alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
4-n-butylresorcinol[no description available]medium10resorcinols
dapivirine[no description available]medium10
nsc 74859[no description available]medium10amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
berbamine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
u-104[no description available]medium10
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one[no description available]medium10glycoside
tizoxanide[no description available]medium10salicylamides
arbutin[no description available]medium10beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
conessine[no description available]medium10steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite
cephaelin[no description available]medium10pyridoisoquinoline
(-)-usnic acid[no description available]medium10usnic acidEC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
acetylleucyl-leucyl-norleucinal[no description available]medium10aldehyde;
tripeptide		cysteine protease inhibitor
resveratrol[no description available]medium10resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
lycopene[no description available]medium10acyclic caroteneantioxidant;
plant metabolite
roflumilast[no description available]medium10aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
L-cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89[no description available]medium10N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
bevirimat[no description available]medium10dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite
benzyloxycarbonylleucyl-leucyl-leucine aldehyde[no description available]medium10amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
gw 257406x[no description available]medium10
shikonin[no description available]medium10hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide[no description available]medium10tropane alkaloid
cmx 001[no description available]medium10
amd 8664[no description available]medium10
bay 41-4109[no description available]medium10
bay 57-1293[no description available]medium10
2'-c-methylcytidine[no description available]medium10
isoxanthohumol[no description available]medium10flavanones
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide[no description available]medium10aromatic ether
mecarbinate[no description available]medium10
acetyl-aspartyl-glutamyl-valyl-aspartal[no description available]medium10tetrapeptideprotease inhibitor
octotropine methylbromide[no description available]medium10
jrf 12[no description available]medium10
3,4'-dihydroxyflavone[no description available]medium10
3-(3,4-dimethoxyphenyl)propenoic acid[no description available]medium10methoxycinnamic acid
isoferulic acid[no description available]medium10ferulic acidsantioxidant;
biomarker;
metabolite
cyclouridine[no description available]medium10
zucapsaicin[no description available]medium10methoxybenzenes;
phenols
nbd 556[no description available]medium10
4,5,6,7-tetrachloroindan-1,3-dione[no description available]medium10
srpin340[no description available]medium10
pr-619[no description available]medium10
p5091[no description available]medium10
trovirdine[no description available]medium10
fti 277[no description available]medium10
u 0126[no description available]medium10aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
vicriviroc[no description available]medium10(trifluoromethyl)benzenes
telaprevir[no description available]medium10cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
yya-021[no description available]medium10
sb 415286[no description available]medium10C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
tak-220[no description available]medium10
jtk-303[no description available]medium10aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		HIV-1 integrase inhibitor
nbd 557[no description available]medium10
5'-o-caffeoylquinic acid[no description available]medium10cinnamate ester;
cyclitol carboxylic acid		plant metabolite
luteolin-7-glucoside[no description available]medium10beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
cyclosporine[no description available]medium10
harmine[no description available]medium10harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
amentoflavone[no description available]medium10biflavonoid;
hydroxyflavone;
ring assembly		angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
baicalein[no description available]medium10trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
genkwanin[no description available]medium10dihydroxyflavone;
monomethoxyflavone		metabolite
hyperoside[no description available]medium10beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite
3-methylquercetin[no description available]medium107-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite
kaempferide[no description available]medium107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
orientin[no description available]medium103'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone		antioxidant;
metabolite
scutellarein[no description available]medium10tetrahydroxyflavonemetabolite
trans-2,3',4,5'-tetrahydroxystilbene[no description available]medium10stilbenoid
polydatin[no description available]medium10beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
chicoric acid[no description available]medium10organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
acteoside[no description available]medium10catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
dorzolamide[no description available]medium10sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
benzyloxycarbonyl-phe-ala-fluormethylketone[no description available]medium10
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester[no description available]medium10carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
casticin[no description available]medium10dihydroxyflavone;
tetramethoxyflavone		apoptosis inducer;
plant metabolite
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one[no description available]medium10dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside[no description available]medium10beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor
tyrphostin ag 555[no description available]medium10
pd 151746[no description available]medium10
batimastat[no description available]medium10hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
solanesol[no description available]medium10nonaprenol;
primary alcohol		plant metabolite
pepstatin[no description available]medium10pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
l 685458[no description available]medium10carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic
bms 806[no description available]medium10
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone[no description available]medium10
tulobuterol hydrochloride[no description available]medium10organic molecular entity
salubrinal[no description available]medium10aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas
germacrone[no description available]medium10germacrane sesquiterpenoid;
olefinic compound		androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid[no description available]medium10
lithospermic acid[no description available]medium10
laq824[no description available]medium10
ekb 569[no description available]medium10aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one[no description available]medium10germacranolide
4,5-di-O-caffeoylquinic acid[no description available]medium10quinic acid
indigo carmine[no description available]medium10
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone[no description available]medium10oligopeptide
belinostat[no description available]medium10hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42[no description available]medium10amidobenzoic acid
chlorhexidine[no description available]medium10biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
gs-7340[no description available]medium106-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester		antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
iniparib[no description available]medium10carbonyl compound;
organohalogen compound
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide[no description available]medium10
pri-2205[no description available]medium10
mk 0752[no description available]medium10
givinostat[no description available]medium20carbamate ester
pd 144418[no description available]medium10
bicyclol[no description available]medium10
midostaurin[no description available]medium50benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
ly 450139[no description available]medium10peptide
mocetinostat[no description available]medium10aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
sb 3ct compound[no description available]medium10aromatic ether
ginsenoside rb1[no description available]medium10ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger
rucaparib[no description available]medium10azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-[no description available]medium10organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
cetilistat[no description available]medium10benzoxazine
ym 201636[no description available]medium10aromatic amide
linagliptin[no description available]medium10aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
odanacatib[no description available]medium10
apilimod[no description available]medium10
apixaban[no description available]medium10aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
betrixaban[no description available]medium10benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban[no description available]medium10chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
saracatinib[no description available]medium10aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide[no description available]medium10tripeptide;
ureas		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
ly 411575[no description available]medium10dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor
galidesivir[no description available]medium10
PB28[no description available]medium10aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
degrasyn[no description available]medium10
epoxomicin[no description available]medium10morpholines;
tripeptide		proteasome inhibitor
pha 680632[no description available]medium10
tmc 353121[no description available]medium10
amd 070[no description available]medium10aminoquinoline
danoprevir[no description available]medium10
bms-626529[no description available]medium10
bms-663068[no description available]medium10
amenamevir[no description available]medium10
vx 765[no description available]medium10dipeptide
Dihydrotanshinone I[no description available]medium10abietane diterpenoidanticoronaviral agent
alogliptin[no description available]medium10nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
fr 180204[no description available]medium10pyrazoles;
ring assembly
quisinostat[no description available]medium10indoles
carfilzomib[no description available]medium10epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
hcv 796[no description available]medium10
resminostat[no description available]medium10
zk 756326[no description available]medium10aromatic ether
balapiravir[no description available]medium10
trametinib[no description available]medium10acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
deoxyarbutin[no description available]medium10
abexinostat[no description available]medium10benzofurans
silvestrol[no description available]medium10dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
narlaprevir[no description available]medium10azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas		anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor
teneligliptin[no description available]medium10amino acid amide
dextrothyroxine[no description available]medium10
veliparib[no description available]medium10benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pf 03491390[no description available]medium10
alloin[no description available]medium10anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols		laxative;
metabolite
mdv 3100[no description available]medium10(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
bms-650032[no description available]medium10oligopeptide
rg 7128[no description available]medium10
oritavancin[no description available]medium10disaccharide derivative;
glycopeptide;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
pevonedistat[no description available]medium10cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
uk 453,061[no description available]medium10aromatic ether
N-(2-aminophenyl)-2-pyrazinecarboxamide[no description available]medium10aromatic amide
tegobuvir[no description available]medium10
pf-429242[no description available]medium10
olaparib[no description available]medium10cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cx 4945[no description available]medium10
pci 34051[no description available]medium10indolecarboxamide
lomibuvir[no description available]medium10thiophenecarboxylic acid
delanzomib[no description available]medium10C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
pitavastatin(1-)[no description available]medium10hydroxy monocarboxylic acid anion
GRL-0617[no description available]medium10benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline		anticoronaviral agent;
protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester[no description available]medium10carbamate ester
niraparib[no description available]medium102-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
jzl 184[no description available]medium10benzodioxoles
gsk 650394[no description available]medium10phenylpyridine
oprozomib[no description available]medium10
az 960[no description available]medium10
golgicide a[no description available]medium10diastereoisomeric mixturecis-Golgi ArfGEF GBF inhibitor
bms-790052[no description available]medium10biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
ixazomib[no description available]medium10benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
ucph 101[no description available]medium10
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine[no description available]medium10aryl sulfide;
thienopyrimidine
baricitinib[no description available]medium10azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
KOM70144[no description available]medium10acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor
e-52862[no description available]medium10
ly2811376[no description available]medium10
anagliptin[no description available]medium10amino acid amide
gardiquimod[no description available]medium10
grazoprevir[no description available]medium20aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative		antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent
abt-450[no description available]medium10
letermovir[no description available]medium20
letermovir[no description available]medium21
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine[no description available]medium20benzoxazole
blz 945[no description available]medium10
azd3839[no description available]medium10
pf 3084014[no description available]medium10
unc 0638[no description available]medium10quinazolines
gs-9620[no description available]medium10
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide[no description available]medium10
bms 708163[no description available]medium10oxadiazole;
ring assembly
jq1 compound[no description available]medium10carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone[no description available]medium10
gsk525762a[no description available]medium10benzodiazepine
ML240[no description available]medium10aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent
birinapant[no description available]medium10dipeptide
ly2886721[no description available]medium10
nms-p118[no description available]medium10
tubastatin a[no description available]medium10hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat[no description available]medium10benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
spautin-1[no description available]medium10
ldn 57444[no description available]medium10
gsk1210151a[no description available]medium10imidazoquinoline
i-bet726[no description available]medium10
acy-1215[no description available]medium10pyrimidinecarboxylic acid
cudc-907[no description available]medium10
tasquinimod[no description available]medium10
gsk1265744[no description available]medium10difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
abt-267[no description available]medium10aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
abt-333[no description available]medium10aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide		antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor
rgfp966[no description available]medium10
rg2833[no description available]medium10
pi-1840[no description available]medium10
acy-738[no description available]medium10
pelabresib[no description available]medium10monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor
gs-5806[no description available]medium10
doravirine[no description available]medium10
gn6958[no description available]medium10
vx-787[no description available]medium10
ledipasvir[no description available]medium10azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor
gs-5816[no description available]medium10carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
g007-lk[no description available]medium10
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide[no description available]medium10
selinexor[no description available]medium20
verdinexor[no description available]medium10
cb-839[no description available]medium10
mk-8742[no description available]medium10carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent
atglistatin[no description available]medium10
xen445[no description available]medium10
santacruzamate a[no description available]medium10organonitrogen compound;
organooxygen compound
ldc4297[no description available]medium10aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
enasidenib[no description available]medium101,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
s 8932[no description available]medium10aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug
nu 1025[no description available]medium10phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
penciclovir[no description available]medium102-aminopurines;
propane-1,3-diols		antiviral drug
4-hydroxyquinazoline[no description available]medium10quinazolines
norclozapine[no description available]medium10dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
azilsartan[no description available]medium101,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent
hesperadin[no description available]medium10
6-bromoindirubin-3'-acetoxime[no description available]medium10
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide[no description available]medium10catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
XL413[no description available]medium10benzofuropyrimidine;
organochlorine compound;
pyrrolidines		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
me0328[no description available]medium10
nvp-tnks656[no description available]medium10
triazoles[no description available]medium1,4741021,2,3-triazole
itraconazole[no description available]medium2810aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
itraconazole[no description available]medium2817aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
4-aminobenzoic acid[no description available]medium10aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
mometasone furoate[no description available]medium1011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol[no description available]medium10benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
floxacillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
abt-199[no description available]medium50aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
abt-199[no description available]medium51aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
cyclosporine[no description available]medium91
l 743,872[no description available]medium1002
vindesine[no description available]medium10methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent
methanol[no description available]medium20alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
hydroxyitraconazole[no description available]medium71
phosphorylcholine[no description available]medium60phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
atazanavir sulfate[no description available]medium21organic sulfate salt
methylcellulose[no description available]medium20
hydroxypropylmethylcellulose acetate succinate[no description available]medium20
galactose[no description available]medium130D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
galactomannan[no description available]medium130oligosaccharide
mannans[no description available]medium130
histidine[no description available]medium10amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
hydrogen[no description available]medium30elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
aldosterone[no description available]medium1011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
azomycin[no description available]medium302C-nitro compound;
imidazoles		antitubercular agent
nnd 502[no description available]medium20dichlorobenzene
tioconazole[no description available]medium20dichlorobenzene;
ether;
imidazoles;
thiophenes
sertaconazole[no description available]medium101-benzothiophenes;
dichlorobenzene;
ether;
imidazoles
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
idelalisib[no description available]medium10aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
fludarabine[no description available]medium30purine nucleoside
piperacillin, tazobactam drug combination[no description available]medium10
fluorine[no description available]medium10diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
staurosporine[no description available]medium30ammonium ion derivative
transforming growth factor beta[no description available]medium10
uric acid[no description available]medium10uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
thiazoles[no description available]medium2901,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
epiglucan[no description available]medium80
pyrazines[no description available]medium10diazine;
pyrazines		Daphnia magna metabolite
gilteritinib[no description available]medium10aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
deoxycholic acid[no description available]medium91bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
amphotericin b, deoxycholate drug combination[no description available]medium71
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester[no description available]medium10
ly335979[no description available]medium10carbopolycyclic compound
hydrazine[no description available]medium10azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
quinoxalines[no description available]medium20mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
carbamates[no description available]medium51amino-acid anion
ergosterol[no description available]medium1503beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
cortisone[no description available]medium2011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
acetonitrile[no description available]medium10aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
methylene blue[no description available]medium20organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
cellulose[no description available]medium20glycoside
tartaric acid[no description available]medium10tartaric acidEscherichia coli metabolite
pyrroles[no description available]medium20pyrrole;
secondary amine
4-aminobenzoic acid[no description available]medium10aminobenzoate;
aromatic amino-acid anion		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
rg7388[no description available]medium10
tolonium chloride[no description available]medium10
cysteine[no description available]medium10cysteiniumfundamental metabolite
s-allylmercaptocysteine[no description available]medium10
phenyl acetate[no description available]medium11benzenes;
phenyl acetates
quinazolines[no description available]medium31azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
dipyrone[no description available]medium10organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
n-vinyl-2-pyrrolidinone[no description available]medium20pyrrolidin-2-ones
lurasidone hydrochloride[no description available]medium11hydrochlorideadrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
betadex[no description available]medium40cyclodextrin
isoxazoles[no description available]medium20isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
alpha-aminopyridine[no description available]medium20
3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine[no description available]medium20
dimethyl 2,3,5,6-tetrachloroterephthalate[no description available]medium10diester;
methyl ester
calcium phosphate, dibasic, anhydrous[no description available]medium10calcium phosphate
tricalcium phosphate[no description available]medium10calcium phosphate
1,7-phenanthroline[no description available]medium10phenanthroline
interleukin-8[no description available]medium20
benzohydroxamic acid[no description available]medium10
antimycin a[no description available]medium10amidobenzoic acid
cytochrome c-t[no description available]medium10
oxadiazoles[no description available]medium20
fluticasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
floxuridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
bithionol[no description available]medium10aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
penconazole[no description available]medium10dichlorobenzene;
triazoles
prochloraz[no description available]medium10amide fungicide;
aromatic ether;
conazole fungicide;
imidazole fungicide;
imidazoles;
trichlorobenzene;
ureas		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
fluorodeoxyglucose f18[no description available]medium102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
adamantane[no description available]medium10adamantanes;
polycyclic alkane
squalene[no description available]medium10triterpenehuman metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
fadrozole[no description available]medium10imidazopyridine
quinuclidines[no description available]medium10quinuclidines;
saturated organic heterobicyclic parent
agar[no description available]medium40
heptakis(2,6-o-dimethyl)beta-cyclodextrin[no description available]medium10
benzoxazoles[no description available]medium101,3-benzoxazoles;
mancude organic heterobicyclic parent
citrulline[no description available]medium10amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
sodium dodecyl sulfate[no description available]medium10organic sodium saltdetergent;
protein denaturant
buprenorphine[no description available]medium11morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic
piperidines[no description available]medium21
eflornithine[no description available]medium10alpha-amino acid;
fluoroamino acid		trypanocidal drug
1-anilino-8-naphthalenesulfonate[no description available]medium10aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
mefloquine[no description available]medium10
u 18666a[no description available]medium10hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
meglumine antimoniate[no description available]medium10
firefly luciferin[no description available]medium101,3-thiazolemonocarboxylic acid;
benzothiazoles;
imidothioate		luciferin
meglumine[no description available]medium10hexosamine;
secondary amino compound
mefenoxam[no description available]medium10acylamino acid fungicide;
anilide fungicide;
D-alanine derivative;
methyl N-(2,6-dimethylphenyl)-N-(methoxyacetyl)alaninate		agrochemical
alanine[no description available]medium10alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
D-fructopyranose[no description available]medium10cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
leukotriene b4[no description available]medium10dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
1-hexadecyl-2-acetyl-glycero-3-phosphocholine[no description available]medium102-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
s 1743[no description available]medium21magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2h-tetrazolium hydroxide[no description available]medium20
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
bilirubin[no description available]medium20biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
loceryl[no description available]medium10morpholine antifungal drug;
tertiary amino compound		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
24,25-dihydrolanosterol[no description available]medium103beta-sterol;
tetracyclic triterpenoid		human metabolite;
mouse metabolite
ebericol[no description available]medium1014alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid		fungal metabolite
bromhexine[no description available]medium10organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
fluorides[no description available]medium20halide anion;
monoatomic fluorine
inositol[no description available]medium10cyclitol;
hexol
tyrosine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
phenylalanine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
bz-423[no description available]medium10
piperazine[no description available]medium10azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
ajoene[no description available]medium10sulfoxide
carbostyril[no description available]medium10monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
nad[no description available]medium10organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
7-hydroxy-4-trifluoromethylcoumarin[no description available]medium10
echinocandin b[no description available]medium10
sch 51048[no description available]medium20
potassium iodide[no description available]medium10potassium saltexpectorant;
radical scavenger
imatinib mesylate[no description available]medium10methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
cephalosporin c[no description available]medium10cephalosporinfungal metabolite
penicillanic acid[no description available]medium10penicillanic acids
tazobactam[no description available]medium10penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
phosphatidylcholines[no description available]medium311,2-diacyl-sn-glycero-3-phosphocholine
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
ici 195739[no description available]medium10
himbacine[no description available]medium10gamma-lactone;
organic heterotricyclic compound;
piperidine alkaloid		muscarinic antagonist
diminazene[no description available]low00carboxamidine;
triazene derivative		antiparasitic agent;
trypanocidal drug
suramin[no description available]low00naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
suramin sodium[no description available]low00organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
pentamidine isethionate[no description available]low00organosulfonate salttrypanocidal drug
ethidium bromide[no description available]low00organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
salicylhydroxamic acid[no description available]low00hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
nucleocidin[no description available]medium006-aminopurines;
adenosines;
diol;
organofluorine compound;
sulfamate ester		antibacterial agent;
bacterial metabolite;
nucleoside antibiotic;
protein synthesis inhibitor;
trypanocidal drug
dehydrocostus lactone[no description available]low00gamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
sesquiterpene lactone		antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 2 inhibitor;
metabolite;
trypanocidal drug
cubebin[no description available]low00benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol		analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug
anonaine[no description available]low00aporphine alkaloid;
organic heteropentacyclic compound;
oxacycle		antineoplastic agent;
antiplasmodial drug;
trypanocidal drug
hinokinin[no description available]low00benzodioxoles;
gamma-lactone;
lignan		trypanocidal drug
komaroviquinone[no description available]low00bridged compound;
lactol;
p-quinones;
tetracyclic diterpenoid		metabolite;
trypanocidal drug
astragalin[no description available]low00beta-D-glucoside;
kaempferol O-glucoside;
monosaccharide derivative;
trihydroxyflavone		plant metabolite;
trypanocidal drug
diminazene aceturate[no description available]low00N-acetylglycinate saltantiparasitic agent;
trypanocidal drug
ergosterol-5,8-peroxide[no description available]low003beta-sterol;
ergostanoid;
organic peroxide;
phytosterols		antimycobacterial drug;
antineoplastic agent;
metabolite;
trypanocidal drug
ancistroealaine a[no description available]medium00aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes		antileishmanial agent;
antiplasmodial drug;
metabolite;
trypanocidal drug
aee 788[no description available]low006-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
quercetin 3-o-glucoside-7-o-rhamnoside[no description available]low00beta-D-glucoside;
quercetin O-glucoside;
trihydroxyflavone		plant metabolite;
trypanocidal drug
amitrole[no description available]low00aromatic amine;
triazoles		carotenoid biosynthesis inhibitor;
EC 1.11.1.6 (catalase) inhibitor;
herbicide
liquid crystal polymer[no description available]low00conazole fungicide;
dichlorobenzene;
organobromine compound;
oxolanes;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
systhane[no description available]low00monochlorobenzenes;
nitrile;
triazoles
guanazole[no description available]low00aromatic amine;
triazoles		antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor
drometrizole[no description available]low00triazoles
suritozole[no description available]low00triazoles
triadimefon[no description available]low00aromatic ether;
hemiaminal ether;
ketone;
monochlorobenzenes;
triazoles
azaconazole[no description available]low00conazole fungicide;
cyclic ketal;
dichlorobenzene;
dioxolane;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
propiconazole[no description available]low00conazole fungicide;
cyclic ketal;
dichlorobenzene;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
loxtidine[no description available]low00aromatic ether;
piperidines;
primary alcohol;
triazoles		H2-receptor antagonist
1,2,4-triazole-3-carboxamide[no description available]low00aromatic amide;
monocarboxylic acid amide;
primary carboxamide;
triazoles		drug metabolite;
human urinary metabolite
flusilazole[no description available]low00conazole fungicide;
monofluorobenzenes;
organosilicon compound;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole[no description available]low00triazoles
tetraconazole[no description available]low00dichlorobenzene;
ether;
organofluorine compound;
triazoles
tebuconazole[no description available]low00monochlorobenzenes;
tertiary alcohol;
triazoles
cyproconazole[no description available]low00cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
triazoles
4-(4-chlorophenyl)-2-phenyl-2-(1,2,4-triazol-1-ylmethyl)butanenitrile[no description available]low00monochlorobenzenes;
nitrile;
triazoles
difenoconazole[no description available]low00aromatic ether;
conazole fungicide;
cyclic ketal;
dioxolane;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
metconazole[no description available]low00conazole fungicide;
cyclopentanols;
monochlorobenzenes;
tertiary alcohol;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
n-(2,4-dichloro-5-(4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1h-1,2,4-triazol-1-yl)phenyl)methanesulfonamide[no description available]low00dichlorobenzene;
organofluorine compound;
sulfonamide;
triazoles		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
fluquinconazole[no description available]low00conazole fungicide;
dichlorobenzene;
organofluorine compound;
quinazolines;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
azocyclotin[no description available]low00organotin acaricide;
triazoles
bitertanol[no description available]low00aromatic ether;
biphenyls;
secondary alcohol;
triazoles
flutriafol[no description available]low00monofluorobenzenes;
tertiary alcohol;
triazoles
triazolealanine[no description available]low00non-proteinogenic alpha-amino acid;
triazoles
forasartan[no description available]low00benzenes;
pyridines;
tetrazoles;
triazoles		angiotensin receptor antagonist;
antihypertensive agent
cafenstrole[no description available]low00benzenes;
sulfone;
triazoles		agrochemical;
antimitotic;
herbicide
fosfluconazole[no description available]low00conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
N3-(1,3,5-trimethyl-4-pyrazolyl)-1H-1,2,4-triazole-3,5-diamine[no description available]low00triazoles
4,5-diphenyl-1,2,3-triazole[no description available]low00benzenes;
ring assembly;
triazoles
2-[[5-[4-(1-piperidinylsulfonyl)phenyl]-1H-1,2,4-triazol-3-yl]thio]-N-(2-thiazolyl)acetamide[no description available]low00triazoles
N-(3-hydroxyphenyl)-2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
3-[5-(2-methoxyethylthio)-4-methyl-1,2,4-triazol-3-yl]benzonitrile[no description available]low00triazoles
2-[[4-(3-methoxyphenyl)-5-[(4-methylphenoxy)methyl]-1,2,4-triazol-3-yl]thio]acetic acid[no description available]low00triazoles
2-[[4-(2,5-dimethylphenyl)-5-(2-methyl-3-furanyl)-1,2,4-triazol-3-yl]thio]-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide[no description available]low00triazoles
N-[2-(4-methoxyphenyl)-6-methyl-5-benzotriazolyl]-3-pyridinecarboxamide[no description available]low00triazoles
2-[[5-[(2-chloroanilino)methyl]-4-phenyl-1,2,4-triazol-3-yl]thio]acetic acid ethyl ester[no description available]low00triazoles
N-(3,4-dimethylphenyl)-2-[(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)thio]acetamide[no description available]low00triazoles
1-(3,4-dihydro-2H-quinolin-1-yl)-2-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)thio]ethanone[no description available]low00triazoles
N-(5-phenyl-1,3,4-thiadiazol-2-yl)-2-[[4-propyl-5-(2-pyridinyl)-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-amine[no description available]low00triazoles
2-[(4-ethyl-5-phenyl-1,2,4-triazol-3-yl)thio]-N-(4-phenyl-2-thiazolyl)acetamide[no description available]low00triazoles
7-(methoxymethyl)-3-(2-methoxyphenyl)-1H-[1,2,4]triazolo[4,3-a]pyrimidin-5-one[no description available]low00triazoles
2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]-N-(4-methylphenyl)acetamide[no description available]low00triazoles
N-cyclopentyl-2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole[no description available]low00triazoles
3-(3,5-dimethoxyphenyl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[[4-amino-5-(4-tert-butylphenyl)-1,2,4-triazol-3-yl]thio]acetic acid propan-2-yl ester[no description available]low00isopropyl ester;
triazoles
6-(2,5-dimethoxyphenyl)-3-(3-propan-2-yloxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
2-[5-[(2-chlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine[no description available]low00triazoles
2-[5-[(2,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine[no description available]low00triazoles
2-[5-[(4-bromophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine[no description available]low00triazoles
2-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione[no description available]low00triazoles
4-[[[4-(2-furanylmethyl)-5-(3-methoxyphenyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile[no description available]low00triazoles
N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2-thiophenecarboxamide[no description available]low00triazoles
2-[[[5-(3-chlorophenyl)-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-1H-benzimidazole[no description available]low00triazoles
5-(4-chlorophenyl)-4h-1,2,4-triazole-3-thiol[no description available]low00triazoles
5-(4-methoxyphenyl)-1,2-dihydro-1,2,4-triazole-3-thione[no description available]low00triazoles
4-cyclohexyl-3-(3-pyridinyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-cyclohexyl-3-(4-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
5-(2-phenyl-4-triazolyl)-2H-tetrazole[no description available]low00triazoles
4-(4-chlorophenyl)-3-(2-quinolinyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
N-[6-methyl-2-(4-methylphenyl)-5-benzotriazolyl]-3-pyridinecarboxamide[no description available]low00triazoles
3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine[no description available]low00triazoles
2-[[(4-phenyl-1,2,4-triazol-3-yl)thio]methyl]imidazo[1,2-a]pyrimidine[no description available]low00triazoles
2-[(5-anilino-4-phenyl-4H-1,2,4-triazol-3-yl)thio]acetic acid[no description available]low00triazoles
4-(2,5-dimethylphenyl)-3-pyridin-4-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-(4-fluorophenyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine[no description available]low00triazoles
1-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoline[no description available]low00triazoles
6-methoxy-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine[no description available]low00triazoles
4-(2-furanylmethyl)-3-pyridin-4-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
N-[2-(4-methoxyphenyl)-5-benzotriazolyl]butanamide[no description available]low00triazoles
3-[(4-methylphenoxy)methyl]-4-phenyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(4-chlorophenyl)-3-[(4-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(3-nitrophenyl)-4-(phenylmethyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-prop-2-enyl-3-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-(2,4-dimethylphenyl)-5-benzotriazolamine[no description available]low00triazoles
N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2,2,2-trichloroacetamide[no description available]low00triazoles
4-(3-chlorophenyl)-3-methyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
1-[3-(4-chlorophenyl)-5-(methylthio)-1,2,4-triazol-1-yl]-1-butanone[no description available]low00triazoles
[3-(4-chlorophenyl)-5-(methylthio)-1,2,4-triazol-1-yl]-(2-furanyl)methanone[no description available]low00triazoles
3-(2-furanyl)-4-(2-methylphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(1,3-dimethyl-4-pyrazolyl)-4-(2-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2-methylphenyl)-3-(5-methyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(3-methylphenyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(1,3-benzodioxol-5-yl)-4-(2,5-dimethylphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(1-benzothiophen-3-yl)-4-(2-methylphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(3-methylphenyl)-3-(5-propan-2-yl-3-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(4,5-dimethyl-3-thiophenyl)-4-(2-methylphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(2-methyl-3-furanyl)-4-(2-methylphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[[4-(2,4-dimethylphenyl)-5-(3-pyridinyl)-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
(5-amino-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone[no description available]low00triazoles
N-[5-(2-chlorophenyl)-1H-1,2,4-triazol-3-yl]-4,6-dimethyl-2-pyrimidinamine[no description available]low00triazoles
3-(4-ethoxyphenyl)-4-(phenylmethyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(4-methylphenyl)-3-(2-pyrazinyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-[4-(2-methylphenyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]-1H-pyridazin-6-one[no description available]low00triazoles
3-[5-(2-furanyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(4-chlorophenyl)-3-(2-phenylethyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-phenyl-3-(thiophen-2-ylmethyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2-methylphenyl)-3-pyridin-4-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[[(5-methyl-4-phenyl-1,2,4-triazol-3-yl)thio]methyl]benzonitrile[no description available]low00triazoles
4-[[5-[(3,4-dichlorophenyl)methylthio]-4-phenyl-1,2,4-triazol-3-yl]methyl]morpholine[no description available]low00triazoles
secinh3[no description available]low00triazoles
2-(2-methylphenoxy)-N-[2-(4-methylphenyl)-5-benzotriazolyl]acetamide[no description available]low00triazoles
4-(4-bromophenyl)-3-[(4-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
N-(4-Methoxybenzoyl)-2-{[4-methyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}ethanehydrazonic acid[no description available]low00triazoles
1-(2,3-dihydroindol-1-yl)-2-[[4-methyl-5-[4-(1-pyrrolidinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]ethanone[no description available]low00triazoles
7-anilino-1-(4-methylphenyl)-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylic acid ethyl ester[no description available]low00triazoles
2-[[5-(2-furanyl)-4-(4-methylphenyl)-1,2,4-triazol-3-yl]thio]-N-(1H-indazol-6-yl)acetamide[no description available]low00triazoles
N-(1,3-benzodioxol-5-yl)-2-[[4-(4-methylphenyl)-5-thiophen-2-yl-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
5-[[[4-(4-fluorophenyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-3-thiophen-2-yl-1,2,4-oxadiazole[no description available]low00triazoles
6-(2,3-dihydroindol-1-ylmethyl)-3-phenylthiazolo[2,3-c][1,2,4]triazole[no description available]low00triazoles
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(4-ethoxyphenyl)-4-triazolecarboxylic acid ethyl ester[no description available]low00triazoles
3-(2,3-dimethyl-1H-indol-5-yl)-4-(3-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[[4-(4-methoxyphenyl)-5-(2-phenylethyl)-1,2,4-triazol-3-yl]thio]-N-(phenylmethyl)acetamide[no description available]low00triazoles
N-(2-phenyl-5-benzotriazolyl)-2,3-dihydro-1,4-benzodioxin-6-carboxamide[no description available]low00triazoles
4-(2-chlorophenyl)-3-(5-methyl-3-phenyl-4-isoxazolyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(4-methoxyphenyl)-3-(4-methylphenyl)-5-[(4-nitrophenyl)methylthio]-1,2,4-triazole[no description available]low00triazoles
6-amino-1-(4-chlorophenyl)-2-oxo-4-(1,2,4-triazol-1-ylmethyl)-5-pyrimidinecarbonitrile[no description available]low00monochlorobenzenes;
nitrile;
pyrimidone;
triazoles
1-[[2-[[4-(4-chlorophenyl)-5-phenyl-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-3-phenylthiourea[no description available]low00triazoles
4-cyano-5-[[2-[[5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-3-methyl-2-thiophenecarboxylic acid ethyl ester[no description available]low00triazoles
4-butyl-3-(5-ethyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-butyl-3-(5-propan-2-yl-3-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-butyl-3-(3-methyl-2-thiophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(1-benzotriazolyl)-3,5-dinitrobenzonitrile[no description available]low00triazoles
4-(2-bromo-4-methylphenyl)-3-[5-(2-furanyl)-1H-pyrazol-3-yl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(1,3-benzodioxol-5-yl)-4-(3-chloro-4-fluorophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(4-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-2-[(4-ethyl-5-phenyl-1,2,4-triazol-3-yl)thio]acetamide[no description available]low00triazoles
3-(4-bromophenyl)-4-(4-methoxyphenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
N-(1,3-benzothiazol-2-yl)-2-[[5-(4-methoxyphenyl)-4-methyl-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
1-(benzenesulfonyl)-3-(4-methoxyphenyl)-5-(methylthio)-1,2,4-triazole[no description available]low00triazoles
1-[5-(2-furanylmethylamino)-3-phenyl-1,2,4-triazol-1-yl]-2-(4-methoxyphenyl)ethanone[no description available]low00triazoles
4-[2-(3,4-dimethoxyphenyl)ethyl]-3-pyridin-4-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
[5-[(4-methoxyphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-(4-nitrophenyl)methanone[no description available]low00triazoles
4-phenyl-3-[2-(phenylmethylthio)ethyl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-hexyl-3-thiophen-2-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-(1,3-benzodioxol-5-yl)-4-phenyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[[4-(4-fluorophenyl)-5-pyridin-4-yl-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide[no description available]low00triazoles
2-[[(5-methyl-4-phenyl-1,2,4-triazol-3-yl)thio]methyl]-1,3-benzothiazole[no description available]low00triazoles
2-[[[5-methyl-4-(2-methylphenyl)-1,2,4-triazol-3-yl]thio]methyl]-1,3-benzothiazole[no description available]low00triazoles
N,N-diethyl-3-[5-(ethylthio)-4-(phenylmethyl)-1,2,4-triazol-3-yl]benzenesulfonamide[no description available]low00triazoles
2-[[(4-ethyl-5-phenyl-1,2,4-triazol-3-yl)thio]methyl]-1,3-benzothiazole[no description available]low00triazoles
2-[[4-amino-5-[4-(difluoromethoxy)phenyl]-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide[no description available]low00triazoles
3-(methylthio)-5-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazole[no description available]low00triazoles
2-methoxy-4-[3-(2-methoxyphenyl)-5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl]phenol[no description available]low00triazoles
3-(2,2-dimethoxyethyl)-4-phenyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]pyridine[no description available]low00triazoles
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[2-(4-fluorophenyl)sulfonylethylthio]-1H-1,2,4-triazol-5-one[no description available]low00triazoles
3-[[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)thio]methyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate[no description available]low00acetylenic compound;
furans;
organofluorine compound;
thioester;
triazoles
4-(1-phenylethyl)-3-pyridin-4-yl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-(5-phenyl-1H-1,2,4-triazol-3-yl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione[no description available]low00triazoles
2-[[[4-(4-methoxyphenyl)-5-phenyl-1,2,4-triazol-3-yl]thio]methyl]-5-phenyl-1,3,4-oxadiazole[no description available]low00triazoles
1-[2,5-dimethyl-1-(2-oxolanylmethyl)-3-pyrrolyl]-2-[(5-phenyl-4-prop-2-enyl-1,2,4-triazol-3-yl)thio]ethanone[no description available]low00triazoles
6-amino-5-[2-[[4-(4-chlorophenyl)-5-[1-(dimethylamino)ethyl]-1,2,4-triazol-3-yl]thio]-1-oxoethyl]-1,3-dimethylpyrimidine-2,4-dione[no description available]low00triazoles
N-[[5-[(4-chlorophenyl)methylthio]-4-phenyl-1,2,4-triazol-3-yl]methyl]-4-ethoxyaniline[no description available]low00triazoles
2-[(4-ethyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)thio]acetic acid methyl ester[no description available]low00triazoles
2-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]thio]acetonitrile[no description available]low00triazoles
2-[[3-(4-chlorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]-N-(5-methyl-3-isoxazolyl)acetamide[no description available]low00triazoles
2-[[3-(4-fluorophenyl)-7-triazolo[4,5-d]pyrimidinyl]thio]butanoic acid ethyl ester[no description available]low00triazoles
2-phenyl-5-(1-piperidinyl)-4-triazolecarbonitrile[no description available]low00triazoles
3-(4-bromophenyl)-4-(2-furanylmethyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
1-[5-amino-3-(4-methoxyphenyl)-1,2,4-triazol-1-yl]-1-propanone[no description available]low00triazoles
N-(2-furanylmethyl)-2-[(3-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)thio]acetamide[no description available]low00triazoles
5-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2-methoxyphenyl)-4-triazolecarboxamide[no description available]low00triazoles
6-[(2-chlorophenyl)methyl]-3-(3-methoxyphenyl)-7-triazolo[4,5-d]pyrimidinone[no description available]low00triazoles
4-(4-methyl-1-oxido-2-triazol-1-iumyl)benzoic acid[no description available]low00triazoles
3-(4-fluorophenyl)-6-[2-oxo-2-(1-pyrrolidinyl)ethyl]-7-triazolo[4,5-d]pyrimidinone[no description available]low00triazoles
5-amino-1-(3,5-dimethylphenyl)-N-(phenylmethyl)-4-triazolecarboxamide[no description available]low00triazoles
6-[(2,5-dimethylphenyl)methyl]-3-(4-fluorophenyl)-7-triazolo[4,5-d]pyrimidinone[no description available]low00triazoles
2-[[3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]-N-(2-oxolanylmethyl)acetamide[no description available]low00triazoles
2-[[3-(4-methoxyphenyl)-7-triazolo[4,5-d]pyrimidinyl]thio]-N-(2-oxolanylmethyl)acetamide[no description available]low00triazoles
epoxiconazole[no description available]low00epoxide;
monochlorobenzenes;
monofluorobenzenes;
triazoles
N-(3,4-dimethylphenyl)-2-[(1-phenyl-1,2,4-triazol-3-yl)thio]acetamide[no description available]low00triazoles
5-methyl-2-(2-phenoxyethyl)-4-phenyl-1,2,4-triazol-3-one[no description available]low00triazoles
3-(6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-3-yl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-butyl-3-(6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-3-yl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-methyl-N'-[2-[(5-methyl-4-phenyl-1,2,4-triazol-3-yl)thio]-1-oxoethyl]benzohydrazide[no description available]low00triazoles
2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-5-methyl-4-(4-methylphenyl)-1,2,4-triazol-3-one[no description available]low00triazoles
4-(2-methylcyclohexyl)-3-(3-pyridinyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2-fluorophenyl)-5-methyl-2-(2-phenoxyethyl)-1,2,4-triazol-3-one[no description available]low00triazoles
1-[5-(2-furanylmethylamino)-3-phenyl-1,2,4-triazol-1-yl]-2-phenylethanone[no description available]low00triazoles
3-(1,5-dimethyl-3-pyrazolyl)-4-phenyl-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(3,4-dimethylphenyl)-3-(5-methyl-3-isoxazolyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
2-[4-(3-fluorophenyl)-3-methyl-5-oxo-1,2,4-triazol-1-yl]acetonitrile[no description available]low00triazoles
2-[[4-phenyl-5-(propylthio)-1,2,4-triazol-3-yl]methylthio]-1,3-benzothiazole[no description available]low00triazoles
3-(4-chloro-1,5-dimethyl-3-pyrazolyl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
6-amino-1,3-dimethyl-5-[2-[[5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]thio]-1-oxoethyl]pyrimidine-2,4-dione[no description available]low00triazoles
2-[[4-(4-chlorophenyl)-5-pyridin-4-yl-1,2,4-triazol-3-yl]thio]-N-(3-methoxyphenyl)-2-phenylacetamide[no description available]low00triazoles
6-[[4-(3-methylphenyl)-5-(propan-2-ylthio)-1,2,4-triazol-3-yl]methyl]-1H-pyrimidine-2,4-dione[no description available]low00triazoles
4-(4-chlorophenyl)-3-[2-(4-methylphenyl)cyclopropyl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[[2-(2-pyridinyl)-1-benzimidazolyl]methyl]-1H-1,2,4-triazole-5-thione[no description available]low00triazoles
3-[[4-phenyl-5-(propylthio)-1,2,4-triazol-3-yl]methyl]-1,3-benzothiazol-2-one[no description available]low00triazoles
N-(3,5-dimethylphenyl)-2-[[4-(4-fluorophenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
N-[(4-fluorophenyl)methyl]-2-[[4-(4-methoxyphenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
N-(4-chlorophenyl)-2-[[4-(4-methoxyphenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
2-[[4-(4-fluorophenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]-N-(2-oxolanylmethyl)acetamide[no description available]low00triazoles
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[4-(4-fluorophenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
3-(4-fluorophenyl)-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine[no description available]low00triazoles
N-(5-methyl-3-isoxazolyl)-2-[[4-(2-methylphenyl)-5-[(2-oxo-1,3-benzothiazol-3-yl)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00triazoles
2-[3-(3-methoxyphenyl)-7-oxo-6-triazolo[4,5-d]pyrimidinyl]-N-(2-oxolanylmethyl)acetamide[no description available]low00triazoles
N-(5-methyl-3-isoxazolyl)-2-[[3-(3-pyridinyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]acetamide[no description available]low00triazoles
N-(2-oxolanylmethyl)-2-[[3-(3-pyridinyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]acetamide[no description available]low00triazoles
1-(4-morpholinyl)-2-[[3-(2-pyridinyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]ethanone[no description available]low00triazoles
N-(2-oxolanylmethyl)-2-(7-oxo-3-phenyl-6-triazolo[4,5-d]pyrimidinyl)acetamide[no description available]low00triazoles
1-(4-morpholinyl)-2-[[3-(3-pyridinyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]ethanone[no description available]low00triazoles
6-[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]-3-(4-ethoxyphenyl)-7-triazolo[4,5-d]pyrimidinone[no description available]low00triazoles
cefatrizine[no description available]low00amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
uniconazole[no description available]low00monochlorobenzenes;
secondary alcohol;
triazoles
diniconazole[no description available]low00dichlorobenzene;
olefinic compound;
secondary alcohol;
triazoles
prothioconazole[no description available]low00cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
thiocarbonyl compound;
triazoles
r 115866[no description available]low00aromatic amine;
benzothiazoles;
secondary amino compound;
triazoles
methampicillin[no description available]low00monochlorobenzenes;
tertiary alcohol;
triazoles		brassinosteroid biosynthesis inhibitor
2-[[3-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]-N-(5-methyl-3-isoxazolyl)acetamide[no description available]low00triazoles
sm 164[no description available]low00benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
3-(2,5-dimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
[2-(2-methoxyethyl)-1-piperidinyl]-[5-[[4-(1,2,4-triazol-1-yl)phenoxy]methyl]-3-isoxazolyl]methanone[no description available]low00triazoles
suvorexant[no description available]low001,3-benzoxazoles;
aromatic amide;
diazepine;
organochlorine compound;
triazoles		central nervous system depressant;
orexin receptor antagonist
6-(3-cyclopentyloxy-4-methoxyphenyl)-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2-chlorophenyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-(3-cyclopentyloxy-4-methoxyphenyl)-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2-fluorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2-chlorophenyl)-6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2-chlorophenyl)-6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2-fluorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2-chlorophenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2-fluorophenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-[2-(trifluoromethyl)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
3-(2,5-dimethoxyphenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]low00triazoles
2-[5-[(3,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine[no description available]low00triazoles
lesinurad[no description available]low00aryl sulfide;
cyclopropanes;
monocarboxylic acid;
naphthalenes;
organobromine compound;
triazoles		uricosuric drug
MK-8353[no description available]low00aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
tertiary alcohol;
triazoles
5-amino-2-phenyl-3H-triazolo[4,5-d]pyrimidin-7-one[no description available]low00triazoles
3-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazol-5-ol[no description available]low00ring assembly;
triazoles
sta 9090[no description available]low00ring assembly;
triazoles
1-(1-naphthyl)piperazine[no description available]low00N-arylpiperazine
cgs 12066[no description available]low00N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline		serotonergic agonist
[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(2-furanyl)methanone[no description available]low00N-arylpiperazine
ly 303511[no description available]low00N-arylpiperazine
1-(3-trifluoromethylphenyl)piperazine[no description available]low00(trifluoromethyl)benzenes;
N-arylpiperazine		environmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic
nan 190[no description available]low00N-alkylpiperazine;
N-arylpiperazine;
phthalimides		serotonergic antagonist
pipemidic acid[no description available]low00amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
n-methylquipazine[no description available]low00aminoquinoline;
N-alkylpiperazine;
N-arylpiperazine		serotonergic agonist
dimethylphenylpiperazinium iodide[no description available]low00N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt		nicotinic acetylcholine receptor agonist
azaperone[no description available]low00aminopyridine;
aromatic ketone;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist
trimazosin[no description available]low00N-arylpiperazine
gepirone[no description available]low00N-arylpiperazine
difloxacin[no description available]low00fluoroquinolone antibiotic;
monocarboxylic acid;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
Mycoplasma genitalium metabolite
ipsapirone[no description available]low00N-arylpiperazine
temafloxacin[no description available]low00amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound
tiodazosin[no description available]low00N-arylpiperazine
enrofloxacin[no description available]low00cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
kampirone[no description available]low00N-arylpiperazine
tandospirone[no description available]low00bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines		antidepressant;
anxiolytic drug
gr 127935[no description available]low001,2,4-oxadiazole;
benzamides;
N-alkylpiperazine;
N-arylpiperazine
6-chloro-2-(1-piperazinyl)pyrazine[no description available]low00N-arylpiperazine
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol[no description available]low00N-arylpiperazine
perospirone[no description available]low00N-arylpiperazine
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine[no description available]low00(trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline		geroprotector;
serotonergic agonist
piperaquine[no description available]low00aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial
vb 20b7[no description available]low00N-arylpiperazine
oxociprofloxacin[no description available]low00cyclopropanes;
N-arylpiperazine;
piperazinone;
quinolinemonocarboxylic acid;
quinolone		drug metabolite
bay-s 9435[no description available]low00cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
organosulfonic acid;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		drug metabolite;
human urinary metabolite
pitrazepin[no description available]low00N-arylpiperazine
eptapirone[no description available]low00N-arylpiperazine
lurasidone[no description available]low001,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
2-[4-(4-fluorophenyl)sulfonyl-1-piperazinyl]-4-(3-methoxyphenyl)thiazole[no description available]low00N-arylpiperazine
4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine[no description available]low00N-arylpiperazine
2-[4-[(1-cyclopentyl-5-tetrazolyl)-(6-quinolinyl)methyl]-1-piperazinyl]-1,3-benzothiazole[no description available]low00N-arylpiperazine
2-furanyl-[4-[3-(4-methoxyphenyl)-7-isothiazolo[4,5-d]pyrimidinyl]-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
[4-[5-tert-butyl-3-[(2-chlorophenyl)methyl]-7-triazolo[4,5-d]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone[no description available]low00N-arylpiperazine
[4-[2-(3-chlorophenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone[no description available]low00N-arylpiperazine
4-[[4-(1,3-benzothiazol-2-yl)-1-piperazinyl]-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-2-methoxyphenol[no description available]low00N-arylpiperazine
2-[4-[1-[1-[(4-methylphenyl)sulfonylmethyl]-5-tetrazolyl]propyl]-1-piperazinyl]-1,3-benzothiazole[no description available]low00N-arylpiperazine
2-cyano-2-[3-[4-(phenylmethyl)-1-piperazinyl]-2-quinoxalinyl]acetic acid 2-methoxyethyl ester[no description available]low002-methoxyethyl ester;
N-arylpiperazine
4-[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]benzofuro[3,2-d]pyrimidine[no description available]low00N-arylpiperazine
2-(2-furanyl)-5-[4-(phenylmethyl)-1-piperazinyl]-4-oxazolecarbonitrile[no description available]low00N-arylpiperazine
LSM-32568[no description available]low00N-arylpiperazine
7-(3,4-dimethoxyphenyl)-4-methyl-2-[4-(phenylmethyl)-1-piperazinyl]-7,8-dihydro-6H-quinazolin-5-one[no description available]low00N-arylpiperazine
3-(4-methoxyphenyl)-2-(4-methyl-1-piperazinyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b]pyrimidin-4-one[no description available]low00N-arylpiperazine
2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine[no description available]low00N-arylpiperazine
4-(1,3-benzothiazol-2-yl)-N-phenyl-1-piperazinecarboxamide[no description available]low00N-arylpiperazine
2-furanyl-[4-(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
[4-(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]-thiophen-2-ylmethanone[no description available]low00N-arylpiperazine
2-(3-chlorophenyl)-9-[4-(2-pyrazinyl)-1-piperazinyl]-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazoline[no description available]low00N-arylpiperazine
2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-1-ethylbenzimidazole[no description available]low00N-arylpiperazine
N-(4-butylphenyl)-4-(2-pyrimidinyl)-1-piperazinecarbothioamide[no description available]low00N-arylpiperazine
[2-[(2-bromophenyl)methoxy]phenyl]-[4-(2-pyrimidinyl)-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
jnj-1661010[no description available]low00N-arylpiperazine
(5-methyl-3-isoxazolyl)[4-(5-propyl-2-pyrimidinyl)piperazino]methanone[no description available]low00N-arylpiperazine
N-[4-[[4-(4-acetamidoanilino)-6-(4-ethyl-1-piperazinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide[no description available]low00N-arylpiperazine
4-[4-methyl-6-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinecarboxylic acid ethyl ester[no description available]low00N-arylpiperazine
dapiprazole[no description available]low00N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
tandutinib[no description available]low00aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
CID 3192987[no description available]low00N-arylpiperazineanticoronaviral agent
[4-(2,7-dimethyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]-(2-furanyl)methanone[no description available]low00N-arylpiperazine
4-[[4-(1,3-benzothiazol-2-yl)-1-piperazinyl]-[1-(2-phenylethyl)-5-tetrazolyl]methyl]phenol[no description available]low00N-arylpiperazine
N-(3-chlorophenyl)-4-[4-(3-methoxyphenyl)-2-thiazolyl]-1-piperazinecarbothioamide[no description available]low00N-arylpiperazine
[4-[5-tert-butyl-3-(phenylmethyl)-7-triazolo[4,5-d]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone[no description available]low00N-arylpiperazine
[5-[(2-methylphenyl)sulfonylmethyl]-2-furanyl]-[4-(2-pyrimidinyl)-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
2-furanyl-[4-(4-tetrazolo[1,5-a]quinoxalinyl)-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
N4-(3,4-dimethylphenyl)-2-(4-ethyl-1-piperazinyl)-5-nitropyrimidine-4,6-diamine[no description available]low00N-arylpiperazine
brl 15572[no description available]low00monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
5-tert-butyl-7-(4-ethyl-1-piperazinyl)-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidine[no description available]low00N-arylpiperazine
(4-chlorophenyl)-[4-(8-nitro-5-quinolinyl)-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
3-(2-methoxyphenyl)-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidine[no description available]low00N-arylpiperazine
3-(4-chlorophenyl)-6-(4-methyl-1-piperazinyl)-1H-pyrimidine-2,4-dione[no description available]low00N-arylpiperazine
3-(3,4-dimethoxyphenyl)-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidine[no description available]low00N-arylpiperazine
3-[[4-[6-(4-morpholinyl)-3-pyridazinyl]-1-piperazinyl]-oxomethyl]-1-benzopyran-2-one[no description available]low00N-arylpiperazine
1-(2-phenylethyl)-4-([1,2,4]triazolo[4,3-a]quinoxalin-4-yl)piperazine-2,6-dione[no description available]low00N-arylpiperazine
vx680[no description available]low00N-arylpiperazine
netupitant[no description available]low00aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes		antiemetic;
neurokinin-1 receptor antagonist
[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone[no description available]low00N-arylpiperazine
flibanserin[no description available]low00benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound		antidepressant;
serotonergic agonist;
serotonergic antagonist
vilazodone[no description available]low001-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile		antidepressant;
serotonergic agonist;
serotonin uptake inhibitor
6-hydroxybuspirone[no description available]low00N-arylpiperazine
vortioxetine[no description available]low00aryl sulfide;
N-arylpiperazine		antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist
sotrastaurin[no description available]low00indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
PDGF receptor tyrosine kinase inhibitor III[no description available]low00aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
quinazolines;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-737[no description available]low00aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
mp470[no description available]low00N-arylpiperazine
bgt226[no description available]low00aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
brexpiprazole[no description available]low00N-arylpiperazine
2-(2,5-difluorophenyl)-5-methyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]methyl]oxazole[no description available]low00N-arylpiperazine
2-(2,4-dimethoxyphenyl)-5-methyl-4-[[4-(4-quinazolinyl)-1-piperazinyl]methyl]oxazole[no description available]low00N-arylpiperazine
tg101209[no description available]low00N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gdc-0068[no description available]low00N-arylpiperazine
sch772984[no description available]low00biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide		analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
3-furanyl-[4-[5-(2-furanyl)-2-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]methanone[no description available]low00N-arylpiperazine
4-[5-oxo-7-(1-piperazinyl)-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]benzoic acid[no description available]low00N-arylpiperazine
2-ethyl-6-fluoro-7-(1-piperazinyl)-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one[no description available]low00N-arylpiperazine
aripiprazole lauroxil[no description available]low00aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist
torin 1[no description available]low00N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
azd4547[no description available]low00benzamides;
N-arylpiperazine;
pyrazoles		fibroblast growth factor receptor antagonist
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea[no description available]low00aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas		antineoplastic agent;
fibroblast growth factor receptor antagonist
4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine[no description available]low00N-arylpiperazine;
thienopyrimidine
gsk343[no description available]low00aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
hg-9-91-01[no description available]low00aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound		antineoplastic agent;
salt-inducible kinase 2 inhibitor
benefin[no description available]low00C-nitro compound;
organofluorine compound;
substituted aniline;
tertiary amino compound		agrochemical;
herbicide
enflurane[no description available]low00ether;
organochlorine compound;
organofluorine compound		anaesthetic
carbonyl cyanide p-trifluoromethoxyphenylhydrazone[no description available]low00aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
fludiazepam[no description available]low001,4-benzodiazepinone;
organochlorine compound;
organofluorine compound		anxiolytic drug
flufenamic acid[no description available]low00aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flumequine[no description available]low003-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic
fluphenazine depot[no description available]low00decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
vanoxerine[no description available]low00ether;
N-alkylpiperazine;
organofluorine compound;
tertiary amino compound		dopamine uptake inhibitor
halothane[no description available]low00haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
isoflurane[no description available]low00organofluorine compoundinhalation anaesthetic
mefloquine hydrochloride[no description available]low00organofluorine compound;
piperidines;
quinolines;
secondary alcohol
methoxyflurane[no description available]low00ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
pipamperone[no description available]low00aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
ritanserin[no description available]low00organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
sb 220025[no description available]low00aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190[no description available]low00imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sevoflurane[no description available]low00ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
fluoroacetic acid[no description available]low00haloacetic acid;
organofluorine compound		EC 4.2.1.3 (aconitate hydratase) inhibitor
spiperone[no description available]low00aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
tosufloxacin[no description available]low001,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
zardaverine[no description available]low00organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
dinitrofluorobenzene[no description available]low00C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
1,1-difluoroethylene[no description available]low00olefinic compound;
organofluorine compound
1,1,1-trifluoro-2-chloroethane[no description available]low00organofluorine compound
chloropentafluoroethane[no description available]low00organochlorine compound;
organofluorine compound
2-fluoroadenosine[no description available]low00adenosines;
organofluorine compound
perfluorotributylamine[no description available]low00organofluorine compoundblood substitute;
greenhouse gas;
solvent
5-fluorouridine[no description available]low00organofluorine compound;
uridines		mutagen
5-fluorotryptophan[no description available]low00non-proteinogenic alpha-amino acid;
organofluorine compound;
tryptophan derivative
bromochlorodifluoromethane[no description available]low00one-carbon compound;
organobromine compound;
organochlorine compound;
organofluorine compound
difluoroacetic acid[no description available]low00monocarboxylic acid;
organofluorine compound
fluroxene[no description available]low00organofluorine compound
2,3,4,5,6-pentafluorobenzyl alcohol[no description available]low00benzyl alcohols;
organofluorine compound
2-fluoroadenine[no description available]low00organofluorine compound;
purines		antineoplastic agent
n-dichlorofluoromethylthio-n',n'-dimethyl-n-p-tolylsulfamide[no description available]low00organochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides		antifungal agrochemical;
genotoxin
hexafluoroisopropanol[no description available]low00organofluorine compound;
secondary alcohol		drug metabolite
dichlofluanid[no description available]low00organochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides		acaricide;
antifungal agrochemical
5-fluorocytidine[no description available]low00cytidines;
organofluorine compound
doxifluridine[no description available]low00organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
flubendazole[no description available]low00aromatic ketone;
benzimidazoles;
carbamate ester;
organofluorine compound		antinematodal drug;
teratogenic agent
flunixin[no description available]low00aminopyridine;
organofluorine compound;
pyridinemonocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
desflurane[no description available]low00organofluorine compoundinhalation anaesthetic
acifluorfen[no description available]low00aromatic ether;
benzoic acids;
C-nitro compound;
monocarboxylic acid;
organochlorine compound;
organofluorine compound		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
triflumuron[no description available]low00aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid[no description available]low00aminopyridine;
aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound		environmental contaminant;
herbicide;
xenobiotic
haloxyfop[no description available]low00aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines
fluazifop-butyl[no description available]low00aromatic ether;
carboxylic ester;
organofluorine compound;
pyridines
fomesafen[no description available]low00aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
4-fluorofentanyl[no description available]low00monocarboxylic acid amide;
organofluorine compound;
piperidines
heptafluorobutyric anhydride[no description available]low00acyclic carboxylic anhydride;
organofluorine compound		chromatographic reagent
perfluorotripropylamine[no description available]low00organofluorine compoundblood substitute
3-fluoropyruvate[no description available]low002-oxo monocarboxylic acid;
organofluorine compound
spiramide[no description available]low00aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
serotonergic antagonist
flunoxaprofen[no description available]low001,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound		antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
halopropane[no description available]low00organofluorine compound
flurithromycin[no description available]low00cyclic ketone;
erythromycin derivative;
organofluorine compound;
semisynthetic derivative		antibacterial drug
fluphenacur[no description available]low00aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organofluorine compound
fluoroacetaldehyde[no description available]low00aldehyde;
organofluorine compound		cardiotoxic agent
fc 75[no description available]low00alkyltetrahydrofuran;
organofluorine compound
hei 712[no description available]low00organofluorine compound;
quinolone
thifluzamide[no description available]low001,3-thiazoles;
anilide fungicide;
aromatic amide;
aromatic ether;
dibromobenzene;
organofluorine compound		antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
fludioxonil[no description available]low00benzodioxoles;
nitrile;
organofluorine compound;
pyrroles		androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist
cloransulam-methyl[no description available]low00methyl ester;
monochlorobenzenes;
organofluorine compound;
sulfonamide;
triazolopyrimidines		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
fluazifop[no description available]low00aromatic ether;
monocarboxylic acid;
organofluorine compound;
pyridines
dithiopyr[no description available]low00organofluorine compound;
pyridines;
thioester
s 53482[no description available]low00benzoxazine;
dicarboximide;
organofluorine compound;
terminal acetylenic compound		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide;
teratogenic agent
clodinafop-propargyl[no description available]low00aromatic ether;
carboxylic ester;
organochlorine compound;
organofluorine compound;
propyzamide;
pyridines		agrochemical;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
herbicide
triflusulfuron-methyl[no description available]low001,3,5-triazines;
aromatic ether;
benzoate ester;
methyl ester;
N-sulfonylurea;
organofluorine compound;
tertiary amino compound		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide
novaluron[no description available]low00aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound
cyfluthrin[no description available]low00aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound		agrochemical;
pyrethroid ester insecticide
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether[no description available]low00organofluorine compound
florfenicol[no description available]low00organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
sc 58125[no description available]low00organofluorine compound;
pyrazoles;
sulfone		antineoplastic agent;
cyclooxygenase 2 inhibitor
5-fluoromethylornithine[no description available]low00organofluorine compound;
ornithine derivative		EC 2.6.1.13 (ornithine aminotransferase) inhibitor
nitroflurbiprofen[no description available]low00biphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent
ezogabine[no description available]low00carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator
garenoxacin[no description available]low00aromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
non-steroidal anti-inflammatory drug
5-fluorowillardiine[no description available]low00L-alanine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound		AMPA receptor agonist
perfluoro-n-methyldecahydroisoquinoline[no description available]low00organofluorine compoundblood substitute
fc 80[no description available]low00alkyltetrahydrofuran;
organofluorine compound
5-fluorouridine 5'-phosphate[no description available]low00organofluorine compound;
pyrimidine ribonucleoside 5'-monophosphate		drug metabolite
canertinib[no description available]low00monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
jte 522[no description available]low001,3-oxazoles;
organofluorine compound;
sulfonamide		cyclooxygenase 2 inhibitor
trifluoromethionine[no description available]low00L-methionine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound
cimicoxib[no description available]low00aromatic ether;
imidazoles;
organochlorine compound;
organofluorine compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
diflomotecan[no description available]low00epsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
5',5',5'-trifluoroleucine[no description available]low00leucine derivative;
non-proteinogenic alpha-amino acid;
organofluorine compound
sorbinil[no description available]low00azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound		antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
2'-deoxy-2-fluoroadenosine[no description available]low00adenosines;
organofluorine compound
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine[no description available]low006-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound		antineoplastic agent;
Hsp90 inhibitor
efinaconazole[no description available]low00conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
favipiravir[no description available]low00hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
ck-0944666[no description available]low00benzamides;
indoles;
organofluorine compound		actin polymerisation inhibitor
2-(3-Chloro-2-fluorophenyl)-2,3-dihydroisothiazol-3-one[no description available]low00organofluorine compound
4-[(3-fluorophenyl)methyl-(3-pyridinylmethyl)amino]-4-oxobutanoic acid[no description available]low00organofluorine compound
transfluthrin[no description available]low00carboxylic ester;
cyclopropanes;
organochlorine compound;
organofluorine compound		pyrethroid ester insecticide
4-(4-fluorophenyl)-3H-thiazole-2-thione[no description available]low00organofluorine compound
2-(4-chlorophenyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole[no description available]low00organofluorine compound
N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide[no description available]low00organofluorine compound
1-(cycloheptylideneamino)-3-(4-fluorophenyl)thiourea[no description available]low00organofluorine compound
2-(2-fluorophenyl)-5-phenyl-4-thieno[2,3-d][1,3]oxazinone[no description available]low00organofluorine compound
N-cyano-N'-(2-fluorophenyl)carbamimidothioic acid [2-(tert-butylamino)-2-oxoethyl] ester[no description available]low00organofluorine compound
N-(4-fluorobenzyl)urea[no description available]low00organofluorine compound
N1-(3-chloro-4-fluorophenyl)-2-(methylthio)acetamide[no description available]low00organofluorine compound
ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate[no description available]low00ethyl ester;
monochlorobenzenes;
organofluorine compound;
pyrazoles;
sulfonamide
4-[1-(4-fluorophenyl)ethyl]-3-thiophen-2-yl-1H-1,2,4-triazole-5-thione[no description available]low00organofluorine compound
1-(4-fluorophenyl)-1-cyclopentanecarboxylic acid [2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl] ester[no description available]low00organofluorine compound
deracoxib[no description available]low00organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline[no description available]low00organic heterotricyclic compound;
organofluorine compound;
pyridines;
secondary amino compound
1-(4-fluorophenyl)-N-methyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carbothioamide[no description available]low00organofluorine compound
2-[[2-[3-(4-fluorophenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-2-oxoethyl]thio]acetic acid butyl ester[no description available]low00organofluorine compound
sc 560[no description available]low00aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
1-[(2-fluorophenyl)methyl]-4-pyrazolamine[no description available]low00organofluorine compound
3-[2,2-dichloro-1-(3-fluoro-4-methylphenyl)ethyl]-1,1-bis(phenylmethyl)urea[no description available]low00organofluorine compound
ro 60-0175[no description available]low00indoles;
organochlorine compound;
organofluorine compound;
primary amino compound
arachidonyltrifluoromethane[no description available]low00fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
cyhalothrin[no description available]low00aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound		agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide
sulindac sulfide[no description available]low00aryl sulfide;
monocarboxylic acid;
organofluorine compound		antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
bw b70c[no description available]low00aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
sulindac sulfone[no description available]low00monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
clodinafop[no description available]low00aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines		EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
phenoxy herbicide
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one[no description available]low00organic heterotetracyclic compound;
organofluorine compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
z-val-ala-asp(ome)-fluoromethylketone[no description available]low00carbamate ester;
organofluorine compound;
tripeptide		apoptosis inhibitor;
protease inhibitor
robenacoxib[no description available]low00aromatic amino acid;
monocarboxylic acid;
organofluorine compound;
phenylacetic acids;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
acrinathrin[no description available]low00cyclopropanecarboxylate ester;
organofluorine compound		pyrethroid ester acaricide;
pyrethroid ester insecticide
bifenthrin[no description available]low00carboxylic ester;
cyclopropanecarboxylate ester;
cyclopropanes;
organochlorine compound;
organofluorine compound		pyrethroid ester acaricide;
pyrethroid ester insecticide
ru 58668[no description available]low0017beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone		anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
nepicastat[no description available]low001,3-dihydroimidazole-2-thiones;
organofluorine compound;
primary amino compound;
tetralins		EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor
gw 501516[no description available]low001,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
noviflumuron[no description available]low00aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
organofluorine compound
flonicamid[no description available]low00nitrile;
organofluorine compound;
pyridinecarboxamide		environmental contaminant;
insecticide;
xenobiotic
4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide[no description available]low00organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
paliperidone palmitate[no description available]low001,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
cangrelor[no description available]low00adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
tafluprost[no description available]low00isopropyl ester;
organofluorine compound;
prostaglandins Falpha		prostaglandin receptor agonist
ticagrelor[no description available]low00aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
am 694[no description available]low00aromatic ketone;
indoles;
organofluorine compound;
organoiodine compound;
synthetic cannabinoid		cannabinoid receptor agonist
NNC 55-0396 (free base)[no description available]low00benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker
vorapaxar[no description available]low00carbamate ester;
lactone;
naphthofuran;
organofluorine compound;
pyridines		cardiovascular drug;
platelet aggregation inhibitor;
protease-activated receptor-1 antagonist
bibw 2992[no description available]low00aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
rolapitant[no description available]low00azaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones		antiemetic;
neurokinin-1 receptor antagonist
r-138727[no description available]low00organofluorine compound
fluoxastrobin[no description available]low00aromatic ether;
dioxazine;
monochlorobenzenes;
organofluorine compound;
oxime O-ether;
pyrimidines;
strobilurin antifungal agent		antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
flumorph[no description available]low00aromatic ether;
enamide;
morpholines;
organofluorine compound;
tertiary carboxamide
fluopicolide[no description available]low00benzamide fungicide;
benzamides;
dichlorobenzene;
monochloropyridine;
organofluorine compound		antifungal agrochemical
gamendazole[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
dichlorobenzene;
indazoles;
olefinic compound;
organofluorine compound		antispermatogenic agent;
eukaryotic translation elongation factor 1alpha 1 inhibitor;
Hsp90 inhibitor;
synthetic oral contraceptive
tedizolid[no description available]low00carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
rx-3117[no description available]low00organofluorine compound;
primary allylic alcohol;
triol		antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug
picoxystrobin[no description available]low00aromatic ether;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
organofluorine compound;
pyridines		antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
bay 63-2521[no description available]low00aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator
penthiopyrad[no description available]low00aromatic amide;
organofluorine compound;
pyrazoles;
thiophenes
tedizolid phosphate[no description available]low00carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles		antimicrobial agent;
prodrug;
protein synthesis inhibitor
tavaborole[no description available]low00benzoxaborole;
organofluorine compound		antifungal agent;
EC 6.1.1.4 (leucine--tRNA ligase) inhibitor;
protein synthesis inhibitor
tembotrione[no description available]low00aromatic ketone;
beta-triketone;
cyclic ketone;
ether;
monochlorobenzenes;
organofluorine compound;
sulfone		agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide
finafloxacin[no description available]low00cyclopropanes;
monocarboxylic acid;
nitrile;
organofluorine compound;
quinolone;
secondary amino compound;
tertiary amino compound		antibacterial drug;
antimicrobial agent
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine[no description available]low00aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate		antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
zstk474[no description available]low00benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
trifloxystrobin[no description available]low00methoxyiminoacetate strobilurin antifungal agent;
methyl ester;
organofluorine compound;
oxime O-ether		antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]pyrazole-4-carboxamide[no description available]low00aromatic amide;
organofluorine compound;
pyrazoles
n-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxamide[no description available]low00aromatic amide;
cyclopropanes;
organofluorine compound;
pyrazoles;
ring assembly
butafenacil[no description available]low00benzoate ester;
diester;
monochlorobenzenes;
olefinic compound;
organofluorine compound		EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
buparlisib[no description available]low00aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
lumacaftor[no description available]low00aromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines		CFTR potentiator;
orphan drug
ro5126766[no description available]low00aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sulfoxaflor[no description available]low00nitrile;
organofluorine compound;
pyridines;
sulfoximide
azd 7545[no description available]low00benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
ph 797804[no description available]low00aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
lde225[no description available]low00aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
dafadine D[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
organofluorine compound;
pyridines		P450 inhibitor
canagliflozin[no description available]low00C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
florbetapir f 18[no description available]low00(18)F radiopharmaceutical;
aromatic ether;
organofluorine compound;
pyridines;
substituted aniline		radioactive imaging agent
navitoclax[no description available]low00aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
dcc-2036[no description available]low00organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
cabozantinib[no description available]low00aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
pexidartinib[no description available]low00aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
TAK-580[no description available]low001,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
dabrafenib[no description available]low001,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
[5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid[no description available]low00organofluorine compoundnon-steroidal anti-inflammatory drug
ro 4929097[no description available]low00dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound		EC 3.4.23.46 (memapsin 2) inhibitor
torin 2[no description available]low00aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline		antineoplastic agent;
mTOR inhibitor
gsk2656157[no description available]low00biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide[no description available]low00aromatic amide;
bridged compound;
olefinic compound;
organochlorine compound;
organofluorine compound;
pyrazoles
vericiguat[no description available]low00aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
pacific blue succinimidyl ester[no description available]low00hydroxycoumarin;
N-hydroxysuccinimide ester;
organofluorine compound		fluorochrome
3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamide[no description available]low00aromatic amide;
monocarboxylic acid amide;
organofluorine compound;
pyrazoles;
trichlorobenzene
oxathiapiprolin[no description available]low001,3-thiazoles;
isoxazoline;
N-acylpiperidine;
organofluorine compound;
pyrazoles;
tertiary carboxamide
5-[[5-(4-fluoro-2-hydroxyphenyl)-2-furanyl]methylidene]thiazolidine-2,4-dione[no description available]low00halophenol;
organofluorine compound
LimKi 3[no description available]low001,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide		LIM kinase inhibitor
ivosidenib[no description available]low00cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
as 1842856[no description available]low00organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound		anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent
praliciguat[no description available]low00aminopyrimidine;
isoxazoles;
monofluorobenzenes;
organofluorine compound;
pyrazoles;
secondary amino compound;
tertiary alcohol		anti-inflammatory agent;
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
MMP-9-IN-1[no description available]low00aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide		antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor
5-(2,5-difluorophenyl)-N-(2-oxolanylmethyl)-6H-1,3,4-thiadiazin-2-amine[no description available]low00organofluorine compound
nirmatrelvir[no description available]low00azabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
sq 22536[no description available]low00nucleoside analogue;
oxolanes		EC 4.6.1.1 (adenylate cyclase) inhibitor
tetrahydrofurfuryl alcohol[no description available]low00oxolanes;
primary alcohol		protic solvent
tetrahydrofuran[no description available]low00cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
tetrahydrofurfuryl methacrylate[no description available]low00oxolanes
botryodiplodin[no description available]low00oxolanes
4-methoxy-2,5-dimethyl-3(2h)-furanone[no description available]low00oxolanes
alborixin[no description available]low00cyclic hemiketal;
monocarboxylic acid;
oxolanes;
polyether antibiotic		ionophore
scorpions[no description available]low00dinotefuran;
oxolanes		neonicotinoid insectide
lariciresinol[no description available]low00aromatic ether;
lignan;
oxolanes;
phenols;
primary alcohol		antifungal agent;
plant metabolite
davanone[no description available]low00oxolanes
1-[1-(1-adamantyl)butyl]-3-(2-oxolanylmethyl)thiourea[no description available]low00oxolanes
lasalocid[no description available]low00beta-hydroxy ketone;
monocarboxylic acid;
monohydroxybenzoic acid;
oxanes;
oxolanes;
polyether antibiotic;
secondary alcohol;
tertiary alcohol		bacterial metabolite;
coccidiostat;
ionophore
jatrophone[no description available]low00oxolanes
isoobtusilactone a[no description available]low00oxolanes
aureothin[no description available]low004-pyranones;
C-nitro compound;
ketene acetal;
olefinic compound;
oxolanes		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor
hetacillin[no description available]low00guaiacols;
lignan;
oxolanes;
polyphenol;
tetrol		plant metabolite
manassantin b[no description available]low00benzodioxoles;
dimethoxybenzene;
lignan;
oxolanes;
secondary alcohol		antineoplastic agent;
metabolite
astragaloside ii[no description available]low00beta-D-glucoside;
monosaccharide derivative;
oxolanes;
pentacyclic triterpenoid;
triterpenoid saponin		plant metabolite
vanilmandelic acid[no description available]low002-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite
4-(2,4-dichlorophenoxy)butyric acid[no description available]low00aromatic ether;
monocarboxylic acid;
organochlorine compound		agrochemical;
phenoxy herbicide;
synthetic auxin
win 52035[no description available]low00aromatic ether
win 52084[no description available]low00aromatic ether
5-(nonyloxy)tryptamine[no description available]low00aromatic ether;
primary amino compound;
tryptamines		serotonergic agonist
methylbufotenin[no description available]low00aromatic ether;
tertiary amino compound;
tryptamine alkaloid		hallucinogen;
plant metabolite
5-methoxytryptamine[no description available]low00aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
ro 48-8071[no description available]low00aromatic ether;
aromatic ketone;
bromobenzenes;
monofluorobenzenes;
olefinic compound;
tertiary amino compound		antineoplastic agent;
EC 5.4.99.7 (lanosterol synthase) inhibitor
rtki cpd[no description available]low00aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
aristolochic acid i[no description available]low00aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin
2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one[no description available]low00aromatic ether;
benzoxazine;
cyclic hydroxamic acid;
lactol		allelochemical;
plant metabolite
bufetolol[no description available]low00aromatic ether
bufexamac[no description available]low00aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
bunitrolol[no description available]low00aromatic ether
bupranolol[no description available]low00aromatic ether
cgp 12177[no description available]low00aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
cirazoline[no description available]low00aromatic ether
clofibric acid[no description available]low00aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
colchicine, (+-)-isomer[no description available]low00acetamides;
alkaloid;
aromatic ether;
carbotricyclic compound		microtubule-destabilising agent;
plant metabolite
croconazole[no description available]low00aromatic ether;
conazole antifungal drug;
imidazole antifungal drug;
monochlorobenzenes
cypermethrin[no description available]low00aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound		agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide
racemethorphan[no description available]low00aromatic ether;
morphinane alkaloid;
morphinane-like compound;
organic heterotetracyclic compound
dibucaine[no description available]low00aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
dilacor xr[no description available]low00acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound
domiphen[no description available]low00aromatic ether
epirizole[no description available]low00aromatic ether
ethoxyquin[no description available]low00aromatic ether;
quinolines		antifungal agrochemical;
food antioxidant;
genotoxin;
geroprotector;
herbicide;
Hsp90 inhibitor;
neuroprotective agent;
UDP-glucuronosyltransferase activator
ethoxzolamide[no description available]low00aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
fenvalerate[no description available]low00aromatic ether;
carboxylic ester;
monochlorobenzenes		pyrethroid ester acaricide;
pyrethroid ester insecticide
gallamine triethiodide[no description available]low00aromatic ether
haloprogin[no description available]low00aromatic ether
ipriflavone[no description available]low00aromatic ether;
isoflavones		bone density conservation agent
ly 171883[no description available]low00acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
mephenesin[no description available]low00aromatic ether;
glycerol ether
methoctramine[no description available]low00aromatic ether;
tetramine		muscarinic antagonist
clorgyline[no description available]low00aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
nisoxetine[no description available]low00aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide[no description available]low00aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
oxprenolol[no description available]low00aromatic ether
pd 153035[no description available]low00aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
piretanide[no description available]low00aromatic ether
pramoxine[no description available]low00aromatic ether;
morpholines		local anaesthetic
proglumetacin[no description available]low00aromatic ether;
benzamides;
carboxylic ester;
monochlorobenzenes;
N-acylindole;
N-alkylpiperazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
propoxur[no description available]low00aromatic ether;
carbamate ester		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
pyrilamine[no description available]low00aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
sulfadimethoxine[no description available]low00aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
tetrahydropapaverine[no description available]low00aromatic ether;
benzylisoquinoline alkaloid;
benzyltetrahydroisoquinoline;
polyether;
secondary amino compound
triclosan[no description available]low00aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
viloxazine[no description available]low00aromatic ether
wb 4101[no description available]low00aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
3,3',5-triiodothyropropionic acid[no description available]low00aromatic ether
methacetin[no description available]low00acetamides;
aromatic ether
mestranol[no description available]low0017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
visnagin[no description available]low00aromatic ether;
furanochromone;
polyketide		anti-inflammatory agent;
antihypertensive agent;
EC 1.1.1.37 (malate dehydrogenase) inhibitor;
phytotoxin;
plant metabolite;
vasodilator agent
2-tert-butyl-4-hydroxyanisole[no description available]low00aromatic ether;
phenols
mecoprop[no description available]low00aromatic ether;
monocarboxylic acid;
monochlorobenzenes
phenetidine[no description available]low00aromatic ether;
substituted aniline
2-methyl-4-chlorophenoxy gamma-butyric acid[no description available]low00aromatic ether;
monocarboxylic acid;
monochlorobenzenes		environmental contaminant;
phenoxy herbicide;
xenobiotic
4-bromophenyl phenyl ether[no description available]low00aromatic ether;
organobromine compound
di-(4-aminophenyl)ether[no description available]low00aromatic ether
phenyl ether[no description available]low00aromatic etherplant metabolite
diglycidyl resorcinol ether[no description available]low00aromatic ether
phenetole[no description available]low00aromatic ether
scoparone[no description available]low00aromatic ether;
coumarins		anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite
dimethoxyphenylethylamine[no description available]low00alkaloid;
aromatic ether;
phenylethylamine		allergen;
plant metabolite
dichlorprop[no description available]low00aromatic ether;
dichlorobenzene;
monocarboxylic acid
3-tert-butyl-4-hydroxyanisole[no description available]low00aromatic ether;
phenols		antioxidant;
human xenobiotic metabolite
ethyl vanillin[no description available]low00aromatic ether;
benzaldehydes;
phenols		antioxidant;
flavouring agent
benzethonium chloride[no description available]low00aromatic ether;
chloride salt;
quaternary ammonium salt		antibacterial agent;
antifungal agent;
antiseptic drug;
antiviral agent;
disinfectant
peucedanin[no description available]low00aromatic ether;
furanocoumarin;
lactone		plant metabolite
phenetidine[no description available]low00aromatic ether;
primary amino compound;
substituted aniline		drug metabolite
6-methoxybenzoxazolinone[no description available]low00aromatic ether;
benzoxazole		antibacterial agent;
anticonvulsant;
antifungal agent;
muscle relaxant;
plant metabolite
3-anisidine[no description available]low00aromatic ether;
substituted aniline
domiphen bromide[no description available]low00aromatic ether
dibrompropamidine[no description available]low00aromatic ether
4-Ethoxyphenol[no description available]low00aromatic ether;
phenols
bulbocapnine[no description available]low00aporphine alkaloid;
aromatic ether;
oxacycle;
phenols		EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
EC 1.4.3.22 (diamine oxidase) inhibitor;
plant metabolite
benzydamine[no description available]low00aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug
xylocholine[no description available]low00aromatic ether
3-methoxycatechol[no description available]low00aromatic ether;
catechols		G-protein-coupled receptor agonist
2-phenoxypropanoic acid[no description available]low00aromatic ether;
carboxylic acid
6-methoxyquinoline[no description available]low00aromatic ether;
quinolines
heliamine[no description available]low00aromatic ether;
diether;
isoquinoline alkaloid;
isoquinolines		plant metabolite
2,4,6-trichlorophenyl 4-nitrophenyl ether[no description available]low00aromatic ether;
C-nitro compound;
chlorobenzenes		EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
etridiazol[no description available]low00aromatic ether;
organochlorine compound;
thiadiazole antifungal agent;
thiadiazoles		antifungal agrochemical;
nitrification inhibitor
toliprolol[no description available]low00aromatic ether
5-methoxyindoleacetic acid[no description available]low00aromatic ether;
indole-3-acetic acids		antibacterial agent;
Brassica napus metabolite;
carcinogenic agent;
human urinary metabolite;
marine xenobiotic metabolite;
rat metabolite
iproclozide[no description available]low00aromatic ether
phenoxyacetic acid[no description available]low00aromatic ether;
monocarboxylic acid		allergen;
Aspergillus metabolite;
human xenobiotic metabolite;
plant growth retardant
nafenopin[no description available]low00aromatic ether;
monocarboxylic acid
methyl vanillate[no description available]low00aromatic ether;
benzoate ester;
phenols		antioxidant;
plant metabolite
5-methoxyindole-2-carboxylic acid[no description available]low00aromatic ether;
indolecarboxylic acid		EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor;
hypoglycemic agent;
plant metabolite
2-isopropoxyphenol[no description available]low00aromatic ether;
phenols
dehydroemetine[no description available]low00aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
1,2-epoxy-3-(p-nitrophenoxy)propane[no description available]low00aromatic ether;
C-nitro compound;
epoxide
laurolitsine[no description available]low00aporphine alkaloid;
aromatic ether;
phenols		HIV-1 integrase inhibitor;
metabolite
metocurine iodide[no description available]low00aromatic ether
ac 45594[no description available]low00aromatic ether
3-phenoxybenzylalcohol[no description available]low00aromatic ether;
benzyl alcohols		marine xenobiotic metabolite
devrinol[no description available]low00aromatic ether;
monocarboxylic acid amide;
naphthalenes
fluorodifen[no description available]low00aromatic ether
acridine half-mustard[no description available]low00aminoacridines;
aromatic ether;
organochlorine compound;
secondary amino compound		mutagen
precocene i[no description available]low00aromatic ether;
chromenes		plant metabolite;
precocenes
oxadiazon[no description available]low00aromatic ether
lofexidine[no description available]low00aromatic ether;
carboxamidine;
dichlorobenzene;
imidazoles		alpha-adrenergic agonist;
antihypertensive agent
phenylglycidyl ether[no description available]low00aromatic ether
phenoxyethanol[no description available]low00aromatic ether;
glycol ether;
primary alcohol		antiinfective agent;
central nervous system depressant
metipranolol[no description available]low00acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
silybin[no description available]low00aromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone		antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite
oxamethacin[no description available]low00aromatic ether;
hydroxamic acid;
N-acylindole;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
canadine[no description available]low00aromatic ether;
berberine alkaloid;
organic heteropentacyclic compound;
oxacycle
7-ethoxycoumarin[no description available]low00aromatic ether;
coumarins
medifoxamine[no description available]low00aromatic ether
chlormethoxynil[no description available]low00aromatic ether
climbazole[no description available]low00aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
4-hexyloxyaniline[no description available]low00aromatic ether;
substituted aniline
2-(4-(2,4-dichlorophenoxy)phenoxy)propionic acid[no description available]low00aromatic ether;
dichlorobenzene;
diether;
monocarboxylic acid
bezafibrate[no description available]low00aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
oxyfluorofen[no description available]low00aromatic etherEC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
levobunolol[no description available]low00aromatic ether;
cyclic ketone;
propanolamine		antiglaucoma drug;
beta-adrenergic antagonist
dichlorfop-methyl[no description available]low00aromatic ether;
dichlorobenzene;
diether;
methyl ester
decamethrin[no description available]low00aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound		agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide
triadimenol[no description available]low00aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
triclopyr[no description available]low00aromatic ether;
chloropyridine;
monocarboxylic acid		agrochemical;
environmental contaminant;
herbicide;
xenobiotic
prenalterol[no description available]low00aromatic ether
st 1059[no description available]low00aromatic ether;
primary amino compound;
secondary alcohol		alpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
fenpropathrin, (+-)-isomer[no description available]low00aromatic ether;
cyclopropanecarboxylate ester		agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide
flutolanil[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
benzamides;
benzanilide fungicide		antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
fenoxaprop ethyl[no description available]low00aromatic ether
triclabendazole[no description available]low00aromatic ether
fluvalinate[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide		agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide
fenoxycarb[no description available]low00aromatic ether;
carbamate ester		environmental contaminant;
insecticide;
juvenile hormone mimic;
xenobiotic
quizalofop-ethyl[no description available]low00aromatic ether;
ethyl ester;
organochlorine compound;
quinoxaline derivative
cetamolol[no description available]low00aromatic ether
methyl bensulfuron[no description available]low00aromatic ether;
methyl ester;
N-sulfonylurea;
pyrimidines		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
disoxaril[no description available]low00aromatic ether
chlorimuron ethyl[no description available]low00aromatic ether;
ethyl ester;
N-sulfonylurea;
organochlorine pesticide;
pyrimidines;
sulfamoylbenzoate		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide
tepoxalin[no description available]low00aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles		antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
pioglitazone hydrochloride[no description available]low00aromatic ether
sulfametrole[no description available]low00aromatic ether;
substituted aniline;
sulfonamide antibiotic;
thiadiazoles
propamidine[no description available]low00aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
hexamidine[no description available]low00aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
o-4-methylthymine[no description available]low00aromatic ether;
methylthymine		human metabolite
fenclofenac[no description available]low00aromatic ether
tetraiodothyroacetic acid[no description available]low002-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid		apoptosis inducer;
human metabolite;
thyroid hormone
fluazuron[no description available]low00aromatic ether;
chloropyridine;
monochlorobenzenes;
N-acylurea;
organochlorine acaricide;
organofluorine acaricide;
phenylureas		acaricide;
mite growth regulator
etiroxate[no description available]low00aromatic ether
etofamide[no description available]low00aromatic ether
d 888[no description available]low00aromatic ether;
nitrile;
tertiary amino compound		anti-arrhythmia drug;
calcium channel blocker;
vasodilator agent
esreboxetine[no description available]low00aromatic ether
guaethol[no description available]low00aromatic ether;
phenols;
volatile organic compound		flavouring agent
5'-nitro-2'-propoxyacetanilide[no description available]low00aromatic ether;
C-nitro compound
suberosin[no description available]low00aromatic ether;
coumarins		anticoagulant;
plant metabolite
4-methoxyestradiol[no description available]low0017beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
phenols		estrogen;
human metabolite;
rat metabolite
toltrazuril[no description available]low00aromatic ether
plafibride[no description available]low00aromatic ether
cinitapride[no description available]low00aromatic ether;
C-nitro compound
isoscopoletin[no description available]low00aromatic ether;
hydroxycoumarin		plant metabolite
ethofenprox[no description available]low00aromatic etherpyrethroid ether insecticide
amezinium[no description available]low00aromatic ether;
primary arylamine;
pyridazinium ion		adrenergic uptake inhibitor;
antihypotensive agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
sympathomimetic agent
rubrofusarin[no description available]low00aromatic ether;
benzochromenone;
phenols;
polyketide		biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
fungal metabolite
triasulfuron[no description available]low001,3,5-triazines;
aromatic ether;
N-sulfonylurea;
organochlorine compound		agrochemical;
herbicide
dauricine[no description available]low00aromatic ether;
bisbenzylisoquinoline alkaloid;
isoquinolines;
phenols;
tertiary amino compound		plant metabolite
uvaretin[no description available]low00aromatic ether;
dihydrochalcones;
polyketide;
resorcinol		antineoplastic agent;
plant metabolite
stictic acid[no description available]low00aromatic ether
pramoxine hydrochloride[no description available]low00aromatic ether
4-methoxybenzylamine[no description available]low00aralkylamino compound;
aromatic ether;
primary amino compound
xanthurenic acid 8-methyl ether[no description available]low00aromatic ether;
monohydroxyquinoline;
quinolinemonocarboxylic acid		carcinogenic agent;
metabolite;
mouse metabolite
adriamycinol[no description available]low00aminoglycoside;
anthracycline antibiotic;
aromatic ether;
deoxy hexoside;
p-quinones;
phenols;
polyol;
tetracenequinones		cardiotoxic agent;
drug metabolite
a 8947[no description available]low00aromatic ether;
biaryl;
N-sulfonylurea;
pyrazole pesticide;
tetrazoles		EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
ethylhydrocupreine[no description available]low00aromatic ether;
cinchona alkaloid		EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
7,8-dihydromethysticin[no description available]low002-pyranones;
aromatic ether
4,5-dimethoxy-2-nitrobenzaldehyde[no description available]low00aromatic ether;
C-nitro compound
bisphenol f diglycidyl ether[no description available]low00aromatic ether;
diarylmethane;
epoxide
oryzemate[no description available]low001,2-benzisothiazole;
aromatic ether;
benzothiazole fungicide;
sulfone		antifungal agrochemical;
plant activator
diflufenican[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
pyridinecarboxamide		carotenoid biosynthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic
hexafluoron[no description available]low00aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organochlorine insecticide;
organofluorine insecticide
diethofencarb[no description available]low00aromatic ether;
carbamate ester;
carbanilate fungicide		antifungal agrochemical
pyriproxyfen[no description available]low00aromatic ether;
pyridines		juvenile hormone mimic
methyl 2-(((((4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl)amino)carbonyl)amino)sulfonyl)benzoate[no description available]low00aromatic ether;
benzoate ester;
diamino-1,3,5-triazine;
methyl ester;
N-sulfonylurea		EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
dpx e9636[no description available]low00aromatic ether;
N-sulfonylurea;
pyridines;
pyrimidines;
sulfone		environmental contaminant;
herbicide;
xenobiotic
aclonifen[no description available]low00aromatic ether;
C-nitro compound;
monochlorobenzenes;
primary amino compound;
substituted aniline		agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
cinosulfuron[no description available]low00aromatic ether
vestitol[no description available]low00aromatic ether;
hydroxyisoflavans;
methoxyisoflavan		anti-inflammatory agent;
phytoalexin;
plant metabolite
laudanine[no description available]low00aromatic ether;
benzylisoquinoline alkaloid;
benzyltetrahydroisoquinoline;
phenols;
racemate
cryptopleurine[no description available]low00alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound		antineoplastic agent;
antiviral agent;
protein synthesis inhibitor
6-hydroxymethylmexiletine[no description available]low00aromatic ether
4-hydroxymexiletine[no description available]low00aromatic ether;
phenols
cloquintocet-mexyl[no description available]low00aromatic ether;
carboxylic ester;
organochlorine compound;
quinolines
bursehernin[no description available]low00aromatic ether;
benzodioxoles;
butan-4-olide;
lignan		plant metabolite
2,2',4,4'-tetrabromodiphenyl ether[no description available]low00aromatic ether;
organobromine compound
allocryptopine[no description available]low00aromatic ether;
cyclic acetal;
cyclic ketone;
dibenzazecine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound
sporidesmin[no description available]low00aromatic ether;
cyclic ketone;
diketone;
organic disulfide;
organic heteropentacyclic compound;
organochlorine compound;
secondary alcohol;
tertiary alcohol;
tertiary amino compound		mycotoxin;
Wnt signalling activator
syringaresinol[no description available]low00aromatic ether;
furofuran;
lignan;
polyether;
polyphenol		plant metabolite
p-methoxy-n-methylphenethylamine[no description available]low00aromatic ether;
secondary amino compound		metabolite
aflatoxin q1[no description available]low00aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human xenobiotic metabolite
u 73122[no description available]low00aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
norverapamil[no description available]low00aromatic ether;
nitrile;
polyether;
secondary amino compound
fumitremorgin a[no description available]low00aromatic ether;
diol;
indole alkaloid;
organic heterohexacyclic compound;
organic peroxide		mycotoxin
deguelin[no description available]low00aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
aristolochic acid ii[no description available]low00aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin
tephrosin[no description available]low00aromatic ether;
cyclic ketone;
organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
pesticide
alpha-hydroxymetoprolol[no description available]low00aromatic ether
5-(tetradecyloxy)-2-furancarboxylic acid[no description available]low00aromatic ether;
furoic acid		antineoplastic agent;
apoptosis inducer;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
PPARalpha agonist
tafenoquine[no description available]low00(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
5-hydroxymethylomeprazole[no description available]low00aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		drug metabolite
mosapride[no description available]low00aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound
ym 12617[no description available]low00aromatic ether;
secondary amino compound;
sulfonamide
cgp 28392[no description available]low00aromatic ether
sodium-binding benzofuran isophthalate[no description available]low001-benzofurans;
aromatic ether;
crown compound;
tetracarboxylic acid		fluorochrome
ay 25545[no description available]low00acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
reboxetine[no description available]low00aromatic ether
b 823-08[no description available]low00aromatic ether
cyclazosin[no description available]low00aromatic amide;
aromatic ether;
furans;
monocarboxylic acid amide;
quinazolines;
quinoxaline derivative		adenosine A2A receptor antagonist
ivabradine[no description available]low00aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound		cardiotonic drug
marsupsin[no description available]low001-benzofurans;
aromatic ether;
polyphenol		antilipemic drug;
hypoglycemic agent;
metabolite
6,6'-bieckol[no description available]low00aromatic ether;
oxacycle;
phlorotannin		anti-HIV-1 agent;
metabolite;
radical scavenger
xibenolol[no description available]low00aromatic ether
cicloprolol[no description available]low00aromatic ether
chs 828[no description available]low00aromatic ether
2-(4-methoxyphenoxy)propanoic acid[no description available]low00aromatic ether;
carboxylic acid
rp 73401[no description available]low00aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide		anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor
2,2',4,4',5,5'-hexabrominated diphenyl ether[no description available]low00aromatic ether;
organobromine compound
varespladib[no description available]low00aromatic ether;
benzenes;
dicarboxylic acid monoamide;
indoles;
monocarboxylic acid;
primary carboxamide		anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor
birb 796[no description available]low00aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
schizandrin b[no description available]low00aromatic ether;
cyclic acetal;
organic heterotetracyclic compound;
oxacycle;
tannin		anti-asthmatic agent;
anti-inflammatory agent;
antilipemic drug;
antioxidant;
apoptosis inhibitor;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
plant metabolite
s 23121[no description available]low00aromatic ether;
dicarboximide;
monochlorobenzenes;
monofluorobenzenes;
pyrroline;
terminal acetylenic compound
acrovestone[no description available]low00acetophenones;
aromatic ether;
olefinic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite
corytuberine[no description available]low00aporphine alkaloid;
aromatic ether;
organic heterotetracyclic compound;
polyphenol;
tertiary amino compound		plant metabolite
actinodaphine[no description available]low00aporphine alkaloid;
aromatic ether;
organic heteropentacyclic compound;
phenols;
secondary amino compound		antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite;
platelet aggregation inhibitor;
topoisomerase inhibitor
isohomovanillic acid[no description available]low00aromatic ether;
phenols;
phenylacetic acids		metabolite
3,5-diiodothyropropionic acid[no description available]low00aromatic ether;
monocarboxylic acid;
organoiodine compound;
phenols
7,8-dihydro-5,6-dehydrokawain[no description available]low002-pyranones;
aromatic ether
4-amino-2-methoxypyrimidine[no description available]low00aminopyrimidine;
aromatic ether;
methylcytosine		metabolite
aristolochic acid D[no description available]low00aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
nephrotoxin;
toxin
myricanone[no description available]low00aromatic ether;
cyclic ketone;
diarylheptanoid;
methoxybenzenes;
phenols		antineoplastic agent;
plant metabolite
pannarin[no description available]low00aldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite
aminopotentidine[no description available]low00aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline		H2-receptor antagonist
aristolochic acid c[no description available]low00aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin
pluviatolide[no description available]low00aromatic ether;
benzodioxoles;
butan-4-olide;
lignan;
phenols		plant metabolite
erysodine[no description available]low00aromatic ether;
diether;
Erythrina alkaloid;
organic heterotetracyclic compound;
phenols		antiparasitic agent;
nicotinic antagonist;
phytogenic insecticide
rubrofusarin B[no description available]low00aromatic ether;
benzochromenone;
naphtho-gamma-pyrone;
phenols;
polyketide		Aspergillus metabolite
ly 293111[no description available]low00aromatic ether
enrasentan[no description available]low00aromatic ether;
benzodioxoles;
indanes;
monocarboxylic acid;
monomethoxybenzene;
primary alcohol		antihypertensive agent;
endothelin receptor antagonist
quizalofop[no description available]low00aromatic ether;
monocarboxylic acid;
organochlorine compound;
quinoxaline derivative
cyhalofop-butyl[no description available]low00aromatic ether
cyperin[no description available]low00aromatic ether
aflatoxin b1[no description available]low00aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
5-o-methyllicoricidin[no description available]low00aromatic ether;
hydroxyisoflavans;
methoxyisoflavan		antibacterial agent;
plant metabolite
pronuciferine[no description available]low00aromatic ether;
cyclic ketone;
isoquinoline alkaloid;
isoquinolines;
organic heterotetracyclic compound		plant metabolite
famoxadone[no description available]low00aromatic ether;
carbohydrazide;
oxazolidinone
dabuzalgron[no description available]low00aromatic ether;
imidazoles;
monochlorobenzenes;
sulfonamide		alpha-adrenergic agonist
fonsecin[no description available]low00aromatic ether;
cyclic hemiketal;
heptaketide;
naphtho-gamma-pyrone;
phenols		Aspergillus metabolite;
marine metabolite
lasofoxifene[no description available]low00aromatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins		antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist
(+-)-Dihydromethysticin[no description available]low002-pyranones;
aromatic ether
2-[2-[2-(2-aminophenoxy)ethoxy]ethoxy]aniline[no description available]low00aromatic ether;
substituted aniline
chondocurine (1beta)-(+-)-isomer[no description available]low00aromatic ether
1-methyl-4-prop-2-enoxy-2-pyrimidinone[no description available]low00aromatic ether;
pyrimidone
noscapine[no description available]low00aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
4-[4-(3-methyl-4-nitrophenoxy)butoxy]benzonitrile[no description available]low00aromatic ether;
C-nitro compound
2-methoxyestrone[no description available]low0017-oxo steroid;
3-hydroxy steroid;
alicyclic ketone;
aromatic ether;
phenolic steroid;
phenols		human metabolite;
mouse metabolite
win 54954[no description available]low00aromatic ether
silychristin[no description available]low001-benzofurans;
aromatic ether;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone		lipoxygenase inhibitor;
metabolite;
prostaglandin antagonist;
radical scavenger
cleomiscosin a[no description available]low00aromatic ether;
delta-lactone;
organic heterotricyclic compound;
phenols;
primary alcohol		anti-inflammatory agent;
metabolite
bispyribac[no description available]low00aromatic ether;
benzoic acids;
monocarboxylic acid;
pyrimidines		herbicide
petunidin-3-glucoside[no description available]low00anthocyanin cation;
aromatic ether;
beta-D-glucoside		antioxidant;
metabolite
malvidin-3-glucoside[no description available]low00anthocyanin cation;
aromatic ether;
beta-D-glucoside		metabolite
dioncophylline c[no description available]low00aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes;
naphthols		antimalarial;
antiplasmodial drug;
metabolite
stigmatellin[no description available]low00aromatic ether;
chromones;
olefinic compound;
phenols		bacterial metabolite;
quinol oxidation site inhibitor
prinomastat[no description available]low00aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines		antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
gancaonin I[no description available]low001-benzofurans;
aromatic ether;
resorcinols		antibacterial agent;
plant metabolite
glycyrin[no description available]low00aromatic ether;
coumarins;
hydroxyisoflavans		antibacterial agent;
metabolite;
plant metabolite
glyasperin D[no description available]low00aromatic ether;
hydroxyisoflavans;
methoxyisoflavan		plant metabolite
licoricidin[no description available]low00aromatic ether;
hydroxyisoflavans;
methoxyisoflavan		antibacterial agent;
plant metabolite
egonol[no description available]low001-benzofurans;
aromatic ether;
benzodioxoles;
primary alcohol		plant metabolite
N-ethylharmine[no description available]low00aromatic ether;
beta-carbolines;
semisynthetic derivative		anti-HIV agent
pf 1163a[no description available]low00aromatic ether;
lactam;
macrolide antibiotic;
secondary alcohol		antifungal agent;
Penicillium metabolite
pf 1163b[no description available]low00aromatic ether;
lactam;
macrolide antibiotic		antifungal agent;
Penicillium metabolite
licocoumarone[no description available]low001-benzofurans;
aromatic ether;
resorcinols		antibacterial agent;
apoptosis inducer;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
LSM-22807[no description available]low00aromatic ether
N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide[no description available]low00aromatic ether
piperlactam s[no description available]low00alkaloid;
aromatic ether;
gamma-lactam;
organic heterotetracyclic compound;
phenols		anti-inflammatory agent;
antioxidant;
plant metabolite
5,5-dioxo-1-(4-phenoxyphenyl)-3a,4,6,6a-tetrahydro-3H-thieno[3,4-b]pyrrol-2-one[no description available]low00aromatic ether
antofine[no description available]low00alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound		angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite
xanthohumol[no description available]low00aromatic ether;
chalcones;
polyphenol		anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite
2-phenoxy-N-(2-pyridinyl)butanamide[no description available]low00aromatic ether
6-amino-4-(2-ethoxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile[no description available]low00aromatic ether;
pyranopyrazole
N-[4-[4-[[1-oxo-2-(1-pyrrolidinyl)ethyl]amino]phenoxy]phenyl]-2-(1-pyrrolidinyl)acetamide[no description available]low00aromatic ether
2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole[no description available]low00aromatic ether
2-[[5-(phenoxymethyl)-4-(2-phenylethyl)-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00aromatic ether
1-(8-methyl-2,5,11,14-tetraoxa-8-azabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)ethanol[no description available]low00aromatic ether
3-[2-(3-phenoxypropyl)-5-tetrazolyl]pyridine[no description available]low00aromatic ether
1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole[no description available]low00aromatic ether
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-[[5-[(3-methylphenoxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide[no description available]low00aromatic ether
6-amino-4-[3-ethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile[no description available]low00aromatic ether;
pyranopyrazole
2-[[5-[(2,3-dimethylphenoxy)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-1-thiophen-2-ylethanone[no description available]low00aromatic ether
(1-methyl-2-imidazolyl)-(4-phenylmethoxyphenyl)methanol[no description available]low00aromatic ether
5-(3-butoxyphenyl)-1,3,4-thiadiazol-2-amine[no description available]low00aromatic ether
3-(2-ethoxy-6-methyl-3-pyridinyl)-5-(2-pyridinyl)-1,2,4-oxadiazole[no description available]low00aromatic ether
6-(3,4,5-triethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole[no description available]low00aromatic ether;
triazolothiadiazole
4-(1-benzotriazolyl)-5-(2-methoxyphenoxy)benzene-1,2-dicarbonitrile[no description available]low00aromatic ether
4-cyclohexyl-3-[(3-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione[no description available]low00aromatic ether
7-ethoxy-9-nitro-5H-benzo[b][1,4]benzoxazepin-6-one[no description available]low00aromatic ether
4-[4-(2-quinoxalinyl)phenoxy]benzene-1,2-dicarbonitrile[no description available]low00aromatic ether
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(phenoxymethyl)-4-triazolecarboxylic acid ethyl ester[no description available]low00aromatic ether
2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide[no description available]low00aromatic ether
2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide[no description available]low00aromatic ether
5-[(4-ethylphenoxy)methyl]-N-(2-pyridinylmethyl)-2-furancarboxamide[no description available]low00aromatic ether
7-methoxy-3,5-dimethyl-2-thiazolo[4,5-d]pyrimidinethione[no description available]low00aromatic ether
N-[4-(4-ethylphenyl)-2-thiazolyl]carbamic acid phenyl ester[no description available]low00aromatic ether
2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide[no description available]low00aromatic ether
1-[[3-(4-chlorophenoxy)phenyl]methyl]-4-ethylpiperazine[no description available]low00aromatic ether
2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol[no description available]low00aromatic ether;
C-nitro compound
4-[[4-(ethylamino)-6-(methylthio)-1,3,5-triazin-2-yl]oxy]benzoic acid ethyl ester[no description available]low00aromatic ether
5-ethyl-3-[[4-(2-methylpropoxy)phenyl]methylthio]-1H-1,2,4-triazole[no description available]low00aromatic ether
[4-[(2-fluorophenyl)methoxy]phenyl]-(1-pyrrolidinyl)methanethione[no description available]low00aromatic ether
5-[(2-chlorophenoxy)methyl]-3-pyridin-4-yl-1,2,4-oxadiazole[no description available]low00aromatic ether
4-(4-phenylmethoxyphenyl)thiadiazole[no description available]low00aromatic ether
N-methyl-2-[[4-methyl-5-[(4-nitrophenoxy)methyl]-1,2,4-triazol-3-yl]thio]acetamide[no description available]low00aromatic ether;
C-nitro compound
2-[[5-(4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-1-(4-morpholinyl)ethanone[no description available]low00aromatic ether
4-(3-pyridinyloxy)benzene-1,2-dicarbonitrile[no description available]low00aromatic ether
N-tert-butyl-2-(4-chloro-3-methylphenoxy)acetamide[no description available]low00aromatic ether
1-(2-furanylmethyl)-3-(4-phenoxyphenyl)thiourea[no description available]low00aromatic ether
1-(2-methylpropyl)-3-(4-phenoxyphenyl)thiourea[no description available]low00aromatic ether
1-cyclopentyl-3-(4-phenoxyphenyl)thiourea[no description available]low00aromatic ether
5-[(4-ethoxyphenoxy)methyl]-N-(3-pyridinyl)-2-furancarboxamide[no description available]low00aromatic ether
2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide[no description available]low00aromatic ether
5-[(2-chlorophenoxy)methyl]-N-(2-thiazolyl)-2-furancarboxamide[no description available]low00aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide[no description available]low00aromatic ether
N-(4,5-dihydrothiazol-2-yl)-2-(2-methylphenoxy)acetamide[no description available]low00aromatic ether
5-(2-fluorophenoxy)-1-methyl-3-nitro-1,2,4-triazole[no description available]low00aromatic ether
1-methyl-5-(1-naphthalenyloxy)-4-nitroimidazole[no description available]low00aromatic ether
1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea[no description available]low00aromatic ether;
C-nitro compound
1-cyclopentyl-3-(2-phenoxyphenyl)thiourea[no description available]low00aromatic ether
N-(1-ethyl-2-benzimidazolyl)-5-[(4-methyl-2-nitrophenoxy)methyl]-2-furancarboxamide[no description available]low00aromatic ether;
C-nitro compound
2-chloro-12-(4-methoxyphenyl)sulfonylquinoxalino[2,3-b][1,4]benzoxazine[no description available]low00aromatic ether
1-(3-methoxy-5-nitrophenyl)-3-(4-methylphenyl)urea[no description available]low00aromatic ether;
C-nitro compound
2-(2-bromo-4-chlorophenoxy)-N-cyclohexyl-N-methylacetamide[no description available]low00aromatic ether
2-furanyl-[4-(4-phenoxyphenyl)sulfonyl-1-piperazinyl]methanone[no description available]low00aromatic ether
4-(2-methoxyphenoxy)-N-(3-pyridinyl)benzenesulfonamide[no description available]low00aromatic ether
1-(3-chlorophenyl)-3-(2-phenoxyphenyl)thiourea[no description available]low00aromatic ether
N-[3-[2-(1-azepanyl)-4,5-dicyanophenoxy]phenyl]acetamide[no description available]low00aromatic ether
2,5-dimethoxy-N-(4-phenoxyphenyl)benzenesulfonamide[no description available]low00aromatic ether
4-[[4-(dimethylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]benzoic acid methyl ester[no description available]low00aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide[no description available]low00aromatic ether
1-[4-[[4-(2-chloro-6-nitrophenoxy)phenyl]methoxy]phenyl]ethanone[no description available]low00aromatic ether
N-[4-[[2-(4-hydroxyphenyl)-1,3-dioxo-5-isoindolyl]oxy]phenyl]-2,2-dimethylpropanamide[no description available]low00aromatic ether
N-[[4-(4-chlorophenoxy)anilino]-sulfanylidenemethyl]benzamide[no description available]low00aromatic ether
2-(4-fluorophenoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide[no description available]low00aromatic ether
4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-propan-2-ylbenzenesulfonamide[no description available]low00aromatic ether
4-(4-tert-butylphenoxy)-5-methoxy-2-phenylpyrimidine[no description available]low00aromatic ether
4-phenoxy-2-phenyl-5-pyrimidinecarboxylic acid ethyl ester[no description available]low00aromatic ether
Src Inhibitor-1[no description available]low00aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
N-[2,5-dioxo-6-(4-phenoxyphenyl)-3-pyrano[3,2-c]pyridinyl]benzamide[no description available]low00aromatic ether
2-(4-chlorophenoxy)-4-(dimethylamino)-3-pyridinecarbonitrile[no description available]low00aromatic ether
6-methyl-5-[2-(2-methylphenoxy)ethyl]-2-sulfanylidene-1H-pyrimidin-4-one[no description available]low00aromatic ether
4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone[no description available]low00aromatic ether
N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine[no description available]low00aromatic ether
4-(phenylmethyl)-3-[2-(4-propoxyphenyl)ethyl]-1H-1,2,4-triazole-5-thione[no description available]low00aromatic ether
1-[[1-oxo-3-(4-propan-2-yloxyphenyl)propyl]amino]-3-(phenylmethyl)thiourea[no description available]low00aromatic ether
N-[3-(3-methylphenoxy)-5-nitrophenyl]-2-(3-nitro-1,2,4-triazol-1-yl)acetamide[no description available]low00aromatic ether
N-bis(2-fluorophenoxy)phosphoryl-3,4-dimethylaniline[no description available]low00aromatic ether
2-[[4-(2-ethoxyanilino)-6-(4-ethoxyanilino)-2-pyrimidinyl]methylidene]propanedinitrile[no description available]low00aromatic ether
5-methyl-3-[(4-pentoxyphenyl)methylthio]-1H-1,2,4-triazole[no description available]low00aromatic ether
4,5-dichloro-1-[2-(4-chlorophenoxy)ethyl]imidazole[no description available]low00aromatic ether
1-butyl-3-(4-phenoxyphenyl)thiourea[no description available]low00aromatic ether
N-(3-cyano-2-thiophenyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]acetamide[no description available]low00aromatic ether
2-(2-bromophenyl)-5-[(2-chlorophenoxy)methyl]-1,3,4-oxadiazole[no description available]low00aromatic ether
5-(4-ethoxyphenyl)-N-(3,4,5,6-tetrahydro-2H-azepin-7-yl)-1,3,4-oxadiazol-2-amine[no description available]low00aromatic ether
4-(4-chloro-2-methylphenoxy)-1-(4-morpholinyl)-1-butanone[no description available]low00aromatic ether
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine[no description available]low00aromatic ether
2-[2-(4-chlorophenoxy)ethylthio]pyrimidine[no description available]low00aromatic ether
5-(3-phenoxypropyl)-3-(3-pyridinyl)-1,2,4-oxadiazole[no description available]low00aromatic ether
N-[(3-ethoxy-2-prop-2-enoxyphenyl)methyl]-2-thiazolamine[no description available]low00aromatic ether
2-(2-bromophenoxy)-N-(2-pyridinylmethyl)acetamide[no description available]low00aromatic ether
4-[2-[(4-chlorophenyl)thio]ethoxy]-3-ethoxybenzaldehyde[no description available]low00aromatic ether
1-(3-fluorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrophenyl)-4H-pyridine-3,5-dicarboxylic acid diethyl ester[no description available]low00aromatic ether;
C-nitro compound
5-(2-ethoxyphenyl)-3H-1,3,4-oxadiazole-2-thione[no description available]low00aromatic ether
N-tert-butyl-4-(2-fluorophenoxy)-1-butanamine[no description available]low00aromatic ether
N-butyl-4-phenoxy-1-butanamine[no description available]low00aromatic ether
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-methylphenyl) ester[no description available]low00aromatic ether
1,3-dimethyl-5-[[2-[2-(4-nitrophenoxy)ethoxy]phenyl]methylidene]-1,3-diazinane-2,4,6-trione[no description available]low00aromatic ether;
C-nitro compound
4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine[no description available]low00aromatic ether
2-[2-(3-ethylphenoxy)ethyl]propanedioic acid diethyl ester[no description available]low00aromatic ether
2,3-dihydro-1,4-dioxin-5-carboxylic acid [2-[4-[4-(2-methylbutan-2-yl)phenoxy]anilino]-2-oxoethyl] ester[no description available]low00aromatic ether
1-[3-(2-bromo-4-chlorophenoxy)propyl]-4-methylpiperidine[no description available]low00aromatic ether
N4-(2-methoxyphenyl)benzene-1,4-diamine[no description available]low00aromatic ether;
substituted aniline
4-(1H-benzimidazol-2-ylthio)butanoic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester[no description available]low00aromatic ether
2-phenoxybenzoic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester[no description available]low00aromatic ether
1-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]ethanone[no description available]low00aromatic ether
N-[6-amino-1-(2-methylpropyl)-2,4-dioxo-5-pyrimidinyl]-2-(2-methylphenoxy)-N-(2-methylpropyl)acetamide[no description available]low00aromatic ether
4-[[6-[(2-methyl-5-thieno[2,3-e][1,3]benzothiazolyl)oxy]-3-pyridinyl]sulfonyl]morpholine[no description available]low00aromatic ether
5-(3-fluorophenoxy)-8-nitroisoquinoline[no description available]low00aromatic ether
1-[4-(2-prop-2-enylphenoxy)butyl]pyrrolidine[no description available]low00aromatic ether
2-(2,4-dibromophenoxy)-N-[oxo-(propan-2-ylamino)methyl]acetamide[no description available]low00aromatic ether
4-phenoxyphenyl 4-hydroxypiperidine-1-carboxylate[no description available]low00aromatic ether
N'-benzoyl-5-(3,5-dichlorophenoxy)-2-furancarbohydrazide[no description available]low00aromatic ether
1-[2-[(4-chlorophenoxy)methyl]-4-thiazolyl]ethanone[no description available]low00aromatic ether
5-(benzyloxy)-2-(hydroxymethyl)-1,4-dihydropyridin-4-one[no description available]low00aromatic ether
2-(4-aminophenoxy)isophthalonitrile[no description available]low00aromatic ether
N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine[no description available]low00aromatic ether
N-[(2-chloro-6-phenoxyphenyl)methyl]benzenesulfonamide[no description available]low00aromatic ether
N-[5-(tert-butyl)-3-isoxazolyl]-N'-[2-(trifluoromethoxy)phenyl]urea[no description available]low00aromatic ether
6-(4-methoxyphenoxy)-2-imidazo[1,2-b]pyridazinecarboxylic acid ethyl ester[no description available]low00aromatic ether
2-fluoro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]acetamide[no description available]low00aromatic ether;
C-nitro compound
2-amino-4-(4,5-dimethoxy-2-nitrophenyl)-7,7-dimethyl-5-oxo-6,8-dihydro-4H-1-benzopyran-3-carbonitrile[no description available]low00aromatic ether;
C-nitro compound
2,4-dichloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide[no description available]low00aromatic ether;
C-nitro compound
1-anilino-3-[4-(3-anilino-2-hydroxypropoxy)phenoxy]-2-propanol[no description available]low00aromatic ether
1-[4-(3-ethoxyphenoxy)butyl]imidazole[no description available]low00aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide[no description available]low00aromatic ether
1-[[2-(2,4-difluorophenoxy)-1-oxopropyl]amino]-3-(2-oxolanylmethyl)thiourea[no description available]low00aromatic ether
N-[[(5-bromo-6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-2-(2-chlorophenoxy)acetamide[no description available]low00aromatic ether
2-[(4-chlorophenyl)sulfonyl-methylamino]-N-(4-methoxy-2-nitrophenyl)acetamide[no description available]low00aromatic ether;
C-nitro compound
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide[no description available]low00aromatic ether
1-(2-fluorophenyl)-3-(4-methoxy-2-nitrophenyl)urea[no description available]low00aromatic ether;
C-nitro compound
2-[[5-[(2-fluorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide[no description available]low00aromatic ether
cyclopropanecarboxylic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester[no description available]low00aromatic ether
dieckol[no description available]low00aromatic ether;
oxacycle;
phlorotannin		anticoagulant;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
metabolite;
radical scavenger
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine[no description available]low00aromatic ether
naproxol[no description available]low00aromatic etherantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
tamoxifen n-oxide[no description available]low00aromatic ether;
tertiary amine oxide		anti-estrogen;
metabolite
diafenthiuron[no description available]low00aromatic ether;
thiourea acaricide;
thiourea insecticide		oxidative phosphorylation inhibitor;
proinsecticide
ospemifene[no description available]low00aromatic ether;
organochlorine compound;
primary alcohol		anti-inflammatory agent;
antineoplastic agent;
estrogen receptor modulator
adefovir[no description available]low00aromatic ether;
aromatic ketone;
biaryl;
cyclic ketone;
naphtho-gamma-pyrone;
organooxygen heterocyclic antibiotic;
polyphenol		antimalarial;
Aspergillus metabolite;
marine metabolite
3-chloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide[no description available]low00aromatic ether;
C-nitro compound
N-(2-hydroxyethyl)-4-[2-nitro-4-(trifluoromethyl)phenoxy]benzamide[no description available]low00aromatic ether
N'-[2-[(4-amino-5-cyano-2-pyrimidinyl)thio]-1-oxoethyl]-2-(4-methylphenoxy)acetohydrazide[no description available]low00aromatic ether
N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide[no description available]low00aromatic ether
6-amino-4-(2-ethoxy-4-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile[no description available]low00aromatic ether;
pyranopyrazole
1-[(2-ethoxyphenyl)methyl]-3-thiophen-2-ylurea[no description available]low00aromatic ether
quinoxyfen[no description available]low00aromatic ether;
monofluorobenzenes;
organochlorine compound;
quinolines		antifungal agrochemical
nafadotride[no description available]low00aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound		dopaminergic antagonist
1-(1-naphthalenyl)-3-[[2-(2-nitrophenoxy)-1-oxoethyl]amino]urea[no description available]low00aromatic ether;
C-nitro compound
2-methyl-1,3-bis(phenylmethoxy)benzene[no description available]low00aromatic ether
1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)urea[no description available]low00aromatic ether
3-[(4-ethylphenoxy)methyl]-4-(6-methylheptan-2-yl)-1H-1,2,4-triazole-5-thione[no description available]low00aromatic ether
2-chloro-N-(2-methyl-6-oxo-5H-benzo[b][1,4]benzoxazepin-8-yl)acetamide[no description available]low00aromatic ether
5-(benzenesulfonyl)-4-(2,6-dimethylphenoxy)-2-phenylpyrimidine[no description available]low00aromatic ether
4-(2-methylphenoxy)-6-phenylfuro[2,3-d]pyrimidine[no description available]low00aromatic ether
1-[4-(2-chlorophenoxy)butyl]imidazole[no description available]low00aromatic ether;
imidazoles;
monochlorobenzenes
N-(2-chlorophenyl)-4-[[(2-methoxy-4-nitroanilino)-sulfanylidenemethyl]hydrazo]-4-oxobutanamide[no description available]low00aromatic ether;
C-nitro compound
N-(2-methoxy-4-nitrophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide[no description available]low00aromatic ether;
C-nitro compound
N-[4-(phenoxymethyl)-2-thiazolyl]-1-adamantanecarboxamide[no description available]low00aromatic ether
hydroxypioglitazone[no description available]low00aromatic ether;
pyridines;
thiazolidinediones		human xenobiotic metabolite
sc-19220[no description available]low00aromatic ether
5-methyl-4-(3-phenoxyphenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-6-carboxylic acid ethyl ester[no description available]low00aromatic ether
8-[4-(4-fluorophenoxy)-3-nitrophenyl]-7-(2-hydroxyethyl)-3-(phenylmethyl)purine-2,6-dione[no description available]low00aromatic ether
2-phenoxybenzoic acid [2-oxo-2-(propan-2-ylamino)ethyl] ester[no description available]low00aromatic ether
2-(4-bromophenoxy)-N'-[2-[(4-methyl-1,2,4-triazol-3-yl)thio]-1-oxoethyl]acetohydrazide[no description available]low00aromatic ether
2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile[no description available]low00aromatic ether;
substituted aniline
N-(4-phenoxyphenyl)-2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide[no description available]low00aromatic ether
5-(3,4-dimethoxyphenyl)-3-(2-furanylmethyl)-4-imino-5H-[1]benzopyrano[2,3-d]pyrimidin-8-ol[no description available]low00aromatic ether
3,3-dimethyl-1,5-dinitro-6-phenoxy-3-azoniabicyclo[3.3.1]non-6-ene[no description available]low00aromatic ether
fraxin[no description available]low00aromatic ether;
beta-D-glucoside;
hydroxycoumarin		anti-inflammatory agent;
hepatoprotective agent;
plant metabolite
fraxetin[no description available]low00aromatic ether;
hydroxycoumarin		anti-inflammatory agent;
antibacterial agent;
antimicrobial agent;
antioxidant;
apoptosis inducer;
apoptosis inhibitor;
Arabidopsis thaliana metabolite;
hepatoprotective agent;
hypoglycemic agent
5,6-dehydrokawain[no description available]low002-pyranones;
aromatic ether
coniferin[no description available]low00aromatic ether;
cinnamyl alcohol beta-D-glucoside;
monosaccharide derivative		plant metabolite
daphnoretin[no description available]low00aromatic ether;
hydroxycoumarin		antineoplastic agent;
antiviral agent;
metabolite
kavain[no description available]low002-pyranones;
aromatic ether
methysticin[no description available]low002-pyranones;
aromatic ether
yangonin[no description available]low002-pyranones;
aromatic ether
hinokiflavone[no description available]low00aromatic ether;
biflavonoid;
hydroxyflavone		antineoplastic agent;
metabolite;
neuroprotective agent
gentiacaulein[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
gentisin[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
isogentisin[no description available]low00aromatic ether;
polyphenol;
xanthones		EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
1,8-dihydroxy-3,7-dimethoxyxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
swerchirin[no description available]low00aromatic ether;
phenols;
xanthones		hypoglycemic agent;
metabolite
1,2,8-trihydroxy-6-methoxyxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		antioxidant;
plant metabolite
wedelolactone[no description available]low00aromatic ether;
coumestans;
delta-lactone;
polyphenol		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
sofalcone[no description available]low00aromatic ether;
chalcones;
monocarboxylic acid		anti-ulcer drug;
antibacterial agent;
gastrointestinal drug;
plant metabolite
neticonazole[no description available]low00aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
pibutidine[no description available]low00aromatic ether;
cyclobutenones;
olefinic compound;
piperidines;
primary amino compound;
pyridines;
secondary amino compound		anti-ulcer drug;
H2-receptor antagonist
purmorphamine[no description available]low00aromatic ether;
morpholines;
purines;
secondary amino compound		osteogenesis regulator;
SMO receptor agonist
8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile[no description available]low00aromatic ether
ro 41-5253[no description available]low00aromatic ether;
benzoic acids;
sulfone;
thiochromane		apoptosis inducer;
retinoic acid receptor alpha antagonist
glycycoumarin[no description available]low00aromatic ether;
coumarins;
resorcinols		antispasmodic drug;
plant metabolite
isoginkgetin[no description available]low00aromatic ether;
biflavonoid		antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
plant metabolite
neoglycyrol[no description available]low00aromatic ether;
coumestans;
delta-lactone;
polyphenol		antineoplastic agent;
plant metabolite
rhamnazin[no description available]low00aromatic ether;
dimethoxyflavone;
phenols;
trihydroxyflavone		antineoplastic agent;
plant metabolite
lichexanthone[no description available]low00aromatic ether;
phenols;
xanthones		plant metabolite
alternariol monomethyl ether[no description available]low00aromatic ether;
benzochromenone		antifungal agent;
fungal metabolite;
mycotoxin
decussatin[no description available]low00aromatic ether;
phenols;
xanthones		plant metabolite
bedaquiline[no description available]low00aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
dimethomorph[no description available]low00aromatic ether;
enamide;
monochlorobenzenes;
morpholine fungicide;
tertiary carboxamide
benanomicin b[no description available]low00aromatic ether;
disaccharide derivative;
L-alanine derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol
pradimicin b[no description available]low00aromatic ether;
L-alanine derivative;
monosaccharide derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol
1,7-dihydroxy-4-methoxyxanthone[no description available]low00aromatic ether;
phenols;
xanthones		metabolite;
plant metabolite
pradimicin a[no description available]low00aromatic ether;
carboxylic acid;
disaccharide derivative;
L-alanine derivative;
p-quinones;
polyphenol;
pradimicin;
secondary alcohol
ici 118551[no description available]low00aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
ochnaflavone[no description available]low00aromatic ether;
biflavonoid;
hydroxyflavone		anti-inflammatory agent;
antiatherogenic agent;
antibacterial agent;
EC 3.1.1.4 (phospholipase A2) inhibitor;
leukotriene antagonist;
plant metabolite
3-(4-fluorophenoxy)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene 1-oxide[no description available]low00aromatic ether
flavasperone[no description available]low00aromatic ether;
naphtho-gamma-pyrone;
phenols		acyl-CoA:cholesterol acyltransferase 2 inhibitor;
antiviral agent;
Aspergillus metabolite;
marine metabolite
4-hydroxycordoin[no description available]low00aromatic ether;
chalcones;
polyphenol		anti-inflammatory agent;
antibacterial agent;
plant metabolite
n-feruloylserotonin[no description available]low00aromatic ether;
cinnamamides;
hydroxyindoles;
phenols;
secondary carboxamide		plant metabolite
tyrphostin ag825[no description available]low00aromatic ether;
benzothiazoles;
enamide;
nitrile;
organic sulfide;
phenols;
primary carboxamide		epidermal growth factor receptor antagonist
kresoxim-methyl[no description available]low00aromatic ether;
methoxyiminoacetate strobilurin antifungal agent;
methyl ester;
oxime O-ether		antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
xenobiotic
5-methoxy-3,6-diphenyl-1,2,4-triazine[no description available]low00aromatic ether
pyrachlostrobin[no description available]low00aromatic ether;
carbamate ester;
carbanilate fungicide;
methoxycarbanilate strobilurin antifungal agent;
monochlorobenzenes;
pyrazoles		antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
xenobiotic
piericidin a[no description available]low00aromatic ether;
methylpyridines;
monohydroxypyridine;
secondary allylic alcohol		antimicrobial agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor;
mitochondrial respiratory-chain inhibitor
metrafenone[no description available]low00aromatic ether;
aryl phenyl ketone fungicide;
benzophenones;
organobromine compound		antifungal agrochemical
2-(4-fluoro-3-(trifluoromethyl)phenoxy)-n-(phenylmethyl)butanamide[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
monocarboxylic acid amide;
monofluorobenzenes
b 43[no description available]low00aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
5-(4-phenylbutoxy)psoralen[no description available]low00aromatic ether;
benzenes;
psoralens		geroprotector;
immunosuppressive agent;
potassium channel blocker
5-ia-85380[no description available]low00aromatic ether
yunaconitine[no description available]low00acetate ester;
aromatic ether;
benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound		antifeedant;
human urinary metabolite;
phytotoxin;
plant metabolite;
xenobiotic
altenusin[no description available]low00aromatic ether;
carboxybiphenyl;
catechols;
hydroxybiphenyls;
polyphenol		antifungal agent;
fungal metabolite
bay 58-2667[no description available]low00aromatic ether;
benzoic acids;
dicarboxylic acid;
tertiary amino compound		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
camostat[no description available]low00aromatic ether;
phenols
lenvatinib[no description available]low00aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
nsc 716970[no description available]low00aromatic amine;
aromatic ether;
indolecarboxamide;
organochlorine compound		antineoplastic agent
lobeglitazone[no description available]low00aromatic ether
etomoxir[no description available]low00aromatic ether
fr 148083[no description available]low00aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone		antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
9-methoxycanthin-6-one[no description available]low00aromatic ether;
indole alkaloid;
organic heterotetracyclic compound		antineoplastic agent;
antiplasmodial drug;
metabolite
varespladib methyl[no description available]low00aromatic ether;
benzenes;
indoles;
methyl ester;
primary carboxamide		anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor;
prodrug
dapagliflozin[no description available]low00aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
naveglitazar[no description available]low00aromatic ether
zm 447439[no description available]low00aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
ustiloxin b[no description available]low00aromatic ether;
heterodetic cyclic peptide;
macrocycle;
phenols;
secondary alcohol;
secondary carboxamide;
sulfoxide		Aspergillus metabolite;
microtubule-destabilising agent;
mycotoxin
hypothemycin[no description available]low00aromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone		antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite
tryprostatin a[no description available]low00aromatic ether;
dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine		breast cancer resistance protein inhibitor
cediranib[no description available]low00aromatic ether
3-iodothyronamine[no description available]low00aromatic ether
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride[no description available]low00aromatic ether;
hydrochloride;
methoxybenzenes;
tertiary amino compound		antipsychotic agent;
receptor modulator
rubraxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		antibacterial agent;
antineoplastic agent;
metabolite
7,8-Dihydroyangonin[no description available]low002-pyranones;
aromatic ether
sch 51344[no description available]low00aromatic amine;
aromatic ether;
primary alcohol;
pyrazoloquinoline;
secondary amino compound		antineoplastic agent
pimavanserin[no description available]low00aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas		5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist
tolfenpyrad[no description available]low00aromatic amide;
aromatic ether;
organochlorine compound;
pyrazole insecticide		agrochemical;
antifungal agent;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor
SIS3 free base[no description available]low00aromatic ether;
enamide;
isoquinolines;
monocarboxylic acid amide;
pyrrolopyridine;
tertiary carboxamide		Smad3 inhibitor
dihydrokavain[no description available]low002-pyranones;
aromatic ether
troglitazone sulfate[no description available]low00aromatic ether;
thiazolidinone
arisugacin[no description available]low00aromatic ether;
delta-lactone;
enone;
organic heterotetracyclic compound;
tertiary alcohol		antimicrobial agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite;
Penicillium metabolite
fonsecinone a[no description available]low00aromatic ether;
aromatic ketone;
biaryl;
cyclic ketone;
naphtho-gamma-pyrone;
polyphenol		antibacterial agent;
Aspergillus metabolite
crenolanib[no description available]low00aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
aiphanol[no description available]low00aromatic ether;
benzodioxine;
lignan;
stilbenoid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
nigerloxin[no description available]low00aromatic ether;
benzamides;
benzoic acids;
phenols;
styrenes		antioxidant;
Aspergillus metabolite;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
lipoxygenase inhibitor;
radical scavenger
msdc-0160[no description available]low00aromatic ether
dihydroxanthohumol[no description available]low00aromatic ether;
dihydrochalcones;
polyphenol		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite
7-phloroeckol[no description available]low00aromatic ether;
phlorotannin		antioxidant;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
metabolite
3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside[no description available]low00aromatic ether;
benzyl alcohols;
beta-D-glucoside;
monosaccharide derivative;
primary alcohol		antineoplastic agent;
metabolite
erastin[no description available]low00aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide		antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor
brivanib[no description available]low00aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
fg-4592[no description available]low00aromatic ether;
isoquinolines;
N-acylglycine		EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
cenicriviroc[no description available]low00aromatic ether;
benzazocine;
diether;
imidazoles;
secondary carboxamide;
sulfoxide		anti-HIV agent;
anti-inflammatory agent;
antirheumatic drug;
chemokine receptor 2 antagonist;
chemokine receptor 5 antagonist
mandipropamid[no description available]low00aromatic ether;
monocarboxylic acid amide;
monochlorobenzenes;
terminal acetylenic compound
glyceryl ferulate[no description available]low001-monoglyceride;
aromatic ether;
enoate ester;
phenols		antioxidant;
plant metabolite;
ultraviolet filter
ki 8751[no description available]low00aromatic ether
ceratamine a[no description available]low00alkaloid;
aromatic ether;
cyclic ketone;
organic heterobicyclic compound;
organobromine compound;
secondary amino compound;
tertiary amine		antimitotic;
metabolite
azd 8931[no description available]low00aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
bay94 9172[no description available]low00(18)F radiopharmaceutical;
aromatic ether;
polyether;
secondary amino compound;
stilbenoid;
substituted aniline		radioactive imaging agent
olodaterol[no description available]low00aromatic ether;
benzoxazine;
phenols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent
dorsomorphin[no description available]low00aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
cj-042794[no description available]low00aromatic ether
hu 308[no description available]low00aromatic ether;
bridged compound;
carbobicyclic compound;
primary allylic alcohol;
synthetic cannabinoid		anti-inflammatory agent;
antihypertensive agent;
apoptosis inhibitor;
bone density conservation agent;
CB2 receptor agonist
ki11502[no description available]low00aromatic ether;
benzamides;
quinolines;
thioureas		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
apremilast[no description available]low00aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
PF-00835231[no description available]low00aromatic ether;
indolecarboxamide;
L-leucine derivative;
primary alcohol;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
drug metabolite;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
chir-265[no description available]low00aromatic ether
aminocandin[no description available]low00aromatic ether;
echinocandin;
homodetic cyclic peptide		antiinfective agent
bay 60-6583[no description available]low00aminopyridine;
aromatic ether;
aryl sulfide;
cyanopyridine;
cyclopropanes;
monocarboxylic acid amide		adenosine A2B receptor agonist;
anti-inflammatory agent;
cardioprotective agent
empagliflozin[no description available]low00aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
4-[5-(4-ethoxyphenyl)-3-isoxazolyl]-N-[(4-methylphenyl)methyl]butanamide[no description available]low00aromatic ether
n-desmethylrosiglitazone[no description available]low00aromatic ether
4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide[no description available]low00aromatic ether
verruculogen[no description available]low00aromatic ether;
diol;
indole alkaloid;
organic heterohexacyclic compound;
organic peroxide		Aspergillus metabolite;
GABA modulator;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
1-O-feruloyl-beta-D-glucose[no description available]low00aromatic ether;
beta-D-glucoside;
cinnamate ester;
phenols		antioxidant;
plant metabolite
2,2',4,5'-tetrabromodiphenyl ether[no description available]low00aromatic ether;
organobromine compound
hexabromodiphenyl ether 154[no description available]low00aromatic ether;
organobromine compound
bde 183[no description available]low00aromatic ether;
organobromine compound
l-798106[no description available]low00aromatic ether;
bromobenzenes;
N-sulfonylcarboxamide		prostaglandin receptor antagonist
aflatoxin m1[no description available]low00aflatoxin;
aromatic ether;
aromatic ketone;
tertiary alcohol		Aspergillus metabolite;
human xenobiotic metabolite;
mammalian metabolite
macitentan[no description available]low00aromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides		antihypertensive agent;
endothelin receptor antagonist;
orphan drug
CDN1163[no description available]low00aromatic ether;
quinolines;
secondary carboxamide		SERCA activator
e 7050[no description available]low00aromatic ether
N-[(5-chloro-2-thiophenyl)methyl]-5-[(2,6-difluorophenoxy)methyl]-3-isoxazolecarboxamide[no description available]low00aromatic ether
dafadine C[no description available]low00aromatic amide;
aromatic ether;
difluorobenzene;
isoxazoles;
N-acylpiperidine;
pyridines		P450 inhibitor
dafadine B[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
monochlorobenzenes;
monofluorobenzenes;
N-acylpiperidine;
pyridines		P450 inhibitor
3-[5-(5-methyl-2-thiophenyl)-1,3,4-oxadiazol-2-yl]-N-[2-(3-pyridinyloxy)propyl]propanamide[no description available]low00aromatic ether
violaceol II[no description available]low00aromatic ether;
catechols;
resorcinols		mycotoxin
pamapimod[no description available]low00aromatic amine;
aromatic ether;
difluorobenzene;
diol;
primary alcohol;
pyridopyrimidine;
secondary amino compound		antirheumatic drug;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
gsk690693[no description available]low001,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024[no description available]low002-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
8-{1-[4-(dimethylamino)phenyl]-3-(pyrrolidin-1-yl)propyl}-5,7-dimethoxy-4-pentyl-2H-chromen-2-one[no description available]low00aromatic ether;
coumarins;
pyrrolidines;
tertiary amino compound
zm323881[no description available]low00aromatic ether;
benzyl ether;
fluorophenol;
halophenol;
monofluorobenzenes;
organic cation;
quinazolines;
secondary amino compound;
substituted aniline		vascular endothelial growth factor receptor antagonist
compound w[no description available]low00aromatic ether
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol[no description available]low00aromatic ether
interiotherin b[no description available]low00aromatic ether;
fatty acid ester;
lignan;
organic heteropentacyclic compound;
oxacycle		anti-HIV agent;
metabolite
5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one[no description available]low00aromatic ether;
homoisoflavonoid;
polyphenol		angiogenesis modulating agent;
plant metabolite
diorcinol[no description available]low00aromatic ether;
phenols		fungal metabolite;
marine metabolite;
metabolite
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol[no description available]low00aromatic ether
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol[no description available]low00aromatic ether
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol[no description available]low00aromatic ether
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol[no description available]low00aromatic ether
mk 5108[no description available]low00aromatic ether
1-azepanyl-[5-[(4-chloro-3,5-dimethylphenoxy)methyl]-3-isoxazolyl]methanone[no description available]low00aromatic ether
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines		geroprotector;
P450 inhibitor
1-[(1-ethyl-3-methyl-4-pyrazolyl)methyl]-N-[4-(2-fluorophenoxy)phenyl]-4-piperidinecarboxamide[no description available]low00aromatic ether
dafadine O[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines;
ring assembly		P450 inhibitor
5-[(3,4-dimethylphenoxy)methyl]-N-methyl-N-(4-oxanylmethyl)-3-isoxazolecarboxamide[no description available]low00aromatic ether
pci 32765[no description available]low00acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
AMG-208[no description available]low00aromatic ether;
quinolines;
triazolopyridazine		antineoplastic agent;
c-Met tyrosine kinase inhibitor
6-methoxyspirotryprostatin b[no description available]low00aromatic ether;
azaspiro compound;
indole alkaloid;
indolones		antineoplastic agent;
Aspergillus metabolite
lucitanib[no description available]low00aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines		antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
act-132577[no description available]low00aromatic ether;
organobromine compound;
pyrimidines;
sulfamides		antihypertensive agent;
drug metabolite;
endothelin receptor antagonist;
xenobiotic metabolite
poziotinib[no description available]low00acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline		antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
gsk 2126458[no description available]low00aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
gsk 1363089[no description available]low00aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea[no description available]low00aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea[no description available]low00aromatic ether
3-cyclohexyl-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea[no description available]low00aromatic ether
3-cyclohexyl-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea[no description available]low00aromatic ether
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide[no description available]low00aromatic ether
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea[no description available]low00aromatic ether
monepantel[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
aryl sulfide;
nitrile;
secondary carboxamide		anthelminthic drug;
nematicide
an2728[no description available]low00aromatic ether;
benzoxaborole;
nitrile		antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
hordatine a[no description available]low00aromatic ether;
benzofurans;
dicarboxylic acid diamide;
guanidines;
phenols		adrenergic antagonist;
metabolite
5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)-3-pyridazinone[no description available]low00aromatic ether
tak-632[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor
lrrk2-in1[no description available]low00aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
quinolobactin[no description available]low00aromatic ether;
monohydroxyquinoline;
phenols;
quinolinemonocarboxylic acid		bacterial metabolite;
siderophore
AZD1979[no description available]low00aromatic ether;
azaspiro compound;
carboxamide;
N-acylazetidine;
oxadiazole;
oxaspiro compound;
oxetanes		melanin-concentrating hormone receptor antagonist
xl765[no description available]low00aromatic amine;
aromatic ether;
benzamides;
quinoxaline derivative;
sulfonamide		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
DMH1[no description available]low00aromatic ether;
pyrazolopyrimidine;
quinolines		antineoplastic agent;
bone morphogenetic protein receptor antagonist;
protein kinase inhibitor
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide[no description available]low00aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
pf 4800567[no description available]low00aromatic ether;
monochlorobenzenes;
oxanes;
pyrazolopyrimidine		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
propenylphosphonic acid[no description available]low00aromatic ether
naloxegol[no description available]low00aromatic ether;
organic heteropentacyclic compound;
phenols;
polyether;
tertiary alcohol		cathartic;
mu-opioid receptor antagonist
ceritinib[no description available]low00aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
HG-10-102-01[no description available]low00aminopyrimidine;
aromatic ether;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
secondary amino compound		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
N-[(5-methyl-2-furanyl)methylideneamino]-2-phenoxybenzamide[no description available]low00aromatic ether
saroglitazar[no description available]low00aromatic ether;
methyl sulfide;
monocarboxylic acid;
pyrroles		hypoglycemic agent;
PPARalpha agonist;
PPARgamma agonist
fertaric acid[no description available]low00aromatic ether;
cinnamate ester;
dicarboxylic acid;
phenols;
tetraric acid derivative
pf-06463922[no description available]low00aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
DDR1-IN-1[no description available]low00(trifluoromethyl)benzenes;
aromatic ether;
benzamides;
N-alkylpiperazine;
oxindoles;
secondary carboxamide		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
MLI-2[no description available]low00aromatic ether;
cyclopropanes;
indazoles;
morpholines;
pyrimidines;
tertiary amino compound		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ap20187[no description available]low00aromatic ether;
carboxylic ester;
N-acylpiperidine;
tertiary amino compound		ligand
biliatresone[no description available]low00aromatic ether;
aromatic ketone;
benzodioxoles;
enone;
phenols		plant metabolite;
toxin
tak 491[no description available]low001,2,4-oxadiazole;
aromatic ether;
benzimidazoles;
carboxylic ester;
cyclic carbonate ester;
dioxolane		angiotensin receptor antagonist;
antihypertensive agent;
prodrug
hydrazinocurcumin[no description available]low00aromatic ether;
olefinic compound;
polyphenol;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
mirodenafil[no description available]low00aromatic ether;
N-alkylpiperazine;
primary alcohol;
pyrrolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
cerulomycin[no description available]low00aldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid		antineoplastic agent;
bacterial metabolite;
marine metabolite
undecylprodigiosin[no description available]low00alkaloid;
aromatic ether;
tripyrrole		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent
sb-590885[no description available]low00aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
2-[[4-(trifluoromethoxy)phenyl]methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one[no description available]low00aromatic ether
PF-07304814[no description available]low00aromatic ether;
indolecarboxamide;
L-leucine derivative;
phosphate monoester;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
prodrug
butoconazole nitrate[no description available]low00aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt
butoconazole[no description available]low00aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
sulconazole, mononitrate, (+-)-isomer[no description available]low00conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt
oxiconazole[no description available]low00conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0low70
2019 Novel Coronavirus Infection0low70
2019-nCoV Disease0low70
2019-nCoV Infection0low70
A-V Dissociation0low10
Abdominal Abscess0low10
Abdominal Pain0low20
Abscess0low40
Abscess, Abdominal0low10
Abscess, Amebic0low20
Abscess, Intra-Abdominal0low10
Abscess, Pulmonary0low10
Abscesses, Pulmonary0low10
Acanthamebiasis0low20
Acanthamoeba Infection0low20
Acanthamoeba Keratitis0low10
Acanthamoeba Meningoencephalitis0low20
Ache0medium21
Acidosis, Diabetic0low40
Acinetobacter Infections0low10
Acquired Autoimmune Hemolytic Anemia0low10
Acquired Nephrogenic Diabetes Insipidus0low10
Actinomycetales Infections0low10
Actinomycete Infections0low10
Actinomycetoma0low130
Acute Disease0medium141
Acute Edematous Pancreatitis0low10
Acute Hepatic Failure0low10
Acute Hypercapnic Respiratory Failure0low10
Acute Hypoxemic Respiratory Failure0low10
Acute Kidney Failure0low40
Acute Kidney Injury0low40
Acute Kidney Insufficiency0low40
Acute Liver Failure0low10
Acute Liver Injury, Drug-Induced0low100
Acute Lymphoid Leukemia0low220
Acute Myelogenous Leukemia0medium11011
Acute Myeloid Leukemia0medium11011
Acute Myeloid Leukemia with Maturation0medium11011
Acute Myeloid Leukemia without Maturation0medium11011
Acute Pancreatitis0low10
Acute Promyelocytic Leukemia0low30
Acute Renal Failure0low40
Acute Renal Injury0low40
Acute Renal Insufficiency0low40
Acute Respiratory Distress Syndrome0low30
Acute Rheumatic Fever0low10
ADH-Resistant Diabetes Insipidus0low10
ADPKD0low10
Adult Polycystic Kidney Disease0low10
Adult Polycystic Kidney Disease Type 10low10
Adult Polycystic Kidney Disease Type 20low10
Adult Respiratory Distress Syndrome0low30
Adverse Drug Event0medium181
Adverse Drug Reaction0medium181
African Lymphoma0low10
African Sleeping Sickness0low10
African Trypanosomiasis0low10
Agammaglobulinemia0low10
Agnogenic Myeloid Metaplasia0low10
AIDS-Related Opportunistic Infections0medium152
Airflow Obstruction, Chronic0low10
Aldosteronism0low30
ALL, Childhood0low220
Allergic Bronchopulmonary Aspergilloses0low90
Allergic Bronchopulmonary Aspergillosis0low90
Allergic Bronchopulmonary Mycosis0medium343
Allergic Reaction0low10
Allergy0low10
Alloxan Diabetes0low10
Alopecia0low10
Alopecia Cicatrisata0low10
Alopecia, Androgenetic0low10
Alopecia, Male Pattern0low10
Alternariosis0low20
Alveolitis, Fibrosing0low20
Amaurosis0low10
Amebiasis0low20
Amebic Meningoencephalitis0low20
Ameboma0low20
Amentia0low10
American Trypanosomiasis0medium572
AML M30low30
Amoebiasis0low20
Androgenetic Alopecia0low10
Androgenic Alopecia0low10
Anemia, Aplastic0low80
Anemia, Fanconi0low10
Anemia, Hemolytic, Autoimmune0low10
Anemia, Hemolytic, Cold Antibody0low10
Anemia, Hemolytic, Idiopathic Acquired0low10
Anemia, Hypoplastic0low80
Aneuploid0low10
Aneuploid Cell0low10
Aneuploidy0low10
Aneurysm0low10
Aneurysm, Bacterial0low10
Aneurysm, Infected0low10
Aneurysm, Mycotic0low10
Aneurysm, Thoracic Aortic0low10
Angina Pectoris0low10
Angor Pectoris0low10
Animal Diseases0low10
ANLL0medium11011
Anorexia0low20
Antibody Deficiency Syndrome0low10
Aortic Aneurysm, Thoracic0low10
Aortic Aneurysm, Thoracoabdominal0low10
Ape Diseases0low10
Aplastic Anaemia0low80
Aplastic Anemia0low80
Apparent Mineralocorticoid Excess Syndrome0low60
Aqueductal Stenosis0low10
ARDS, Human0low30
Arrhythmia0low10
Arrhythmias, Cardiac0low10
Arrythmia0low10
Arterial Obstructive Diseases0low10
Arterial Occlusive Diseases0low10
Arthritides, Bacterial0low30
Arthritis, Acute Rheumatic0low10
Arthritis, Bacterial0low30
Arthritis, Infectious0low30
Arthritis, Psoriatic0low10
Arthritis, Rheumatic, Acute0low10
Arthritis, Rheumatoid0low20
Arthritis, Septic0low30
Arthritis, Suppurative0low30
Arthritis, Viral0low30
Asialia0low10
Aspergilloses, Allergic Bronchopulmonary0low90
Aspergilloses, Bronchopulmonary0low210
Aspergillosis, Allergic Bronchopulmonary0low90
Aspergillosis, Bronchopulmonary0low210
Aspergillosis, Bronchopulmonary Allergic0low90
Aspergillosis, Nervous System Invasive0low50
Aspergillus Infection0medium1746
Asthma0low10
Asthma, Bronchial0low10
Astrocytoma, Grade IV0low20
Asystole0low10
Atrial Fibrillation0low10
Atrioventricular Dissociation0low10
Auricular Fibrillation0low10
Auriculo-Ventricular Dissociation0low10
Autoimmune Diabetes0low40
Autoimmune Haemolytic Anaemia0low10
Autoimmune Hemolytic Anemia0low10
Autoimmune Thrombocytopenia0low10
Autoimmune Thrombocytopenic Purpura0low10
Autosomal Dominant Polycystic Kidney0low10
Autosomal Recessive Chronic Granulomatous Disease0medium82
Avian Diseases0low10
B-Cell Chronic Lymphocytic Leukemia0low20
B-Cell Leukemia0low10
B-Cell Leukemia, Chronic0low20
B-Cell Malignancy, Low-Grade0low20
B-Lymphocytic Leukemia0low10
B-Lymphocytic Leukemia, Chronic0low20
Bacteremia0low10
Bacterial Aneurysm0low10
Bacterial Aneurysms0low10
Bacterial Arthritides0low30
Bacterial Arthritis0low30
Bacterial Disease0low10
Bacterial Infection0low10
Bacterial Infections0low10
Bacterial Infections, Central Nervous System0low10
Bacterial Infections, Gram-Negative0low10
Bacterial Pneumonia0low20
Balamuthia Infection0low20
Balamuthia mandrillaris CNS Infection0low20
Balamuthia mandrillaris Meningoencephalitis0low20
Baldness0low10
Baldness, Male Pattern0low10
Benign Intracranial Hypertension0low10
Benign Neoplasms0medium151
Benign Neoplasms, Brain0low10
Bilateral Blindness0low10
Bilateral Headache0low10
Bird Diseases0low10
Black Fever0low20
Blastomycosis0low50
Blastomycosis, North American0low50
Blindness0low10
Blindness, Acquired0low10
Blindness, Bilateral0low10
Blindness, Complete0low10
Blindness, Hysterical0low10
Blindness, Legal0low10
Blindness, Monocular0low10
Blindness, Transient0low10
Blindness, Unilateral0low10
Blood Diseases0low150
Blood Poisoning0low60
Blood Pressure, High0low70
Bloodstream Infection0low60
Blow Out Fracture0low10
Blow-Out Fractures0low10
Body Weight0medium42
Bone Diseases0low20
Bone Marrow Fibrosis0low10
Brain Abscess0low70
Brain Abscess, Child0low70
Brain Abscess, Multiple0low70
Brain Abscess, Pyogenic0low70
Brain Abscess, Sterile0low70
Brain Cancer0low10
Brain Diseases0low110
Brain Disorders0low110
Brain Edema0low10
Brain Inflammation0low10
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Swelling0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Breast Cancer0low20
Breast Carcinoma0low20
Breast Neoplasms0low20
Breast Tumors0low20
Breathing Sounds0low10
Brill-Symmers Disease0low10
Bronchial Asthma0low10
Bronchial Diseases0low10
Bronchitis0low20
Bronchopulmonary Aspergilloses0low210
Bronchopulmonary Aspergilloses, Allergic0low90
Bronchopulmonary Aspergillosis0low210
Bronchopulmonary Aspergillosis, Allergic0low90
Bronze Diabetes0low10
Bronzed Cirrhosis0low10
Buckley Syndrome0low10
Burkitt Cell Leukemia0low10
Burkitt Leukemia0low10
Burkitt Lymphoma0low10
Burkitt Tumor0low10
Burkitt's Leukemia0low10
Burkitt's Lymphoma0low10
Burkitt's Tumor0low10
Burns0low20
C gattii Infection0low200
C neoformans Infection0low200
C. gattii Infection0low200
C. neoformans Infection0low200
Cancer0medium151
Cancer of Brain0low10
Cancer of Breast0low20
Cancer of Liver0low10
Cancer of Lung0medium31
Cancer of Maxillary Sinus0low10
Cancer of Skin0low40
Cancer of the Brain0low10
Cancer of the Breast0low20
Cancer of the Liver0low10
Cancer of the Lung0medium31
Cancer of the Skin0low40
Cancer of the Thymus0low10
Cancer of Thymus0low10
Cancer, Hepatocellular0low10
Candida Infection0medium823
Candidemia0low50
Candidiasis, Chronic Mucocutaneous0low10
Candidiasis, Cutaneous0low10
Candidiasis, Genital0low30
Candidiasis, Invasive0low30
Candidiasis, Vulvovaginal0low30
Canine Diseases0low50
Carcinoma, Basal Cell0low40
Carcinoma, Basal Cell, Pigmented0low40
Carcinoma, Epidermoid0low30
Carcinoma, Hepatocellular0low10
Carcinoma, Non-Small Cell Lung0medium11
Carcinoma, Non-Small-Cell Lung0medium11
Carcinoma, Planocellular0low30
Carcinoma, Squamous0low30
Carcinoma, Squamous Cell0low30
Carcinoma, Thymic0low10
Cardiac Arrest0low10
Cardiac Arrhythmia0low10
Cardiac Arrhythmias0low10
Cardiac Dysrhythmia0low10
Cardiac Failure0low30
Cardiomyopathies0low20
Cardiomyopathies, Primary0low20
Cardiomyopathies, Secondary0low20
Cardiomyopathy, Chagas0low30
Cardiopulmonary Arrest0low10
Carditis0low10
Carotid Artery Thrombosis0low10
Carotid Thrombosis0low10
Cat Diseases0low30
Catheter-Associated Infections0low20
Catheter-Related Infections0low20
Cavernous Sinus Thrombophlebitis0low20
Cavernous Sinus Thrombosis0low20
Cavernous Sinus, Phlebitis, Septic0low20
Caverous Sinus Septic Phlebitis0low20
CD4-Positive T-Lymphocytopenia, Idiopathic0low10
CD4+ T-Lymphocytopenia0low10
CD4+ T-Lymphocytopenia, Idiopathic0low10
Cellulitis, Orbital0low20
Central Nervous System Bacterial Infections0low10
Central Nervous System Disease0low20
Central Nervous System Diseases0low20
Central Nervous System Disorder0low20
Central Nervous System Disorders0low20
Central Nervous System Disorders, Intracranial0low110
Central Nervous System Fungal Infections0medium171
Central Nervous System Intracranial Disorders0low110
Central Nervous System Mycoses0medium171
Central Nervous System Phaeohyphomycosis0low10
Central Nervous System Phaeohyphomycosis, Primary0low10
Central Nervous System Protozoal Infections0low20
Central Nervous System Syphilis0low10
Central Nervous System Toxoplasmosis0low10
Centrala nervsystemets sjukdomar@sv0low20
Cephalalgia0low10
Cephalgia0low10
Cephalodynia0low10
Cerebral Abscess0low70
Cerebral Cryptococcosis0low60
Cerebral Edema0low10
Cerebral Edema, Cytotoxic0low10
Cerebral Edema, Vasogenic0low10
Cerebral Nocardiosis0low10
Cerebral Phaeohyphomycosis0low10
Cerebral Protozoal Infections0low20
Cerebral Toxoplasmosis0low10
Cerebral Ventriculomegaly0low10
Cerebromeningitis0low10
Chagas Cardiomyopathy0low30
Chagas' Cardiomyopathy0low30
Chagas' Disease0medium572
Chemical and Drug Induced Liver Injury0low100
Chemically-Induced Liver Toxicity0low100
Chemotherapy-Induced Acral Erythema0low10
Chemotherapy-Induced Palmoplantar Erythrodysesthesia0low10
Choked Disk0low10
Cholera Infantum0medium81
Chorioretinitis0low10
Choroby OUN@pl0low20
Chromoblastomycosis0low70
Chromomycosis0low70
Chronic Airflow Obstruction0low10
Chronic Disease0medium194
Chronic Granulomatous Disease0medium82
Chronic Granulomatous Disease, Atypical0medium82
Chronic Granulomatous Disease, X-Linked0medium82
Chronic Hepatitis B0low10
Chronic Hepatitis B Virus Infection0low10
Chronic Hepatitis C0low10
Chronic Idiopathic Myelofibrosis0low10
Chronic Illness0medium194
Chronic Kidney Diseases0low10
Chronic Kidney Failure0medium31
Chronic Kidney Insufficiency0low10
Chronic Lymphocytic Leukemia0low20
Chronic Necrotizing Pulmonary Aspergillosis0medium343
Chronic Obstructive Airway Disease0low10
Chronic Obstructive Lung Disease0low10
Chronic Obstructive Pulmonary Disease0low10
Chronic Obstructive Pulmonary Diseases0low10
Chronic Renal Diseases0low10
Chronic Renal Insufficiency0low10
Chronically Ill0medium194
Cirrhosis, Liver0low20
Clinically Isolated CNS Demyelinating Syndrome0low10
Clinically Isolated Syndrome, CNS Demyelinating0low10
Clostridioides difficile Infection0low10
Clostridioides Infections0low10
Clostridioides perfringens Food Poisoning0low10
Clostridioides perfringens Infections0low10
Clostridioides sordellii Infection0low10
Clostridium difficile Infection0low10
Clostridium difficile Infections0low10
Clostridium Infections0low10
Clostridium perfringens Food Poisoning0low10
Clostridium perfringens Infections0low10
Clostridium sordellii Infection0low10
Clostridium sordellii Infections0low10
CNS Disease0low20
CNS Diseases0low20
CNS Disorders, Intracranial0low110
CNS Fungal Infections0medium171
CNS Protozoal Infections0low20
Co-infection0low40
COAD0low10
Coccidioides immitis Infection0medium162
Coinfection0low40
Cold Agglutinin Disease0low10
Cold Antibody Disease0low10
Cold Antibody Hemolytic Anemia0low10
Colicky Pain0low20
Colitis Gravis0low10
Colitis, Granulomatous0low10
Colitis, Ulcerative0low10
Colonic Inertia0low10
Common Carotid Artery Thrombosis0low10
Common Variable Hypogammaglobulinemia0low10
Common Variable Immune Deficiency0low10
Common Variable Immunodeficiency0low10
Communicable Diseases, Emerging0low10
Communicable Diseases, Re-Emerging0low10
Communicable Diseases, Reemerging0low10
Communicating Hydrocephalus0low10
Complication, Intraoperative0low10
Complication, Peroperative0low10
Complication, Postoperative0low210
Complications of Diabetes Mellitus0low120
Complications, Infectious Pregnancy0low10
Congenital Hydrocephalus0low10
Congenital Nephrogenic Diabetes Insipidus0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Heart Failure0low30
Conn Syndrome0low30
Conn's Syndrome0low30
Constipation0low10
COPD0low10
Corneal Ulcer0low70
Coronavirus Disease 20190low70
Coronavirus Disease-190low70
COVID-190low70
COVID-19 Pandemic0low70
COVID-19 Pandemics0low70
COVID-19 Virus Disease0low70
COVID-19 Virus Infection0low70
COVID190low70
Crackles0low10
Cranial Nerve II Diseases0low10
Cranial Nerve II Disorder0low10
Cranial Pain0low10
Critical Illness0medium132
Critically Ill0medium132
Crohn Disease0low10
Crohn's Disease0low10
Crohn's Enteritis0low10
Cross Infection0low70
Cryptococcal Meningitis0low60
Cryptococcosis0low200
Cryptococcus gattii Infection0low200
Cryptococcus Infection0low200
Cryptococcus Infections0low200
Cryptococcus neoformans Infection0low200
Curling Ulcer0low10
Curling's Ulcer0low10
Cushing Syndrome0low10
Cushing's Syndrome0low10
Cutaneous Alternariosis0low20
Cutaneous Phaeohyphomycosis0low100
Cyst0low20
Cystic Fibrosis0low120
Cystic Fibrosis of Pancreas0low120
Cysts0low20
Cytochrome B-Negative Granulomatous Disease, Chronic, X-Linked0medium82
Cytochrome B-Positive Granulomatous Disease, Chronic, X-Linked0medium82
Cytomegalic Inclusion Disease0low50
Cytomegalovirus0low10
Cytomegalovirus Infections0low50
Cytotoxic Brain Edema0low10
Cytotoxic Cerebral Edema0low10
Daytime Sleepiness0low10
Daytime Somnolence0low10
Decreased Intraocular Pressure-Associated Papilledema0low10
Deficiency Syndrome, Immunologic0low10
Deficiency Syndromes, Antibody0low10
Deficiency Syndromes, Immunologic0low10
Delayed Graft Function0low10
Dementia0low10
Demyelinating Diseases0low10
Demyelinating Disorders0low10
Demyelination0low10
Dental Plaque0low10
Dermal Alternariosis0low20
Dermatitis0low10
Dermatitis Medicamentosa0low10
Dermatitis Verrucosa0low70
Dermatitis, Adverse Drug Reaction0low10
Dermatitis, Contact, Phototoxic0low10
Dermatitis, Phototoxic0low10
Dermatomycoses0medium311
Dermatomycosis0medium311
Dermatophyte Infection0medium311
Dermatophytoses0low20
Dermatophytosis0low20
Dermatoses0low10
Dermatosis0low10
Diabetes Complications0low120
Diabetes Insipidus Renalis0low10
Diabetes Insipidus, Nephrogenic0low10
Diabetes Insipidus, Nephrogenic, Autosomal0low10
Diabetes Insipidus, Nephrogenic, Type 10low10
Diabetes Insipidus, Nephrogenic, Type I0low10
Diabetes Insipidus, Nephrogenic, Type II0low10
Diabetes Insipidus, Nephrogenic, X-Linked0low10
Diabetes Mellitus0low70
Diabetes Mellitus, Adult-Onset0low50
Diabetes Mellitus, Brittle0low40
Diabetes Mellitus, Experimental0low10
Diabetes Mellitus, Insulin-Dependent0low40
Diabetes Mellitus, Insulin-Dependent, 10low40
Diabetes Mellitus, Juvenile-Onset0low40
Diabetes Mellitus, Ketosis-Prone0low40
Diabetes Mellitus, Ketosis-Resistant0low50
Diabetes Mellitus, Maturity-Onset0low50
Diabetes Mellitus, Non Insulin Dependent0low50
Diabetes Mellitus, Non-Insulin-Dependent0low50
Diabetes Mellitus, Noninsulin Dependent0low50
Diabetes Mellitus, Noninsulin-Dependent0low50
Diabetes Mellitus, Slow-Onset0low50
Diabetes Mellitus, Stable0low50
Diabetes Mellitus, Sudden-Onset0low40
Diabetes Mellitus, Type 10low40
Diabetes Mellitus, Type 20low50
Diabetes Mellitus, Type I0low40
Diabetes Mellitus, Type II0low50
Diabetes-Related Complications0low120
Diabetes, Autoimmune0low40
Diabetes, Bronze0low10
Diabetic Acidosis0low40
Diabetic Complications0low120
Diabetic Glomerulosclerosis0low10
Diabetic Ketoacidosis0low40
Diabetic Ketosis0low40
Diabetic Kidney Disease0low10
Diabetic Nephropathies0low10
Diabetic Nephropathy0low10
Diarrhea0medium61
Diathesis0low40
Diffuse Large B-Cell Lymphoma0low10
Diffuse Large-Cell Lymphoma0low10
Diffuse Mixed Small and Large Cell Lymphoma0low10
Diffuse Mixed-Cell Lymphoma0low10
Diffuse Small Cleaved-Cell Lymphoma0low10
Diffuse Undifferentiated Lymphoma0low10
Diffuse Well-Differentiated Lymphocytic Lymphoma0low20
Diffuse, Large B-Cell, Lymphoma0low10
Disease Exacerbation0low50
Disease Models, Animal0low840
Disease Progression0low50
Disease Susceptibility0low40
Disease, Pulmonary0low30
Diseases of Pharynx0medium31
Diseases, Animal0low10
Diseases, Pulmonary0low30
Disorders of Excessive Somnolence0low10
Disrupted In B-Cell Malignancy0low20
Disseminated Fungal Infection0medium823
Disseminated Fusariosis0low110
Disseminated Trichosporonosis0low60
Dizziness0low10
Dizzyness0low10
Doenu00E7as do Sistema Nervoso Central@pt0low20
DOES (Disorders of Excessive Somnolence)0low10
Dog Diseases0low50
Drug Eruptions0low10
Drug Side Effects0medium181
Drug Toxicity0medium181
Drug-Induced Acute Liver Injury0low100
Drug-Induced Liver Disease0low100
Drug-Induced Liver Injury0low100
Drug-Related Side Effects and Adverse Reactions0medium181
Duncan Disease0low10
Duncan's Syndrome0low10
Duodenal Ulcer0low10
Dyschezia0low10
Dysmyelopoietic Syndromes0medium327
Dysphonia0low10
E coli Infections0low20
E. coli Infection0low20
Ear Infection0low10
Ear Inflammation0low10
Ebola Hemorrhagic Fever0low10
Ebola Infection0low10
Ebola Virus Disease0low10
Ebola Virus Infection0low10
Ebolavirus Infection0low10
Edema of the Optic Disc0low10
Edema of the Optic Disk0low10
Electrocardiogram QT Prolonged0low50
Emesis0low10
Emphysema0low10
Empyema0low20
Encephalitis0low10
Encephalitis, Rasmussen0low10
Encephalomeningitis0low10
Encephalon Diseases0low110
Encephalopathy0low110
Encephalopathy, Hepatic0low10
Encephalopathy, Hepatocerebral0low10
Encephalopathy, Portal-Systemic0low10
Encephalopathy, Portosystemic0low10
Encephalopathy, Toxic0low20
End-Stage Kidney Disease0medium31
End-Stage Renal Disease0medium31
Endocarditis0low20
Endomyocardial Fibrosis0low10
Endophthalmitis0low70
Endotoxin Shock0low30
Enfermedades del Sistema Nervioso Central@es0low20
Enteritis0low10
Enteritis, Granulomatous0low10
Enteritis, Regional0low10
Entomophthoramycosis0medium401
Epidermophytosis0low20
Epithelioma, Basal Cell0low40
Epstein-Barr Virus Infection, Familial Fatal0low10
Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males0low10
Erythema0low10
Erythrophagocytic Lymphohistiocytosis, Familial0low10
Escherichia coli Infections0low20
Esophageal Diseases0medium31
Esophagitis0low10
ESRD0medium31
Ethmoid Sinusitis0medium41
Ethmoidal Sinusitis0medium41
Eumycetoma0low130
Excessive Daytime Sleepiness0low10
Excessive Somnolence Disorders0low10
Exostoses0low10
Exostosis0low10
Experimental Diabetes Mellitus0low10
Experimental Lung Inflammation0low70
External Carotid Artery Thrombosis0low10
External Ophthalmoplegia0low10
Extravascular Hemolysis0low40
Eye Infections, Fungal0low210
Facial Injuries0low10
Familial Atrial Fibrillation0low10
Familial Dementia0low10
Familial Erythrophagocytic Lymphohistiocytosis0low10
Familial Fatal Epstein-Barr Infection0low10
Familial Hemochromatosis0low10
Familial Hemophagocytic Histiocytosis0low10
Familial Hemophagocytic Lymphocytosis0low10
Familial Hemophagocytic Lymphohistiocytosis0low10
Familial Hemophagocytic Reticulosis0low10
Familial Histiocytic Reticulosis0low10
Familial Waldenstrom's Macroglobulinaemia0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Fasciitis, Necrotizing0low20
Fascitis, Necrotizing0low20
Fatigue0low10
Febrile Neutropenia0low40
Feline Diseases0low30
Female Pattern Baldness0low10
Femoral Neoplasms0low10
Fetal Cerebral Ventriculomegaly0low10
Fever0medium101
Fever of Unknown Origin0low10
Fever, Zika0low10
Fibrocystic Disease of Pancreas0low120
Fibroses, Pulmonary0low20
Fibrosis, Bone Marrow0low10
Fibrosis, Liver0low20
Fibrosis, Pulmonary0low20
Follicular Large-Cell Lymphoma0low10
Follicular Lymphoma0low10
Follicular Lymphoma, Giant0low10
Follicular Lymphoma, Grade 10low10
Follicular Lymphoma, Grade 20low10
Follicular Lymphoma, Grade 30low10
Follicular Mixed-Cell Lymphoma0low10
Foot Dermatoses0medium51
Foot Dermatosis0medium51
Foster-Kennedy Syndrome0low10
Fractures, Blow-Out0low10
Fulminant Hepatic Failure0low10
Fulminant Hepatic Failure with Cerebral Edema0low10
Fulminating Hepatic Failure0low10
Fulminating Liver Failure0low10
Functional Gastrointestinal Disorders0medium81
Fungal Aneurysm0low10
Fungal Diseases0medium30929
Fungal Eye Infections0low210
Fungal Infections0medium30929
Fungal Infections, Central Nervous System0medium171
Fungal Lung Diseases0medium483
Fungal Meningitis0medium41
Fungal Skin Diseases0medium311
Fungemia0medium273
Fungus Diseases0medium30929
Fungus Infections0medium30929
Fusariosis0low110
Fusarium Infection0low110
Fusiform Aneurysm0low10
Gangrene0low10
Gastric Diseases0low20
Gastrointestinal Diseases0medium81
Gastrointestinal Disorders0medium81
Gastrointestinal Disorders, Functional0medium81
General Paralysis0low10
General Paralysis of the Insane0low10
General Paresis0low10
General Paresis of the Insane0low10
Generalized Headache0low10
Genetic Hemochromatosis0low10
Genital Vulvovaginal Candidiasis0low30
Geotrichosis0low30
Germinoblastoma0medium11
Giant Cell Glioblastoma0low20
Giant Follicular Lymphoma0low10
Gilchrist Disease0low50
Gilchrist's Disease0low50
Glaucoma0low10
Glioblastoma Multiforme0low20
Glomerulosclerosis, Diabetic0low10
Graft vs Host Disease0medium294
Graft-Versus-Host Disease0medium294
Graft-vs-Host Disease0medium294
Gram-Negative Bacterial Infections0low10
Granulocytic Leukemia0low70
Granulocytic Leukemia, Chronic0low20
Granuloma0low20
Granuloma, Hodgkin0low10
Granuloma, Hodgkin's0low10
Granuloma, Hodgkins0low10
Granuloma, Malignant0low10
Granulomas0low20
Granulomatosis with Polyangiitis0low20
Granulomatosis, Wegener's0low20
Granulomatous Disease, Chronic, X-Linked0medium82
Granulomatous Disease, Chronic, X-Linked, Variant0medium82
Granulomous Cerebral Cryptococcosis0low60
Grippe0medium31
Group A Strep Infection0low10
Group A Streptococcal Infection0low10
Group A Streptococcal Infections0low10
Group B Strep Infection0low10
Group B Streptococcal Infection0low10
Group B Streptococcal Infections0low10
Haemochromatosis0low10
Haemolysis0low40
Hair Loss0low10
Hairy Cell Leukemia0low10
Hallucination of Body Sensation0low20
Hallucinations0low20
Hallucinations, Auditory0low20
Hallucinations, Dissociative0low20
Hallucinations, Elementary0low20
Hallucinations, Formed, of People0low20
Hallucinations, Gustatory0low20
Hallucinations, Hypnagogic0low20
Hallucinations, Hypnapompic0low20
Hallucinations, Internal Body Sensation0low20
Hallucinations, Kinesthetic0low20
Hallucinations, Mood Congruent0low20
Hallucinations, Mood Incongruent0low20
Hallucinations, Olfactory0low20
Hallucinations, Organic0low20
Hallucinations, Reflex0low20
Hallucinations, Sensory0low20
Hallucinations, Somatic0low20
Hallucinations, Tactile0low20
Hallucinations, Verbal Auditory0low20
Hallucinations, Visual0low20
Hallucinations, Visual, Formed0low20
Hallucinations, Visual, Unformed0low20
Hand-Foot Syndrome0low10
Head Pain0low10
Headache0low10
Health Care Associated Infection0low70
Health Care Associated Infections0low70
Healthcare Associated Infections0low70
Heart Arrest0low10
Heart Block0low10
Heart Decompensation0low30
Heart Disease, Ischemic0low10
Heart Failure0low30
Heart Failure, Congestive0low30
Heart Failure, Left-Sided0low30
Heart Failure, Right-Sided0low30
Hematologic Diseases0low150
Hematologic Malignancies0medium568
Hematologic Malignancy0medium568
Hematologic Neoplasms0medium568
Hematological Diseases0low150
Hematological Malignancies0medium568
Hematological Neoplasms0medium568
Hematopoetic Myelodysplasia0medium327
Hematopoietic Malignancies0medium568
Hematopoietic Neoplasms0medium568
Hemicrania0low10
Hemochromatoses0low10
Hemochromatosis0low10
Hemolysis0low40
Hemolytic Anemia, Autoimmune0low10
Hemophagocytic Lymphohistiocytosis Familial -10low10
Hemophagocytic Lymphohistiocytosis, Familial0low10
Hemophagocytic Lymphohistiocytosis, Familial, 10low10
Hemophagocytic Reticulosis, Familial0low10
Hemophagocytic Syndrome0low10
Hemophagocytic Syndrome, Infection-Associated0low10
Hemophagocytic Syndrome, Reactive0low10
Hemophagocytic Syndromes0low10
Hemoptysis0low20
Hemorrhage, Retrobulbar0low10
Hemorrhagic Fever, Ebola0low10
Hepatic Cancer0low10
Hepatic Cirrhosis0low20
Hepatic Coma0low10
Hepatic Encephalopathy0low10
Hepatic Failure0low10
Hepatic Failure, Acute0low10
Hepatic Failure, Fulminant0low10
Hepatic Neoplasms0low10
Hepatic Stupor0low10
Hepatitis0low20
Hepatitis B0low10
Hepatitis B Virus Infection0low10
Hepatitis B Virus Infection, Chronic0low10
Hepatitis B, Chronic0low10
Hepatitis C, Chronic0low10
Hepatitis, Drug-Induced0low100
Hepatitis, Toxic0low100
Hepatocellular Cancer0low10
Hepatocellular Carcinoma0low10
Hepatocerebral Encephalopathy0low10
Hepatoma0low10
HIE Syndrome0low10
HIES, Autosomal Dominant0low10
HIES, Autosomal Recessive0low10
Histiocytic Lymphoma0low10
Histiocytic Lymphoma, Diffuse0low10
Histiocytic Lymphoma, Nodular0low10
Histoplasma capsulatum Infection0medium81
Histoplasma Infection0medium81
Histoplasmosis0medium81
HIV Coinfection0low120
HIV Infections0low120
HIV-Related Opportunistic Infections0medium152
Hodgkin Disease0low10
Hodgkin Lymphoma0low10
Hodgkin Lymphoma, Adult0low10
Hodgkin's Disease0low10
Hodgkin's Lymphoma0low10
Hodgkins Disease0low10
Homologous Wasting Disease0medium294
Hospital Infections0low70
Hospital-Acquired Condition0low10
HTLV-III Infections0low120
HTLV-III-LAV Infections0low120
Human Flu0medium31
Human Influenza0medium31
Human Mammary Carcinoma0low20
Hydrocephalus0low10
Hydrocephalus Ex-Vacuo0low10
Hydrocephaly0low10
Hyper-IgE Recurrent Infection Syndrome, Autosomal Recessive0low10
Hyper-IgE Syndrome0low10
Hyper-IgE Syndrome, Autosomal Dominant0low10
Hyper-IgE Syndrome, Autosomal Recessive0low10
Hyper-Immunoglobulin E Syndrome, Autosomal Dominant0low10
Hyper-Immunoglobulin E Syndrome, Autosomal Recessive0low10
Hyperaldosteronism0low30
Hypercalcemia0low10
Hypercapnic Acute Respiratory Failure0low10
Hypercapnic Respiratory Failure0low10
Hypercortisolism0low10
Hyperimmunoglobulin E-Recurrent Infection Syndrome0low10
Hyperimmunoglobulin E, Recurrent Infection Syndrome0low10
Hyperimmunoglobulinemia E Syndrome0low10
Hyperkinetic Dysphonia0low10
Hyperlipemia0low20
Hyperlipidemia0low20
Hyperlipidemias0low20
Hypersensitivity0low10
Hypersomnia0low10
Hypersomnia, Recurrent0low10
Hypersomnolence0low10
Hypersomnolence Disorders0low10
Hypersomnolence Disorders, Primary0low10
Hypersomnolence Disorders, Secondary0low10
Hypertension0low70
Hyperuricemia0low10
Hypoalbuminemia0low20
Hypogammaglobulinemia0low10
Hypogammaglobulinemia, Acquired0low10
Hypokalemia0low50
Hypopotassemia0low50
Hyposalivation0low10
Hypoxemic Acute Respiratory Failure0low10
Hypoxemic Respiratory Failure0low10
Iatrogenic Disease0low10
IDDM0low40
Idiopathic Autoimmune Hemolytic Anemia0low10
Idiopathic CD4 Positive T-Lymphocytopenia0low10
Idiopathic CD4-Positive T-Lymphocytopenia0low10
Idiopathic CD4+ T-Lymphocytopenia0low10
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low20
Idiopathic Intracranial Hypertension0low10
Idiopathic Myelofibrosis0low10
Idiopathic Proctocolitis0low10
Idiopathic Thrombocytopenic Purpura0low10
Ileal Diseases0low10
Ileitis, Regional0low10
Ileitis, Terminal0low10
Ileocolitis0low10
Ileus0low10
Immune Reconstitution Disease0low10
Immune Reconstitution Inflammatory Syndrome0low10
Immune Reconstitution Syndrome0low10
Immune Restoration Disease0low10
Immune Restoration Syndrome0low10
Immune Thrombocytopenia0low10
Immune Thrombocytopenic Purpura0low10
Immunodeficiency 50low10
Immunodeficiency, Common Variable0low10
Immunodeficiency, X-Linked Progressive Combined Variable0low10
Immunoglobulin Deficiency, Late-Onset0low10
Immunologic Deficiency Syndrome0low10
Immunologic Deficiency Syndromes0low10
Immunological Deficiency Syndromes0low10
Inclusion Disease0low50
Increased Intracranial Pressure-Associated Papilledema0low10
Infant, Newborn, Diseases0low10
Infected Aneurysm0low10
Infection, Bacterial0low10
Infection, Central Nervous System, Protozoal0low20
Infection, Cross0low70
Infection, Postoperative Wound0low50
Infection, Surgical Wound0low50
Infection, Wound0low10
Infections, Acinetobacter0low10
Infections, Actinomycetales0low10
Infections, Actinomycete0low10
Infections, Bacterial0low10
Infections, Bacterial, Central Nervous System0low10
Infections, Clostridium0low10
Infections, Cytomegalovirus0low50
Infections, E coli0low20
Infections, Escherichia coli0low20
Infections, Fungal, Central Nervous System0medium171
Infections, Gram-Negative Bacterial0low10
Infections, Hospital0low70
Infections, Klebsiella0low10
Infections, Listeria0low10
Infections, Mimae0low10
Infections, Nocardia0low10
Infections, Nosocomial0low70
Infections, Orthomyxoviridae0low10
Infections, Orthomyxovirus0low10
Infections, Picornaviridae0low10
Infections, Picornavirus0low10
Infections, Plasmodium0low10
Infections, Prosthesis-Related0low20
Infections, Protozoal, Central Nervous System0low20
Infections, Respiratory0low80
Infections, Respiratory Tract0low80
Infections, Serratia0low10
Infections, Soft Tissue0low40
Infections, Staphylococcal0low10
Infections, Streptococcal0low10
Infections, Upper Respiratory0low80
Infections, Upper Respiratory Tract0low80
Infectious Arthritis0low30
Infectious Diseases, Emerging0low10
Infectious Diseases, Re-Emerging0low10
Infectious Diseases, Reemerging0low10
Infectious Endophthalmitis0low70
Infectious Pregnancy Complications0low10
Infective Endocarditis0low20
Inflammation0low20
Inflammation, Brain0low10
Inflammatory Bowel Disease 10low10
Inflammatory Bowel Disease, Ulcerative Colitis Type0low10
Inflammatory Rheumatism0low10
Influenza0medium31
Influenza in Humans0medium31
Influenza, Human0medium31
Injuries0low20
Injuries and Wounds0low20
Injuries, Facial0low10
Injuries, Leg0low20
Injuries, Mandibular0low10
Injuries, Surgical0low10
Injuries, Wounds0low20
Innate Inflammatory Response0low20
Insulin-Dependent Diabetes Mellitus 10low40
Internal Carotid Artery Thrombosis0low10
Internal Ophthalmoplegia0low10
Intertrigo0low10
Intestinal Diseases0low10
Intestinal Obstruction0low10
Intestinal Perforation0low10
Intra-Abdominal Infections0low10
Intraabdominal Infections0low10
Intracapillary Glomerulosclerosis0low10
Intracranial Central Nervous System Disorders0low110
Intracranial CNS Disorders0low110
Intracranial Edema0low10
Intracranial Hypertension, Benign0low10
Intracranial Hypertension, Idiopathic0low10
Intracranial Neoplasms0low10
Intracranial Toxoplasmosis0low10
Intraoperative Complications0low10
Intravascular Hemolysis0low40
Invasive Fungal Infections0medium823
Invasive Fusariosis0low110
Invasive Mycoses0medium823
Invasive Pulmonary Aspergillosis0medium343
Invasive Pulmonary Fusariosis0low110
Invasive Trichosporonosis0low60
Iodamoebiasis0low20
Iron Storage Disorder0low10
Ischemia, Myocardial0low10
Ischemic Heart Disease0low10
Japanese Summer-Type Hypersensitivity Pneumonitis0low60
Jaw Fractures0low10
Jejunal Diseases0low10
Job Syndrome0low10
Job-Buckley Syndrome0low10
Job's Syndrome0low10
Jorge Lobo Disease0low10
Jorge Lobo's Disease0low10
Juvenile Paresis0low10
Juvenile-Onset Diabetes0low40
Kahler Disease0low20
Kala-Azar0low20
Keloidal Blastomycosis0low10
Keratitis0low70
Keratitis, Acanthamoeba0low10
Keratitis, Ulcerative0low70
Keskushermoston sairaudet@fi0low20
Ketoacidosis, Diabetic0low40
Ketosis, Diabetic0low40
Kidney Diseases0low40
Kidney Failure0medium21
Kidney Failure, Acute0low40
Kidney Failure, Chronic0medium31
Kidney Insufficiency0medium21
Kidney Insufficiency, Acute0low40
Kidney Insufficiency, Chronic0low10
Kidney, Polycystic, Autosomal Dominant0low10
Kimmelstiel-Wilson Disease0low10
Kimmelstiel-Wilson Syndrome0low10
Klebsiella Infections0low10
Koch's Disease0low20
Kochs Disease0low20
Lacazia loboi Infection0low10
Lacaziosis0low10
Lacaziosis-like Disease0low10
Large Lymphoid Lymphoma, Diffuse0low10
Large Lymphoid Lymphoma, Nodular0low10
Large-Cell Lymphoma, Diffuse0low10
Large-Cell Lymphoma, Follicular0low10
Laryngitis0low10
Lassitude0low10
Left-Sided Heart Failure0low30
Leg Injuries0low20
Leg Ulcer0low20
Leishmania Infection0low30
Leishmaniasis0low30
Leishmaniasis, American0low30
Leishmaniasis, Cutaneous0low30
Leishmaniasis, Diffuse Cutaneous0low10
Leishmaniasis, New World0low30
Leishmaniasis, Old World0low30
Leishmaniasis, Visceral0low20
Leucocythaemia0medium173
Leucocythemia0medium173
Leukemia, Acute Lymphoblastic0low220
Leukemia, Acute Monocytic0low10
Leukemia, Acute Myelogenous0medium11011
Leukemia, Acute Myeloid0medium11011
Leukemia, Acute Promyelocytic0low30
Leukemia, B Cell, Chronic0low20
Leukemia, B-Cell0low10
Leukemia, B-Cell, Chronic0low20
Leukemia, Chronic Lymphatic0low20
Leukemia, Chronic Lymphocytic0low20
Leukemia, Chronic Lymphocytic, B-Cell0low20
Leukemia, Chronic Myelogenous0low20
Leukemia, Chronic Myeloid0low20
Leukemia, Granulocytic0low70
Leukemia, Granulocytic, Chronic0low20
Leukemia, Hairy Cell0low10
Leukemia, Lymphoblastic0low220
Leukemia, Lymphoblastic, Acute0low220
Leukemia, Lymphoblastic, Acute, L10low220
Leukemia, Lymphoblastic, Acute, L20low220
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low220
Leukemia, Lymphoblastic, Acute, T Cell0low10
Leukemia, Lymphoblastic, Acute, T-Cell0low10
Leukemia, Lymphoblastic, Burkitt-Type0low10
Leukemia, Lymphoblastic, Chronic0low20
Leukemia, Lymphocytic, Acute0low220
Leukemia, Lymphocytic, Acute T Cell0low10
Leukemia, Lymphocytic, Acute, L10low220
Leukemia, Lymphocytic, Acute, L20low220
Leukemia, Lymphocytic, Acute, T-Cell0low10
Leukemia, Lymphocytic, B Cell0low10
Leukemia, Lymphocytic, B-Cell0low10
Leukemia, Lymphocytic, Chronic0low20
Leukemia, Lymphocytic, Chronic, B Cell0low20
Leukemia, Lymphocytic, Chronic, B-Cell0low20
Leukemia, Lymphocytic, L30low10
Leukemia, Lymphoid, Acute0low220
Leukemia, Monoblastic, Acute0low10
Leukemia, Monocytic, Acute0low10
Leukemia, Monocytic, Chronic0low70
Leukemia, Myeloblastic, Acute0medium11011
Leukemia, Myelocytic0low70
Leukemia, Myelocytic, Acute0medium11011
Leukemia, Myelocytic, Chronic0low20
Leukemia, Myelogenous0low70
Leukemia, Myelogenous, Acute0medium11011
Leukemia, Myelogenous, Chronic0low20
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0low20
Leukemia, Myelogenous, Ph1 Positive0low20
Leukemia, Myelogenous, Ph1-Positive0low20
Leukemia, Myeloid0low70
Leukemia, Myeloid, Acute, M10medium11011
Leukemia, Myeloid, Acute, M20medium11011
Leukemia, Myeloid, Acute, M30low30
Leukemia, Myeloid, Acute, M40low10
Leukemia, Myeloid, Acute, M50low10
Leukemia, Myeloid, Chronic0low20
Leukemia, Myeloid, Naegeli-Type0low10
Leukemia, Myeloid, Ph1 Positive0low20
Leukemia, Myeloid, Ph1-Positive0low20
Leukemia, Myeloid, Philadelphia Positive0low20
Leukemia, Myeloid, Philadelphia-Positive0low20
Leukemia, Myeloid, Schilling Type0low10
Leukemia, Myeloid, Schilling-Type0low10
Leukemia, Myelomonocytic, Acute0low10
Leukemia, Nonlymphoblastic, Acute0medium11011
Leukemia, Nonlymphocytic, Acute0medium11011
Leukemia, Pre-B-Cell0low20
Leukemia, Progranulocytic0low30
Leukemia, Promyelocytic, Acute0low30
Leukemia, T-Cell, Acute0low10
Leukemic Reticuloendotheliosis0low10
Libman-Sacks Disease0low30
Light-Headedness0low10
Lightheadedness0low10
Lipemia0low20
Lipidemia0low20
Lipidoses0low20
Lipidosis0low20
Lipoidosis0low20
Listeria Infections0low10
Listeriosis0low10
Liver Cancer0low10
Liver Cancer, Adult0low10
Liver Cell Carcinoma0low10
Liver Cell Carcinoma, Adult0low10
Liver Cirrhosis0low20
Liver Diseases0low80
Liver Dysfunction0low80
Liver Failure0low10
Liver Failure, Acute0low10
Liver Failure, Fulminant0low10
Liver Fibrosis0low20
Liver Injury, Drug-Induced0low100
Liver Injury, Drug-Induced, Acute0low100
Liver Neoplasms0low10
Lobar Pneumonia0low70
Lobomycosis0low10
Lobomycosis-like Disease0low10
Long QT Syndrome0low50
Lung Abscess0low10
Lung Aspergillosis0low210
Lung Cancer0medium31
Lung Diseases0low30
Lung Diseases, Fungal0medium483
Lung Inflammation0low70
Lung Neoplasms0medium31
Lung Sounds0low10
Lupus Erythematosus Disseminatus0low30
Lupus Erythematosus, Systemic0low30
Lymphatic Sarcoma0low10
Lymphoblastic Leukemia0low220
Lymphoblastic Leukemia, Acute0low220
Lymphoblastic Leukemia, Acute, Adult0low220
Lymphoblastic Leukemia, Acute, Childhood0low220
Lymphoblastic Leukemia, Acute, L10low220
Lymphoblastic Leukemia, Acute, L20low220
Lymphoblastic Leukemia, Acute, T Cell0low10
Lymphoblastic Leukemia, Acute, T-Cell0low10
Lymphoblastic Leukemia, Chronic0low20
Lymphoblastic Lymphoma0low220
Lymphocyte Depletion Hodgkin's Lymphoma0low10
Lymphocyte-Rich Classical Hodgkin's Lymphoma0low10
Lymphocytic Leukemia, Acute0low220
Lymphocytic Leukemia, B-Cell0low10
Lymphocytic Leukemia, Chronic0low20
Lymphocytic Leukemia, Chronic, B Cell0low20
Lymphocytic Leukemia, Chronic, B-Cell0low20
Lymphocytic Leukemia, L10low220
Lymphocytic Leukemia, L20low220
Lymphocytic Leukemia, L30low10
Lymphocytic Leukemia, T Cell, Acute0low10
Lymphocytic Leukemia, T-Cell, Acute0low10
Lymphocytic Lymphoma0low20
Lymphocytic Lymphoma, Diffuse, Well Differentiated0low20
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0low20
Lymphocytic Lymphoma, Nodular, Poorly Differentiated0low10
Lymphocytic Lymphoma, Nodular, Poorly-Differentiated0low10
Lymphocytic Lymphoma, Well Differentiated0low20
Lymphocytic Lymphoma, Well-Differentiated0low20
Lymphocytopenia0low10
Lymphogranuloma, Malignant0low10
Lymphohistiocytosis, Hemophagocytic0low10
Lymphoma0medium11
Lymphoma, Atypical Diffuse Small Lymphoid0low10
Lymphoma, Burkitt0low10
Lymphoma, Diffuse0low10
Lymphoma, Diffuse Large-Cell0low10
Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Follicular0low10
Lymphoma, Follicular Large-Cell0low10
Lymphoma, Follicular, Grade 10low10
Lymphoma, Follicular, Grade 20low10
Lymphoma, Follicular, Grade 30low10
Lymphoma, Follicular, Mixed Cell0low10
Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Follicular, Mixed Small and Large Lymphoid0low10
Lymphoma, Follicular, Small and Large Cleaved Cell0low10
Lymphoma, Follicular, Small and Large Cleaved-Cell0low10
Lymphoma, Giant Follicular0low10
Lymphoma, High-Grade0low10
Lymphoma, Histiocytic0low10
Lymphoma, Histiocytic, Diffuse0low10
Lymphoma, Histiocytic, Nodular0low10
Lymphoma, Intermediate-Grade0low10
Lymphoma, Large B-Cell, Diffuse0low10
Lymphoma, Large Cell, Diffuse0low10
Lymphoma, Large Cell, Follicular0low10
Lymphoma, Large Lymphoid, Diffuse0low10
Lymphoma, Large Lymphoid, Nodular0low10
Lymphoma, Large-Cell, Diffuse0low10
Lymphoma, Large-Cell, Follicular0low10
Lymphoma, Low-Grade0low10
Lymphoma, Lymphoblastic0low220
Lymphoma, Lymphocytic0low20
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0low20
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0low20
Lymphoma, Lymphocytic, Nodular, Poorly Differentiated0low10
Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated0low10
Lymphoma, Lymphocytic, Plasmacytoid0low10
Lymphoma, Lymphocytic, Well Differentiated0low20
Lymphoma, Lymphocytic, Well-Differentiated0low20
Lymphoma, Lymphoplasmacytoid0low10
Lymphoma, Lymphoplasmacytoid, CLL0low20
Lymphoma, Malignant0medium11
Lymphoma, Mixed0low10
Lymphoma, Mixed Cell, Diffuse0low10
Lymphoma, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Mixed Small and Large Cell, Diffuse0low10
Lymphoma, Mixed-Cell0low10
Lymphoma, Mixed-Cell, Diffuse0low10
Lymphoma, Mixed-Cell, Follicular0low10
Lymphoma, Nodular0low10
Lymphoma, Nodular, Large Follicular Center Cell0low10
Lymphoma, Nodular, Large Follicular Center-Cell0low10
Lymphoma, Nodular, Mixed Lymphocytic Histiocytic0low10
Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Nodular, Mixed Small and Large Cell0low10
Lymphoma, Non-Hodgkin0low10
Lymphoma, Non-Hodgkin, Familial0low10
Lymphoma, Non-Hodgkin's0low10
Lymphoma, Non-Hodgkins0low10
Lymphoma, Nonhodgkin's0low10
Lymphoma, Nonhodgkins0low10
Lymphoma, Pleomorphic0low10
Lymphoma, Small and Large Cleaved-Cell, Diffuse0low10
Lymphoma, Small Cleaved Cell, Diffuse0low10
Lymphoma, Small Cleaved Cell, Follicular0low10
Lymphoma, Small Cleaved-Cell, Diffuse0low10
Lymphoma, Small Cleaved-Cell, Follicular0low10
Lymphoma, Small Follicular Center-Cell0low10
Lymphoma, Small Lymphocytic0low20
Lymphoma, Small Lymphocytic, Plasmacytoid0low20
Lymphoma, Small Lymphoid, Follicular0low10
Lymphoma, Small Non-Cleaved-Cell0low10
Lymphoma, Small Noncleaved-Cell0low10
Lymphoma, Small-Cell0low20
Lymphoma, T Cell, Peripheral0low10
Lymphoma, T-Cell, Peripheral0low10
Lymphoma, Undifferentiated0low10
Lymphoma, Undifferentiated, Diffuse0low10
Lymphopenia0low10
Lymphoplasmacytoid Lymphoma, CLL0low20
Lymphoproliferative Disease, X-Linked0low10
Lymphoproliferative Disorders0low10
Lymphoproliferative Syndrome, X-Linked, 10low10
Lymphosarcoma0low10
M3 ANLL0low30
Macroglobulinemia0low10
Maculopapular Drug Eruption0low10
Maculopapular Exanthem0low10
Madura Foot0low130
Maduromycosis0low130
Maladie du systu00E8me nerveux central@fr0low20
Malaria0low10
Malattie del sistema nervoso centrale@it0low20
Male Pattern Baldness0low10
Malignancies, Hematologic0medium568
Malignancy0medium151
Malignancy, Hematologic0medium568
Malignant Neoplasm of Breast0low20
Malignant Neoplasms0medium151
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0low20
Mammary Cancer0low20
Mammary Carcinoma, Human0low20
Mammary Neoplasm, Human0low20
Mammary Neoplasms, Human0low20
Mandibular Injuries0low10
Marsh Fever0low10
Maternal Sepsis0low10
Maturity-Onset Diabetes0low50
Maturity-Onset Diabetes Mellitus0low50
Maxillary Diseases0low20
Maxillary Sinus Cancer0low10
Maxillary Sinus Neoplasms0low10
Maxillary Sinusitis0medium31
Mediastinitis0low10
Mediastinum Inflammation0low10
Megacolon, Toxic0low10
Meningitis, Cryptococcal0low60
Meningitis, Fungal0medium41
Meningoencephalitis0low10
Meningoencephalitis, Protozoal0low20
Microbial Superinvasion0low10
Milk-Alkali Syndrome0low10
Mimae Infections0low10
Mineralocorticoid Excess Syndrome, Apparent0low60
Mixed Cellularity Hodgkin's Lymphoma0low10
Mixed Infection0low40
Mixed Small and Large Cell Lymphoma, Diffuse0low10
Mixed-Cell Lymphoma0low10
Mixed-Cell Lymphoma, Diffuse0low10
Mixed-Cell Lymphoma, Follicular0low10
MODS0low10
MODY0low50
Moniliasis0medium823
Moniliasis, Cutaneous0low10
Moniliasis, Oral0medium132
Moniliasis, Vulvovaginal0low30
Monoblastic Leukemia, Acute0low10
Monocytic Leukemia, Acute0low10
Monocytic Leukemia, Chronic0low70
Morbid Obesity0medium21
Morbilliform Drug Reaction0low10
Morbilliform Exanthem0low10
Mouth Diseases0low30
Mouth Dryness0low10
Mucorales Infection0medium1761
Mucorales Infections0medium1761
Mucormycoses0medium1761
Mucositis0medium71
Mucoviscidosis0low120
Multiple Myeloma0low20
Multiple Organ Dysfunction Syndrome0low10
Multiple Organ Failure0low10
Multiple Pulmonary Nodules0low10
Muscle Weakness0low10
Muscular Weakness0low10
Musculoskeletal Pain0low10
Mycetoma0low130
Mycobacterium tuberculosis Infection0low20
Mycoses, Central Nervous System0medium171
Mycosis, Ocular0low210
Mycotic Aneurysm0low10
Mycotic Infections, Ocular0low210
Myeloblastic Leukemia, Acute0medium11011
Myelocytic Leukemia0low70
Myelocytic Leukemia, Acute0medium11011
Myelocytic Leukemia, Chronic0low20
Myelodysplastic Syndromes0medium327
Myelofibrosis0low10
Myelofibrosis With Myeloid Metaplasia0low10
Myelogenous Leukemia0low70
Myelogenous Leukemia, Acute0medium11011
Myelogenous Leukemia, Chronic0low20
Myelogenous Leukemia, Ph1-Positive0low20
Myeloid Leukemia0low70
Myeloid Leukemia, Acute0medium11011
Myeloid Leukemia, Acute, M10medium11011
Myeloid Leukemia, Acute, M20medium11011
Myeloid Leukemia, Acute, M30low30
Myeloid Leukemia, Acute, M40low10
Myeloid Leukemia, Acute, M50low10
Myeloid Leukemia, Chronic0low20
Myeloid Leukemia, Naegeli-Type0low10
Myeloid Leukemia, Ph1-Positive0low20
Myeloid Leukemia, Philadelphia-Positive0low20
Myeloid Leukemia, Schilling-Type0low10
Myeloid Metaplasia0low10
Myeloma-Multiple0low20
Myeloma, Multiple0low20
Myeloma, Plasma-Cell0low20
Myelomatosis0low20
Myelomonocytic Leukemia, Acute0low10
Myelosclerosis0low10
Myelosis, Nonleukemic0low10
Myocardial Diseases0low20
Myocardial Diseases, Primary0low20
Myocardial Diseases, Secondary0low20
Myocardial Failure0low30
Myocardial Ischemia0low10
Myocardiopathies0low20
Myocarditis0low10
Myocarditis, Chagas0low30
Naegleria fowleri Infection0low20
Naegleria fowleri Meningoencephalitis0low20
Nagana0low10
Nail Fungus0medium113
Narcosis0low10
Nasal Catarrh0low40
Nasal Diseases0low90
Nasal Disorders0low90
Nausea0low10
Necrosis0low50
Necrotizing Pneumonia0low10
Necrotizing Pyelonephritis0low10
Neglected Diseases0low10
nemoci centru00E1lnu00EDho nervovu00E9ho systu00E9mu@cs0low20
Neonatal Diseases0low10
Neoplasia0medium151
Neoplasm0medium151
Neoplasms, Benign0medium151
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0low20
Neoplasms, Hematologic0medium568
Neoplasms, Hematopoietic0medium568
Neoplasms, Hepatic0low10
Neoplasms, Intracranial0low10
Neoplasms, Liver0low10
Neoplasms, Lung0medium31
Neoplasms, Maxillary Sinus0low10
Neoplasms, Pulmonary0medium31
Neoplasms, Skin0low40
Neoplasms, Thymic0low10
Neoplasms, Thymus0low10
Nephrogenic Diabetes Insipidus0low10
Nephrogenic Diabetes Insipidus, Type I0low10
Nephrogenic Diabetes Insipidus, Type II0low10
Nerve Pain0low10
Nervous System Diseases0low10
Nervous System Disorders0low10
Nervous System Invasive Aspergillosis0low50
Nervous System Poisoning0low20
Neural-Optical Lesion0low10
Neuralgia0low10
Neuralgia, Atypical0low10
Neuralgia, Iliohypogastric Nerve0low10
Neuralgia, Ilioinguinal0low10
Neuralgia, Perineal0low10
Neuralgia, Stump0low10
Neuralgia, Supraorbital0low10
Neuralgia, Vidian0low10
Neuroaspergillosis0low50
Neurodynia0low10
Neurologic Adducter Spastic Dysphonia0low10
Neurologic Disorders0low10
Neurological Disorders0low10
Neuropathic Pain0low10
Neurosyphilis0low10
Neurosyphilis, Asymptomatic0low10
Neurosyphilis, Gummatous0low10
Neurosyphilis, Juvenile0low10
Neurosyphilis, Secondary0low10
Neurosyphilis, Symptomatic0low10
Neurotoxic Disorders0low20
Neurotoxicity Syndromes0low20
Neurotoxin Diseases0low20
Neurotoxin Disorders0low20
Neurotoxoplasmosis0low10
NIDDM0low50
Nocardia asteroides Infection0low10
Nocardia Infections0low10
Nocardiosis0low10
Nodular Glomerulosclerosis0low10
Nodular Large Follicular Center-Cell Lymphoma0low10
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma0low10
Nodular Sclerosing Hodgkin's Lymphoma0low10
Non-Hodgkin Lymphoma0low10
Non-Hodgkin's Lymphoma0low10
Non-Small Cell Lung Cancer0medium11
Non-Small Cell Lung Carcinoma0medium11
Non-Small-Cell Lung Carcinoma0medium11
Noninsulin-Dependent Diabetes Mellitus0low50
Nonlymphoblastic Leukemia, Acute0medium11011
Nonlymphocytic Leukemia, Acute0medium11011
Nonsmall Cell Lung Cancer0medium11
Nose Diseases0low90
Nosocomial Infections0low70
Obesity0medium21
Obesity, Morbid0medium21
Obesity, Severe0medium21
Obstructive Hydrocephalus0low10
Ocular Headache0low10
Ocular Infections, Fungal0low210
Oculomotor Paralysis0low10
Oculomycosis0low210
Onychomycosis0medium113
Ophthalmia0low70
Ophthalmoparesis0low10
Ophthalmoplegia0low10
Opportunistic Infections0medium453
Opportunistic Infections, AIDS-Related0medium152
Opportunistic Infections, HIV-Related0medium152
Optic Disc Disorders0low10
Optic Disc Edema0low10
Optic Disk Disorders0low10
Optic Disk Edema0low10
Optic Nerve Diseases0low10
Optic Nerve Papillitis0low10
Optic Neuropathy0low10
Optic Papilla Edema0low10
Orbital Cellulitis0low20
Orbital Diseases0low120
Orbital Fracture0low10
Orbital Fractures0low10
Organ Dysfunction Syndrome, Multiple0low10
Organ Failure, Multiple0low10
Organic Tremor Dysphonia0low10
Oriental Sore0low30
Orphan Diseases0low10
Orthomyxoviridae Infections0low10
Orthomyxovirus Infections0low10
Orthostasis0low10
Orthostatic Headache0low10
Osteogenic Sarcoma0low20
Osteomyelitis0low60
Osteosarcoma0low20
Osteosarcoma Tumor0low20
Otitis0low10
Otitis Media, Purulent0low20
Otitis Media, Suppurative0low20
Pachymeningitis, Fungal0medium41
Pain0medium21
Pain, Burning0medium21
Pain, Crushing0medium21
Pain, Migratory0medium21
Pain, Radiating0medium21
Pain, Splitting0medium21
Paludism0low10
Pancreatic Cystic Fibrosis0low120
Pancreatic Parenchyma with Edema0low10
Pancreatic Parenchymal Edema0low10
Pancreatitis0low10
Pancreatitis, Acute0low10
Pancreatitis, Acute Edematous0low10
Pancytopenia0low20
Papilledema0low10
Papilledema Associated with Decreased Intraocular Pressure0low10
Papilledema Associated with Increased Intracranial Pressure0low10
Papillitis0low10
Papillitis, Optic0low10
Paralysis, General0low10
Paranasal Sinus Diseases0low70
Parasite Infections0low10
Parasitemia0low60
Parasitic Diseases0low10
Parasitic Infections0low10
Paretic Neurosyphilis0low10
Paroxysmal Atrial Fibrillation0low10
Paroxysmal Nerve Pain0low10
Pattern Baldness0low10
Pediatric Respiratory Distress Syndrome0low30
Pemphigus0low10
Pemphigus Foliaceus0low10
Pemphigus Vulgaris0low10
Periorbital Headache0low10
Periostitis0low30
Peripancreatic Fat Necrosis0low10
Peripheral Nerve Diseases0low40
Peripheral Nervous System Disease0low40
Peripheral Nervous System Diseases0low40
Peripheral Nervous System Disorders0low40
Peripheral Neuropathies0low40
Peripheral T-Cell Lymphoma0low10
Peritonitis0low40
Peroperative Complications0low10
Persistent Atrial Fibrillation0low10
Phaeohyphomycosis0low100
Phaeohyphomycosis, Central Nervous System0low10
Phaeohyphomycosis, Central Nervous System, Primary0low10
Pharyngeal Diseases0medium31
Pharynx Diseases0medium31
Phlebitis, Cavernous Sinus, Septic0low20
Phonation Disorders0low10
Phototoxic Contact Dermatitis0low10
Phototoxic Dermatitis0low10
Phototoxicity0low10
Phycomycosis0medium401
Picornaviridae Infections0low10
Picornavirus Infections0low10
Pigmentary Cirrhosis0low10
Plaque, Dental0low10
Plasma Cell Myeloma0low20
Plasmodium Infections0low10
Pleural Rub0low10
Pneumonia0low70
Pneumonia, Bacterial0low20
Pneumonia, Lobar0low70
Pneumonia, Necrotizing0low10
Pneumonia, Viral0low10
Pneumonitis0low70
Pneumothorax0low10
Pneumothorax, Primary Spontaneous0low10
PNS (Peripheral Nervous System) Diseases0low40
PNS Diseases0low40
Poisoning, Blood0low60
Poisoning, Nervous System0low20
Polyarthritis Rheumatica0low10
Polycystic Kidney Disease 20low10
Polycystic Kidney Disease, Adult0low10
Polycystic Kidney Disease, Adult Type 20low10
Polycystic Kidney Disease, Adult, Type II0low10
Polycystic Kidney Disease, Autosomal Dominant0low10
Polycystic Kidney Disease, Type 20low10
Polycystic Kidney, Autosomal Dominant0low10
Polycystic Kidney, Type 1 Autosomal Dominant Disease0low10
Polycystic Kidney, Type 2 Autosomal Dominant Disease0low10
Polymicrobial Infection0low40
Pongidae Diseases0low10
Portal-Systemic Encephalopathy0low10
Portosystemic Encephalopathy0low10
Post-Traumatic Hydrocephalus0low10
Postoperative Complications0low210
Postoperative Wound Infection0low50
Pre B-ALL0low20
Pre-B ALL0low20
Pre-B-Cell Leukemia0low20
Precursor B-Cell Lymphoblastic Leukemia0low20
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma0low20
Precursor B-Cell Lymphoblastic Lymphoma0low20
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low220
Precursor T-Cell Lymphoblastic Leukemia0low10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma0low10
Precursor T-Cell Lymphoblastic Lymphoma0low10
Pregnancy0low20
Pregnancy Complications, Infectious0low10
Pregnancy, Infectious Complications0low10
Pressure Pneumothorax0low10
Primary Amebic Meningoencephalitis0low20
Primary Brain Neoplasms0low10
Primary Central Nervous System Phaeohyphomycosis0low10
Primary Cutaneous Nocardiosis0low10
Primary Graft Dysfunction0low10
Primary Hemochromatosis0low10
Primary Hemophagocytic Hymphohistiocytosis0low10
Primary Hemophagocytic Lymphohistiocytosis0low10
Primary Hyperaldosteronism0low30
Primary Hypersomnia Disorders0low10
Primary Hypersomnolence Disorders0low10
Primary Macroglobulinemia0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Myelofibrosis0low10
Primary Myocardial Diseases0low20
Primary Peritonitis0low40
Primary Spontaneous Pneumothorax0low10
Progranulocytic Leukemia0low30
Promyelocytic Leukemia, Acute0low30
Prosthesis Related Infection0low20
Prosthesis-Related Infection0low20
Prosthesis-Related Infections0low20
Proteinuria0low10
Protozoal Infections, Central Nervous System0low20
Protozoal Infections, Cerebral0low20
Protozoal Meningoencephalitis0low20
Pseudopelade0low10
Pseudotumor Cerebri0low10
Psoriasis Arthropathica0low10
Psoriasis, Arthritic0low10
Psoriatic Arthritis0low10
Psoriatic Arthropathy0low10
Pulmonary Abscess0low10
Pulmonary Abscesses0low10
Pulmonary Aspergillosis0low210
Pulmonary Aspergillosis - Invasive0medium343
Pulmonary Cancer0medium31
Pulmonary Consumption0low10
Pulmonary Cystic Fibrosis0low120
Pulmonary Disease0low30
Pulmonary Disease, Chronic Obstructive0low10
Pulmonary Diseases0low30
Pulmonary Fibroses0low20
Pulmonary Fibrosis0low20
Pulmonary Fungal Diseases0medium483
Pulmonary Fungal Infections0medium483
Pulmonary Fusariosis0low110
Pulmonary Inflammation0low70
Pulmonary Neoplasms0medium31
Pulmonary Nocardiosis0low10
Pulmonary Phthisis0low10
Pulmonary Tuberculoses0low10
Pulmonary Tuberculosis0low10
Purpura, Thrombocytopenic, Autoimmune0low10
Purpura, Thrombocytopenic, Idiopathic0low10
Purtilo Syndrome0low10
Pyaemia0low60
Pyelonephritis0low10
Pyelonephritis, Acute Necrotizing0low10
Pyemia0low60
Pyohemia0low60
Pyrexia0medium101
Rales0low10
Rare Diseases0low10
Rasmussen Encephalitis0low10
Rasmussen Syndrome0low10
Rasmussen's Syndrome0low10
Reactive Hemophagocytic Syndrome0low10
Recrudescence0medium161
Recurrence0medium161
Regional Enteritis0low10
Relapse0medium161
Remittent Fever0low10
Renal Disease, End-Stage0medium31
Renal Failure0medium21
Renal Failure, Acute0low40
Renal Failure, Chronic0medium31
Renal Failure, End-Stage0medium31
Renal Insufficiency0medium21
Renal Insufficiency, Acute0low40
Renal Insufficiency, Chronic0low10
Research-Related Injuries0low20
Respiratory Depression0low10
Respiratory Distress Syndrome0low30
Respiratory Distress Syndrome, Acute0low30
Respiratory Distress Syndrome, Adult0low30
Respiratory Distress Syndrome, Pediatric0low30
Respiratory Failure0low10
Respiratory Infections0low80
Respiratory Insufficiency0low10
Respiratory Sounds0low10
Respiratory Tract Infections0low80
Reticuloendotheliosis, Leukemic0low10
Reticulolymphosarcoma0medium11
Reticulosarcoma0low10
Reticulosis, Familial Histiocytic0low10
Reticulum Cell Sarcoma0low10
Reticulum-Cell Sarcoma0low10
Retinal Edema0low10
Retro-Ocular Headache0low10
Retrobulbar Hemorrhage0low10
Rheumatic Arthritis0low10
Rheumatic Fever0low10
Rheumatism, Acute Articular0low10
Rheumatism, Articular, Acute0low10
Rheumatoid Arthritis0low20
Rhinitis0low40
Rhinitis, Allergic, Nonseasonal0low10
Rhinitis, Allergic, Perennial0low10
Rhonchi0low10
Right-Sided Heart Failure0low30
Ringworm0low20
Rodent Diseases0low10
Rodent Ulcer0low40
Runt Disease0medium294
Saccular Aneurysm0low10
Salivary Gland Virus Disease0low50
San Joaquin Valley Fever0medium162
Sappinia diploidea Meningoencephalitis0low20
Sarcoma, Germinoblastic0medium11
Sarcoma, Lymphatic0low10
Sarcoma, Osteogenic0low20
Sarcoma, Reticulum-Cell0low10
SARS Coronavirus 2 Infection0low70
SARS-CoV-2 Infection0low70
Second Cranial Nerve Diseases0low10
Secondary Hypersomnia Disorders0low10
Secondary Hypersomnolence Disorders0low10
Secondary Infection0low40
Secondary Infections0low40
Secondary Myocardial Diseases0low20
Secondary Neurosyphilis0low10
Secondary Peritonitis0low40
Senile Paranoid Dementia0low10
Sensitivity and Specificity0medium111
Sepsis0low60
Sepsis during Pregnancy0low10
Sepsis in Pregnancy0low10
Septic Phlebitis, Cavernous Sinus0low20
Septic Shock0low30
Septicemia0low60
Serratia Infections0low10
Severe Sepsis0low60
Sharp Headache0low10
Shock Lung0low30
Shock, Endotoxic0low30
Shock, Septic0low30
Shock, Toxic0low30
Side Effects of Drugs0medium181
Silicosis0low10
Sinus Infections0low120
Sinusitis0low120
Sinusitis, Ethmoid0medium41
Sinusitis, Maxillary0medium31
Skin and Subcutaneous Tissue Disorders0low10
Skin Cancer0low40
Skin Diseases0low10
Skin Diseases, Fungal0medium311
Skin Neoplasms0low40
Skin Ulcer0low10
Small Cleaved-Cell Lymphoma, Diffuse0low10
Small Cleaved-Cell Lymphoma, Follicular0low10
Small Follicular Center-Cell Lymphoma0low10
Small Non-Cleaved-Cell Lymphoma0low10
Small Noncleaved-Cell Lymphoma0low10
Small-Cell Lymphoma0low20
Soft Tissue Infections0low40
Spastic Dysphonia0low10
Spastic Dysphonia, Neurologic Adducter0low10
Spinal Diseases0low10
Splenic Diseases0low10
Spontaneous Pneumothorax0low10
Sporothrix brasiliensis Infection0low90
Sporothrix Infection0low90
Sporothrix schenckii Infection0low90
Sporotrichosis0low90
Squamous Cell Carcinoma0low30
SREDIu0160NJI u017DIVu010CANI SUSTAV, BOLESTI@hr0low20
Staphylococcal Infections0low10
Staphylococcus aureus Infection0low10
Stenocardia0low10
Stomach Diseases0low20
Stomatitis, Denture0low10
Streptococcal Infections0low10
Streptozocin Diabetes0low10
Streptozotocin Diabetes0low10
Stridor0low10
Stupor0low10
Subcutaneous Alternariosis0low20
Subcutaneous Phaeohyphomycosis0low100
Sudden Visual Loss0low10
Suffering, Physical0medium21
Summer-Type Hypersensitivity Pneumonitis0low60
Superinfection0low10
Superinvasion, Microbial0low10
Suppurative Arthritis0low30
Surgical Injuries0low10
Surgical Site Infection0low50
Surgical Wound Infection0low50
Susceptibility, Disease0low40
Swine Influenza0low10
Sykdommer i sentralnervesystemet@no0low20
Syphilis, Central Nervous System0low10
Syphilis, CNS0low10
Systemic Lupus Erythematosus0low30
T-ALL0low10
T-Cell Acute Lymphocytic Leukemia0low10
T-Cell Leukemia, Acute0low10
T-Cell Lymphoma, Peripheral0low10
T-Lymphocytic Leukemia, Acute0low10
T-Lymphocytopenia, Idiopathic CD4-Positive0low10
T-Lymphocytopenia, Idiopathic CD4+0low10
T-Lymphotropic Virus Type III Infections, Human0low120
Tension Pneumothorax0low10
Thoracoabdominal Aortic Aneurysm0low10
Throbbing Headache0low10
Thrombocytopenia0low10
Thrombocytopenic Purpura, Autoimmune0low10
Thrombopenia0low10
Thrombosis, Carotid0low10
Thrombosis, Carotid Artery0low10
Thrombosis, Cavernous Sinus0low20
Thrombosis, Common Carotid Artery0low10
Thrombosis, External Carotid Artery0low10
Thrombosis, Internal Carotid Artery0low10
Thrush0medium132
Thymic Cancer0low10
Thymic Neoplasms0low10
Thymic Tumors0low10
Thymoma0low10
Thymus Cancer0low10
Thymus Neoplasms0low10
Thymus Tumors0low10
Thyroid Diseases0low10
Tinea0low20
Tinea Corporis0low20
Tinea Unguium0medium113
Torsade de Pointes0low10
Torsades de Pointes0low10
Toruloma0low60
Torulosis0low200
Toxic Encephalitis0low20
Toxic Hepatitis0low100
Toxic Megacolon0low10
Toxic Shock0low30
Toxic Shock Syndrome0low30
Toxicity, Drug0medium181
Toxoplasmosis, Central Nervous System0low10
Toxoplasmosis, Cerebral0low10
Tracheitis0low10
Trauma0low20
Trichophyton mentagrophytes Infection0low20
Trichophytosis0low20
Trichosporon Infection0low60
Trichosporonosis0low60
Troisier-Hanot-Chauffard Syndrome0low10
Trypanosoma cruzi Infection0medium572
Trypanosomiasis, African0low10
Trypanosomiasis, Cardiovascular0low30
Trypanosomiasis, South American0medium572
Tuberculoses, Pulmonary0low10
Tuberculosis0low20
Tuberculosis, Pulmonary0low10
Tumor Lysis Syndrome0low10
Tumors0medium151
Tumors, Breast0low20
Tumour Lysis Syndrome0low10
Type 1 Diabetes0low40
Type 1 Diabetes Mellitus0low40
Type 2 Diabetes0low50
Type 2 Diabetes Mellitus0low50
u041Du0415u0420u0412u041Du041Eu0419 u0421u0418u0421u0422u0415u041Cu042B u0426u0415u041Du0422u0420u0410u041Bu042Cu041Du041Eu0419 u0411u041Eu041Bu0415u0417u041Du0418@ru0low20
u4E2Du67A2u795Eu7D4Cu7CFBu75BEu60A3@ja0low20
Ulcer0low10
Ulcer, Rodent0low40
Ulcerative Colitis0low10
Undifferentiated Lymphoma0low10
Unilateral Blindness0low10
Unilateral Headache0low10
Upper Respiratory Infections0low80
Upper Respiratory Tract Infection0low80
Upper Respiratory Tract Infections0low80
Urinary Tract Infections0low20
Vaginal Yeast Infection0low30
Vaginal Yeast Infections0low30
Vaginitis0low10
Vaginitis, Monilial0low30
Valley Fever0medium162
Vasogenic Brain Edema0low10
Vasogenic Cerebral Edema0low10
Vasopressin-Resistant Diabetes Insipidus0low10
Ventilatory Depression0low10
Vertex Headache0low10
Vomiting0low10
Von Recklenhausen-Applebaum Disease0low10
Waldenstrom Macroglobulinemia0low10
Waldenstrom's Macroglobulinaemia0low10
Waldenstrom's Macroglobulinemia0low10
Wegener Granulomatosis0low20
Wegener's Granulomatosis0low20
Werlhof Disease0low10
Werlhof's Disease0low10
Wheezing0low10
Wound Infection0low10
Wound Infection, Postoperative0low50
Wound Infection, Surgical0low50
Wounds0low20
Wounds and Injuries0low20
Wounds and Injury0low20
Wounds, Injury0low20
X-Linked Chronic Granulomatous Disease0medium82
X-Linked Lymphoproliferative Disease0low10
X-Linked Lymphoproliferative Disorder0low10
X-Linked Lymphoproliferative Syndrome0low10
Xerostomia0low10
Zentralnervensystemkrankheiten@de0low20
Ziekte, centraalzenuwstelsel-@nl0low20
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10
Zygomycosis0medium401
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Disease Models, Animal0low10
Fever, Zika0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (43)

ArticleYear
Association of adverse effects with high serum posaconazole concentrations.
Medical mycology, Aug-02, Volume: 61, Issue: 8		2023
Elevated posaconazole trough concentrations are not associated with increased risk for posaconazole toxicity in lung transplant recipients.
Clinical transplantation, Volume: 37, Issue: 1		2023
Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
Cancer chemotherapy and pharmacology, Volume: 90, Issue: 3		2022
Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database.
Expert opinion on drug safety, Volume: 21, Issue: 8		2022
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections.
Expert opinion on pharmacotherapy, Volume: 23, Issue: 2		2022
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
PloS one, Volume: 14, Issue: 3		2019
Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.
The Journal of antimicrobial chemotherapy, 04-01, Volume: 74, Issue: 4		2019
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.
Mycoses, Volume: 62, Issue: 1		2019
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
Journal of clinical psychopharmacology, Volume: 38, Issue: 4		2018
S-allylmercaptocysteine attenuates posaconazole-induced adverse effects in mice through antioxidation and anti-inflammation.
International immunopharmacology, Volume: 58		2018
Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia.
Journal of pediatric hematology/oncology, Volume: 40, Issue: 5		2018
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
The Journal of antimicrobial chemotherapy, Dec-01, Volume: 72, Issue: 12		2017
Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease.
Future microbiology, Volume: 12		2017
Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
International journal of antimicrobial agents, Volume: 50, Issue: 3		2017
[Efficacy and Safety of Posaconazoleon for Primary Antifungal Prophylaxis against Invasive Fungal Disease in Patients with Stem Cell Transplantation].
Zhongguo shi yan xue ye xue za zhi, Volume: 25, Issue: 3		2017
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Antimicrobial agents and chemotherapy, Volume: 61, Issue: 8		2017
Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation.
The Journal of antimicrobial chemotherapy, 08-01, Volume: 72, Issue: 8		2017
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Journal of cancer research and clinical oncology, Volume: 143, Issue: 7		2017
A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.
BMC pharmacology & toxicology, 01-31, Volume: 18, Issue: 1		2017
An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Expert opinion on drug safety, Volume: 16, Issue: 3		2017
Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 12		2016
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 3		2016
Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 2		2015
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
Internal medicine journal, Volume: 44, Issue: 12b		2014
Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, Volume: 49, Issue: 4		2016
Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 11		2014
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 7		2014
Safety of posaconazole.
Expert opinion on drug safety, Volume: 12, Issue: 2		2013
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
The Journal of antimicrobial chemotherapy, Volume: 67, Issue: 11		2012
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Volume: 18, Issue: 9		2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, Volume: 7, Issue: 12		2011
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Dec-15, Volume: 51, Issue: 12		2010
Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation.
Bone marrow transplantation, Volume: 46, Issue: 5		2011
Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Volume: 17, Issue: 4		2011
Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.
Journal of clinical pharmacy and therapeutics, Volume: 34, Issue: 3		2009
Posaconazole-increased vincristine neurotoxicity in a child: a case report.
Journal of pediatric hematology/oncology, Volume: 31, Issue: 4		2009
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Sep-01, Volume: 45, Issue: 5		2007
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 6		2006
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Jun-15, Volume: 42, Issue: 12		2006
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 2		2006
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Journal of clinical pharmacology, Volume: 45, Issue: 2		2005
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.
Antimicrobial agents and chemotherapy, Volume: 47, Issue: 9		2003
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (6)

ArticleYear
Dementia-Like Symptoms Associated With Posaconazole.
Journal of pharmacy practice, Volume: 35, Issue: 1		2022
Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
International journal of clinical pharmacology and therapeutics, Volume: 51, Issue: 9		2013
Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
Expert review of anti-infective therapy, Volume: 7, Issue: 2		2009
Refractory coccidioidomycosis treated with posaconazole.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Jun-15, Volume: 40, Issue: 12		2005
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
International journal of clinical practice, Volume: 58, Issue: 6		2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (91)

ArticleYear
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.
Clinical drug investigation, Volume: 43, Issue: 9		2023
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.
Clinical and translational science, Volume: 16, Issue: 10		2023
Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
Clinical pharmacokinetics, Volume: 62, Issue: 7		2023
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
Drugs, Volume: 83, Issue: 1		2023
A Review of Population Pharmacokinetic Models of Posaconazole.
Drug design, development and therapy, Volume: 16		2022
Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-01, Volume: 178		2022
Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
Cancer chemotherapy and pharmacology, Volume: 90, Issue: 3		2022
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study.
Mycoses, Volume: 65, Issue: 6		2022
Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling.
The AAPS journal, 01-05, Volume: 24, Issue: 1		2022
Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jan-01, Volume: 168		2022
Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis.
The Journal of antimicrobial chemotherapy, 11-12, Volume: 76, Issue: 12		2021
Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats.
Drug design, development and therapy, Volume: 15		2021
Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug-Drug Interactions of Selinexor with Posaconazole in Rats.
Drug design, development and therapy, Volume: 15		2021
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Therapeutic drug monitoring, 08-01, Volume: 43, Issue: 4		2021
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.
The Journal of antimicrobial chemotherapy, 04-13, Volume: 76, Issue: 5		2021
Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose study.
Die Pharmazie, 10-01, Volume: 75, Issue: 10		2020
Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Current drug metabolism, Volume: 21, Issue: 13		2020
Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
International journal of antimicrobial agents, Volume: 56, Issue: 4		2020
Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
Expert opinion on drug metabolism & toxicology, Volume: 16, Issue: 7		2020
From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
Mycoses, Volume: 63, Issue: 8		2020
Pharmacokinetics and Pharmacodynamics of Posaconazole.
Drugs, Volume: 80, Issue: 7		2020
Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
Critical care (London, England), Jun-06, Volume: 23, Issue: 1		2019
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
PloS one, Volume: 14, Issue: 3		2019
The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 26, Issue: 1		2020
A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration.
International journal of antimicrobial agents, Volume: 52, Issue: 4		2018
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
Antimicrobial agents and chemotherapy, Volume: 62, Issue: 7		2018
Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
Clinical pharmacokinetics, Volume: 58, Issue: 1		2019
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Journal of clinical pharmacology, Volume: 58, Issue: 7		2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology, Volume: 81, Issue: 3		2018
Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.
The Journal of infectious diseases, 03-13, Volume: 217, Issue: 7		2018
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
The Journal of antimicrobial chemotherapy, Dec-01, Volume: 72, Issue: 12		2017
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, 03-01, Volume: 72, Issue: suppl_1		2017
Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats.
Drugs in R&D, Volume: 17, Issue: 2		2017
Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.
Journal of pharmaceutical sciences, Volume: 106, Issue: 2		2017
Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 24, Issue: 1		2018
The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Aug-25, Volume: 91		2016
Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.
Antimicrobial agents and chemotherapy, Volume: 60, Issue: 6		2016
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 3		2016
A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients.
International journal of antimicrobial agents, Volume: 47, Issue: 1		2016
Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
The Pediatric infectious disease journal, Volume: 35, Issue: 2		2016
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Volume: 21, Issue: 9		2015
Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
American journal of veterinary research, Volume: 76, Issue: 5		2015
Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 6		2015
Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 2		2015
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 11		2014
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 11		2014
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 7		2014
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 7		2014
Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.
The Journal of infectious diseases, Nov-15, Volume: 208, Issue: 10		2013
Liquid chromatography-mass spectrometry method for the quantification of posaconazole in human plasma: application to pharmacokinetics following single-dose administration in the fasted state and with a high-fat meal.
Die Pharmazie, Volume: 68, Issue: 3		2013
A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
Therapeutic drug monitoring, Volume: 35, Issue: 2		2013
Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.
Pharmacotherapy, Volume: 33, Issue: 1		2013
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
Antimicrobial agents and chemotherapy, Volume: 57, Issue: 1		2013
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
The Journal of antimicrobial chemotherapy, Volume: 67, Issue: 11		2012
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 8		2012
Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction.
Current medical research and opinion, Volume: 28, Issue: 4		2012
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 5		2012
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.
European journal of clinical pharmacology, Volume: 68, Issue: 6		2012
Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
Expert opinion on drug metabolism & toxicology, Volume: 8, Issue: 1		2012
Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.
Antimicrobial agents and chemotherapy, Volume: 55, Issue: 7		2011
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.
The Journal of infectious diseases, May-01, Volume: 203, Issue: 9		2011
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
The Journal of antimicrobial chemotherapy, Volume: 65, Issue: 10		2010
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 9		2010
Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Journal of clinical pharmacology, Volume: 51, Issue: 1		2011
Pharmacokinetic/pharmacodynamic profile of posaconazole.
Clinical pharmacokinetics, Volume: 49, Issue: 6		2010
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 5		2010
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Current medical research and opinion, Volume: 26, Issue: 2		2010
Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.
Current medical research and opinion, Volume: 26, Issue: 1		2010
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 1		2010
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 53, Issue: 11		2009
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
Journal of acquired immune deficiency syndromes (1999), Aug-01, Volume: 51, Issue: 4		2009
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 53, Issue: 7		2009
Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Clinical therapeutics, Volume: 31, Issue: 2		2009
Effects of oral posaconazole on the pharmacokinetics of sirolimus.
Current medical research and opinion, Volume: 25, Issue: 3		2009
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 53, Issue: 2		2009
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Pharmacotherapy, Volume: 28, Issue: 10		2008
Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.
Therapeutic drug monitoring, Volume: 30, Issue: 2		2008
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Pharmacotherapy, Volume: 27, Issue: 12		2007
Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
Pharmacotherapy, Volume: 27, Issue: 6		2007
Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.
Current medical research and opinion, Volume: 23, Issue: 3		2007
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 51, Issue: 2		2007
Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Mycoses, Volume: 49 Suppl 1		2006
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 6		2006
Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 5		2006
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 2		2006
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Journal of clinical pharmacology, Volume: 45, Issue: 2		2005
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 3		2004
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 1		2004
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.
Antimicrobial agents and chemotherapy, Volume: 47, Issue: 9		2003
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Antimicrobial agents and chemotherapy, Volume: 45, Issue: 3		2001
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.
Antimicrobial agents and chemotherapy, Volume: 44, Issue: 3		2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (76)

ArticleYear
The Impact of Hypromellose on Pharmaceutical Properties of Alginate Microparticles as Novel Drug Carriers for Posaconazole.
International journal of molecular sciences, Jun-28, Volume: 24, Issue: 13		2023
Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
Antimicrobial agents and chemotherapy, 07-18, Volume: 67, Issue: 7		2023
Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
Clinical pharmacokinetics, Volume: 62, Issue: 7		2023
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
Drugs, Volume: 83, Issue: 1		2023
Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-01, Volume: 178		2022
Biopredictive capability assessment of two dissolution/permeation assays, µFLUX™ and PermeaLoop™, using supersaturating formulations of Posaconazole.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Sep-01, Volume: 176		2022
Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Volume: 28, Issue: 7		2022
Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling.
The AAPS journal, 01-05, Volume: 24, Issue: 1		2022
Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis.
Journal of clinical pharmacy and therapeutics, Volume: 47, Issue: 3		2022
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Therapeutic drug monitoring, 08-01, Volume: 43, Issue: 4		2021
Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
Molecular pharmaceutics, 12-07, Volume: 17, Issue: 12		2020
PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Journal of pharmacokinetics and pharmacodynamics, Volume: 47, Issue: 5		2020
The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
International journal of pharmaceutics, Jan-05, Volume: 573		2020
Evaluation of posaconazole plasma concentrations achieved with the delayed-release tablets in Korean high-risk patients with haematologic malignancy.
Mycoses, Volume: 63, Issue: 2		2020
Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids.
Molecular pharmaceutics, 12-02, Volume: 16, Issue: 12		2019
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.
The Journal of antimicrobial chemotherapy, 04-01, Volume: 74, Issue: 4		2019
Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Basic & clinical pharmacology & toxicology, Volume: 124, Issue: 1		2019
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
Antimicrobial agents and chemotherapy, Volume: 62, Issue: 7		2018
Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jul-01, Volume: 119		2018
Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
Clinical pharmacokinetics, Volume: 58, Issue: 1		2019
Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Mar-30, Volume: 115		2018
Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
Scientific reports, 01-26, Volume: 8, Issue: 1		2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology, Volume: 81, Issue: 3		2018
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
The European journal of health economics : HEPAC : health economics in prevention and care, Volume: 19, Issue: 4		2018
Enhancement of dissolution rate through eutectic mixture and solid solution of posaconazole and benznidazole.
International journal of pharmaceutics, Jun-15, Volume: 525, Issue: 1		2017
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, 03-01, Volume: 72, Issue: suppl_1		2017
Preparation and evaluation of posaconazole-loaded enteric microparticles in rats.
Drug development and industrial pharmacy, Volume: 43, Issue: 4		2017
Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole.
Drug metabolism and pharmacokinetics, Volume: 31, Issue: 5		2016
Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.
Molecular pharmaceutics, 08-01, Volume: 13, Issue: 8		2016
Characterization and In Vitro Evaluation of the Complexes of Posaconazole with β- and 2,6-di-O-methyl-β-cyclodextrin.
AAPS PharmSciTech, 01-01, Volume: 18, Issue: 1		2017
Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression.
Journal of pharmacy practice, Volume: 30, Issue: 2		2017
Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.
Medical mycology, Volume: 54, Issue: 2		2016
Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.
Clinica chimica acta; international journal of clinical chemistry, Oct-23, Volume: 450		2015
Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Mycoses, Volume: 58, Issue: 7		2015
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 8		2015
Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
American journal of veterinary research, Volume: 76, Issue: 5		2015
Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 6		2015
Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Journal of cancer research and clinical oncology, Volume: 141, Issue: 9		2015
Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
Pharmacotherapy, Volume: 35, Issue: 2		2015
Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
Current opinion in infectious diseases, Volume: 27, Issue: 6		2014
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 11		2014
Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation.
BioMed research international, Volume: 2014		2014
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 7		2014
Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
Pharmacotherapy, Volume: 33, Issue: 10		2013
Safety of posaconazole.
Expert opinion on drug safety, Volume: 12, Issue: 2		2013
Making sense of posaconazole therapeutic drug monitoring: a practical approach.
Current opinion in infectious diseases, Volume: 25, Issue: 6		2012
Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 12		2012
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 11		2012
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
The Journal of antimicrobial chemotherapy, Volume: 67, Issue: 11		2012
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 8		2012
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 6		2012
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 5		2012
Triazole antifungal agents in invasive fungal infections: a comparative review.
Drugs, Dec-24, Volume: 71, Issue: 18		2011
Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection.
Therapeutic drug monitoring, Volume: 33, Issue: 6		2011
Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
Clinical pharmacokinetics, Nov-01, Volume: 50, Issue: 11		2011
Posaconazole: clinical pharmacokinetics and drug interactions.
Mycoses, Volume: 54 Suppl 1		2011
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.
British journal of clinical pharmacology, Volume: 70, Issue: 4		2010
Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 9		2010
Pharmacokinetic/pharmacodynamic profile of posaconazole.
Clinical pharmacokinetics, Volume: 49, Issue: 6		2010
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
Journal of medicinal chemistry, May-27, Volume: 53, Issue: 10		2010
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 1		2010
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 53, Issue: 11		2009
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint.
Journal of the National Comprehensive Cancer Network : JNCCN, Volume: 6, Issue: 2		2008
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Dec-15, Volume: 45, Issue: 12		2007
Posaconazole: a next-generation triazole antifungal.
Future microbiology, Volume: 2, Issue: 3		2007
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Antimicrobial agents and chemotherapy, Volume: 51, Issue: 3		2007
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.
Mycoses, Volume: 49 Suppl 1		2006
Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.
Clinical pharmacokinetics, Volume: 44, Issue: 2		2005
Disposition of posaconazole following single-dose oral administration in healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 9		2004
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 3		2004
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
British journal of clinical pharmacology, Volume: 57, Issue: 2		2004
New antifungal agents.
Dermatologic clinics, Volume: 21, Issue: 3		2003
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.
Antimicrobial agents and chemotherapy, Volume: 44, Issue: 3		2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (166)

ArticleYear
Triazole Antifungal Quantification for Therapeutic Drug Monitoring in Serum by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Posaconazole, Voriconazole, Itraconazole, and Hydroxyitraconazole.
Methods in molecular biology (Clifton, N.J.), Volume: 2737		2024
Association of adverse effects with high serum posaconazole concentrations.
Medical mycology, Aug-02, Volume: 61, Issue: 8		2023
The Impact of Hypromellose on Pharmaceutical Properties of Alginate Microparticles as Novel Drug Carriers for Posaconazole.
International journal of molecular sciences, Jun-28, Volume: 24, Issue: 13		2023
Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
Antimicrobial agents and chemotherapy, 07-18, Volume: 67, Issue: 7		2023
Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
Clinical pharmacokinetics, Volume: 62, Issue: 7		2023
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
Drugs, Volume: 83, Issue: 1		2023
Progress of triazole antifungal agent posaconazole in individualized therapy.
Journal of clinical pharmacy and therapeutics, Volume: 47, Issue: 12		2022
Model-Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection.
Journal of clinical pharmacology, Volume: 63, Issue: 4		2023
A Review of Population Pharmacokinetic Models of Posaconazole.
Drug design, development and therapy, Volume: 16		2022
Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation.
European journal of clinical pharmacology, Volume: 78, Issue: 10		2022
Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-01, Volume: 178		2022
Gellan gum-based in situ gelling ophthalmic nanosuspension of Posaconazole.
Drug delivery and translational research, Volume: 12, Issue: 12		2022
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study.
Mycoses, Volume: 65, Issue: 6		2022
Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.
Mycoses, Volume: 65, Issue: 3		2022
Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole.
International journal of dermatology, Volume: 61, Issue: 12		2022
Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jan-01, Volume: 168		2022
Evaluation of Voriconazole and Posaconazole Dosing in Patients With Thermal Burn Injuries.
Journal of burn care & research : official publication of the American Burn Association, 07-01, Volume: 43, Issue: 4		2022
Posaconazole treatment of refractory coccidioidomycosis in dogs.
Journal of veterinary internal medicine, Volume: 35, Issue: 6		2021
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 28, Issue: 6		2022
Subtherapeutic posaconazole prophylaxis in a gastric bypass patient following hematopoietic stem cell transplantation.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 07-09, Volume: 78, Issue: 14		2021
Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies.
Drug delivery and translational research, Volume: 12, Issue: 3		2022
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Therapeutic drug monitoring, 08-01, Volume: 43, Issue: 4		2021
Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
Journal of pediatric hematology/oncology, 07-01, Volume: 43, Issue: 5		2021
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.
The Journal of antimicrobial chemotherapy, 04-13, Volume: 76, Issue: 5		2021
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Cancer chemotherapy and pharmacology, Volume: 87, Issue: 4		2021
Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients.
Medical mycology, Jul-06, Volume: 59, Issue: 7		2021
Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
European journal of medicinal chemistry, Dec-01, Volume: 207		2020
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Minerva medica, Volume: 111, Issue: 5		2020
Experience using intravenous posaconazole in paediatric and young adult oncology patients.
The Journal of antimicrobial chemotherapy, 12-01, Volume: 75, Issue: 12		2020
Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
Molecular pharmaceutics, 12-07, Volume: 17, Issue: 12		2020
Management of posaconazole-induced pseudohyperaldosteronism.
The Journal of antimicrobial chemotherapy, 12-01, Volume: 75, Issue: 12		2020
Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
International journal of antimicrobial agents, Volume: 56, Issue: 4		2020
Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas' disease drug discovery.
PLoS neglected tropical diseases, Volume: 14, Issue: 7		2020
Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.
Pediatric transplantation, Volume: 24, Issue: 6		2020
Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
Leukemia & lymphoma, Volume: 61, Issue: 10		2020
Implications for IV posaconazole dosing in the era of obesity.
The Journal of antimicrobial chemotherapy, 04-01, Volume: 75, Issue: 4		2020
Evaluation of target attainment of oral posaconazole suspension in immunocompromised children.
The Journal of antimicrobial chemotherapy, 03-01, Volume: 75, Issue: 3		2020
Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole.
Marine drugs, Dec-09, Volume: 17, Issue: 12		2019
The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
International journal of pharmaceutics, Jan-05, Volume: 573		2020
Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
The Journal of antimicrobial chemotherapy, 12-01, Volume: 74, Issue: 12		2019
Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
Critical care (London, England), Jun-06, Volume: 23, Issue: 1		2019
Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
Mycoses, Volume: 62, Issue: 8		2019
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
PloS one, Volume: 14, Issue: 3		2019
Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients.
Journal of the Pediatric Infectious Diseases Society, Sep-25, Volume: 8, Issue: 4		2019
Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?
Journal of pharmacy practice, Volume: 33, Issue: 2		2020
A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration.
International journal of antimicrobial agents, Volume: 52, Issue: 4		2018
Posaconazole in immunocompromised pediatric patients.
Expert review of anti-infective therapy, Volume: 16, Issue: 7		2018
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
Journal of clinical psychopharmacology, Volume: 38, Issue: 4		2018
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
Antimicrobial agents and chemotherapy, Volume: 62, Issue: 7		2018
Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
BMC infectious diseases, 04-02, Volume: 18, Issue: 1		2018
Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review.
Clinical and investigative medicine. Medecine clinique et experimentale, 03-27, Volume: 41, Issue: 1		2018
S-allylmercaptocysteine attenuates posaconazole-induced adverse effects in mice through antioxidation and anti-inflammation.
International immunopharmacology, Volume: 58		2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology, Volume: 81, Issue: 3		2018
Use of Intravenous Posaconazole in Hematopoietic Stem Cell Transplant Patients.
Journal of pediatric hematology/oncology, Volume: 40, Issue: 4		2018
Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
European journal of haematology, Volume: 100, Issue: 3		2018
Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
The Journal of antimicrobial chemotherapy, 03-01, Volume: 73, Issue: 3		2018
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
Mycoses, Volume: 61, Issue: 3		2018
Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
The Journal of antimicrobial chemotherapy, Jan-01, Volume: 73, Issue: 1		2018
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
The Journal of antimicrobial chemotherapy, Dec-01, Volume: 72, Issue: 12		2017
Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience.
Journal of the Pediatric Infectious Diseases Society, Sep-01, Volume: 6, Issue: 3		2017
In Situ Characterization of Pharmaceutical Formulations by Dynamic Nuclear Polarization Enhanced MAS NMR.
The journal of physical chemistry. B, 08-31, Volume: 121, Issue: 34		2017
Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
Antimicrobial agents and chemotherapy, Volume: 61, Issue: 10		2017
Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
Therapeutic drug monitoring, Volume: 39, Issue: 5		2017
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
The European journal of health economics : HEPAC : health economics in prevention and care, Volume: 19, Issue: 4		2018
Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.
Mycoses, Volume: 60, Issue: 9		2017
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, 03-01, Volume: 72, Issue: suppl_1		2017
Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats.
Drugs in R&D, Volume: 17, Issue: 2		2017
Posaconazole Plasma Monitoring in Immunocompromised Children.
Journal of the Pediatric Infectious Diseases Society, Nov-24, Volume: 6, Issue: 4		2017
A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.
BMC pharmacology & toxicology, 01-31, Volume: 18, Issue: 1		2017
An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Expert opinion on drug safety, Volume: 16, Issue: 3		2017
Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.
Journal of clinical pharmacy and therapeutics, Volume: 42, Issue: 1		2017
Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
Mycoses, Volume: 60, Issue: 4		2017
Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.
Journal of pharmaceutical sciences, Volume: 106, Issue: 2		2017
Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 24, Issue: 1		2018
Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole.
Drug metabolism and pharmacokinetics, Volume: 31, Issue: 5		2016
Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.
Molecular pharmaceutics, 08-01, Volume: 13, Issue: 8		2016
The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Aug-25, Volume: 91		2016
Quantification of the Triazole Antifungal Compounds Voriconazole and Posaconazole in Human Serum or Plasma Using Liquid Chromatography Electrospray Tandem Mass Spectrometry (HPLC-ESI-MS/MS).
Methods in molecular biology (Clifton, N.J.), Volume: 1383		2016
Dosing of antifungal agents in obese people.
Expert review of anti-infective therapy, Volume: 14, Issue: 2		2016
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 3		2016
An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jan-20, Volume: 82		2016
Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
The Pediatric infectious disease journal, Volume: 35, Issue: 2		2016
Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection.
Diagnostic microbiology and infectious disease, Volume: 84, Issue: 1		2016
Contribution of a Simple Bioassay in Effective Therapeutic Drug Monitoring of Posaconazole and Voriconazole.
Therapeutic drug monitoring, Volume: 37, Issue: 5		2015
Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 10		2015
Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Mycoses, Volume: 58, Issue: 7		2015
Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
American journal of veterinary research, Volume: 76, Issue: 5		2015
Eumycetoma and actinomycetoma--an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy.
Journal of the European Academy of Dermatology and Venereology : JEADV, Volume: 29, Issue: 10		2015
Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
Pharmacotherapy, Volume: 35, Issue: 2		2015
Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Mycoses, Volume: 58, Issue: 3		2015
Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
Therapeutic drug monitoring, Volume: 37, Issue: 4		2015
Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 2		2015
Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
Current opinion in infectious diseases, Volume: 27, Issue: 6		2014
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 11		2014
Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
European journal of haematology, Volume: 94, Issue: 3		2015
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 10		2014
Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 21, Issue: 6		2015
Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Volume: 20, Issue: 11		2014
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 7		2014
Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
Medecine et maladies infectieuses, Volume: 44, Issue: 4		2014
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (25)

ArticleYear
Drug-drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment.
The Journal of antimicrobial chemotherapy, 06-01, Volume: 78, Issue: 6		2023
Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan.
Clinical and translational science, Volume: 14, Issue: 6		2021
Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug-Drug Interactions of Selinexor with Posaconazole in Rats.
Drug design, development and therapy, Volume: 15		2021
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Cancer chemotherapy and pharmacology, Volume: 87, Issue: 4		2021
PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Journal of pharmacokinetics and pharmacodynamics, Volume: 47, Issue: 5		2020
Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Volume: 25, Issue: 7		2019
Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?
Journal of pharmacy practice, Volume: 33, Issue: 2		2020
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
Journal de mycologie medicale, Volume: 28, Issue: 2		2018
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Journal of clinical pharmacology, Volume: 58, Issue: 7		2018
Synergistic drug combination effectively blocks Ebola virus infection.
Antiviral research, Volume: 137		2017
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Clinical pharmacology in drug development, Volume: 6, Issue: 3		2017
Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.
Antimicrobial agents and chemotherapy, Volume: 60, Issue: 6		2016
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
Expert opinion on drug metabolism & toxicology, Volume: 10, Issue: 4		2014
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
The Journal of antimicrobial chemotherapy, Volume: 68, Issue: 12		2013
Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
International journal of antimicrobial agents, Volume: 40, Issue: 6		2012
Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction.
Current medical research and opinion, Volume: 28, Issue: 4		2012
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
Antimicrobial agents and chemotherapy, Volume: 55, Issue: 4		2011
Posaconazole: clinical pharmacokinetics and drug interactions.
Mycoses, Volume: 54 Suppl 1		2011
Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.
Clinical drug investigation, Volume: 29, Issue: 7		2009
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.
Antimicrobial agents and chemotherapy, Volume: 52, Issue: 10		2008
Antifungal agents--clinical pharmacokinetics and drug interactions.
Mycoses, Volume: 51 Suppl 1		2008
Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Leukemia, Volume: 22, Issue: 3		2008
Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
Current medical research and opinion, Volume: 23, Issue: 6		2007
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 3		2004
Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 3		2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]